[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is a rare skin condition that is characterized by the growth of thick, scaly patches on the skin, often in response to an underlying cancer. Here are some synonyms for Acrokeratosis paraneoplastica:\n1. Acrokeratosis paraneoplastic syndrome: This term is used to describe the combination of Acrokeratosis paraneoplastica and an underlying cancer.\n2. Paraneoplastic acrokeratosis: This term is used to describe the condition when the thick, scaly patches on the skin are associated with an underlying cancer, but the cancer is not necessarily present in the skin itself.\n3. Acrokeratosis-paraneoplastic syndrome: This term is used to describe the combination of Acrokeratosis paraneoplastica and an underlying cancer, and it emphasizes the association between the two conditions.\n4. Keratosis paraneoplastica: This term is used to describe the condition when the thick, scaly patches on the skin are associated with an underlying cancer, but the cancer is not necessarily present in the skin itself.\n5. Paraneoplastic keratosis: This term is used to describe the condition when the thick, scaly patches on the skin are associated with an underlying cancer, but the cancer is not necessarily present in the skin itself.\n6. Acrokeratosis-related cancer: This term is used to describe the condition when the thick, scaly patches on the skin are associated with an underlying cancer, and it emphasizes the potential link between the two conditions.\n7. Paraneoplastic cutaneous syndrome: This term is used to describe the condition when the thick, scaly patches on the skin are associated with an underlying cancer, and it emphasizes the potential link between the two conditions.\n8. Cutaneous paraneoplastic syndrome: This term is used to describe the condition when the thick, scaly patches on the skin are associated with an underlying cancer, and it emphasizes the potential link between the two conditions.\n9. Paraneoplastic dermatosis: This term is used to describe the condition when the thick, scaly patches on the skin are associated with an underlying cancer, and it emphasizes the potential link between the two conditions.\n10. Ac",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is a rare skin condition characterized by thick, scaly patches on the skin.\n2. Acrokeratosis paraneoplastic syndrome is a synonym for Acrokeratosis paraneoplastica.\n3. Paraneoplastic acrokeratosis is used to describe the condition when associated with an underlying cancer.\n4. Keratosis paraneoplastica is another synonym for Acrokeratosis paraneoplastica.\n5. Paraneoplastic keratosis is a term used for Acrokeratosis paraneoplastica when associated with an underlying cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is a rare skin condition characterized by thick, scaly patches on the skin.",
      "Acrokeratosis paraneoplastic syndrome is a synonym for Acrokeratosis paraneoplastica.",
      "Paraneoplastic acrokeratosis is used to describe the condition when associated with an underlying cancer.",
      "Keratosis paraneoplastica is another synonym for Acrokeratosis paraneoplastica.",
      "Paraneoplastic keratosis is a term used for Acrokeratosis paraneoplastica when associated with an underlying cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Acrokeratosis paraneoplastica is also known as Bazex syndrome, not Acrokeratosis paraneoplastic syndrome.\n3. TRUE\n4. FALSE [correction]: There is no condition known as Keratosis paraneoplastica; the correct term is Acrokeratosis paraneoplastica or Bazex syndrome.\n5. FALSE [correction]: Paraneoplastic keratosis is not a recognized term for Acrokeratosis paraneoplastica when associated with an underlying cancer; the correct term remains Acrokeratosis paraneoplastica or Bazex syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that can affect the brain and nervous system. While they share some similarities, they are distinct conditions with different causes and clinical presentations. Here's a detailed comparison of the two syndromes:\n1. Cause:\nWeaver syndrome is caused by mutations in the PTEN gene, which encodes a protein that regulates cell growth and division. Sotos syndrome, on the other hand, is caused by mutations in the NSD1 gene, which plays a critical role in regulating gene expression.\n2. Presentation:\nBoth Weaver syndrome and Sotos syndrome can cause a range of developmental delays, intellectual disability, and behavioral problems. However, the severity and nature of these symptoms can vary significantly between the two conditions.\nWeaver syndrome typically presents with a more mild phenotype, characterized by:\n* Delayed gross motor skills development (e.g., sitting, standing, walking)\n* Delayed fine motor skills development (e.g., grasping, manipulating objects)\n* Intellectual disability, ranging from mild to moderate\n* Behavioral problems, such as anxiety, hyperactivity, and difficulty with social interactions\nSotos syndrome, on the other hand, tends to be more severe and can cause a wider range of symptoms, including:\n* Severe intellectual disability (often with a full-scale IQ below 50)\n* Delayed gross motor skills development\n* Delayed fine motor skills development\n* Distinctive facial features, such as a large head, narrow eyes, and a prominent forehead\n* Short stature\n* Cardiac problems, such as ventricular septal defects or atrial septal defects\n* Increased risk of seizures\n3. Other features:\nWeaver syndrome can also cause a range of other symptoms, including:\n* Distinctive facial features, such as a flat nasal bridge, wide set eyes, and a small jaw\n* Hearing loss or visual impairment\n* Sleep disturbances, such as sleep apnea or insomnia\n* Gastrointestinal problems, such as constipation or gastroesophageal reflux disease",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by mutations in the PTEN gene.\n2. Sotos syndrome is caused by mutations in the NSD1 gene.\n3. Individuals with Weaver syndrome can experience delayed gross and fine motor skills development, intellectual disability, and behavioral problems.\n4. Sotos syndrome can cause severe intellectual disability, distinctive facial features, short stature, cardiac problems, and an increased risk of seizures.\n5. Weaver syndrome may also present with distinctive facial features, hearing loss or visual impairment, sleep disturbances, and gastrointestinal problems.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by mutations in the PTEN gene.",
      "Sotos syndrome is caused by mutations in the NSD1 gene.",
      "Individuals with Weaver syndrome can experience delayed gross and fine motor skills development, intellectual disability, and behavioral problems.",
      "Sotos syndrome can cause severe intellectual disability, distinctive facial features, short stature, cardiac problems, and an increased risk of seizures.",
      "Weaver syndrome may also present with distinctive facial features, hearing loss or visual impairment, sleep disturbances, and gastrointestinal problems."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Sotos syndrome can cause overgrowth (leading to tall stature), distinctive facial features, intellectual disability, and an increased risk of tumors, not necessarily short stature or cardiac problems.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "JASPAR (Joint Analysis of Sequence and Function) is a widely used database of physical and functional genomics data for understanding the regulation of gene expression. Here are the releases of the JASPAR database:\n1. JASPAR Release 1 (2002): This was the first release of the JASPAR database, which contained 127 transcription factor binding sites (TFBSs) from 10 organisms, including humans, mice, and yeast.\n2. JASPAR Release 2 (2004): This release added 155 new TFBSs from 12 organisms, and improved the quality and accuracy of the existing TFBSs.\n3. JASPAR Release 3 (2006): This release included 237 new TFBSs from 14 organisms, and improved the prediction algorithms for TFBSs.\n4. JASPAR Release 4 (2008): This release added 327 new TFBSs from 16 organisms, and improved the accuracy of the TFBS predictions.\n5. JASPAR Release 5 (2010): This release included 447 new TFBSs from 20 organisms, and improved the prediction algorithms for TFBSs.\n6. JASPAR Release 6 (2012): This release added 567 new TFBSs from 22 organisms, and improved the accuracy of the TFBS predictions.\n7. JASPAR Release 7 (2014): This release included 677 new TFBSs from 24 organisms, and improved the prediction algorithms for TFBSs.\n8. JASPAR Release 8 (2016): This release added 777 new TFBSs from 26 organisms, and improved the accuracy of the TFBS predictions.\n9. JASPAR Release 9 (2018): This release included 977 new TFBSs from 28 organisms, and improved the prediction algorithms for TFBSs.\n10. JASPAR Release 10 (2020): This is the latest release of the JASPAR database, which includes 1,177 new TFBSs from",
    "llama-2-7b-chat-hf_fact_raw": "1. The first release of the JASPAR database occurred in 2002 and contained 127 transcription factor binding sites from 10 organisms.\n2. JASPAR Release 2 in 2004 added 155 new TFBSs from 12 organisms.\n3. JASPAR Release 6 in 2012 added 567 new TFBSs from 22 organisms.\n4. JASPAR Release 8 in 2016 added 777 new TFBSs from 26 organisms.\n5. The latest release, JASPAR Release 10 in 2020, includes 1,177 new TFBSs.",
    "llama-2-7b-chat-hf_fact": [
      "The first release of the JASPAR database occurred in 2002 and contained 127 transcription factor binding sites from 10 organisms.",
      "JASPAR Release 2 in 2004 added 155 new TFBSs from 12 organisms.",
      "JASPAR Release 6 in 2012 added 567 new TFBSs from 22 organisms.",
      "JASPAR Release 8 in 2016 added 777 new TFBSs from 26 organisms.",
      "The latest release, JASPAR Release 10 in 2020, includes 1,177 new TFBSs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The latest release, JASPAR Release 10 in 2020, includes 1,357 new TFBSs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein is a viral protein that is encoded by the KP4 virus, which is a member of the Parvoviridae family. The KP4 protein is one of the most well-studied viral proteins and has been found to play a crucial role in the replication and pathogenesis of the virus. Here are some of the key functions of the KP4 protein:\n1. DNA binding: The KP4 protein is able to bind to DNA, which is essential for its role in the replication of the virus. The protein recognizes and binds to specific DNA sequences, known as origins of replication, which are necessary for the initiation of viral DNA replication.\n2. Replication initiation: Once the KP4 protein has bound to the origin of replication, it helps to recruit other viral proteins, such as the helicase and primase, which are necessary for the initiation of viral DNA replication. The KP4 protein acts as a platform for these proteins to bind and initiate the replication process.\n3. Inhibition of host cell proteins: The KP4 protein can also inhibit the activity of host cell proteins that might interfere with the replication of the virus. For example, the KP4 protein has been shown to inhibit the activity of the host cell protein, p53, which is a tumor suppressor that can interfere with viral replication.\n4. Induction of apoptosis: The KP4 protein has been shown to induce apoptosis, or programmed cell death, in host cells. This can help to eliminate host cells that are infected with the virus and prevent them from producing interferon, which is a potent antiviral molecule.\n5. Modulation of the immune response: The KP4 protein can also modulate the immune response by interacting with immune cells and suppressing their activity. For example, the KP4 protein has been shown to inhibit the activation of T cells, which are important immune cells that can recognize and attack infected cells.\n6. Cell-to-cell spread: The KP4 protein can also facilitate the cell-to-cell spread of the virus by promoting the fusion of infected cells with nearby uninfected cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the KP4 virus, a member of the Parvoviridae family.\n2. The KP4 protein has the ability to bind to DNA at specific sequences known as origins of replication.\n3. The KP4 protein assists in recruiting other viral proteins necessary for viral DNA replication initiation.\n4. The KP4 protein can inhibit the activity of host cell proteins, such as p53.\n5. The KP4 protein can induce apoptosis in host cells.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is encoded by the KP4 virus, a member of the Parvoviridae family.",
      "The KP4 protein has the ability to bind to DNA at specific sequences known as origins of replication.",
      "The KP4 protein assists in recruiting other viral proteins necessary for viral DNA replication initiation.",
      "The KP4 protein can inhibit the activity of host cell proteins, such as p53.",
      "The KP4 protein can induce apoptosis in host cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is encoded by the Ustilago maydis virus H1, a member of the Totiviridae family.\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "DITPA, also known as 3,5-diiodothyropropionic acid, is a synthetic thyroid hormone analog that has been used in both experimental and clinical studies. Here is a detailed answer to your question:\nWhat is DITPA?\nDITPA is a synthetic compound that is structurally similar to the thyroid hormone triiodothyronine (T3). It is composed of a tyrosine ring with three iodine atoms, which gives it a similar structure to T3. DITPA is used as a thyroid hormone analog in experimental and clinical studies due to its ability to mimic the actions of T3 in the body.\nMechanism of Action\nDITPA works by binding to thyroid hormone receptors in the body, which triggers a cascade of cellular signaling events that are similar to those triggered by T3. This results in increased metabolism, growth, and development, as well as changes in gene expression. DITPA has been shown to have a longer half-life than T3, which allows it to remain active in the body for a longer period of time.\nExperimental Studies\nDITPA has been used in a variety of experimental studies to investigate the role of thyroid hormones in various physiological processes. For example, DITPA has been used to study the effects of thyroid hormones on fetal development during pregnancy. In these studies, DITPA has been shown to mimic the effects of T3 on fetal growth and development, highlighting the importance of thyroid hormones in this process.\nClinical Studies\nDITPA has also been used in clinical studies to investigate the effects of thyroid hormone replacement therapy in patients with hypothyroidism. Hypothyroidism is a condition in which the thyroid gland does not produce enough thyroid hormones, leading to a range of symptoms including fatigue, weight gain, and cold intolerance. DITPA has been shown to be effective in restoring normal thyroid hormone levels in these patients, improving their symptoms and quality of life.\nAdvantages and Limitations\nOne of the main advantages of using DITPA in experimental and clinical studies is its ability to mimic the actions of T3 in the body",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a synthetic thyroid hormone analog used in experimental and clinical studies.\n2. DITPA is structurally similar to the thyroid hormone triiodothyronine (T3).\n3. DITPA binds to thyroid hormone receptors in the body and triggers cellular signaling events.\n4. DITPA has been used in studies to investigate the role of thyroid hormones on fetal development during pregnancy.\n5. DITPA has been used in clinical studies for thyroid hormone replacement therapy in patients with hypothyroidism.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a synthetic thyroid hormone analog used in experimental and clinical studies.",
      "DITPA is structurally similar to the thyroid hormone triiodothyronine (T3).",
      "DITPA binds to thyroid hormone receptors in the body and triggers cellular signaling events.",
      "DITPA has been used in studies to investigate the role of thyroid hormones on fetal development during pregnancy.",
      "DITPA has been used in clinical studies for thyroid hormone replacement therapy in patients with hypothyroidism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: DITPA has been used in clinical studies for metabolic disorders and heart failure, but not for thyroid hormone replacement therapy in patients with hypothyroidism.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "The COUGER tool is a software tool designed to help researchers and practitioners in the field of organizational behavior and human resources (OBHR) to conduct organizational culture assessments. The acronym COUGER stands for \"Culture, Ownership, Unity, Growth, and Engagement,\" which reflects the five key dimensions of organizational culture that the tool measures.\nThe COUGER tool is based on a comprehensive literature review of OBHR research and is designed to be used by organizations of all sizes and industries. It assesses an organization's culture across five dimensions:\n1. Culture: This dimension measures the shared values, beliefs, and norms that define an organization's culture. It includes items such as \"Our organization has a clear and consistent set of values and beliefs\" and \"Our organization's culture is supportive of innovation and creativity.\"\n2. Ownership: This dimension measures the degree to which employees feel a sense of ownership and responsibility for the organization's success. It includes items such as \"Employees are encouraged to take ownership of their work\" and \"Employees feel a strong sense of responsibility to the organization.\"\n3. Unity: This dimension measures the degree to which employees feel a sense of unity and collaboration within the organization. It includes items such as \"Employees work well together as a team\" and \"There is a strong sense of camaraderie among employees.\"\n4. Growth: This dimension measures the degree to which employees feel that the organization is committed to their personal and professional growth. It includes items such as \"The organization provides opportunities for professional development\" and \"Employees feel that their skills and knowledge are valued and recognized.\"\n5. Engagement: This dimension measures the degree to which employees are emotionally and intellectually engaged in their work. It includes items such as \"Employees are motivated to do their best work\" and \"Employees feel a strong sense of purpose and meaning in their work.\"\nThe COUGER tool provides a comprehensive assessment of an organization's culture by scoring each dimension on a scale of 1-5, with higher scores indicating a stronger culture in that dimension. The tool also provides a detailed report of the organization's culture, including recommendations for improvement.\nOverall, the COUGER tool is a valuable resource for organizations looking to",
    "llama-2-7b-chat-hf_fact_raw": "1. The COUGER tool is designed to help researchers and practitioners conduct organizational culture assessments.\n2. COUGER stands for \"Culture, Ownership, Unity, Growth, and Engagement.\"\n3. The tool assesses an organization's culture across five dimensions: Culture, Ownership, Unity, Growth, and Engagement.\n4. The COUGER tool is based on a comprehensive literature review of organizational behavior and human resources research.\n5. The tool provides a detailed report of the organization's culture, including recommendations for improvement.",
    "llama-2-7b-chat-hf_fact": [
      "The COUGER tool is designed to help researchers and practitioners conduct organizational culture assessments.",
      "COUGER stands for \"Culture, Ownership, Unity, Growth, and Engagement.\"",
      "The tool assesses an organization's culture across five dimensions: Culture, Ownership, Unity, Growth, and Engagement.",
      "The COUGER tool is based on a comprehensive literature review of organizational behavior and human resources research.",
      "The tool provides a detailed report of the organization's culture, including recommendations for improvement."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: COUGER stands for \"Culture of Ownership for Unchallengeable Growth, Excellence, and Renewal.\"\n3. FALSE [correction]: The tool assesses an organization's culture across four dimensions: Culture, Ownership, Growth, and Engagement.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available to treat Tick-borne Encephalitis (TBE), which is a viral infection transmitted through the bite of an infected tick. The most common drugs used to treat TBE are:\n1. Antiviral medications: These drugs can help reduce the replication of the virus in the body and alleviate symptoms. The most commonly used antiviral medications for TBE are ribavirin and acyclovir.\nRibavirin: This drug is an antiviral medication that has been shown to be effective in reducing the severity of TBE symptoms and improving survival rates. It works by inhibiting the replication of the virus in the body. Ribavirin is usually given intravenously or orally, and the dosage and duration of treatment depend on the severity of the infection.\nAcyclovir: This drug is also an antiviral medication that is commonly used to treat TBE. It works by inhibiting the replication of the virus in the body and can help reduce the severity of symptoms. Acyclovir is usually given orally, and the dosage and duration of treatment depend on the severity of the infection.\n2. Corticosteroids: These drugs can help reduce inflammation in the brain and alleviate symptoms such as headache, fever, and confusion. Corticosteroids are usually given orally or intravenously, and the dosage and duration of treatment depend on the severity of the infection.\n3. Immunoglobulins: These drugs contain antibodies that can help neutralize the virus and reduce the severity of symptoms. Immunoglobulins are usually given intravenously, and the dosage and duration of treatment depend on the severity of the infection.\n4. Supportive care: In addition to medication, supportive care is important in managing TBE. This may include rest, hydration, and management of fever and pain.\nIt's important to note that the most effective treatment for TBE is early diagnosis and treatment, as the virus can cause significant damage to the brain and nervous system if left untreated. If you suspect you or someone you know has TBE, it's",
    "llama-2-7b-chat-hf_fact_raw": "1. Tick-borne Encephalitis (TBE) is a viral infection transmitted through the bite of an infected tick.\n2. Ribavirin is an antiviral medication used to treat TBE and can be given intravenously or orally.\n3. Acyclovir is an antiviral medication commonly used to treat TBE and is usually given orally.\n4. Corticosteroids are used to treat TBE to reduce inflammation in the brain and alleviate symptoms.\n5. Immunoglobulins containing antibodies for TBE are usually given intravenously.",
    "llama-2-7b-chat-hf_fact": [
      "Tick-borne Encephalitis (TBE) is a viral infection transmitted through the bite of an infected tick.",
      "Ribavirin is an antiviral medication used to treat TBE and can be given intravenously or orally.",
      "Acyclovir is an antiviral medication commonly used to treat TBE and is usually given orally.",
      "Corticosteroids are used to treat TBE to reduce inflammation in the brain and alleviate symptoms.",
      "Immunoglobulins containing antibodies for TBE are usually given intravenously."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Ribavirin is not used to treat TBE; instead, supportive care is the primary treatment for TBE.\n3. FALSE [correction]: Acyclovir is not used to treat TBE; it is used for herpes virus infections. There is no specific antiviral medication for TBE.\n4. TRUE [correction]: While there is no specific treatment for TBE, corticosteroids may be used in severe cases to reduce inflammation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with information on genome browsers for DNA shape annotations. There are several databases available that offer DNA shape annotations, each with its own unique features and capabilities. Here are some of the most popular genome browsers for DNA shape annotations:\n1. UCSC Genome Browser: The University of California, Santa Cruz (UCSC) Genome Browser is a widely used tool for exploring genomic data. It provides DNA shape annotations, including base pair resolution 3D structures, for a variety of organisms, including humans, mice, and worms. The browser allows users to visualize and interact with the genomic data, including zooming, panning, and searching for specific features.\n2. Ensembl Genome Browser: Ensembl is a comprehensive and integrated genomic resource that provides DNA shape annotations for a wide range of organisms. The Ensembl Genome Browser offers high-quality genomic data, including base pair resolution 3D structures, for many organisms. It also provides a variety of tools and features for exploring and analyzing the genomic data, including visualization, filtering, and searching.\n3. HMMER Genome Browser: HMMER is a genome browser that provides DNA shape annotations for a variety of organisms, including humans, mice, and worms. It uses hidden Markov models (HMMs) to predict the 3D structure of DNA, and it provides a variety of tools and features for exploring and analyzing the genomic data.\n4. ChromHMM Genome Browser: ChromHMM is a genome browser that provides DNA shape annotations for a variety of organisms, including humans, mice, and worms. It uses HMMs to predict the 3D structure of DNA, and it provides a variety of tools and features for exploring and analyzing the genomic data.\n5. PyMOL Genome Browser: PyMOL is a molecular visualization tool that can also be used as a genome browser. It provides DNA shape annotations, including base pair resolution 3D structures, for a variety of organisms. PyMOL offers a variety of tools and features for exploring and analyzing the genomic data, including visualization, filtering, and searching.\n6. IGB: The Integrative Genomics Viewer (IGB) is a genome browser",
    "llama-2-7b-chat-hf_fact_raw": "1. UCSC Genome Browser provides DNA shape annotations for various organisms including humans, mice, and worms.\n2. Ensembl Genome Browser offers DNA shape annotations and genomic data for a wide range of organisms.\n3. HMMER Genome Browser uses hidden Markov models to predict the 3D structure of DNA for several organisms.\n4. ChromHMM Genome Browser provides DNA shape annotations and uses HMMs for various organisms including humans, mice, and worms.\n5. PyMOL can be used as a genome browser and provides DNA shape annotations for multiple organisms.",
    "llama-2-7b-chat-hf_fact": [
      "UCSC Genome Browser provides DNA shape annotations for various organisms including humans, mice, and worms.",
      "Ensembl Genome Browser offers DNA shape annotations and genomic data for a wide range of organisms.",
      "HMMER Genome Browser uses hidden Markov models to predict the 3D structure of DNA for several organisms.",
      "ChromHMM Genome Browser provides DNA shape annotations and uses HMMs for various organisms including humans, mice, and worms.",
      "PyMOL can be used as a genome browser and provides DNA shape annotations for multiple organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: HMMER Genome Browser uses hidden Markov models to predict protein sequences, not the 3D structure of DNA.\n4. UNKNOWN\n5. FALSE [correction]: PyMOL is a molecular visualization system, not a genome browser, and does not provide DNA shape annotations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes for the enzyme enzyme histone methyltransferase 2 (EZH2), which plays a crucial role in regulating gene expression by modifying histone proteins. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Rubinstein-Taybi Syndrome (RTB): This is a rare genetic disorder caused by mutations in the EZH2 gene. It is characterized by developmental delays, intellectual disability, short stature, and distinctive facial features.\n2. Noonan Syndrome: This is a rare genetic disorder that affects the development of various systems in the body, including the heart, face, and limbs. Mutations in the EZH2 gene are a common cause of Noonan Syndrome.\n3. Cdkn2a/p16-mutated Melanoma: EZH2 mutations have been found to be associated with aggressive melanoma, a type of skin cancer.\n4. Hidradenitis Suppurativa (HS): HS is a chronic skin condition characterized by recurring abscesses and nodules, often in the apocrine gland-rich areas of the body. Mutations in the EZH2 gene have been identified in some cases of HS.\n5. Prostate Cancer: EZH2 mutations have been found to be associated with aggressive prostate cancer, particularly in cases with high Gleason scores.\n6. Breast Cancer: EZH2 mutations have been identified in some cases of breast cancer, particularly in basal-like breast cancer subtype.\n7. Osteosarcoma: EZH2 mutations have been found to be associated with osteosarcoma, a type of bone cancer.\n8. Malignant Gliomas: EZH2 mutations have been identified in some cases of malignant gliomas, including glioblastoma.\n9. Chronic Lymphocytic Leukemia (CLL): EZH2 mutations have been found to be associated with CLL, a type of blood cancer.\n10. Multiple Myeloma: EZH2 mutations have been identified in some",
    "llama-2-7b-chat-hf_fact_raw": "1. The EZH2 gene is associated with Rubinstein-Taybi Syndrome, which is characterized by developmental delays and distinctive facial features.\n2. Noonan Syndrome, which affects various systems in the body, is commonly caused by mutations in the EZH2 gene.\n3. Aggressive melanoma has been associated with mutations in the EZH2 gene.\n4. Mutations in the EZH2 gene have been identified in some cases of Hidradenitis Suppurativa, a chronic skin condition.\n5. EZH2 gene mutations are associated with aggressive prostate cancer, particularly in cases with high Gleason scores.",
    "llama-2-7b-chat-hf_fact": [
      "The EZH2 gene is associated with Rubinstein-Taybi Syndrome, which is characterized by developmental delays and distinctive facial features.",
      "Noonan Syndrome, which affects various systems in the body, is commonly caused by mutations in the EZH2 gene.",
      "Aggressive melanoma has been associated with mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene have been identified in some cases of Hidradenitis Suppurativa, a chronic skin condition.",
      "EZH2 gene mutations are associated with aggressive prostate cancer, particularly in cases with high Gleason scores."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The EZH2 gene is associated with Weaver syndrome, not Rubinstein-Taybi Syndrome.\n2. FALSE [correction]: Noonan Syndrome is commonly caused by mutations in the PTPN11 gene, not the EZH2 gene.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Certainly! Dimer-to-tetramer transition refers to the process by which a protein that exists as a dimer (a molecule composed of two identical subunits) converts into a tetramer (a molecule composed of four identical subunits). This transition can occur through various mechanisms, including protein-protein interactions, changes in pH or temperature, or the binding of small molecules. Here are some human proteins that are known to undergo dimer-to-tetramer transition:\n1. Hemoglobin: Hemoglobin is a protein in red blood cells that carries oxygen from the lungs to the body's tissues. It exists as a tetramer in its native state, but can undergo a dimer-to-tetramer transition in response to changes in pH or oxygen availability.\n2. Myoglobin: Myoglobin is a protein found in muscle cells that stores oxygen for use during exercise. Like hemoglobin, it exists as a tetramer in its native state but can undergo a dimer-to-tetramer transition in response to changes in pH or oxygen availability.\n3. Enolase: Enolase is an enzyme involved in glycolysis, the breakdown of glucose for energy production. It exists as a dimer in its native state but can undergo a dimer-to-tetramer transition in response to changes in pH or the presence of certain substrates.\n4. Pyruvate kinase: Pyruvate kinase is an enzyme involved in the final step of glycolysis, the conversion of pyruvate to acetyl-CoA. It exists as a dimer in its native state but can undergo a dimer-to-tetramer transition in response to changes in pH or the presence of certain substrates.\n5. Phosphofructokinase-1: Phosphofructokinase-1 is an enzyme involved in the first step of glycolysis, the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate. It exists as a dimer in its native state but can undergo a dimer-to-",
    "llama-2-7b-chat-hf_fact_raw": "1. Hemoglobin is a protein in human red blood cells that carries oxygen and can undergo a dimer-to-tetramer transition.\n2. Myoglobin is a protein found in human muscle cells that stores oxygen and can undergo a dimer-to-tetramer transition.\n3. Enolase is a human enzyme involved in glycolysis that can undergo a dimer-to-tetramer transition.\n4. Pyruvate kinase is a human enzyme involved in glycolysis that can undergo a dimer-to-tetramer transition.\n5. Phosphofructokinase-1 is a human enzyme involved in glycolysis that can undergo a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_fact": [
      "Hemoglobin is a protein in human red blood cells that carries oxygen and can undergo a dimer-to-tetramer transition.",
      "Myoglobin is a protein found in human muscle cells that stores oxygen and can undergo a dimer-to-tetramer transition.",
      "Enolase is a human enzyme involved in glycolysis that can undergo a dimer-to-tetramer transition.",
      "Pyruvate kinase is a human enzyme involved in glycolysis that can undergo a dimer-to-tetramer transition.",
      "Phosphofructokinase-1 is a human enzyme involved in glycolysis that can undergo a dimer-to-tetramer transition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Myoglobin is a protein found in muscle cells that stores oxygen but does not undergo a dimer-to-tetramer transition. It exists as a monomer.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Phospholamban (PLN) is a protein that plays a crucial role in the regulation of cardiac contractility and energy metabolism. PLN is a regulatory subunit of the Na+/Ca2+ exchanger (NCX), which is responsible for maintaining the proper balance of intracellular calcium ions (Ca2+) in cardiac muscle cells. PLN acts as a brake on the NCX, inhibiting its activity and allowing Ca2+ to enter the cell.\nSeveral proteins have been found to interact with PLN and have anti-apoptotic effects, meaning they help protect cells from undergoing programmed cell death (apoptosis). Here are some examples:\n1. Bcl-2: Bcl-2 (B-cell lymphoma 2) is a family of proteins that regulate apoptosis by modulating the permeability of the mitochondrial membrane to Ca2+. Bcl-2 proteins can bind to PLN and inhibit its interaction with the NCX, thereby protecting cells from apoptosis.\n2. Bcl-xL: Bcl-xL (B-cell lymphoma 2-associated protein X-linked) is a member of the Bcl-2 family that has been shown to interact with PLN and inhibit apoptosis in cardiac myocytes.\n3. AKT: AKT (protein kinase B) is a serine/threonine kinase that plays a key role in cell survival and metabolism. AKT has been shown to interact with PLN and promote its anti-apoptotic effects in cardiac myocytes.\n4. mTOR: mTOR (mechanistic target of rapamycin) is a key regulator of cell growth and metabolism. mTOR has been shown to interact with PLN and promote its anti-apoptotic effects in cardiac myocytes.\n5. PI3K: PI3K (phosphatidylinositol 3-kinase) is a lipid kinase that plays a key role in cell survival and metabolism. PI3K has been shown to interact with PLN and promote its anti-apoptotic effects in cardiac",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 proteins can bind to phospholamban (PLN) and inhibit its interaction with the Na+/Ca2+ exchanger (NCX).\n2. Bcl-xL is a member of the Bcl-2 family that interacts with PLN and inhibits apoptosis in cardiac myocytes.\n3. AKT is a serine/threonine kinase that interacts with PLN and promotes its anti-apoptotic effects in cardiac myocytes.\n4. mTOR is a regulator of cell growth and metabolism that interacts with PLN and promotes its anti-apoptotic effects in cardiac myocytes.\n5. PI3K is a lipid kinase that interacts with PLN and promotes its anti-apoptotic effects in cardiac myocytes.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 proteins can bind to phospholamban (PLN) and inhibit its interaction with the Na+/Ca2+ exchanger (NCX).",
      "Bcl-xL is a member of the Bcl-2 family that interacts with PLN and inhibits apoptosis in cardiac myocytes.",
      "AKT is a serine/threonine kinase that interacts with PLN and promotes its anti-apoptotic effects in cardiac myocytes.",
      "mTOR is a regulator of cell growth and metabolism that interacts with PLN and promotes its anti-apoptotic effects in cardiac myocytes.",
      "PI3K is a lipid kinase that interacts with PLN and promotes its anti-apoptotic effects in cardiac myocytes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements require specific scientific knowledge in the field of molecular biology and interactions among proteins and enzymes in cardiac myocytes. Without access to the relevant scientific literature or expertise, it is not possible to accurately determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that vitamin D supplementation can reduce the incidence of falls in older people in clinical trials. Here are some key findings from relevant studies:\n1. A 2014 meta-analysis published in the Journal of the American Geriatrics Society found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults. The meta-analysis included 13 randomized controlled trials involving over 12,000 participants.\n2. A 2019 Cochrane review found that vitamin D supplementation reduced the risk of falls in older people by 15% compared to placebo. The review included 21 randomized controlled trials involving over 16,000 participants.\n3. A 2017 study published in the Journal of Bone and Mineral Research found that vitamin D supplementation reduced the risk of falls in older adults with low baseline vitamin D levels. The study included 1,035 participants aged 65 years and older who were randomized to receive either vitamin D3 or placebo for 12 months.\n4. A 2018 study published in the Journal of Gerontology found that vitamin D supplementation improved balance and reduced the risk of falls in older adults with mobility limitations. The study included 160 participants aged 70 years and older who were randomized to receive either vitamin D3 or placebo for 12 months.\n5. A 2020 study published in the Journal of the American Medical Directors Association found that vitamin D supplementation reduced the risk of falls in older adults with cognitive impairment. The study included 100 participants aged 65 years and older who were randomized to receive either vitamin D3 or placebo for 12 months.\nIt's worth noting that while these studies suggest a potential benefit of vitamin D supplementation in reducing the risk of falls in older people, the evidence is not yet definitive. More research is needed to confirm these findings and to determine the optimal dosage and duration of vitamin D supplementation for fall prevention. Additionally, it's important to consult with a healthcare provider before starting any new supplement regimen.",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2014 meta-analysis in the Journal of the American Geriatrics Society associated vitamin D supplementation with a significant reduction in the risk of falls in older adults, with over 12,000 participants in the included trials.\n2. The 2019 Cochrane review found vitamin D supplementation reduced the risk of falls in older people by 15% versus placebo, analyzing 21 randomized controlled trials with over 16,000 participants.\n3. The 2017 study published in the Journal of Bone and Mineral Research found that older adults with low baseline vitamin D levels had reduced risk of falls when supplemented with vitamin D, including 1,035 participants.\n4. A 2018 study in the Journal of Gerontology reported that vitamin D supplementation improved balance and reduced falls in older adults with mobility limitations, involving 160 participants.\n5. The 2020 study in the Journal of the American Medical Directors Association showed vitamin D supplementation reduced fall risk in older adults with cognitive impairment, based on data from 100 participants.",
    "llama-2-7b-chat-hf_fact": [
      "A 2014 meta-analysis in the Journal of the American Geriatrics Society associated vitamin D supplementation with a significant reduction in the risk of falls in older adults, with over 12,000 participants in the included trials.",
      "The 2019 Cochrane review found vitamin D supplementation reduced the risk of falls in older people by 15% versus placebo, analyzing 21 randomized controlled trials with over 16,000 participants.",
      "The 2017 study published in the Journal of Bone and Mineral Research found that older adults with low baseline vitamin D levels had reduced risk of falls when supplemented with vitamin D, including 1,035 participants.",
      "A 2018 study in the Journal of Gerontology reported that vitamin D supplementation improved balance and reduced falls in older adults with mobility limitations, involving 160 participants.",
      "The 2020 study in the Journal of the American Medical Directors Association showed vitamin D supplementation reduced fall risk in older adults with cognitive impairment, based on data from 100 participants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\nJarid2 (Jumonji H3-like 2) is a histone H3 lysine 9-specific demethylase that plays a crucial role in regulating the epigenetic landscape of various cell types, including T cells. Th17 cells are a subtype of T cells that are involved in the immune response and are known to play a role in the development of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.\nStudies have shown that Jarid2 is highly expressed in Th17 cells and plays a critical role in regulating the expression of miR-155, a microRNA that is known to be involved in the regulation of Th17 cell differentiation and function. Specifically, Jarid2 has been shown to demethylate the promoter region of the miR-155 gene, leading to its activation and the subsequent upregulation of miR-155 expression.\nmiR-155, in turn, plays a critical role in regulating the expression of genes involved in Th17 cell differentiation and function, including the transcription factors retinoic acid-related orphan receptor gamma t (Rorgt) and interleukin-21 (Il21). miR-155 also regulates the expression of genes involved in the production of pro-inflammatory cytokines, such as interleukin-17 (Il17) and tumor necrosis factor-alpha (Tnfa).\nIn addition, Jarid2 has been shown to regulate the expression of genes involved in the maintenance of Th17 cell homeostasis, including the cell surface receptor CD40 ligand (CD40L).\nOverall, the association between Jarid2 and miR-155 in Th17 cells is complex and involves the regulation of multiple genes involved in Th17 cell differentiation, function, and homeostasis. Understanding the molecular mechanisms underlying this association may provide insights into the development of new therapeutic strategies for the treatment of autoimmune diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone H3 lysine 9-specific demethylase that regulates the epigenetic landscape of T cells.\n2. Th17 cells are a subtype of T cells involved in immune responses and autoimmune diseases like multiple sclerosis and rheumatoid arthritis.\n3. Jarid2 is highly expressed in Th17 cells and regulates the expression of miR-155 by demethylating its gene promoter region.\n4. miR-155 regulates the expression of genes involved in Th17 cell differentiation and function, such as Rorgt and Il21.\n5. Jarid2 also regulates the expression of genes involved in Th17 cell homeostasis, including CD40 ligand (CD40L).",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone H3 lysine 9-specific demethylase that regulates the epigenetic landscape of T cells.",
      "Th17 cells are a subtype of T cells involved in immune responses and autoimmune diseases like multiple sclerosis and rheumatoid arthritis.",
      "Jarid2 is highly expressed in Th17 cells and regulates the expression of miR-155 by demethylating its gene promoter region.",
      "miR-155 regulates the expression of genes involved in Th17 cell differentiation and function, such as Rorgt and Il21.",
      "Jarid2 also regulates the expression of genes involved in Th17 cell homeostasis, including CD40 ligand (CD40L)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone demethylase but a regulatory protein that can recruit the Polycomb Repressive Complex 2 (PRC2) to chromatin, which impacts histone methylation.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human HoxD cluster contains 8 genes. The Hox genes are a group of homeobox-containing genes that play a crucial role in the development and patterning of the embryo. The HoxD cluster is located on chromosome 2 and consists of the following genes:\n1. HOXD1\n2. HOXD2\n3. HOXD3\n4. HOXD4\n5. HOXD5\n6. HOXD6\n7. HOXD7\n8. HOXD8\nEach of these genes encodes a protein that contains a homeobox domain, a conserved DNA-binding motif that is involved in the regulation of gene expression. The HoxD genes are expressed in a specific order along the anteroposterior (head-tail) axis of the embryo, with each gene being active at a specific stage of development. This sequential activation of Hox genes is thought to be responsible for the establishment of the body plan during embryonic development.\nIn addition to their role in development, the HoxD genes have also been implicated in the development of certain cancers, such as leukemia and breast cancer. Mutations in these genes can lead to the misregulation of gene expression, which can contribute to the development of cancer.\nOverall, the human HoxD cluster contains 8 genes that play a critical role in the development and patterning of the embryo, and their dysregulation can have serious consequences for human health.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human HoxD cluster contains 8 genes.\n2. The Hox genes are important in the development and patterning of the embryo.\n3. The HoxD cluster is located on chromosome 2.\n4. Each HoxD gene encodes a protein containing a homeobox domain.\n5. Mutations in HoxD genes can contribute to the development of cancers such as leukemia and breast cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The human HoxD cluster contains 8 genes.",
      "The Hox genes are important in the development and patterning of the embryo.",
      "The HoxD cluster is located on chromosome 2.",
      "Each HoxD gene encodes a protein containing a homeobox domain.",
      "Mutations in HoxD genes can contribute to the development of cancers such as leukemia and breast cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HoxD cluster contains 9 genes.\n2. TRUE\n3. FALSE [correction]: The HoxD cluster is located on chromosome 2 in mice, but in humans, it is located on chromosome 17.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and gene expression. Phosphorylation of CK1 by other kinases can regulate its activity, localization, and interactions with other proteins. Here are some common phosphorylation consensus motifs found in CK1:\n1. Thr-Gly-Thr (TGT) sequence: This is a conserved consensus motif for CK1 phosphorylation, found in the activation loop of the enzyme. Thr-Gly-Thr phosphorylation is known to activate CK1, and it is mediated by various kinases, including CK1 itself.\n2. Ser-Gly-X-Ser/Thr (SGS) sequence: This consensus motif is found in the substrate-binding site of CK1 and is important for the enzyme's catalytic activity. SGS phosphorylation can regulate CK1's substrate specificity and activity.\n3. Thr-X-Tyr (TXY) sequence: This consensus motif is found in the C-terminal region of CK1 and is involved in protein-protein interactions. Thr-X-Tyr phosphorylation can modulate CK1's interactions with other proteins and affect its localization and activity.\n4. Ser-X-Gly (SXG) sequence: This consensus motif is found in the N-terminal region of CK1 and is involved in protein-protein interactions. Ser-X-Gly phosphorylation can regulate CK1's interactions with other proteins and affect its localization and activity.\n5. Pro-X-X-Pro (PXP) sequence: This consensus motif is found in the C-terminal region of CK1 and is involved in protein-protein interactions. Pro-X-X-Pro phosphorylation can modulate CK1's interactions with other proteins and affect its localization and activity.\n6. Thr-X-Ser/Thr (TXS) sequence: This consensus motif is found in the substrate-binding site of",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine protein kinase.\n2. Thr-Gly-Thr (TGT) is a conserved consensus motif for CK1 phosphorylation, located in the enzyme's activation loop.\n3. Ser-Gly-X-Ser/Thr (SGS) is a consensus motif found in CK1's substrate-binding site.\n4. Thr-X-Tyr (TXY) is a consensus motif found in the C-terminal region of CK1, involved in protein-protein interactions.\n5. Pro-X-X-Pro (PXP) is a consensus motif found in the C-terminal region of CK1, also involved in protein-protein interactions.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine protein kinase.",
      "Thr-Gly-Thr (TGT) is a conserved consensus motif for CK1 phosphorylation, located in the enzyme's activation loop.",
      "Ser-Gly-X-Ser/Thr (SGS) is a consensus motif found in CK1's substrate-binding site.",
      "Thr-X-Tyr (TXY) is a consensus motif found in the C-terminal region of CK1, involved in protein-protein interactions.",
      "Pro-X-X-Pro (PXP) is a consensus motif found in the C-terminal region of CK1, also involved in protein-protein interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Ser-X-X-Ser/Thr (SXXS/T) is a conserved consensus motif for CK1 phosphorylation, located in the enzyme's activation loop.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes several different proteins/isoforms, including:\n1. Aspartate beta-hydroxylase (ASPH): This is the primary isoform encoded by the ASPH gene, and it plays a crucial role in the biosynthesis of the neurotransmitters serotonin and dopamine. Aspartate beta-hydroxylase is a key enzyme in the rate-limiting step of the tryptophan biosynthesis pathway, converting L-tryptophan to 5-hydroxytryptophan (5-HTP).\n2. 5-Hydroxytryptophan (5-HTP): 5-HTP is an amino acid that is produced from L-tryptophan by the action of aspartate beta-hydroxylase. It is a precursor to the neurotransmitters serotonin and melatonin, and it has been shown to have antidepressant and anxiolytic effects in some studies.\n3. Serotonin (5-HT): Serotonin is a neurotransmitter that is produced from 5-HTP by the action of the enzyme aromatic amino acid decarboxylase (AADC). Serotonin is involved in a wide range of physiological and psychological processes, including mood regulation, appetite, and sleep.\n4. Melatonin: Melatonin is a hormone that is produced from 5-HTP by the action of the enzyme melatonin synthase (MTN). Melatonin is involved in the regulation of sleep-wake cycles and has been shown to have antioxidant and anti-inflammatory effects.\n5. Prolactin: Prolactin is a hormone that is produced from the ASPH gene in response to stress and other stimuli. It plays a role in the regulation of lactation and has been implicated in a variety of physiological and psychological processes, including mood regulation and immune function.\n6. Osteopontin: Osteopontin is a protein that is produced from the ASPH gene in response",
    "llama-2-7b-chat-hf_fact_raw": "1. The primary isoform encoded by the ASPH gene is aspartate beta-hydroxylase.\n2. Aspartate beta-hydroxylase is involved in converting L-tryptophan to 5-hydroxytryptophan (5-HTP).\n3. 5-Hydroxytryptophan (5-HTP) is an amino acid precursor to the neurotransmitters serotonin and melatonin.\n4. Serotonin is produced from 5-HTP by the action of the enzyme aromatic amino acid decarboxylase (AADC).\n5. Melatonin is produced from 5-HTP by the action of the enzyme melatonin synthase (MTN).",
    "llama-2-7b-chat-hf_fact": [
      "The primary isoform encoded by the ASPH gene is aspartate beta-hydroxylase.",
      "Aspartate beta-hydroxylase is involved in converting L-tryptophan to 5-hydroxytryptophan (5-HTP).",
      "5-Hydroxytryptophan (5-HTP) is an amino acid precursor to the neurotransmitters serotonin and melatonin.",
      "Serotonin is produced from 5-HTP by the action of the enzyme aromatic amino acid decarboxylase (AADC).",
      "Melatonin is produced from 5-HTP by the action of the enzyme melatonin synthase (MTN)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Aspartate beta-hydroxylase is involved in the hydroxylation of aspartyl and asparaginyl residues in proteins, not in converting L-tryptophan to 5-HTP.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Melatonin is produced from serotonin, not directly from 5-HTP, by the action of the enzymes serotonin N-acetyltransferase and O-methyltransferase.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin, also known as Jardiance, is a medication used to treat type 2 diabetes. It was approved by the US Food and Drug Administration (FDA) in 2014.\nEmpagliflozin was approved on July 8, 2014, by the FDA for the treatment of adults with type 2 diabetes to improve glycemic control, which is the ability of the body to regulate blood sugar levels. It was approved based on the results of clinical trials that demonstrated its safety and effectiveness in lowering blood sugar levels and improving glycemic control in people with type 2 diabetes.\nSince its approval, empagliflozin has become a widely used medication for the treatment of type 2 diabetes, and it is available in a variety of formulations, including tablets, oral suspensions, and injectable forms. It is important to note that empagliflozin is not approved for the treatment of type 1 diabetes or diabetic ketoacidosis, and it should only be used under the guidance of a healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin is a medication used to treat type 2 diabetes.\n2. The US Food and Drug Administration (FDA) approved Empagliflozin in 2014.\n3. The FDA approved Empagliflozin specifically on July 8, 2014.\n4. Empagliflozin was approved for improving glycemic control in adults with type 2 diabetes.\n5. Empagliflozin is not approved for the treatment of type 1 diabetes or diabetic ketoacidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin is a medication used to treat type 2 diabetes.",
      "The US Food and Drug Administration (FDA) approved Empagliflozin in 2014.",
      "The FDA approved Empagliflozin specifically on July 8, 2014.",
      "Empagliflozin was approved for improving glycemic control in adults with type 2 diabetes.",
      "Empagliflozin is not approved for the treatment of type 1 diabetes or diabetic ketoacidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The FDA approved Empagliflozin specifically on August 1, 2014.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Lon1 is a protein that plays a crucial role in the DNA damage response pathway in plants. In Arabidopsis, loss of the Lon1 protein has been shown to have significant effects on plant growth and development. Here are some of the key results of loss of Lon1 in Arabidopsis:\n1. Increased sensitivity to DNA-damaging agents: Lon1 is involved in the repair of DNA double-strand breaks, and loss of the protein leads to increased sensitivity to DNA-damaging agents such as ionizing radiation and certain chemotherapeutic drugs. Plants lacking Lon1 are more susceptible to DNA damage and are more likely to undergo genetic instability and mutations.\n2. Delayed growth and development: Lon1 is required for the proper progression of cell division and differentiation in Arabidopsis. Loss of Lon1 leads to delayed growth and development, including delayed flowering and reduced plant height.\n3. Changes in gene expression: Lon1 regulates the expression of a number of genes involved in DNA repair, cell cycle regulation, and apoptosis. Loss of Lon1 leads to changes in the expression of these genes, which can result in altered plant phenotypes.\n4. Increased oxidative stress: Lon1 has been shown to play a role in protecting against oxidative stress in Arabidopsis. Loss of Lon1 leads to increased sensitivity to oxidative stress, as evidenced by increased levels of reactive oxygen species (ROS) and lipid peroxidation.\n5. Altered cellular structure: Lon1 is involved in the regulation of cellular structure and organization in Arabidopsis. Loss of Lon1 leads to alterations in the organization of the endoplasmic reticulum and the Golgi apparatus, as well as changes in the distribution of certain organelles.\n6. Impaired nutrient uptake and utilization: Lon1 is involved in the regulation of nutrient uptake and utilization in Arabidopsis. Loss of Lon1 leads to impaired nutrient uptake and utilization, as well as changes in the expression of genes involved in nutrient transport and metabolism.\n7. Changes in horm",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1 is involved in the repair of DNA double-strand breaks in Arabidopsis.\n2. Loss of Lon1 protein in Arabidopsis leads to increased sensitivity to DNA-damaging agents.\n3. Arabidopsis plants lacking Lon1 experience delayed growth and development.\n4. Loss of Lon1 protein in Arabidopsis results in increased oxidative stress.\n5. Loss of Lon1 leads to alterations in the organization of the endoplasmic reticulum and the Golgi apparatus in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1 is involved in the repair of DNA double-strand breaks in Arabidopsis.",
      "Loss of Lon1 protein in Arabidopsis leads to increased sensitivity to DNA-damaging agents.",
      "Arabidopsis plants lacking Lon1 experience delayed growth and development.",
      "Loss of Lon1 protein in Arabidopsis results in increased oxidative stress.",
      "Loss of Lon1 leads to alterations in the organization of the endoplasmic reticulum and the Golgi apparatus in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can confirm that there is no direct evidence of a linker histone in the yeast genome. Histones are small, positively charged proteins that play a crucial role in compacting and organizing DNA into nucleosomes, which are the building blocks of chromatin. In eukaryotic cells, including yeast, there are five main histone proteins: histones H2A, H2B, H3, and H4.\nHowever, there are some studies that have suggested the presence of a linker histone in yeast. A linker histone is a hypothetical protein that is thought to connect the nucleosomes and play a role in the higher-level organization of chromatin. While there is no direct evidence of a linker histone in the yeast genome, some studies have suggested that it may be present in a modified form.\nFor example, a study published in the journal Nature in 2013 found that the yeast H3 protein contains a conserved region that is similar to the linker histone of metazoans. This region, called the H3-K56ac domain, is found in the H3 protein of yeast and is enriched in regions of the genome that are involved in transcriptional regulation. The authors of the study suggested that this domain may play a role in connecting nucleosomes and organizing chromatin in a way that is similar to the function of linker histones in metazoans.\nAnother study published in the journal Cell in 2017 found that the yeast H3 protein is modified by the addition of a methyl group at position K4, which is a modification that is typically associated with linker histones in metazoans. This modification was found to be enriched in regions of the genome that are involved in transcriptional regulation, and the authors of the study suggested that it may play a role in organizing chromatin in a way that is similar to the function of linker histones.\nWhile these studies suggest that there may be some similarity between the histone proteins of yeast and linker histones in other organisms, there is currently no direct evidence of a linker histone in the yeast genome. Further research is needed to fully understand the role of histones in organizing chromatin in yeast and other eukaryotic cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no direct evidence of a linker histone in the yeast genome.\n2. Yeast, as a eukaryotic cell, has five main histone proteins: histones H2A, H2B, H3, and H4.\n3. A study published in Nature in 2013 found a conserved region in the yeast H3 protein similar to the linker histone of metazoans.\n4. The H3-K56ac domain in the yeast H3 protein is enriched in regions involved in transcriptional regulation.\n5. A study in Cell in 2017 found that the yeast H3 protein is modified by the addition of a methyl group at position K4.",
    "llama-2-7b-chat-hf_fact": [
      "There is no direct evidence of a linker histone in the yeast genome.",
      "Yeast, as a eukaryotic cell, has five main histone proteins: histones H2A, H2B, H3, and H4.",
      "A study published in Nature in 2013 found a conserved region in the yeast H3 protein similar to the linker histone of metazoans.",
      "The H3-K56ac domain in the yeast H3 protein is enriched in regions involved in transcriptional regulation.",
      "A study in Cell in 2017 found that the yeast H3 protein is modified by the addition of a methyl group at position K4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Yeast, as a eukaryotic cell, has four main histone proteins: histones H2A, H2B, H3, and H4. \n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can help lower cholesterol levels. Here are some studies and findings that support this claim:\n1. A 2013 study published in the Journal of Functional Foods found that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL (\"bad\") cholesterol levels in healthy adults. The study involved 40 participants who were randomly assigned to drink either tomato juice or a placebo.\n2. A 2011 study published in the European Journal of Nutrition found that drinking tomato juice for 6 weeks reduced LDL cholesterol levels by 10% in healthy adults. The study involved 20 participants who were given either tomato juice or a placebo.\n3. A 2009 study published in the Journal of Agricultural and Food Chemistry found that lycopene, the antioxidant found in tomatoes, can help lower cholesterol levels by inhibiting the absorption of dietary cholesterol in the gut. The study found that lycopene reduced cholesterol absorption by 30% in healthy adults.\n4. A 2016 review of 14 studies on the effects of tomato juice on cholesterol levels published in the Journal of Food Science and Technology found that tomato juice consumption was associated with significant reductions in total cholesterol, LDL cholesterol, and triglycerides. The review concluded that tomato juice may be a useful adjunct to traditional cholesterol-lowering therapies.\n5. A 2018 study published in the Journal of Nutrition and Metabolism found that drinking tomato juice for 8 weeks improved insulin sensitivity and reduced inflammation in healthy adults. The study involved 40 participants who were randomly assigned to drink either tomato juice or a placebo.\nIt's important to note that while these studies suggest that tomato juice may help lower cholesterol levels, the evidence is not yet conclusive. More research is needed to fully understand the effects of tomato juice on cholesterol levels and overall cardiovascular health. Additionally,",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2013 study in the Journal of Functional Foods reported that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.\n2. A 2011 study in the European Journal of Nutrition found that drinking tomato juice for 6 weeks reduced LDL cholesterol levels by 10% in healthy adults.\n3. A 2009 study in the Journal of Agricultural and Food Chemistry discovered that lycopene from tomatoes can lower cholesterol levels by inhibiting dietary cholesterol absorption.\n4. A 2016 review of 14 studies published in the Journal of Food Science and Technology found tomato juice consumption associated with significant reductions in total cholesterol, LDL cholesterol, and triglycerides.\n5. A 2018 study in the Journal of Nutrition and Metabolism observed that drinking tomato juice for 8 weeks improved insulin sensitivity and reduced inflammation in healthy adults.",
    "llama-2-7b-chat-hf_fact": [
      "A 2013 study in the Journal of Functional Foods reported that drinking tomato juice for 12 weeks significantly reduced total cholesterol and LDL cholesterol levels in healthy adults.",
      "A 2011 study in the European Journal of Nutrition found that drinking tomato juice for 6 weeks reduced LDL cholesterol levels by 10% in healthy adults.",
      "A 2009 study in the Journal of Agricultural and Food Chemistry discovered that lycopene from tomatoes can lower cholesterol levels by inhibiting dietary cholesterol absorption.",
      "A 2016 review of 14 studies published in the Journal of Food Science and Technology found tomato juice consumption associated with significant reductions in total cholesterol, LDL cholesterol, and triglycerides.",
      "A 2018 study in the Journal of Nutrition and Metabolism observed that drinking tomato juice for 8 weeks improved insulin sensitivity and reduced inflammation in healthy adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are two proteins that play important roles in regulating mRNA stability in cells. Here's a detailed explanation of how they work:\nHsp70:\nHsp70 is a molecular chaperone that helps to protect cells from stress by maintaining protein homeostasis. It can also play a role in regulating mRNA stability by interacting with the 3' untranslated region (UTR) of target mRNAs. Hsp70 can bind to the 3' UTR of mRNAs and prevent the degradation of these mRNAs by inhibiting the activity of the RNA-degrading enzyme, ribonuclease. This can lead to an increase in the stability of the mRNAs and a subsequent increase in protein production.\nHsp110:\nHsp110 is another molecular chaperone that plays a role in regulating mRNA stability. Unlike Hsp70, Hsp110 does not directly bind to the 3' UTR of mRNAs, but instead works by inhibiting the activity of the RNA-degrading enzyme, ribonuclease. Hsp110 can bind to ribonuclease and prevent it from degrading mRNAs, leading to an increase in mRNA stability.\nBoth Hsp70 and Hsp110 can also regulate mRNA stability by modulating the translation of mRNAs. Hsp70 can bind to the 5' cap of mRNAs and prevent the initiation of translation, while Hsp110 can bind to the 3' UTR of mRNAs and inhibit the termination of translation. By regulating translation, these chaperones can also affect the stability of mRNAs.\nIn addition to their direct effects on mRNA stability, Hsp70 and Hsp110 can also regulate mRNA stability by modulating the activity of other proteins that are involved in mRNA degradation. For example, Hsp70 can bind to the RNA-degrading enzyme, ribonuclease, and prevent it from degrading mRNAs.\nOverall, Hsp70 and",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 is a molecular chaperone that interacts with the 3' untranslated region (UTR) of target mRNAs.\n2. Hsp70 inhibits the activity of the RNA-degrading enzyme, ribonuclease, leading to increased mRNA stability.\n3. Hsp110 is a molecular chaperone that inhibits the activity of ribonuclease, preventing mRNA degradation.\n4. Hsp70 can bind to the 5' cap of mRNAs and prevent the initiation of translation.\n5. Hsp110 can bind to the 3' UTR of mRNAs and inhibit the termination of translation.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 is a molecular chaperone that interacts with the 3' untranslated region (UTR) of target mRNAs.",
      "Hsp70 inhibits the activity of the RNA-degrading enzyme, ribonuclease, leading to increased mRNA stability.",
      "Hsp110 is a molecular chaperone that inhibits the activity of ribonuclease, preventing mRNA degradation.",
      "Hsp70 can bind to the 5' cap of mRNAs and prevent the initiation of translation.",
      "Hsp110 can bind to the 3' UTR of mRNAs and inhibit the termination of translation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hsp70 does not inhibit ribonuclease activity; its function is to assist in the correct folding of proteins.\n3. UNKNOWN\n4. FALSE [correction]: Hsp70 binds to nascent polypeptide chains and partially folded proteins, not to the 5' cap of mRNAs.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in the regulation of thyroid hormone metabolism. There are three isoforms of deiodinases found in skeletal muscle:\n1. Type 1 deiodinase (D1): This is the most abundant form of deiodinase in skeletal muscle, accounting for approximately 70% of total deiodinase activity. D1 is responsible for converting T4 to T3 within muscle cells, and it is the primary enzyme involved in the regulation of local T3 levels.\n2. Type 2 deiodinase (D2): D2 is less abundant than D1 in skeletal muscle, but it still plays a significant role in the regulation of T3 levels. D2 is responsible for converting both T4 and T3 to reverse T3 (rT3), which can inhibit the activity of T3.\n3. Type 3 deiodinase (D3): D3 is the least abundant form of deiodinase in skeletal muscle, but it has been shown to play a role in the regulation of T3 levels in certain tissues, including muscle. D3 is responsible for converting T4 to T3, but it is less efficient than D1 at this conversion.\nThe expression of these deiodinases in skeletal muscle is regulated by a variety of factors, including thyroid hormone levels, nutrient availability, and exercise. For example, exercise has been shown to increase the expression of D1 in skeletal muscle, which can enhance the conversion of T4 to T3 and improve muscle function.\nIn summary, the three deiodinases present in skeletal muscle are D1, D2, and D3. These enzymes play a crucial role in regulating the levels of T3 in muscle cells, and their expression is regulated by a variety of factors. Understanding the regulation of deiodinases in skeletal muscle is important for understanding the mechanisms of thyroid hormone action and how they impact muscle function.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are three isoforms of deiodinases found in skeletal muscle: Type 1 (D1), Type 2 (D2), and Type 3 (D3).\n2. Type 1 deiodinase (D1) accounts for approximately 70% of total deiodinase activity in skeletal muscle.\n3. D1 enzyme is responsible for converting T4 to T3 within muscle cells.\n4. Type 2 deiodinase (D2) is less abundant than D1 in skeletal muscle and is responsible for converting both T4 and T3 to reverse T3 (rT3).\n5. Exercise has been shown to increase the expression of D1 deiodinase in skeletal muscle.",
    "llama-2-7b-chat-hf_fact": [
      "There are three isoforms of deiodinases found in skeletal muscle: Type 1 (D1), Type 2 (D2), and Type 3 (D3).",
      "Type 1 deiodinase (D1) accounts for approximately 70% of total deiodinase activity in skeletal muscle.",
      "D1 enzyme is responsible for converting T4 to T3 within muscle cells.",
      "Type 2 deiodinase (D2) is less abundant than D1 in skeletal muscle and is responsible for converting both T4 and T3 to reverse T3 (rT3).",
      "Exercise has been shown to increase the expression of D1 deiodinase in skeletal muscle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Certainly! Inflammatory caspase proteins are a subfamily of caspases that play a crucial role in the regulation of inflammation. Here are some of the key inflammatory caspase proteins:\n1. Caspase-1 (also known as interleukin-1 beta converting enzyme, or ICE): Caspase-1 is a cytosolic caspase that is activated in response to pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α). Activated caspase-1 processes these cytokines to their active forms, which then trigger an inflammatory response.\n2. Caspase-4 (also known as macrophage inflammatory protein-1 alpha, or MIP-1α): Caspase-4 is a cytosolic caspase that is primarily expressed in immune cells, such as macrophages and T cells. Activated caspase-4 processes the cytokine tumor necrosis factor-alpha (TNF-α) and also plays a role in the regulation of apoptosis.\n3. Caspase-5 (also known as FLICE-inhibitory protein, or FLIP): Caspase-5 is a cytosolic caspase that is primarily expressed in T cells and natural killer cells. Activated caspase-5 inhibits the activity of other caspases, such as caspase-8, and plays a role in the regulation of apoptosis.\n4. Caspase-6 (also known as FLICE-associated protein, or FLAP): Caspase-6 is a cytosolic caspase that is primarily expressed in immune cells, such as T cells and macrophages. Activated caspase-6 processes the cytokine tumor necrosis factor-alpha (TNF-α) and also plays a role in the regulation of apoptosis.\n5. Caspase-7 (also known as apoptosis-related cysteine peptidase, or ARC): Caspase-7 is a cytosolic cas",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is also known as interleukin-1 beta converting enzyme (ICE).\n2. Caspase-4 is also known as macrophage inflammatory protein-1 alpha (MIP-1α).\n3. Caspase-5 is also known as FLICE-inhibitory protein (FLIP).\n4. Caspase-6 is also known as FLICE-associated protein (FLAP).\n5. Caspase-7 is also known as apoptosis-related cysteine peptidase (ARC).",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is also known as interleukin-1 beta converting enzyme (ICE).",
      "Caspase-4 is also known as macrophage inflammatory protein-1 alpha (MIP-1α).",
      "Caspase-5 is also known as FLICE-inhibitory protein (FLIP).",
      "Caspase-6 is also known as FLICE-associated protein (FLAP).",
      "Caspase-7 is also known as apoptosis-related cysteine peptidase (ARC)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-4 is not known as macrophage inflammatory protein-1 alpha (MIP-1α); it is known as Caspase-11 in mice.\n3. FALSE [correction]: Caspase-8 is also known as FLICE-inhibitory protein (FLIP), not Caspase-5.\n4. FALSE [correction]: Caspase-6 is not known as FLICE-associated protein (FLAP); FLAP is associated with Caspase-8.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a known link between Aurora B kinase and Polycomb protein Ring1B. Both of these proteins play important roles in the regulation of cellular processes, including cell division and gene expression, and they have been shown to interact and coordinate their functions in various ways.\nAurora B kinase is a serine/threonine kinase that is involved in the regulation of mitosis, the process by which a cell divides into two daughter cells. It is a key component of the spindle checkpoint, which ensures that cells only enter mitosis when the chromosomes are properly aligned and attached to the spindle fibers. Aurora B kinase is also involved in the regulation of chromosome segregation and the formation of the spindle apparatus.\nPolycomb protein Ring1B, on the other hand, is a transcriptional repressor that is involved in the regulation of gene expression, particularly during cell differentiation and development. It is a member of the Polycomb group (PcG) protein family, which are involved in the maintenance of gene silencing through the modification of histone proteins. Ring1B is specifically involved in the regulation of genes involved in cell cycle progression and DNA repair.\nStudies have shown that Aurora B kinase and Ring1B interact and coordinate their functions in various ways. For example, Aurora B kinase has been shown to phosphorylate and activate Ring1B, which leads to the repression of target genes involved in cell cycle progression. Conversely, Ring1B has been shown to inhibit the activity of Aurora B kinase, which can lead to the premature separation of chromosomes during mitosis.\nAdditionally, both Aurora B kinase and Ring1B have been implicated in the development and progression of cancer. Aurora B kinase has been shown to be overexpressed in various types of cancer, including breast, ovarian, and lung cancer, and has been linked to the development of resistance to chemotherapy. Ring1B, on the other hand, has been shown to be downregulated in many types of cancer, and its loss has been linked to the development of cancer.\nIn summary, there is a clear link between Aurora B kinase and Polycomb protein Ring1B, as they interact and coordinate",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and Polycomb protein Ring1B are known to interact and coordinate their functions in cellular processes.\n2. Aurora B kinase is involved in the regulation of mitosis and is a key component of the spindle checkpoint.\n3. Polycomb protein Ring1B is a transcriptional repressor involved in the regulation of gene expression during cell differentiation and development.\n4. Aurora B kinase has been shown to phosphorylate and activate Ring1B.\n5. Both Aurora B kinase and Ring1B have been implicated in the development and progression of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and Polycomb protein Ring1B are known to interact and coordinate their functions in cellular processes.",
      "Aurora B kinase is involved in the regulation of mitosis and is a key component of the spindle checkpoint.",
      "Polycomb protein Ring1B is a transcriptional repressor involved in the regulation of gene expression during cell differentiation and development.",
      "Aurora B kinase has been shown to phosphorylate and activate Ring1B.",
      "Both Aurora B kinase and Ring1B have been implicated in the development and progression of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates refer to the variations in the nucleotide sequences surrounding the splice sites that are not part of the consensus splice site sequences. These motifs can play important roles in the splicing process and have been implicated in various diseases. Here are some of the most frequent non-canonical sequence motifs found at the donor and acceptor splice sites in vertebrates:\nDonor Splice Site Motifs:\n1. GU-rich sequences: GU-rich sequences are found upstream of the donor splice site and are characterized by a high content of purine (G) and pyrimidine (C) nucleotides. These sequences are thought to act as a binding site for the spliceosome and enhance the recognition of the donor splice site. Examples of GU-rich sequences include the GT-rich sequences found in the introns of the human genes encoding the proteins IRF5 and IRF7.\n2. AG-rich sequences: AG-rich sequences are found downstream of the donor splice site and are characterized by a high content of adenine (A) and guanine (G) nucleotides. These sequences are thought to act as a binding site for the spliceosome and enhance the recognition of the donor splice site. Examples of AG-rich sequences include the AG-rich sequences found in the introns of the human genes encoding the proteins KRAS and BRAF.\n3. UG-rich sequences: UG-rich sequences are found upstream of the donor splice site and are characterized by a high content of uridine (U) and guanine (G) nucleotides. These sequences are thought to act as a binding site for the spliceosome and enhance the recognition of the donor splice site. Examples of UG-rich sequences include the UG-rich sequences found in the introns of the human genes encoding the proteins TP53 and BRCA1.\n4. G-rich sequences: G-rich sequences are found downstream of the donor splice site and are characterized by a high content of guanine (G) nucleotides. These sequences are thought to act as a",
    "llama-2-7b-chat-hf_fact_raw": "1. Non-canonical sequence motifs at donor and acceptor splice sites in vertebrates are variations in nucleotide sequences that are not part of consensus splice site sequences.\n2. GU-rich sequences upstream of the donor splice site in vertebrates are characterized by a high content of purine (G) and pyrimidine (C) nucleotides and are thought to act as a binding site for the spliceosome.\n3. AG-rich sequences downstream of the donor splice site in vertebrates are characterized by a high content of adenine (A) and guanine (G) nucleotides and are thought to act as a binding site for the spliceosome.\n4. UG-rich sequences upstream of the donor splice site in vertebrates are characterized by a high content of uridine (U) and guanine (G) nucleotides and are thought to act as a binding site for the spliceosome.\n5. G-rich sequences downstream of the donor splice site in vertebrates are characterized by a high content of guanine (G) nucleotides.",
    "llama-2-7b-chat-hf_fact": [
      "Non-canonical sequence motifs at donor and acceptor splice sites in vertebrates are variations in nucleotide sequences that are not part of consensus splice site sequences.",
      "GU-rich sequences upstream of the donor splice site in vertebrates are characterized by a high content of purine (G) and pyrimidine (C) nucleotides and are thought to act as a binding site for the spliceosome.",
      "AG-rich sequences downstream of the donor splice site in vertebrates are characterized by a high content of adenine (A) and guanine (G) nucleotides and are thought to act as a binding site for the spliceosome.",
      "UG-rich sequences upstream of the donor splice site in vertebrates are characterized by a high content of uridine (U) and guanine (G) nucleotides and are thought to act as a binding site for the spliceosome.",
      "G-rich sequences downstream of the donor splice site in vertebrates are characterized by a high content of guanine (G) nucleotides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GU-rich sequences upstream of the donor splice site in vertebrates are characterized by a high content of guanine (G) and uridine (U) nucleotides, not purine (G) and pyrimidine (C) nucleotides, and are thought to act as a binding site for the spliceosome.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "S6K1 (Serine/Threonine kinase 1) is a key regulator of protein synthesis and cellular metabolism, and it is acetylated in response to various cellular signals. Here are some of the events that result in the acetylation of S6K1:\n1. Insulin signaling: Insulin activation of the insulin receptor triggers the phosphorylation and activation of the downstream signaling protein IRS1, which in turn phosphorylates and activates S6K1. Acetylation of S6K1 by the enzyme Sirtuin 1 (SIRT1) is also observed in response to insulin signaling.\n2. Nutrient availability: S6K1 is also acetylated in response to changes in nutrient availability, particularly the presence of amino acids. When amino acids are abundant, they can activate the mTORC1 complex, which in turn phosphorylates and activates S6K1.\n3. Growth factors: Growth factors such as EGF, IGF-1, and FGF can also activate S6K1 through the activation of the PI3K/Akt signaling pathway. This leads to the phosphorylation and activation of S6K1, which in turn promotes protein synthesis and cellular proliferation.\n4. Cellular stress: S6K1 is also acetylated in response to cellular stress, such as oxidative stress, heat shock, and UV radiation. This acetylation is mediated by the enzyme Sirtuin 1 (SIRT1) and is thought to play a role in protecting cells against stress-induced damage.\n5. Hormonal regulation: Hormones such as corticosteroids and thyroid hormones can also regulate S6K1 activity by modulating its acetylation status. For example, corticosteroids can increase the acetylation of S6K1, while thyroid hormones can decrease its acetylation.\nIn summary, S6K1 is acetylated in response to a variety of cellular signals, including insulin signaling",
    "llama-2-7b-chat-hf_fact_raw": "1. S6K1 is acetylated in response to insulin signaling.\n2. The enzyme Sirtuin 1 (SIRT1) acetylates S6K1 in response to insulin signaling.\n3. Nutrient availability, particularly the presence of amino acids, can lead to the acetylation of S6K1.\n4. Growth factors such as EGF, IGF-1, and FGF activate the PI3K/Akt signaling pathway which leads to the activation and acetylation of S6K1.\n5. Cellular stress, including oxidative stress, heat shock, and UV radiation, results in the acetylation of S6K1 mediated by SIRT1.",
    "llama-2-7b-chat-hf_fact": [
      "S6K1 is acetylated in response to insulin signaling.",
      "The enzyme Sirtuin 1 (SIRT1) acetylates S6K1 in response to insulin signaling.",
      "Nutrient availability, particularly the presence of amino acids, can lead to the acetylation of S6K1.",
      "Growth factors such as EGF, IGF-1, and FGF activate the PI3K/Akt signaling pathway which leads to the activation and acetylation of S6K1.",
      "Cellular stress, including oxidative stress, heat shock, and UV radiation, results in the acetylation of S6K1 mediated by SIRT1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The enzyme Sirtuin 1 (SIRT1) deacetylates S6K1, it does not acetylate it.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Cellular stress, including oxidative stress, heat shock, and UV radiation, may result in the deacetylation of S6K1 mediated by SIRT1.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that affects the nervous system, particularly the cerebellum and brainstem. The exact cause of EA6 is not fully understood, but research has identified several genetic mutations that are associated with the disorder.\nEA6 is caused by mutations in the ATP1A3 gene, which encodes a protein called alpha-1 subunit of the P/Q-type calcium channel. This protein plays a critical role in regulating the flow of calcium ions into neurons, which is essential for proper neuronal function. Mutations in the ATP1A3 gene lead to a decrease in the function of the P/Q-type calcium channel, resulting in impaired neuronal function and the symptoms of EA6.\nThe mutations that cause EA6 are inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is enough to cause the disorder. The disorder typically affects individuals of European descent, although it can occur in individuals of other ethnicities as well.\nThe symptoms of EA6 typically begin in childhood or adolescence and can vary in severity and frequency. Common symptoms include:\n1. Ataxia: Loss of coordination and balance, which can lead to difficulty with walking, gait disturbances, and falls.\n2. Dysarthria: Slurred speech and difficulty articulating words.\n3. Dysphagia: Difficulty swallowing and eating.\n4. Nystagmus: Involuntary eye movements.\n5. Vision problems: Blurred vision, double vision, or loss of peripheral vision.\n6. Seizures: Some individuals with EA6 may experience seizures, which can be a sign of the disorder.\n7. Cognitive impairment: Some individuals with EA6 may experience cognitive impairment, including difficulty with memory, attention, and learning.\n8. Emotional disturbances: Some individuals with EA6 may experience emotional disturbances, including anxiety, depression, and mood swings.\nThe symptoms of EA6 can vary in severity and frequency, and may progress over time. There is currently no",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is a rare genetic disorder that affects the cerebellum and brainstem.\n2. EA6 is caused by mutations in the ATP1A3 gene.\n3. The ATP1A3 gene encodes the alpha-1 subunit of the P/Q-type calcium channel.\n4. Mutations in the ATP1A3 gene lead to impaired neuronal function.\n5. The mutations that cause EA6 are inherited in an autosomal dominant pattern.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is a rare genetic disorder that affects the cerebellum and brainstem.",
      "EA6 is caused by mutations in the ATP1A3 gene.",
      "The ATP1A3 gene encodes the alpha-1 subunit of the P/Q-type calcium channel.",
      "Mutations in the ATP1A3 gene lead to impaired neuronal function.",
      "The mutations that cause EA6 are inherited in an autosomal dominant pattern."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ATP1A3 gene encodes the alpha-3 subunit of the sodium/potassium-transporting ATPase.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify DNA by adding a methyl group to the cytosine base in a CpG dinucleotide, resulting in 5-methylcytosine (5-mC). This modification is known to play a crucial role in regulating gene expression and is found in various organisms, including animals.\nIn animals, 5-mC is primarily found in the promoter regions of genes, where it can repress gene transcription by recruiting histone-modifying enzymes that alter the chromatin structure and create a more compact, inactive chromatin structure. 5-mC can also be used to mark genes for epigenetic inheritance, ensuring that the modified gene expression is passed on to daughter cells during cell division.\nStudies have shown that 5-mC is present in various animal species, including mammals, birds, and fish. For example, in mammals, 5-mC is found in the promoter regions of genes involved in cell differentiation, development, and immune response. In birds, 5-mC is found in the promoter regions of genes involved in embryonic development and immune response. In fish, 5-mC is found in the promoter regions of genes involved in development and stress response.\nThere are several chromomethylases that have been identified in animal genomes, including:\n1. DNA methyltransferase 1 (Dnmt1): This enzyme is responsible for maintaining 5-mC levels in mammalian genomes and is essential for the proper development and function of various tissues, including the nervous system, immune system, and reproductive system.\n2. Dnmt3a and Dnmt3b: These enzymes are involved in the de novo methylation of CpG islands in mammalian genomes and are important for the regulation of gene expression during embryonic development and cell differentiation.\n3. KDM5B (LSD1): This enzyme is responsible for demethylating 5-mC from histone H3 lysine 4 (H3K4) in mammalian",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that add a methyl group to the cytosine base in a CpG dinucleotide, resulting in 5-methylcytosine.\n2. 5-methylcytosine plays a crucial role in regulating gene expression and is found in animal genomes.\n3. In animals, 5-methylcytosine is primarily found in the promoter regions of genes.\n4. DNA methyltransferase 1 (Dnmt1) is responsible for maintaining 5-methylcytosine levels in mammalian genomes.\n5. Dnmt3a and Dnmt3b are involved in the de novo methylation of CpG islands in mammalian genomes.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that add a methyl group to the cytosine base in a CpG dinucleotide, resulting in 5-methylcytosine.",
      "5-methylcytosine plays a crucial role in regulating gene expression and is found in animal genomes.",
      "In animals, 5-methylcytosine is primarily found in the promoter regions of genes.",
      "DNA methyltransferase 1 (Dnmt1) is responsible for maintaining 5-methylcytosine levels in mammalian genomes.",
      "Dnmt3a and Dnmt3b are involved in the de novo methylation of CpG islands in mammalian genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Certainly! There are several packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis. Here are some of the most popular ones:\n1. TFBScore: TFBScore is a package that provides a comprehensive set of tools for the analysis of TFBSs. It can be used to predict TFBSs in both DNA sequences and ChIP-seq data. The package includes several algorithms for TFBS prediction, including the popular TFBS prediction tool, TFSEARCH.\n2. ChIPseek: ChIPseek is a package specifically designed for the analysis of ChIP-seq data. It can be used to identify regions of the genome that are bound by transcription factors, as well as to predict the binding sites of specific transcription factors. ChIPseek includes several tools for peak calling, motif analysis, and visualization.\n3. HISAT2: HISAT2 is a spliced aligner that can be used for TFBS analysis. It can be used to align RNA-seq reads to a reference genome and identify regions of the genome that are bound by transcription factors. HISAT2 includes several tools for peak calling, motif analysis, and visualization.\n4. STAR: STAR is a high-performance aligner that can be used for TFBS analysis. It can be used to align RNA-seq reads to a reference genome and identify regions of the genome that are bound by transcription factors. STAR includes several tools for peak calling, motif analysis, and visualization.\n5. DeepTools: DeepTools is a package that provides a comprehensive set of tools for the analysis of ChIP-seq data. It can be used to identify regions of the genome that are bound by transcription factors, as well as to predict the binding sites of specific transcription factors. DeepTools includes several tools for peak calling, motif analysis, and visualization.\n6. GSEA: GSEA (Gene Set Enrichment Analysis) is a package that can be used to identify gene sets that are enriched in regions of the genome that are bound by transcription factors. It can be used to identify specific transcription factors that are associated with particular gene sets.\n7. GenomicTraversal: GenomicTraversal is a",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBScore is a package in R/Bioconductor that provides tools for the analysis of transcription factor binding sites.\n2. ChIPseek is a package designed for the analysis of ChIP-seq data to identify regions bound by transcription factors.\n3. HISAT2 is a spliced aligner in R/Bioconductor used for transcription factor binding site analysis.\n4. STAR is an aligner in R/Bioconductor that can identify regions of the genome bound by transcription factors.\n5. DeepTools is a package in R/Bioconductor for analyzing ChIP-seq data and predicting transcription factor binding sites.",
    "llama-2-7b-chat-hf_fact": [
      "TFBScore is a package in R/Bioconductor that provides tools for the analysis of transcription factor binding sites.",
      "ChIPseek is a package designed for the analysis of ChIP-seq data to identify regions bound by transcription factors.",
      "HISAT2 is a spliced aligner in R/Bioconductor used for transcription factor binding site analysis.",
      "STAR is an aligner in R/Bioconductor that can identify regions of the genome bound by transcription factors.",
      "DeepTools is a package in R/Bioconductor for analyzing ChIP-seq data and predicting transcription factor binding sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: HISAT2 is a fast and sensitive spliced aligner, but it is primarily used for mapping RNA-Seq reads and not specifically for transcription factor binding site analysis.\n4. FALSE [correction]: STAR is an aligner used for RNA-seq data and not specifically for identifying regions bound by transcription factors.\n5. FALSE [correction]: DeepTools is a suite of python tools for the efficient analysis of high-throughput sequencing data, such as ChIP-seq, but it is not a package in R/Bioconductor.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some ongoing and completed clinical trials related to the prevention of sarcopenia:\n1. A Randomized Controlled Trial to Evaluate the Efficacy and Safety of TAK-243 in Healthy Older Adults (TAK-243-001): This trial, conducted by Takeda Pharmaceuticals, is investigating the safety and efficacy of TAK-243, a small molecule inhibitor of the enzyme PI3K delta, in healthy older adults. The trial is designed to assess the effects of TAK-243 on muscle mass, strength, and function in older adults.\n2. Effects of Resistance Training on Sarcopenia in Older Adults (RESIST): This trial, conducted by the University of California, Los Angeles (UCLA), is examining the effects of resistance training on muscle mass, strength, and function in older adults. The trial is randomizing participants to either a resistance training program or a control group and assessing the outcomes at 12 and 24 weeks.\n3. A Randomized Controlled Trial of the Effects of Omega-3 Fatty Acids on Sarcopenia in Older Adults (OMEGA-Sarcopenia): This trial, conducted by the University of Oxford, is investigating the effects of omega-3 fatty acid supplementation on muscle mass, strength, and function in older adults. The trial is randomizing participants to either an omega-3 supplement or a placebo and assessing the outcomes at 12 months.\n4. The Effects of Dietary Protein on Sarcopenia in Older Adults (PROTEIN-Sarcopenia): This trial, conducted by the University of Sydney, is examining the effects of different protein intake levels on muscle mass, strength, and function in older adults. The trial is randomizing participants to one of three protein intake levels and assessing the outcomes at 12 months.\n5. The Effects of Exercise and Nutrition on Sarcopenia in Older Adults (ENSARC): This trial, conducted by the University of Alabama at Birmingham, is exam",
    "llama-2-7b-chat-hf_fact_raw": "1. Takeda Pharmaceuticals is conducting a trial called TAK-243-001 on the effects of TAK-243 on muscle mass, strength, and function in older adults.\n2. The University of California, Los Angeles (UCLA) is examining the effects of resistance training on sarcopenia in older adults through the RESIST trial.\n3. The University of Oxford is investigating the effects of omega-3 fatty acid supplementation on sarcopenia in older adults in the OMEGA-Sarcopenia trial.\n4. The University of Sydney is conducting the PROTEIN-Sarcopenia trial to examine the effects of different protein intake levels on sarcopenia in older adults.\n5. The University of Alabama at Birmingham is involved in a trial examining the effects of exercise and nutrition on sarcopenia in older adults, known as ENSARC.",
    "llama-2-7b-chat-hf_fact": [
      "Takeda Pharmaceuticals is conducting a trial called TAK-243-001 on the effects of TAK-243 on muscle mass, strength, and function in older adults.",
      "The University of California, Los Angeles (UCLA) is examining the effects of resistance training on sarcopenia in older adults through the RESIST trial.",
      "The University of Oxford is investigating the effects of omega-3 fatty acid supplementation on sarcopenia in older adults in the OMEGA-Sarcopenia trial.",
      "The University of Sydney is conducting the PROTEIN-Sarcopenia trial to examine the effects of different protein intake levels on sarcopenia in older adults.",
      "The University of Alabama at Birmingham is involved in a trial examining the effects of exercise and nutrition on sarcopenia in older adults, known as ENSARC."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without specific context or access to the details of these trials, it is not possible to verify the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins that can be used to identify and analyze these features. Here are some of the most popular and widely used databases:\n1. Membrane Protein Database (MPD): This database contains a comprehensive collection of structural and functional information on membrane proteins, including their molecular recognition features. MPD includes data from a wide range of sources, including X-ray crystallography, NMR spectroscopy, and computational modeling.\n2. Protein Data Bank (PDB): The PDB is a comprehensive database of 3D structures of proteins, including membrane proteins. The PDB contains structures of membrane proteins in various states, including bound and unbound states, which can be used to identify molecular recognition features.\n3. Membrane Protein Structural Database (MPSD): This database contains structural information on membrane proteins, including their three-dimensional structures, functional sites, and binding sites. MPSD also includes data on the membrane-spanning segments of these proteins.\n4. Membrane Protein Interaction Database (MPI): This database contains information on the interactions between membrane proteins and other molecules, including ligands, substrates, and other proteins. MPI includes data on the binding affinity, specificity, and kinetics of these interactions.\n5. Protein-Ligand Interaction Database (PLID): This database contains information on the interactions between proteins and ligands, including the binding affinity, specificity, and kinetics of these interactions. PLID includes data on a wide range of protein-ligand interactions, including those involving membrane proteins.\n6. Membrane Protein-Ligand Interaction Database (MPLI): This database contains information on the interactions between membrane proteins and ligands, including the binding affinity, specificity, and kinetics of these interactions. MPLI includes data on a wide range of membrane protein-ligand interactions.\n7. Membrane Protein Structural Alignment Database (MPSAD): This database contains structural information on membrane proteins, including their three-dimensional structures, functional sites, and binding sites. MPSAD also includes data on the membrane-spanning segments of these proteins.\n8. Membrane Protein-",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Database (MPD) contains structural and functional information on membrane proteins.\n2. The Protein Data Bank (PDB) is a database of 3D structures of proteins, including membrane proteins.\n3. The Membrane Protein Structural Database (MPSD) contains structural information on membrane proteins.\n4. The Membrane Protein Interaction Database (MPI) contains information on interactions between membrane proteins and other molecules.\n5. The Protein-Ligand Interaction Database (PLID) contains information on interactions between proteins and ligands, including those involving membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Database (MPD) contains structural and functional information on membrane proteins.",
      "The Protein Data Bank (PDB) is a database of 3D structures of proteins, including membrane proteins.",
      "The Membrane Protein Structural Database (MPSD) contains structural information on membrane proteins.",
      "The Membrane Protein Interaction Database (MPI) contains information on interactions between membrane proteins and other molecules.",
      "The Protein-Ligand Interaction Database (PLID) contains information on interactions between proteins and ligands, including those involving membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The correct name is the Membrane Protein Structure Database (MPSD).\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Yes, rivaroxaban is metabolized in the kidneys to a limited extent. Rivaroxaban is a direct oral anticoagulant (DOAC) that is primarily metabolized by the liver enzyme CYP2C9, with a minor contribution from CYP3A4. However, the kidneys also play a role in the elimination of rivaroxaban, particularly in patients with impaired liver function.\nStudies have shown that approximately 20-30% of rivaroxaban is metabolized in the kidneys, primarily through the action of the enzyme uridine diphosphate glucuronosyltransferase (UGT). This means that the kidneys are responsible for a significant portion of rivaroxaban's metabolism, particularly in patients with liver dysfunction.\nIt is important to note that the kidneys play a critical role in the elimination of rivaroxaban in patients with impaired liver function, such as those with hepatic cirrhosis or liver failure. In these patients, the kidneys may be responsible for a larger portion of rivaroxaban metabolism, which can affect the drug's efficacy and safety.\nIn summary, while the liver is the primary site of rivaroxaban metabolism, the kidneys also play a significant role in the drug's elimination, particularly in patients with impaired liver function. Therefore, it is important to monitor rivaroxaban levels in these patients and adjust the dosage as needed to ensure optimal efficacy and safety.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the kidneys to a limited extent.\n2. Rivaroxaban is primarily metabolized by the liver enzyme CYP2C9.\n3. Approximately 20-30% of rivaroxaban is metabolized in the kidneys.\n4. The enzyme uridine diphosphate glucuronosyltransferase (UGT) is involved in the metabolism of rivaroxaban in the kidneys.\n5. The kidneys play a critical role in the elimination of rivaroxaban in patients with impaired liver function.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the kidneys to a limited extent.",
      "Rivaroxaban is primarily metabolized by the liver enzyme CYP2C9.",
      "Approximately 20-30% of rivaroxaban is metabolized in the kidneys.",
      "The enzyme uridine diphosphate glucuronosyltransferase (UGT) is involved in the metabolism of rivaroxaban in the kidneys.",
      "The kidneys play a critical role in the elimination of rivaroxaban in patients with impaired liver function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Rivaroxaban is primarily metabolized by the liver enzymes CYP3A4 and CYP2J2.\n3. TRUE\n4. FALSE [correction]: UGT enzymes are involved in the metabolism of rivaroxaban, but this process occurs predominantly in the liver, not the kidneys.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 (also known as retinoic acid receptor alpha 2) is a nuclear receptor that plays a crucial role in regulating various physiological processes, including cell growth, differentiation, and survival. In the heart, TRalpha2 has been shown to regulate the expression of several genes involved in cardiac function and development. Here are some of the genes that are known to be regulated by TRalpha2 in the heart:\n1. Atrial natriuretic factor (ANF): TRalpha2 regulates the expression of the ANF gene, which encodes a hormone that helps regulate blood pressure and fluid balance in the body.\n2. Brain natriuretic peptide (BNP): TRalpha2 also regulates the expression of the BNP gene, which encodes a hormone that helps regulate cardiac function and blood pressure.\n3. Cardiac troponin I (TNNI): TRalpha2 regulates the expression of the TNNI gene, which encodes a protein that plays a crucial role in the regulation of cardiac contraction.\n4. GATA4: TRalpha2 regulates the expression of the GATA4 gene, which encodes a transcription factor that is involved in the development and maintenance of the cardiac conduction system.\n5. GATA6: TRalpha2 regulates the expression of the GATA6 gene, which encodes a transcription factor that is involved in the development and maintenance of the cardiac conduction system.\n6. Hypoxia-inducible factor 1 alpha (HIF1A): TRalpha2 regulates the expression of the HIF1A gene, which encodes a transcription factor that plays a crucial role in response to hypoxia.\n7. Krox-20: TRalpha2 regulates the expression of the Krox-20 gene, which encodes a transcription factor that is involved in the development and maintenance of the cardiac conduction system.\n8. Myosin heavy chain 7 (MHC7): TRalpha2 regulates the expression of the MHC7 gene, which encodes a protein that plays a crucial role in the regulation of cardiac contraction.\n9. Nuclear factor of kappa light chain enhancer in B cells 1 (NF-κ",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 regulates the expression of the Atrial natriuretic factor (ANF) gene in the heart.\n2. TRalpha2 regulates the expression of the Brain natriuretic peptide (BNP) gene in the heart.\n3. TRalpha2 regulates the expression of the Cardiac troponin I (TNNI) gene in the heart.\n4. TRalpha2 regulates the expression of the GATA4 gene in the heart.\n5. TRalpha2 regulates the expression of the GATA6 gene in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 regulates the expression of the Atrial natriuretic factor (ANF) gene in the heart.",
      "TRalpha2 regulates the expression of the Brain natriuretic peptide (BNP) gene in the heart.",
      "TRalpha2 regulates the expression of the Cardiac troponin I (TNNI) gene in the heart.",
      "TRalpha2 regulates the expression of the GATA4 gene in the heart.",
      "TRalpha2 regulates the expression of the GATA6 gene in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without specific scientific context or evidence from reputable sources, it's not possible to determine the accuracy of these statements about gene regulation.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can provide you with a list of available biomedical question answering systems. These systems are designed to help healthcare professionals, researchers, and students quickly and accurately find answers to biomedical questions by leveraging large amounts of biomedical literature and data. Here are some of the most popular biomedical question answering systems:\n1. PubMed Central (PMC): PMC is a free full-text database of biomedical and life sciences journal literature. It contains over 30 million articles, including peer-reviewed research articles, book chapters, and conference proceedings.\n2. Google Scholar (GS): GS is a free search engine that indexes scholarly literature across many disciplines and sources, including articles, theses, books, and conference papers. It provides a way to search for and retrieve biomedical literature based on relevance, citation count, and author.\n3. BioMed Central (BMC): BMC is a publisher of open-access biomedical journals, including BMC Biology, BMC Medicine, and BMC Genomics. It also provides a question answering system called BMC Informatics, which allows users to ask questions and receive answers on a variety of biomedical topics.\n4. Semantic Scholar: Semantic Scholar is a free academic search engine that uses natural language processing and machine learning to extract relevant information from biomedical literature. It can answer questions on a wide range of biomedical topics, including gene function, disease mechanisms, and drug interactions.\n5. AI-Powered Biomedical Question Answering System (ABQAS): ABQAS is a machine learning-based question answering system that can answer biomedical questions based on a large corpus of biomedical literature. It uses a combination of natural language processing and machine learning techniques to identify relevant answers to user questions.\n6. Biomedical Information and Retrieval System (BIRS): BIRS is a question answering system developed by the National Library of Medicine (NLM). It uses a combination of natural language processing and machine learning techniques to answer biomedical questions based on a large corpus of biomedical literature.\n7. Biomedical Knowledge Extraction System (BKES): BKES is a question answering system developed by the University of California, Los Angeles (UCLA). It uses a combination of natural",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central (PMC) is a free full-text database containing over 30 million articles of biomedical and life sciences journal literature.\n2. Google Scholar (GS) is a free search engine that indexes scholarly literature across many disciplines, including biomedical literature.\n3. BioMed Central (BMC) publishes open-access biomedical journals and provides a question answering system called BMC Informatics.\n4. Semantic Scholar is a free academic search engine that uses natural language processing and machine learning to extract information from biomedical literature.\n5. The Biomedical Information and Retrieval System (BIRS) is developed by the National Library of Medicine (NLM) and answers biomedical questions based on a large corpus of literature.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central (PMC) is a free full-text database containing over 30 million articles of biomedical and life sciences journal literature.",
      "Google Scholar (GS) is a free search engine that indexes scholarly literature across many disciplines, including biomedical literature.",
      "BioMed Central (BMC) publishes open-access biomedical journals and provides a question answering system called BMC Informatics.",
      "Semantic Scholar is a free academic search engine that uses natural language processing and machine learning to extract information from biomedical literature.",
      "The Biomedical Information and Retrieval System (BIRS) is developed by the National Library of Medicine (NLM) and answers biomedical questions based on a large corpus of literature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PubMed Central (PMC) is a free full-text database containing over 6 million articles of biomedical and life sciences journal literature.\n2. TRUE\n3. FALSE [correction]: BioMed Central (BMC) publishes open-access biomedical journals, but does not provide a question answering system called BMC Informatics.\n4. TRUE\n5. FALSE [correction]: The correct name is the National Center for Biotechnology Information (NCBI), and one of its services is PubMed, which includes a search system for biomedical literature, not specifically a question answering system. The National Library of Medicine (NLM) develops and hosts PubMed.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The betalain pathway is a complex metabolic pathway involved in the biosynthesis of betalains, a class of natural pigments found in plants. The activation of the betalain pathway is regulated by several transcription factors, including:\n1. ABSCISIC ACID INSENSITIVE 3 (ABI3): ABI3 is a transcription factor that plays a key role in regulating the expression of genes involved in the betalain pathway. ABI3 is activated by abscisic acid (ABA), a plant hormone that regulates seed maturation, stomatal closure, and stress responses. ABI3 binds to specific DNA sequences in the promoter regions of betalain biosynthetic genes and activates their transcription.\n2. WRINKLED1 (WRI1): WRI1 is another transcription factor that regulates the expression of genes involved in the betalain pathway. WRI1 is activated by light and other signaling pathways and binds to specific DNA sequences in the promoter regions of betalain biosynthetic genes.\n3. MYB72: MYB72 is a transcription factor that belongs to the MYB family of transcription factors. It is involved in the regulation of the betalain pathway and other metabolic pathways. MYB72 is activated by light and other signaling pathways and binds to specific DNA sequences in the promoter regions of betalain biosynthetic genes.\n4. BETA-AMYLASE 1 (BAM1): BAM1 is an enzyme that regulates the expression of genes involved in the betalain pathway. BAM1 is activated by light and other signaling pathways and binds to specific DNA sequences in the promoter regions of betalain biosynthetic genes.\n5. CYCLING DIOXIN BINDING PROTEIN 1 (CDB1): CDB1 is a transcription factor that regulates the expression of genes involved in the betalain pathway. CDB1 is activated by light and other signaling pathways and binds to specific DNA sequences in the promoter regions of betalain biosynthetic",
    "llama-2-7b-chat-hf_fact_raw": "1. ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor that regulates the expression of genes in the betalain pathway and is activated by abscisic acid.\n2. WRINKLED1 (WRI1) is a transcription factor that regulates the expression of genes in the betalain pathway and is activated by light.\n3. MYB72 is a member of the MYB family of transcription factors and is involved in the regulation of the betalain pathway.\n4. BETA-AMYLASE 1 (BAM1) is an enzyme that binds to specific DNA sequences in the promoter regions of betalain biosynthetic genes.\n5. CYCLING DIOXIN BINDING PROTEIN 1 (CDB1) is a transcription factor that regulates the expression of genes in the betalain pathway.",
    "llama-2-7b-chat-hf_fact": [
      "ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor that regulates the expression of genes in the betalain pathway and is activated by abscisic acid.",
      "WRINKLED1 (WRI1) is a transcription factor that regulates the expression of genes in the betalain pathway and is activated by light.",
      "MYB72 is a member of the MYB family of transcription factors and is involved in the regulation of the betalain pathway.",
      "BETA-AMYLASE 1 (BAM1) is an enzyme that binds to specific DNA sequences in the promoter regions of betalain biosynthetic genes.",
      "CYCLING DIOXIN BINDING PROTEIN 1 (CDB1) is a transcription factor that regulates the expression of genes in the betalain pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ABSCISIC ACID INSENSITIVE 3 (ABI3) is a transcription factor that regulates the expression of genes during seed development and is activated by abscisic acid, not specifically related to the betalain pathway.\n2. FALSE [correction]: WRINKLED1 (WRI1) is a transcription factor that regulates fatty acid biosynthesis in plants, not specifically related to the betalain pathway, and it is activated by sugars, not light.\n3. UNKNOWN\n4. FALSE [correction]: BETA-AMYLASE 1 (BAM1) is an enzyme that breaks down starch into sugars, not a DNA-binding protein involved in the regulation of betalain biosynthetic genes.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Global quantitative phosphoproteomic analyses are indeed emerging as a powerful tool for understanding the complex dynamics of protein phosphorylation in various biological systems. Enrichment of phosphorylated peptides is a crucial step in these analyses, as it allows for the identification and quantification of phosphorylated proteins in a highly sensitive and specific manner. Here are some of the preferred technologies for enrichment of phosphorylated peptides:\n1. TiO2-based enrichment: TiO2 is a widely used sorbent for phosphorylated peptide enrichment due to its high affinity for phosphate groups. TiO2-based enrichment methods involve the capture of phosphorylated peptides using TiO2 particles, followed by washing and elution of the captured peptides.\n2. C18-based enrichment: C18 is another commonly used sorbent for phosphorylated peptide enrichment. C18-based methods involve the capture of phosphorylated peptides using C18 columns, followed by washing and elution of the captured peptides.\n3. IMAC (Immobilized Metal Affinity Chromatography): IMAC is a highly specific and sensitive method for enriching phosphorylated peptides. In this method, phosphorylated peptides are captured using immobilized metal ions (e.g., Ni2+ or Cu2+), followed by washing and elution of the captured peptides.\n4. PVDF-based enrichment: PVDF (Polyvinylidene fluoride) is a membrane-based sorbent that has shown high affinity for phosphorylated peptides. PVDF-based enrichment methods involve the capture of phosphorylated peptides using PVDF membranes, followed by washing and elution of the captured peptides.\n5. Graphene-based enrichment: Graphene is a highly sensitive and specific sorbent for phosphorylated peptide enrichment. Graphene-based methods involve the capture of phosphorylated peptides using graphene sheets, followed by washing",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment methods use TiO2 particles to capture phosphorylated peptides.\n2. C18-based enrichment methods use C18 columns to capture phosphorylated peptides.\n3. Immobilized Metal Affinity Chromatography (IMAC) enriches phosphorylated peptides using immobilized metal ions.\n4. PVDF-based enrichment methods use Polyvinylidene fluoride membranes to capture phosphorylated peptides.\n5. Graphene-based enrichment methods use graphene sheets to capture phosphorylated peptides.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment methods use TiO2 particles to capture phosphorylated peptides.",
      "C18-based enrichment methods use C18 columns to capture phosphorylated peptides.",
      "Immobilized Metal Affinity Chromatography (IMAC) enriches phosphorylated peptides using immobilized metal ions.",
      "PVDF-based enrichment methods use Polyvinylidene fluoride membranes to capture phosphorylated peptides.",
      "Graphene-based enrichment methods use graphene sheets to capture phosphorylated peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "The Palmini classification is a system used to rate the severity of obsessive-compulsive disorder (OCD). The classification system was developed by Dr. Giovanni Palmini and is based on the frequency and severity of obsessive thoughts and compulsive behaviors.\nAccording to the Palmini classification, OCD can be classified into four subtypes based on the severity of symptoms:\n1. Mild OCD: This subtype is characterized by mild symptoms that do not significantly interfere with daily life. Individuals with mild OCD may experience occasional intrusive thoughts or compulsions, but they are able to function normally without significant distress or impairment.\n2. Moderate OCD: This subtype is characterized by more severe symptoms than mild OCD, but still do not significantly interfere with daily life. Individuals with moderate OCD may experience frequent intrusive thoughts or compulsions, and may have difficulty functioning in certain situations.\n3. Severe OCD: This subtype is characterized by severe symptoms that significantly interfere with daily life. Individuals with severe OCD may experience intrusive thoughts or compulsions that are frequent and intense, and may have difficulty functioning in most situations.\n4. Extreme OCD: This subtype is characterized by the most severe symptoms of OCD, which significantly interfere with daily life and cause significant distress or impairment. Individuals with extreme OCD may experience intrusive thoughts or compulsions that are extremely frequent and intense, and may have difficulty functioning in any situation.\nIt is important to note that the Palmini classification is not a diagnostic tool, but rather a way to rate the severity of OCD symptoms. A diagnosis of OCD can only be made by a qualified mental health professional using the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate the severity of obsessive-compulsive disorder (OCD).\n2. The classification system was developed by Dr. Giovanni Palmini.\n3. The Palmini classification includes four subtypes of OCD: mild, moderate, severe, and extreme.\n4. The Palmini classification is based on the frequency and severity of obsessive thoughts and compulsive behaviors.\n5. The Palmini classification is not a diagnostic tool, but a way to rate the severity of OCD symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate the severity of obsessive-compulsive disorder (OCD).",
      "The classification system was developed by Dr. Giovanni Palmini.",
      "The Palmini classification includes four subtypes of OCD: mild, moderate, severe, and extreme.",
      "The Palmini classification is based on the frequency and severity of obsessive thoughts and compulsive behaviors.",
      "The Palmini classification is not a diagnostic tool, but a way to rate the severity of OCD symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Y-BOCS (Yale-Brown Obsessive Compulsive Scale) is commonly used to rate the severity of obsessive-compulsive disorder (OCD), not the Palmini classification.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Yes, viruses have been implicated in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland and is characterized by the sudden onset of symptoms such as pain in the neck, swelling, and difficulty swallowing. While the exact cause of subacute thyroiditis is not fully understood, there is evidence to suggest that viral infections play a role in its development.\nSeveral viruses have been linked to the development of subacute thyroiditis, including:\n1. Influenza virus: Studies have shown that influenza virus infection can trigger an immune response that leads to the development of subacute thyroiditis.\n2. Adenovirus: Adenovirus infection has also been linked to the development of subacute thyroiditis.\n3. Herpesvirus: Herpesvirus infections, including herpes simplex virus and herpes zoster virus, have been associated with subacute thyroiditis.\n4. Enterovirus: Enterovirus infections, which are common causes of viral gastroenteritis, have also been linked to subacute thyroiditis.\n5. Respiratory syncytial virus (RSV): RSV infection has been implicated in the development of subacute thyroiditis, particularly in children.\nIt is thought that these viruses may trigger an immune response in the thyroid gland, leading to inflammation and the production of autoantibodies that can damage the thyroid gland. The autoantibodies can also lead to the formation of nodules in the thyroid gland, which can cause the symptoms of subacute thyroiditis.\nIt is important to note that the exact mechanisms by which viruses contribute to the development of subacute thyroiditis are not fully understood and are the subject of ongoing research. However, the evidence suggests that viral infections play a role in the etiology of this condition.\nIn conclusion, while the exact cause of subacute thyroiditis is not fully understood, there is evidence to suggest that viruses, particularly influenza, adenovirus, herpesvirus, enterovirus, and RSV, may play a role in its development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is an inflammatory condition that affects the thyroid gland.\n2. Subacute thyroiditis can be characterized by symptoms such as pain in the neck, swelling, and difficulty swallowing.\n3. Viral infections are suggested to play a role in the development of subacute thyroiditis.\n4. Influenza virus, adenovirus, herpesvirus, enterovirus, and respiratory syncytial virus (RSV) have been linked to subacute thyroiditis.\n5. Viruses may trigger an immune response in the thyroid gland leading to the production of autoantibodies that can damage the gland.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is an inflammatory condition that affects the thyroid gland.",
      "Subacute thyroiditis can be characterized by symptoms such as pain in the neck, swelling, and difficulty swallowing.",
      "Viral infections are suggested to play a role in the development of subacute thyroiditis.",
      "Influenza virus, adenovirus, herpesvirus, enterovirus, and respiratory syncytial virus (RSV) have been linked to subacute thyroiditis.",
      "Viruses may trigger an immune response in the thyroid gland leading to the production of autoantibodies that can damage the gland."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including inflammation, immune response, and cell survival. Recent studies have shown that STAT3 is involved in the regulation of autophagy, a cellular process that helps to maintain cellular homeostasis by degrading and recycling damaged or dysfunctional cellular components.\nEIF2AK2 (Eukaryotic Translation Initiation Factor 2-Associated Kinase 2) is a protein kinase that regulates the translation initiation complex and is involved in the regulation of autophagy. EIF2AK2 has been shown to suppress autophagy by inhibiting the activity of the mTOR (Mechanistic Target of Rapamycin) pathway, which is a key regulator of autophagy.\nRecent studies have suggested that STAT3 may also play a role in the regulation of autophagy, particularly in the context of cancer. For example, one study found that STAT3 is required for the suppression of autophagy in breast cancer cells, and that inhibition of STAT3 leads to the re-activation of autophagy and the inhibition of cancer cell growth. Another study found that STAT3 regulates the expression of genes involved in autophagy in colon cancer cells.\nHowever, the relationship between STAT3 and EIF2AK2 in the regulation of autophagy is complex and context-dependent. While EIF2AK2 has been shown to suppress autophagy by inhibiting the mTOR pathway, STAT3 has been shown to have both pro-autophagic and anti-autophagic effects, depending on the cellular context. For example, STAT3 has been shown to promote autophagy in some cancer cell lines, while inhibiting it in others.\nIn summary, STAT3 is involved in the regulation of autophagy, but the extent of its involvement depends on the cellular context and the specific cellular process being studied. While EIF2AK2 has been shown to suppress autophagy by inhibiting the mTOR pathway, the relationship between STAT3 and EIF2AK2 in this process is complex and context",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is a transcription factor that is involved in various cellular processes such as inflammation, immune response, and cell survival.\n2. Recent studies have shown STAT3 is involved in the regulation of autophagy.\n3. EIF2AK2 is a protein kinase that regulates the translation initiation complex and the regulation of autophagy.\n4. EIF2AK2 suppresses autophagy by inhibiting the activity of the mTOR pathway.\n5. The relationship between STAT3 and EIF2AK2 in the regulation of autophagy is complex and context-dependent.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is a transcription factor that is involved in various cellular processes such as inflammation, immune response, and cell survival.",
      "Recent studies have shown STAT3 is involved in the regulation of autophagy.",
      "EIF2AK2 is a protein kinase that regulates the translation initiation complex and the regulation of autophagy.",
      "EIF2AK2 suppresses autophagy by inhibiting the activity of the mTOR pathway.",
      "The relationship between STAT3 and EIF2AK2 in the regulation of autophagy is complex and context-dependent."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: EIF2AK2 promotes autophagy by phosphorylating eIF2α, which leads to the inhibition of the translation initiation complex.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for genomic analysis, specifically for the analysis of next-generation sequencing (NGS) data. It is a powerful and flexible tool that can be used for a wide range of genomic analysis tasks, including:\n1. Read alignment: Theatre can align sequencing reads to a reference genome, allowing researchers to identify variations such as single nucleotide polymorphisms (SNPs), insertions, deletions, and structural variations.\n2. Variant calling: Theatre can identify and classify variants in the aligned reads, including both common and rare variants. It can also predict the impact of these variants on gene function and protein structure.\n3. Genome assembly: Theatre can be used to assemble genomes from NGS data, allowing researchers to reconstruct the complete DNA sequence of an organism. This is particularly useful for organisms with complex genomes or for regions of the genome that are difficult to assemble using other methods.\n4. Transcriptome analysis: Theatre can be used to analyze RNA-seq data, allowing researchers to identify and quantify gene expression levels, identify novel transcripts, and study the regulation of gene expression.\n5. Epigenomics analysis: Theatre can be used to analyze epigenetic marks such as DNA methylation and histone modifications, which play a crucial role in gene regulation and cellular differentiation.\n6. Genome-wide association studies (GWAS): Theatre can be used to identify genetic variants associated with complex diseases or traits by analyzing genome-wide data.\n7. Functional genomics: Theatre can be used to study the functional impact of genetic variants, gene expression levels, and epigenetic marks on gene function and protein structure.\n8. Genome engineering: Theatre can be used to design and construct genetic circuits, such as gene drives, that can be used to modify organisms for specific purposes.\n9. Genome-wide gene expression analysis: Theatre can be used to analyze gene expression levels across the genome, allowing researchers to identify differentially expressed genes and study the regulation of gene expression.\n10. Genome-wide methylation analysis: Theatre can be used to analyze DNA methylation levels across the genome, allowing researchers to identify differentially methylated regions and study the role of DNA methylation in",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a software tool designed for genomic analysis of next-generation sequencing (NGS) data.\n2. Theatre can be used for read alignment to identify variations in a reference genome.\n3. Theatre can perform variant calling to classify and predict the impact of variants on gene function and protein structure.\n4. Theatre can be used to assemble genomes from NGS data for organisms with complex genomes.\n5. Theatre is capable of analyzing epigenetic marks such as DNA methylation and histone modifications.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a software tool designed for genomic analysis of next-generation sequencing (NGS) data.",
      "Theatre can be used for read alignment to identify variations in a reference genome.",
      "Theatre can perform variant calling to classify and predict the impact of variants on gene function and protein structure.",
      "Theatre can be used to assemble genomes from NGS data for organisms with complex genomes.",
      "Theatre is capable of analyzing epigenetic marks such as DNA methylation and histone modifications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Theatre is not a software tool; the correct term might be \"Galaxy\" or another bioinformatics platform.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the specific implementation and the size of the sequences. However, we can provide a general overview of the complexity of the algorithm.\nThe Smith-Waterman algorithm is an efficient algorithm for comparing two biological sequences (DNA, RNA, or protein) to find the best local alignment between them. The algorithm works by computing the similarity between the two sequences by comparing their corresponding elements (i.e., nucleotides or amino acids) and assigning scores based on the similarity.\nThe time complexity of the Smith-Waterman algorithm can be analyzed as follows:\n1. Sequence Preprocessing: The algorithm requires O(n) time to preprocess the sequences, where n is the length of the sequences. This involves converting the sequences into a matrix representation, where each element in the matrix represents the presence or absence of a particular nucleotide or amino acid in the sequence.\n2. Scoring Matrix Computation: The next step is to compute the scoring matrix, which involves calculating the similarity between each pair of elements in the two sequences. The time complexity of this step is O(n^2), where n is the length of the sequences.\n3. Dynamic Programming: The core of the Smith-Waterman algorithm is the dynamic programming algorithm, which involves computing the optimal local alignment between the two sequences. The time complexity of this step is O(n^3), where n is the length of the sequences.\n4. Alignment Computation: Once the scoring matrix is computed, the algorithm uses dynamic programming to find the optimal local alignment between the two sequences. The time complexity of this step is O(n^3), where n is the length of the sequences.\n5. Output: The final step is to output the aligned sequences, which takes O(1) time.\nTherefore, the overall time complexity of the Smith-Waterman algorithm is O(n^3 + n^2), where n is the length of the sequences. This means that the algorithm's time complexity increases rapidly with the length of the sequences, making it less efficient for comparing long sequences.\nIt's worth noting that there are several variations of the Smith-Waterman algorithm that can improve its efficiency, such as using a sliding window approach or using a pre-computed scoring matrix. These variations can reduce the",
    "llama-2-7b-chat-hf_fact_raw": "1. The Smith-Waterman algorithm is used for comparing two biological sequences to find the best local alignment.\n2. The time complexity for sequence preprocessing in the Smith-Waterman algorithm is O(n).\n3. Computing the scoring matrix in the Smith-Waterman algorithm has a time complexity of O(n^2).\n4. The dynamic programming step in the Smith-Waterman algorithm has a time complexity of O(n^3).\n5. The overall time complexity of the Smith-Waterman algorithm is O(n^3 + n^2).",
    "llama-2-7b-chat-hf_fact": [
      "The Smith-Waterman algorithm is used for comparing two biological sequences to find the best local alignment.",
      "The time complexity for sequence preprocessing in the Smith-Waterman algorithm is O(n).",
      "Computing the scoring matrix in the Smith-Waterman algorithm has a time complexity of O(n^2).",
      "The dynamic programming step in the Smith-Waterman algorithm has a time complexity of O(n^3).",
      "The overall time complexity of the Smith-Waterman algorithm is O(n^3 + n^2)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: The dynamic programming step in the Smith-Waterman algorithm has a time complexity of O(n^2).\n5. FALSE [correction]: The overall time complexity of the Smith-Waterman algorithm is O(n^2).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 (Flavocoxid Reductase 1) is a member of the Solute Carrier (SLC) family of transmembrane proteins. Specifically, FLVCR1 belongs to the SLC22A1 subfamily of the SLC family.\nThe SLC22A1 subfamily is responsible for the transport of a wide range of endogenous and exogenous compounds, including amino acids, sugars, and xenobiotics (foreign compounds). FLVCR1 is specifically involved in the transport of flavocoxid, a compound that is involved in the biosynthesis of the antibiotic chloramphenicol.\nOther members of the SLC22A1 subfamily include:\n* SLC22A1 (Fructose 1,6-bisphosphate Aldolase 1)\n* SLC22A2 (Glycerol-3-phosphate Dehydrogenase 1)\n* SLC22A3 (Sugar Alcohol 3-Phosphate Dehydrogenase 1)\n* SLC22A4 (Fructose-Bisphosphate Aldolase 1)\n* SLC22A5 (Glycerol-3-Phosphate Dehydrogenase 2)\n* SLC22A6 (Sugar Alcohol 3-Phosphate Dehydrogenase 2)\n* SLC22A7 (Fructose-Bisphosphate Aldolase 2)\n* SLC22A8 (Glycerol-3-phosphate Dehydrogenase 3)\n* SLC22A9 (Sugar Alcohol 3-Phosphate Dehydrogenase 3)\n* SLC22A10 (Fructose-Bisphosphate Aldolase 3)\nIt's worth noting that the SLC22A1 subfamily is also known as the \"fructose transporter\" subfamily, as many of its members are involved in the transport of fructose and other sugars.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the Solute Carrier (SLC) family of transmembrane proteins.\n2. FLVCR1 belongs to the SLC22A1 subfamily.\n3. The SLC22A1 subfamily is involved in the transport of endogenous and exogenous compounds, including amino acids, sugars, and xenobiotics.\n4. FLVCR1 is specifically involved in the transport of flavocoxid.\n5. The SLC22A1 subfamily is also known as the \"fructose transporter\" subfamily.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the Solute Carrier (SLC) family of transmembrane proteins.",
      "FLVCR1 belongs to the SLC22A1 subfamily.",
      "The SLC22A1 subfamily is involved in the transport of endogenous and exogenous compounds, including amino acids, sugars, and xenobiotics.",
      "FLVCR1 is specifically involved in the transport of flavocoxid.",
      "The SLC22A1 subfamily is also known as the \"fructose transporter\" subfamily."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: FLVCR1 belongs to the SLC49A subfamily.\n3. TRUE\n4. FALSE [correction]: FLVCR1 is specifically involved in the transport of feline leukemia virus subgroup C cellular receptor 1.\n5. FALSE [correction]: The SLC22A1 subfamily is also known as the \"organic cation transporter\" subfamily.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Certainly! GATA-1 is a transcription factor that plays a crucial role in regulating gene expression during erythropoiesis, the process of red blood cell production. The biotinylation tagging approach has been used to identify GATA-1 interacting partners, which are proteins that bind to and interact with GATA-1. Here are some of the key interacting partners of GATA-1 that have been identified using this approach:\n1. BCL-6: BCL-6 is a transcription factor that is involved in the regulation of GATA-1-dependent gene expression. Biotinylation tagging studies have shown that BCL-6 interacts with GATA-1 and is required for the proper activation of GATA-1-dependent genes.\n2. KLF-1: KLF-1 (Krueppel-like factor 1) is a transcription factor that has been shown to interact with GATA-1 and regulate the expression of GATA-1-dependent genes. Biotinylation tagging studies have demonstrated that KLF-1 binds to GATA-1 and is required for the proper function of GATA-1 in erythropoiesis.\n3. TFAP2A: TFAP2A (transcription factor AP-2 alpha) is a transcription factor that has been shown to interact with GATA-1 and regulate the expression of GATA-1-dependent genes. Biotinylation tagging studies have demonstrated that TFAP2A binds to GATA-1 and is required for the proper function of GATA-1 in erythropoiesis.\n4. TAL1: TAL1 (transcription factor 1) is a transcription factor that has been shown to interact with GATA-1 and regulate the expression of GATA-1-dependent genes. Biotinylation tagging studies have demonstrated that TAL1 binds to GATA-1 and is required for the proper function of GATA-1 in erythropoiesis.\n5. EKLF: EKLF (erythroid Krüppel-like factor) is a transcription factor that has been shown to interact with GATA-1 and regulate the expression of GATA-1-dependent genes.",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 is a transcription factor that regulates gene expression during erythropoiesis.\n2. BCL-6 is a transcription factor that interacts with GATA-1 and is involved in the regulation of GATA-1-dependent gene expression.\n3. KLF-1 (Krueppel-like factor 1) is a transcription factor that binds to GATA-1 and is required for GATA-1's function in erythropoiesis.\n4. TFAP2A (transcription factor AP-2 alpha) has been shown to bind to GATA-1, interacting with and affecting its function.\n5. TAL1 (transcription factor 1) binds to GATA-1 and is required for the proper function of GATA-1 in erythropoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 is a transcription factor that regulates gene expression during erythropoiesis.",
      "BCL-6 is a transcription factor that interacts with GATA-1 and is involved in the regulation of GATA-1-dependent gene expression.",
      "KLF-1 (Krueppel-like factor 1) is a transcription factor that binds to GATA-1 and is required for GATA-1's function in erythropoiesis.",
      "TFAP2A (transcription factor AP-2 alpha) has been shown to bind to GATA-1, interacting with and affecting its function.",
      "TAL1 (transcription factor 1) binds to GATA-1 and is required for the proper function of GATA-1 in erythropoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: KLF-1 (Krueppel-like factor 1) does not bind to GATA-1 but instead cooperates with GATA-1 to regulate erythroid gene expression.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (TATA-box protein 10) and GATA1 (GATA-binding protein 1) are both transcription factors that play critical roles in regulating gene expression in various cell types, including hematopoietic cells. When these two proteins interact, they can modulate the expression of target genes involved in hematopoiesis, immune response, and cell fate determination.\nStudies have shown that TAF10 and GATA1 interact in a complex manner, with TAF10 enhancing the activity of GATA1 by promoting its binding to specific DNA sequences. GATA1 is a transcription factor that recognizes and binds to the GATA motif, a specific DNA sequence found in the promoter regions of genes involved in hematopoiesis. TAF10 can also bind to the GATA motif, but it does so in a manner that enhances the binding of GATA1.\nThe outcome of TAF10 interacting with GATA1 can vary depending on the specific context and cell type. In general, the interaction between TAF10 and GATA1 can lead to the activation of genes involved in hematopoiesis, such as the expression of globin genes, which are responsible for the production of hemoglobin in red blood cells. TAF10 can also regulate the expression of genes involved in the differentiation and maturation of hematopoietic cells, such as the expression of cytokine receptors and signaling molecules.\nIn addition, the interaction between TAF10 and GATA1 can also influence the expression of genes involved in immune response and cell fate determination. For example, TAF10 can regulate the expression of genes involved in the production of cytokines and chemokines, which are important for immune cell function and activation. TAF10 can also influence the expression of genes involved in cell fate determination, such as the expression of genes involved in the maintenance of stem cell self-renewal or differentiation.\nOverall, the outcome of TAF10 interacting with GATA1 is complex and context-dependent, and can lead to the regulation of a wide range of genes involved in hematopoiesis, immune response, and cell fate determination.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 and GATA1 are transcription factors that regulate gene expression in various cell types, including hematopoietic cells.\n2. TAF10 enhances the activity of GATA1 by promoting its binding to specific DNA sequences.\n3. GATA1 recognizes and binds to the GATA motif in the promoter regions of genes involved in hematopoiesis.\n4. The interaction between TAF10 and GATA1 can activate genes involved in the production of hemoglobin in red blood cells.\n5. TAF10 can regulate the expression of cytokines and chemokines, important for immune cell function and activation.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 and GATA1 are transcription factors that regulate gene expression in various cell types, including hematopoietic cells.",
      "TAF10 enhances the activity of GATA1 by promoting its binding to specific DNA sequences.",
      "GATA1 recognizes and binds to the GATA motif in the promoter regions of genes involved in hematopoiesis.",
      "The interaction between TAF10 and GATA1 can activate genes involved in the production of hemoglobin in red blood cells.",
      "TAF10 can regulate the expression of cytokines and chemokines, important for immune cell function and activation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several decision support systems (DSS) available for chronic pain management. These systems are designed to help healthcare professionals and patients make informed decisions about the management of chronic pain, taking into account various factors such as the type and severity of the pain, the patient's medical history, and the available treatment options.\nHere are some examples of DSS for chronic pain management:\n1. Chronic Pain Management Decision Support System (CPMDSS): This system is a web-based tool that provides healthcare professionals with evidence-based recommendations for the management of chronic pain. It takes into account the patient's medical history, current symptoms, and treatment preferences to provide personalized recommendations.\n2. Pain-Q: This is a mobile app that provides patients with a personalized pain management plan based on their medical history and current symptoms. It also offers a pain diary and medication reminders to help patients track their pain and adhere to their treatment plan.\n3. Pain-Rx: This is a web-based tool that provides healthcare professionals with a comprehensive database of pain management medications, including their mechanisms of action, side effects, and drug interactions. It also offers decision support algorithms to help healthcare professionals choose the most appropriate medication for each patient.\n4. Pain-Mind: This is a mobile app that provides patients with cognitive-behavioral therapy (CBT) techniques and strategies to manage chronic pain. It also offers a pain diary and relaxation exercises to help patients manage their pain.\n5. Pain-Tracker: This is a mobile app that allows patients to track their pain levels and symptoms over time. It also offers a pain diary and medication reminders to help patients stay on top of their pain management plan.\n6. Pain-Pro: This is a web-based tool that provides healthcare professionals with a comprehensive database of pain management resources, including articles, videos, and continuing education courses. It also offers decision support algorithms to help healthcare professionals stay up-to-date on the latest pain management research and best practices.\n7. Pain-Coach: This is a mobile app that provides patients with personalized coaching and support for managing chronic pain. It offers a pain diary, medication remind",
    "llama-2-7b-chat-hf_fact_raw": "1. Chronic Pain Management Decision Support System (CPMDSS) is a web-based tool for the management of chronic pain.\n2. Pain-Q is a mobile app that offers a personalized pain management plan and medication reminders.\n3. Pain-Rx is a web-based tool with a database of pain management medications and decision support algorithms.\n4. Pain-Mind is a mobile app that provides cognitive-behavioral therapy techniques for managing chronic pain.\n5. Pain-Tracker is a mobile app that allows patients to track pain levels and symptoms over time.",
    "llama-2-7b-chat-hf_fact": [
      "Chronic Pain Management Decision Support System (CPMDSS) is a web-based tool for the management of chronic pain.",
      "Pain-Q is a mobile app that offers a personalized pain management plan and medication reminders.",
      "Pain-Rx is a web-based tool with a database of pain management medications and decision support algorithms.",
      "Pain-Mind is a mobile app that provides cognitive-behavioral therapy techniques for managing chronic pain.",
      "Pain-Tracker is a mobile app that allows patients to track pain levels and symptoms over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: There is no provided context to confirm the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that plays a crucial role in angiogenesis, the process of blood vessel formation. It is a member of the interferon-induced protein 1 (IFITM) family and is primarily localized to the endoplasmic reticulum (ER) and the Golgi apparatus.\nAngiogenin is synthesized in the cytoplasm as an inactive precursor protein, which is then processed to produce the mature, active protein. The mature angiogenin protein is then transported to the ER and Golgi apparatus, where it is stored and ready to be secreted.\nOnce secreted, angiogenin can traffic to various cellular compartments, including the plasma membrane, the extracellular space, and the subcellular compartments. Within these compartments, angiogenin can interact with various cellular proteins and play a role in regulating various cellular processes, including cell signaling, adhesion, and migration.\nIn terms of subcellular localization, angiogenin has been shown to localize to various subcellular compartments, including:\n1. Endoplasmic reticulum (ER): Angiogenin is primarily localized to the ER, where it is involved in the regulation of protein synthesis and folding.\n2. Golgi apparatus: Angiogenin is also localized to the Golgi apparatus, where it is involved in the regulation of protein transport and secretion.\n3. Plasma membrane: Angiogenin can also localize to the plasma membrane, where it can interact with various cellular proteins and play a role in cell signaling and adhesion.\n4. Extracellular space: Angiogenin can also localize to the extracellular space, where it can interact with other proteins and play a role in regulating various cellular processes, including cell migration and invasion.\n5. Subcellular compartments: Angiogenin has also been shown to localize to various subcellular compartments, including lysosomes, mitochondria, and the nucleus.\nIn summary, angiogenin is primarily localized to the ER and Golgi apparatus, but it can also traffic to other subcellular compartments, including the plasma membrane",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is primarily localized to the endoplasmic reticulum (ER) and the Golgi apparatus.\n2. The mature angiogenin protein is stored and ready to be secreted in the ER and Golgi apparatus.\n3. Angiogenin can interact with various cellular proteins within subcellular compartments, including the plasma membrane, extracellular space, and subcellular compartments.\n4. Angiogenin has been shown to localize to the plasma membrane and play a role in cell signaling and adhesion.\n5. Angiogenin can also localize to the extracellular space, lysosomes, mitochondria, and the nucleus.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is primarily localized to the endoplasmic reticulum (ER) and the Golgi apparatus.",
      "The mature angiogenin protein is stored and ready to be secreted in the ER and Golgi apparatus.",
      "Angiogenin can interact with various cellular proteins within subcellular compartments, including the plasma membrane, extracellular space, and subcellular compartments.",
      "Angiogenin has been shown to localize to the plasma membrane and play a role in cell signaling and adhesion.",
      "Angiogenin can also localize to the extracellular space, lysosomes, mitochondria, and the nucleus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Angiogenin is primarily localized to the nucleus and the cytoplasm.\n2. FALSE [correction]: The mature angiogenin protein is not stored in the ER and Golgi apparatus. It is released from cells to act in the extracellular environment.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a medication that is primarily used to treat angina, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. While its primary mechanism of action is to improve blood flow to the heart, ranolazine has been shown to have additional effects on kinase signaling activation in the heart.\nKinases are enzymes that play a crucial role in various cellular signaling pathways, including those involved in cardiac function. In the heart, kinases are involved in the regulation of contraction, relaxation, and electrical conduction. Dysregulation of kinase signaling can lead to various cardiac diseases, including hypertension, heart failure, and arrhythmias.\nRanolazine has been shown to affect kinase signaling activation in the heart in several ways:\n1. Inhibition of the L-type calcium channel: Ranolazine binds to the L-type calcium channel, which is responsible for the influx of calcium ions into the cardiac muscle cell. This inhibition can lead to a decrease in the activation of the enzyme protein kinase C (PKC), which is involved in the regulation of contraction and relaxation of the heart muscle.\n2. Activation of the ATP-sensitive potassium channel: Ranolazine also activates the ATP-sensitive potassium channel, which is responsible for the efflux of potassium ions from the cardiac muscle cell. This can lead to a decrease in the activation of the enzyme mitogen-activated protein kinase (MAPK), which is involved in the regulation of cell proliferation and differentiation.\n3. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway: Ranolazine has been shown to inhibit the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and proliferation.\n4. Modulation of the extracellular signal-regulated kinase (ERK) pathway: Ranolazine has been shown to modulate the ERK pathway, which is involved in the regulation of cell proliferation, differentiation, and survival.\n5",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine is primarily used to treat angina by improving blood flow to the heart muscle.\n2. Kinases are enzymes involved in the regulation of contraction, relaxation, and electrical conduction in the heart.\n3. Ranolazine inhibits the L-type calcium channel, potentially decreasing the activation of protein kinase C in the heart muscle.\n4. Ranolazine activates the ATP-sensitive potassium channel, which may decrease the activation of mitogen-activated protein kinase in the cardiac muscle cell.\n5. Ranolazine has been shown to inhibit the phosphatidylinositol 3-kinase/Akt signaling pathway in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine is primarily used to treat angina by improving blood flow to the heart muscle.",
      "Kinases are enzymes involved in the regulation of contraction, relaxation, and electrical conduction in the heart.",
      "Ranolazine inhibits the L-type calcium channel, potentially decreasing the activation of protein kinase C in the heart muscle.",
      "Ranolazine activates the ATP-sensitive potassium channel, which may decrease the activation of mitogen-activated protein kinase in the cardiac muscle cell.",
      "Ranolazine has been shown to inhibit the phosphatidylinositol 3-kinase/Akt signaling pathway in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Vsr endonuclease is an enzyme that plays a crucial role in the bacterial SOS response, a mechanism that helps bacteria repair DNA damage caused by environmental stressors or mutations. The regulation of Vsr endonuclease is complex and involves multiple factors, including transcriptional regulation, post-transcriptional modification, and protein-protein interactions.\nWhile the regulation of Vsr endonuclease is not directly linked to the growth phase of bacteria, there are some indirect connections. For example, the SOS response is typically induced in response to DNA damage, which can occur at any time during the growth cycle of bacteria. Therefore, the regulation of Vsr endonuclease is indirectly linked to the growth phase through the induction of the SOS response.\nIn addition, some studies have shown that the expression of Vsr endonuclease is influenced by the availability of nutrients and the growth phase of the bacteria. For example, in E. coli, the expression of vsr is repressed in the stationary phase of growth, when nutrients are scarce, and induced in the exponential phase, when nutrients are abundant. This suggests that the regulation of Vsr endonuclease is not solely dependent on the growth phase but also on the availability of nutrients.\nIn summary, while the regulation of Vsr endonuclease is not directly linked to the growth phase of bacteria, there are indirect connections through the induction of the SOS response and the availability of nutrients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vsr endonuclease is involved in the bacterial SOS response to repair DNA damage.\n2. The regulation of Vsr endonuclease involves transcriptional regulation, post-transcriptional modification, and protein-protein interactions.\n3. The SOS response in bacteria can be induced at any time during the growth cycle.\n4. Expression of Vsr endonuclease in E. coli is repressed during the stationary phase of growth.\n5. Expression of Vsr endonuclease in E. coli is induced during the exponential phase of growth.",
    "llama-2-7b-chat-hf_fact": [
      "Vsr endonuclease is involved in the bacterial SOS response to repair DNA damage.",
      "The regulation of Vsr endonuclease involves transcriptional regulation, post-transcriptional modification, and protein-protein interactions.",
      "The SOS response in bacteria can be induced at any time during the growth cycle.",
      "Expression of Vsr endonuclease in E. coli is repressed during the stationary phase of growth.",
      "Expression of Vsr endonuclease in E. coli is induced during the exponential phase of growth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The SOS response in bacteria is generally induced following DNA damage, and it is not accurate to say that it can be induced at any time during the growth cycle without specific triggers.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Computational tools for the prediction of beta-barrel transmembrane proteins are software programs that use algorithms and statistical models to predict the structure and function of these proteins. Here are some of the commonly used computational tools for predicting beta-barrel transmembrane proteins:\n1. BARLIGHT: BARLIGHT is a web server that uses a combination of sequence analysis and structural modeling techniques to predict the structure and function of beta-barrel transmembrane proteins. It can predict the transmembrane helices, the membrane-spanning domain, and the binding sites of the protein.\n2. TMHMM: TMHMM is a widely used tool for predicting the transmembrane helices of beta-barrel transmembrane proteins. It uses a combination of sequence analysis and structural modeling techniques to predict the transmembrane helices and their orientation in the membrane.\n3. PredictProtein: PredictProtein is a web server that can predict the structure and function of beta-barrel transmembrane proteins. It uses a combination of sequence analysis and structural modeling techniques to predict the transmembrane helices, the membrane-spanning domain, and the binding sites of the protein.\n4. Phobius: Phobius is a web server that uses a combination of sequence analysis and structural modeling techniques to predict the structure and function of beta-barrel transmembrane proteins. It can predict the transmembrane helices, the membrane-spanning domain, and the binding sites of the protein.\n5. TOPP: TOPP is a web server that uses a combination of sequence analysis and structural modeling techniques to predict the structure and function of beta-barrel transmembrane proteins. It can predict the transmembrane helices, the membrane-spanning domain, and the binding sites of the protein.\n6. Membrane Protein Structure Prediction (MPSP): MPSP is a web server that uses a combination of sequence analysis and structural modeling techniques to predict the structure of beta-barrel transmembrane proteins. It can predict the transmembrane helices, the membrane-spanning domain, and the binding sites of the protein.\n7. PHD-TOP: PHD-TOP is a web server that uses a combination of",
    "llama-2-7b-chat-hf_fact_raw": "1. BARLIGHT is a web server that predicts the structure and function of beta-barrel transmembrane proteins.\n2. TMHMM is a tool used for predicting the transmembrane helices of beta-barrel transmembrane proteins.\n3. PredictProtein is a web server that can predict the structure and function of beta-barrel transmembrane proteins.\n4. Phobius is a web server that predicts the structure and function of beta-barrel transmembrane proteins.\n5. MPSP is a web server that predicts the structure of beta-barrel transmembrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "BARLIGHT is a web server that predicts the structure and function of beta-barrel transmembrane proteins.",
      "TMHMM is a tool used for predicting the transmembrane helices of beta-barrel transmembrane proteins.",
      "PredictProtein is a web server that can predict the structure and function of beta-barrel transmembrane proteins.",
      "Phobius is a web server that predicts the structure and function of beta-barrel transmembrane proteins.",
      "MPSP is a web server that predicts the structure of beta-barrel transmembrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TMHMM is a tool used for predicting transmembrane helices in proteins, not specifically for beta-barrel transmembrane proteins.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is a system used to classify and diagnose eating disorders, specifically binge eating disorder (BED) and bulimia nervosa (BN). The Galassi classification system was developed by Dr. Carolyn Galassi and her colleagues in 2006, and it is based on a comprehensive evaluation of the individual's symptoms, behaviors, and psychological characteristics.\nThe Galassi classification system uses a hierarchical structure to categorize eating disorders into three main categories:\n1. Binge Eating Disorder (BED): This category includes individuals who experience recurrent episodes of binge eating, which is defined as consuming large amounts of food in a short period of time, often accompanied by feelings of guilt, shame, or self-criticism. BED can also involve other symptoms such as avoidance of dieting, feelings of lack of control over eating, and preoccupation with food.\n2. Bulimia Nervosa (BN): This category includes individuals who experience recurrent episodes of binge eating, followed by behaviors such as self-induced vomiting, laxative use, or excessive exercise to try to compensate for the consumed calories. BN can also involve other symptoms such as fear of gaining weight, body image distortion, and difficulty maintaining relationships.\n3. Other Specified Feeding or Eating Disorders (OSFED): This category includes individuals who experience symptoms of an eating disorder that do not meet the full criteria for BED or BN, but are still causing significant distress and impairment in their daily life. Examples of OSFED include avoidant/restrictive food intake disorder (ARFID), pica, and other specified feeding or eating disorders.\nIt's important to note that the Galassi classification system is not a substitute for a comprehensive clinical evaluation and diagnosis by a qualified mental health professional. If you or someone you know is experiencing symptoms of an eating disorder, it's important to seek professional help from a licensed therapist or psychologist.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification system is used to classify and diagnose eating disorders.\n2. It was developed by Dr. Carolyn Galassi and her colleagues in 2006.\n3. The system categorizes eating disorders into three main categories: Binge Eating Disorder (BED), Bulimia Nervosa (BN), and Other Specified Feeding or Eating Disorders (OSFED).\n4. BED is characterized by recurrent episodes of binge eating with feelings of guilt, shame, or self-criticism.\n5. BN involves recurrent episodes of binge eating followed by compensatory behaviors such as self-induced vomiting or excessive exercise.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification system is used to classify and diagnose eating disorders.",
      "It was developed by Dr. Carolyn Galassi and her colleagues in 2006.",
      "The system categorizes eating disorders into three main categories: Binge Eating Disorder (BED), Bulimia Nervosa (BN), and Other Specified Feeding or Eating Disorders (OSFED).",
      "BED is characterized by recurrent episodes of binge eating with feelings of guilt, shame, or self-criticism.",
      "BN involves recurrent episodes of binge eating followed by compensatory behaviors such as self-induced vomiting or excessive exercise."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification system is not used for classifying and diagnosing eating disorders; it is a system used for classifying pleural effusion (fluid in the pleura of the lung).\n2. UNKNOWN\n3. FALSE [correction]: Eating disorders are classified into categories such as Anorexia Nervosa (AN), Bulimia Nervosa (BN), Binge Eating Disorder (BED), and Other Specified Feeding or Eating Disorder (OSFED) in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), not the Galassi classification system.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro-Thyroiditis, is a rare autoimmune disorder that affects the thyroid gland. It is characterized by the presence of autoantibodies that attack the thyroid gland, leading to inflammation and damage to the gland. Here are some common features of Shapiro syndrome:\n1. Thyroiditis: Shapiro syndrome is characterized by inflammation of the thyroid gland, which can lead to the formation of nodules or lumps in the gland.\n2. Autoantibodies: People with Shapiro syndrome produce autoantibodies that attack the thyroid gland, leading to inflammation and damage to the gland. These autoantibodies can also affect other parts of the body, such as the skin and joints.\n3. Hypothyroidism: Shapiro syndrome can cause hypothyroidism, a condition in which the thyroid gland does not produce enough thyroid hormones. This can lead to symptoms such as fatigue, weight gain, and cold intolerance.\n4. Thyroid nodules: Shapiro syndrome can cause the formation of nodules or lumps in the thyroid gland, which can be benign or malignant.\n5. Eye problems: Shapiro syndrome can cause eye problems such as dry eyes, eye pain, and vision loss.\n6. Skin problems: Shapiro syndrome can cause skin problems such as rashes, itching, and skin thickening.\n7. Joint problems: Shapiro syndrome can cause joint problems such as pain, stiffness, and swelling in the joints.\n8. Neurological problems: Shapiro syndrome can cause neurological problems such as headaches, memory loss, and difficulty concentrating.\n9. Hair loss: Shapiro syndrome can cause hair loss, particularly on the scalp.\n10. Fatigue: Shapiro syndrome can cause fatigue, which can be severe in some cases.\n11. Weight gain: Shapiro syndrome can cause weight gain, particularly in the midsection.\n12. Cold intolerance: Shapiro syndrome can cause cold intolerance,",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is an autoimmune disorder that affects the thyroid gland.\n2. The condition is characterized by the presence of autoantibodies that attack the thyroid gland.\n3. Shapiro syndrome can cause hypothyroidism, leading to symptoms such as fatigue, weight gain, and cold intolerance.\n4. The syndrome can lead to the formation of nodules or lumps in the thyroid gland.\n5. Shapiro syndrome can cause eye, skin, joint, and neurological problems, as well as hair loss, fatigue, and weight gain.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is an autoimmune disorder that affects the thyroid gland.",
      "The condition is characterized by the presence of autoantibodies that attack the thyroid gland.",
      "Shapiro syndrome can cause hypothyroidism, leading to symptoms such as fatigue, weight gain, and cold intolerance.",
      "The syndrome can lead to the formation of nodules or lumps in the thyroid gland.",
      "Shapiro syndrome can cause eye, skin, joint, and neurological problems, as well as hair loss, fatigue, and weight gain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is not an autoimmune disorder that affects the thyroid gland; it is a rare neurological condition characterized by recurrent episodes of hypothermia and sweating.\n2. FALSE [correction]: The condition is not characterized by the presence of autoantibodies that attack the thyroid gland.\n3. FALSE [correction]: Shapiro syndrome does not cause hypothyroidism. The symptoms listed are associated with hypothyroidism, not Shapiro syndrome.\n4. FALSE [correction]: Shapiro syndrome does not lead to the formation of nodules or lumps in the thyroid gland.\n5. FALSE [correction]: Shapiro syndrome does not cause eye, skin, joint, and neurological problems, nor does it cause hair loss, fatigue, and weight gain. These are symptoms of other conditions, not Shapiro syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 (BRAG1-related gene 1) is a gene that has been associated with several diseases, primarily due to mutations in the gene. Here are some of the diseases linked to mutations within BRAG1:\n1. Bragg-Gaudin Syndrome: Bragg-Gaudin syndrome is a rare genetic disorder caused by mutations in the BRAG1 gene. It is characterized by a range of symptoms including intellectual disability, seizures, delayed speech and language development, and distinctive facial features.\n2. Intellectual Disability: Mutations in the BRAG1 gene have been identified as a cause of intellectual disability, which is a neurodevelopmental disorder characterized by below-average intelligence and cognitive abilities.\n3. Autism Spectrum Disorder (ASD): Some studies have suggested that mutations in the BRAG1 gene may increase the risk of developing autism spectrum disorder (ASD), a neurodevelopmental disorder characterized by social and communication impairments.\n4. Schizophrenia: Research has also implicated the BRAG1 gene in the development of schizophrenia, a mental illness characterized by hallucinations, delusions, and disorganized thinking.\n5. Epilepsy: Mutations in the BRAG1 gene have been linked to an increased risk of epilepsy, a neurological disorder characterized by seizures.\n6. Neurofibromatosis Type 1 (NF1): Some studies have suggested that mutations in the BRAG1 gene may increase the risk of developing neurofibromatosis type 1 (NF1), a genetic disorder characterized by the growth of benign tumors on nerves.\n7. Cancer: Mutations in the BRAG1 gene have been identified in various types of cancer, including breast, ovarian, and colorectal cancer.\nIt is important to note that the above list is not exhaustive and the BRAG1 gene has been implicated in other diseases as well. Additionally, the severity of the disease symptoms can vary greatly depending on the specific mutation and the individual affected.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the BRAG1 gene can cause Bragg-Gaudin syndrome, characterized by intellectual disability, seizures, and distinctive facial features.\n2. Intellectual disability has been identified as a result of mutations in the BRAG1 gene.\n3. Studies suggest a link between mutations in the BRAG1 gene and an increased risk of autism spectrum disorder (ASD).\n4. The BRAG1 gene has been implicated in the development of schizophrenia.\n5. Mutations in the BRAG1 gene have been linked to an increased risk of epilepsy.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the BRAG1 gene can cause Bragg-Gaudin syndrome, characterized by intellectual disability, seizures, and distinctive facial features.",
      "Intellectual disability has been identified as a result of mutations in the BRAG1 gene.",
      "Studies suggest a link between mutations in the BRAG1 gene and an increased risk of autism spectrum disorder (ASD).",
      "The BRAG1 gene has been implicated in the development of schizophrenia.",
      "Mutations in the BRAG1 gene have been linked to an increased risk of epilepsy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Protein phosphatase 1 (PP1) is an enzyme that dephosphorylates various protein substrates, playing a crucial role in various cellular processes, including signal transduction, cell cycle regulation, and protein degradation. PP1 is inhibited by several proteins, but the main inhibitor of PP1 is the protein called \"PP1-specific inhibitor 1\" (PIN1).\nPIN1 was first identified in the early 1990s and was found to be a specific inhibitor of PP1. PIN1 is a 14-kDa protein that contains a conserved N-terminal domain, which is responsible for its inhibitory activity towards PP1. PIN1 binds to the active site of PP1, thereby preventing the enzyme from dephosphorylating its substrates.\nPIN1 has been shown to play a crucial role in various cellular processes, including cell cycle regulation, apoptosis, and stress responses. For example, PIN1 has been shown to inhibit the activity of PP1 during the G1/S checkpoint, thereby preventing uncontrolled cell proliferation. PIN1 has also been shown to play a role in the regulation of apoptosis, with PP1 being a key player in the execution of apoptotic signals.\nIn addition to PIN1, there are other proteins that have been identified as inhibitors of PP1, including protein phosphatase 2A (PP2A), protein phosphatase 2B (PP2B), and the tumor suppressor protein, p53. However, PIN1 is the most well-studied and well-characterized inhibitor of PP1, and it is the main inhibitor of PP1 in most cellular contexts.\nIn summary, the main inhibitor of protein phosphatase 1 (PP1) is PP1-specific inhibitor 1 (PIN1), a 14-kDa protein that binds to the active site of PP1 and prevents the enzyme from dephosphorylating its substrates.",
    "llama-2-7b-chat-hf_fact_raw": "1. The main inhibitor of protein phosphatase 1 (PP1) is a protein called \"PP1-specific inhibitor 1\" (PIN1).\n2. PIN1 was first identified in the early 1990s as a specific inhibitor of PP1.\n3. The inhibitory activity of PIN1 towards PP1 is due to its conserved N-terminal domain.\n4. PIN1 plays a role in various cellular processes, such as cell cycle regulation, apoptosis, and stress responses.\n5. PIN1 inhibits the activity of PP1 during the G1/S checkpoint to prevent uncontrolled cell proliferation.",
    "llama-2-7b-chat-hf_fact": [
      "The main inhibitor of protein phosphatase 1 (PP1) is a protein called \"PP1-specific inhibitor 1\" (PIN1).",
      "PIN1 was first identified in the early 1990s as a specific inhibitor of PP1.",
      "The inhibitory activity of PIN1 towards PP1 is due to its conserved N-terminal domain.",
      "PIN1 plays a role in various cellular processes, such as cell cycle regulation, apoptosis, and stress responses.",
      "PIN1 inhibits the activity of PP1 during the G1/S checkpoint to prevent uncontrolled cell proliferation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The main inhibitor of protein phosphatase 1 (PP1) is not a protein called \"PP1-specific inhibitor 1\" (PIN1), but rather \"Inhibitor-1\" (I-1) or \"Inhibitor-2\" (I-2).\n2. FALSE [correction]: PIN1 was first identified in the early 1990s, but it is not a specific inhibitor of PP1.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria such as Bacillus subtilis generate genetic mutations in response to environmental cues, particularly during stationary phase. This process is a form of adaptive evolution, where bacteria evolve to better survive and persist in their environment.\nThere are several mechanisms that underlie adaptive mutagenesis in Bacillus subtilis:\n1. DNA damage response: Bacillus subtilis has a robust DNA damage response system that can induce mutations in response to DNA damage. This system includes the SOS response, which is a global response to DNA damage that involves the activation of various enzymes and repair pathways. The SOS response can lead to the formation of mutations, including point mutations, insertions, and deletions.\n2. Base excision repair (BER): BER is a repair pathway that removes damaged or incorrect bases from DNA. In Bacillus subtilis, BER is mediated by several enzymes, including DNA glycosylases, apurinic/apyrimidinic endonucleases, and DNA polymerases. During stationary phase, the levels of damaged DNA bases can increase, leading to an increased mutation rate.\n3. Mismatch repair (MMR): MMR is a repair pathway that corrects mismatched bases that have been improperly paired during DNA replication. In Bacillus subtilis, MMR is mediated by several enzymes, including the MutS and MutL proteins. During stationary phase, the levels of mismatched bases can increase, leading to an increased mutation rate.\n4. Recombinational repair: Recombinational repair is a repair pathway that involves the exchange of genetic material between two homologous DNA molecules. In Bacillus subtilis, recombinational repair is mediated by the RecA protein. During stationary phase, the levels of DNA damage can increase, leading to an increased mutation rate.\n5. Programmed mutation (PM): PM is a mechanism by which bacteria can intentionally introduce mutations into their genome. In Bacillus subtilis, PM is mediated by the PM-1 protein, which can introduce specific mutations into the genome",
    "llama-2-7b-chat-hf_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis is a response to environmental cues during the stationary phase.\n2. The DNA damage response in Bacillus subtilis includes the SOS response, which can lead to mutations.\n3. Base excision repair in Bacillus subtilis involves DNA glycosylases, apurinic/apyrimidinic endonucleases, and DNA polymerases.\n4. Mismatch repair in Bacillus subtilis is mediated by the MutS and MutL proteins.\n5. Recombinational repair in Bacillus subtilis is mediated by the RecA protein.",
    "llama-2-7b-chat-hf_fact": [
      "Adaptive mutagenesis in Bacillus subtilis is a response to environmental cues during the stationary phase.",
      "The DNA damage response in Bacillus subtilis includes the SOS response, which can lead to mutations.",
      "Base excision repair in Bacillus subtilis involves DNA glycosylases, apurinic/apyrimidinic endonucleases, and DNA polymerases.",
      "Mismatch repair in Bacillus subtilis is mediated by the MutS and MutL proteins.",
      "Recombinational repair in Bacillus subtilis is mediated by the RecA protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erythromelalgia, is a rare and complex disorder characterized by episodes of intense burning pain, redness, and warmth in the hands and feet. The exact cause of erucism is not fully understood, but research suggests that it may be related to abnormalities in the nervous system, particularly in the nerves that control blood flow and temperature regulation.\nThere are several potential causes and contributing factors that may trigger or exacerbate erucism, including:\n1. Genetic mutations: Some cases of erucism have been linked to genetic mutations, particularly in the genes that code for proteins involved in the regulation of blood flow and temperature.\n2. Autoimmune disorders: Erucism may be associated with autoimmune disorders, such as rheumatoid arthritis or lupus, which can cause inflammation and damage to the nerves.\n3. Nerve compression or injury: Compression or injury to the nerves that control blood flow and temperature can cause erucism. This may occur due to trauma, surgery, or repetitive motion injuries.\n4. Neurological disorders: Certain neurological disorders, such as multiple sclerosis or peripheral neuropathy, can cause erucism by affecting the nerves that control blood flow and temperature.\n5. Infections: Infections, such as Lyme disease or shingles, can cause erucism by affecting the nerves that control blood flow and temperature.\n6. Medications: Certain medications, such as beta blockers, can cause erucism as a side effect.\n7. Hormonal changes: Hormonal changes, such as those that occur during pregnancy or menopause, can cause erucism in some individuals.\n8. Other medical conditions: Certain medical conditions, such as hypothyroidism or anemia, can cause erucism by affecting the nerves that control blood flow and temperature.\nIt is important to note that erucism is a rare disorder, and the exact cause may not be identified in some cases. A thorough medical evaluation and diagnostic testing are necessary to determine the underlying cause of erucism in an individual.\nTreatment for erucism typically",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism may be related to abnormalities in the nervous system, particularly in the nerves that control blood flow and temperature regulation.\n2. Genetic mutations in genes that code for proteins involved in the regulation of blood flow and temperature have been linked to some cases of erucism.\n3. Autoimmune disorders, such as rheumatoid arthritis or lupus, may be associated with erucism by causing inflammation and damage to the nerves.\n4. Compression or injury to nerves that control blood flow and temperature can cause erucism.\n5. Infections like Lyme disease or shingles can affect the nerves that control blood flow and temperature, resulting in erucism.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism may be related to abnormalities in the nervous system, particularly in the nerves that control blood flow and temperature regulation.",
      "Genetic mutations in genes that code for proteins involved in the regulation of blood flow and temperature have been linked to some cases of erucism.",
      "Autoimmune disorders, such as rheumatoid arthritis or lupus, may be associated with erucism by causing inflammation and damage to the nerves.",
      "Compression or injury to nerves that control blood flow and temperature can cause erucism.",
      "Infections like Lyme disease or shingles can affect the nerves that control blood flow and temperature, resulting in erucism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: \"Erucism\" usually refers to skin irritation caused by contact with certain caterpillars, not a condition related to the nervous system. It seems possible that the statements may be mixing up or confusing terms. Without clear context or definitions, the truth of these statements cannot be determined.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat a variety of medical conditions. Here are some of the most common indications for hydrochlorothiazide:\n1. Hypertension (High Blood Pressure): Hydrochlorothiazide is often used to treat hypertension, or high blood pressure, as it helps to reduce the amount of fluid in the body and lower blood pressure.\n2. Heart Failure: Hydrochlorothiazide can help to reduce the workload on the heart in people with heart failure, as it helps to reduce the amount of fluid in the body and improve blood flow.\n3. Kidney Disease: Hydrochlorothiazide can help to reduce the amount of fluid in the body and improve urine production in people with kidney disease, as it helps to increase the amount of urine produced.\n4. Edema (Fluid Retention): Hydrochlorothiazide is often used to treat edema, or fluid retention, in the legs, ankles, and feet.\n5. Nephrotic Syndrome: Hydrochlorothiazide can help to reduce the amount of protein in the urine in people with nephrotic syndrome, a condition in which the kidneys leak large amounts of protein into the urine.\n6. Type 2 Diabetes: Hydrochlorothiazide can help to improve blood sugar control in people with type 2 diabetes, as it helps to increase insulin sensitivity and reduce the amount of glucose in the blood.\n7. Gastrointestinal Diseases: Hydrochlorothiazide can help to treat gastrointestinal diseases such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) by reducing fluid retention and improving bowel function.\n8. Cystitis: Hydrochlorothiazide can help to treat cystitis, a bladder infection caused by bacteria, by reducing the amount of fluid in the bladder and improving urine production.\n9. Prostatitis: Hydrochlorothiazide can help to treat prostatitis, a condition in which the prostate gland becomes",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension by reducing the amount of fluid in the body and lowering blood pressure.\n2. Hydrochlorothiazide is used to reduce the workload on the heart in people with heart failure.\n3. Hydrochlorothiazide is used to improve urine production in people with kidney disease.\n4. Hydrochlorothiazide is used to treat edema or fluid retention in the legs, ankles, and feet.\n5. Hydrochlorothiazide can help to reduce the amount of protein in the urine in people with nephrotic syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat hypertension by reducing the amount of fluid in the body and lowering blood pressure.",
      "Hydrochlorothiazide is used to reduce the workload on the heart in people with heart failure.",
      "Hydrochlorothiazide is used to improve urine production in people with kidney disease.",
      "Hydrochlorothiazide is used to treat edema or fluid retention in the legs, ankles, and feet.",
      "Hydrochlorothiazide can help to reduce the amount of protein in the urine in people with nephrotic syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Hydrochlorothiazide is not typically used to reduce the amount of protein in the urine for people with nephrotic syndrome; other medications such as ACE inhibitors or ARBs are commonly used for this purpose.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Silicon is a versatile material that has been used in various medical applications, including the treatment of urinary incontinence.\nThere are several ways in which silicon is used in the treatment of incontinence:\n1. Silicon-based meshes: Silicon-based meshes are used to treat stress urinary incontinence (SUI), which is the most common type of urinary incontinence. These meshes are made of a porous, silicon-based material that is implanted in the pelvic floor to support the urethra and prevent leakage.\n2. Silicon catheters: Silicon catheters are used to treat urinary retention, which is the inability to urinate due to a blockage in the urinary tract. Silicon catheters are flexible and can be inserted through the urethra to drain urine from the bladder.\n3. Silicon-coated implants: Some implants, such as pelvic floor implants, are coated with a layer of silicon to improve their biocompatibility and reduce the risk of inflammation or rejection.\n4. Silicon-based drug delivery systems: Silicon-based drug delivery systems are being developed to treat urinary incontinence. These systems use silicon-based materials to deliver drugs directly to the bladder or urethra, reducing the risk of side effects and improving the effectiveness of the treatment.\n5. Silicon-based sensors: Silicon-based sensors are being developed to detect changes in the bladder and urethra that can indicate urinary incontinence. These sensors can be implanted in the body and can provide real-time feedback to help diagnose and treat incontinence.\nSilicon has several advantages as a material for treating incontinence. It is biocompatible, meaning it does not cause an immune response or rejection in the body. It is also flexible and can be shaped to fit the specific needs of each patient. Additionally, silicon is relatively inexpensive and can be easily produced in large quantities, making it a cost-effective material for medical devices.\nHowever, it is important to note that silicon is not a cure for incontinence",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of urinary incontinence.\n2. Silicon-based meshes are implanted in the pelvic floor to support the urethra and prevent leakage in stress urinary incontinence treatment.\n3. Silicon catheters are used to drain urine from the bladder in cases of urinary retention.\n4. Silicon-coated implants, such as pelvic floor implants, are used to improve biocompatibility and reduce inflammation or rejection risks.\n5. Silicon-based drug delivery systems are being developed to deliver drugs directly to the bladder or urethra in urinary incontinence treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of urinary incontinence.",
      "Silicon-based meshes are implanted in the pelvic floor to support the urethra and prevent leakage in stress urinary incontinence treatment.",
      "Silicon catheters are used to drain urine from the bladder in cases of urinary retention.",
      "Silicon-coated implants, such as pelvic floor implants, are used to improve biocompatibility and reduce inflammation or rejection risks.",
      "Silicon-based drug delivery systems are being developed to deliver drugs directly to the bladder or urethra in urinary incontinence treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of urinary incontinence.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Intracranial aneurysms are abnormal bulges or balloon-like pouches that can occur in the blood vessels of the brain. While the exact cause of intracranial aneurysms is not fully understood, research has suggested that there may be an association between the moon cycle and the risk of rupture for these aneurysms. Here are some details on the possible link between the moon cycle and intracranial aneurysm rupture risk:\n1. Hormonal changes: The moon cycle is associated with changes in hormone levels, particularly estrogen and progesterone. These hormonal fluctuations have been linked to changes in blood vessel diameter and blood pressure, which can affect the integrity of blood vessels in the brain and increase the risk of aneurysm rupture.\n2. Barometric pressure: The moon cycle is also associated with changes in barometric pressure, which can affect the pressure inside the skull and increase the risk of aneurysm rupture. Some studies have suggested that changes in barometric pressure may be more pronounced during the full moon phase, which may increase the risk of aneurysm rupture during this time.\n3. Sleep patterns: The moon cycle can also affect sleep patterns, with some studies suggesting that people are more likely to experience insomnia and other sleep disruptions during the full moon phase. Disrupted sleep patterns can increase the risk of aneurysm rupture, as the brain is more susceptible to changes in blood pressure and other physiological factors during these times.\n4. Genetic predisposition: Some studies have suggested that there may be a genetic component to the association between the moon cycle and intracranial aneurysm rupture risk. For example, certain genetic variations may affect the way the body responds to hormonal changes or barometric pressure fluctuations, increasing the risk of aneurysm rupture during the full moon phase.\n5. Other factors: Other factors that may contribute to the association between the moon cycle and intracranial aneurysm rupture risk include changes in altitude, exposure to bright light, and certain environmental factors. For example, people who live at high altitudes may be more susceptible to aneurysm rupture during the full moon phase due to changes in",
    "llama-2-7b-chat-hf_fact_raw": "1. Research has suggested an association between the moon cycle and the risk of rupture for intracranial aneurysms.\n2. Hormonal changes, particularly in estrogen and progesterone, during the moon cycle have been linked to changes in blood vessel diameter and blood pressure.\n3. Changes in barometric pressure associated with the moon cycle can affect the pressure inside the skull.\n4. Sleep disruptions during the full moon phase can increase the risk of intracranial aneurysm rupture.\n5. Certain genetic variations may affect the body's response to hormonal changes or barometric pressure fluctuations during the full moon phase.",
    "llama-2-7b-chat-hf_fact": [
      "Research has suggested an association between the moon cycle and the risk of rupture for intracranial aneurysms.",
      "Hormonal changes, particularly in estrogen and progesterone, during the moon cycle have been linked to changes in blood vessel diameter and blood pressure.",
      "Changes in barometric pressure associated with the moon cycle can affect the pressure inside the skull.",
      "Sleep disruptions during the full moon phase can increase the risk of intracranial aneurysm rupture.",
      "Certain genetic variations may affect the body's response to hormonal changes or barometric pressure fluctuations during the full moon phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The statements provided are related to medical and scientific research which would require access to specific studies and data to confirm their veracity. Without such access, it is not possible to determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein is known to regulate the splicing process in various cell types. HuR (Human RNA-binding protein 1) is a member of the RNA-binding protein (RBP) family and plays a crucial role in the regulation of mRNA splicing, which is the process by which the precursor messenger RNA (pre-mRNA) is converted into the mature mRNA molecule.\nHuR protein is a key regulator of the splicing process by binding to the intron-exon junctions of pre-mRNA and facilitating the splicing reaction. HuR recognizes specific sequences in the pre-mRNA and recruits the splicing machinery, including the spliceosome, to the intron-exon junctions. This leads to the removal of introns and the formation of mature mRNA molecules.\nStudies have shown that HuR regulates the splicing of a wide range of pre-mRNAs, including those involved in various cellular processes such as cell growth, differentiation, and survival. For example, HuR has been shown to regulate the splicing of the Bcl-2 pre-mRNA, which encodes a pro-apoptotic protein involved in the regulation of programmed cell death.\nIn addition to its role in splicing, HuR has been implicated in other cellular processes, including translation, mRNA stability, and protein degradation. Dysregulation of HuR has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections.\nIn summary, HuR protein plays a crucial role in regulating the splicing process by recognizing specific sequences in pre-mRNA and facilitating the splicing reaction. Its dysregulation has been implicated in various diseases, highlighting the importance of this protein in maintaining cellular homeostasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein regulates the splicing process in various cell types.\n2. HuR is a member of the RNA-binding protein (RBP) family.\n3. HuR protein regulates mRNA splicing by binding to intron-exon junctions and facilitating the splicing reaction.\n4. HuR has been shown to regulate the splicing of Bcl-2 pre-mRNA, involved in programmed cell death.\n5. Dysregulation of HuR has been implicated in diseases such as cancer, neurodegenerative disorders, and viral infections.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein regulates the splicing process in various cell types.",
      "HuR is a member of the RNA-binding protein (RBP) family.",
      "HuR protein regulates mRNA splicing by binding to intron-exon junctions and facilitating the splicing reaction.",
      "HuR has been shown to regulate the splicing of Bcl-2 pre-mRNA, involved in programmed cell death.",
      "Dysregulation of HuR has been implicated in diseases such as cancer, neurodegenerative disorders, and viral infections."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: HuR protein regulates mRNA splicing by binding to AU-rich elements in the mRNA and influencing the selection of alternative splice sites, not necessarily the intron-exon junctions.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha (PA) is a small protein that plays a crucial role in various cellular processes, including protein synthesis, cell signaling, and immune response. The c-terminal peptide of PA, also known as prothymosin alpha c-terminal peptide (PCT), is a 12-amino acid peptide derived from the C-terminal region of PA. Here are some of the known functions of PCT:\n1. Regulation of protein synthesis: PCT has been shown to stimulate protein synthesis in various cell types, including muscle cells, by enhancing the activity of ribosomes and increasing the translation efficiency of mRNAs.\n2. Cell signaling: PCT has been implicated in various cell signaling pathways, including the activation of protein kinase C (PKC) and the inhibition of mitogen-activated protein kinase (MAPK). These pathways are involved in a wide range of cellular processes, including cell proliferation, differentiation, and survival.\n3. Immune response: PCT has been shown to have immunomodulatory effects, including the activation of immune cells such as macrophages and T cells, and the regulation of cytokine production.\n4. Anti-inflammatory effects: PCT has been shown to have anti-inflammatory effects in various models of inflammation, including the inhibition of cytokine production and the reduction of inflammatory cell infiltration.\n5. Neuroprotection: PCT has been shown to have neuroprotective effects in various models of neurodegeneration, including the protection of neurons against oxidative stress and the inhibition of neuroinflammation.\n6. Cardiovascular protection: PCT has been shown to have cardiovascular protective effects in various models of cardiovascular disease, including the reduction of inflammation and the improvement of cardiac function.\n7. Anti-cancer effects: PCT has been shown to have anti-cancer effects in various models of cancer, including the inhibition of tumor growth and the induction of apoptosis (programmed cell death).\n8. Anti-aging effects: PCT has been shown to have",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (PCT) is a 12-amino acid peptide derived from the C-terminal region of prothymosin alpha.\n2. PCT stimulates protein synthesis in various cell types by enhancing ribosome activity and translation efficiency of mRNAs.\n3. PCT is involved in cell signaling pathways, including the activation of protein kinase C and inhibition of mitogen-activated protein kinase.\n4. PCT has immunomodulatory effects, such as activating immune cells and regulating cytokine production.\n5. PCT has anti-inflammatory effects, including the reduction of inflammatory cell infiltration and inhibition of cytokine production.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (PCT) is a 12-amino acid peptide derived from the C-terminal region of prothymosin alpha.",
      "PCT stimulates protein synthesis in various cell types by enhancing ribosome activity and translation efficiency of mRNAs.",
      "PCT is involved in cell signaling pathways, including the activation of protein kinase C and inhibition of mitogen-activated protein kinase.",
      "PCT has immunomodulatory effects, such as activating immune cells and regulating cytokine production.",
      "PCT has anti-inflammatory effects, including the reduction of inflammatory cell infiltration and inhibition of cytokine production."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C is a protein that is involved in the regulation of intracellular calcium levels, and it is known to fibrillize (form insoluble fibers) under certain conditions. The fibrillization of cystatin C is a complex process that involves the aggregation of the protein into oligomers and fibrils, and it is influenced by a variety of factors, including pH, temperature, and the presence of certain ions or molecules.\nOne peptide that has been identified as playing a pivotal role in the fibrillization of human cystatin C is the peptide sequence Gly-Asp-Gly-Asp-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly-G",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you understand the relationship between the administration of the cytoprotective prodrug \"amifostine\" (ethyol) and the concentration of protein HIF-1α.\nHIF-1α (Hypoxia-Inducible Factor-1 alpha) is a transcription factor that plays a crucial role in response to hypoxia, a condition of low oxygen availability in the body. HIF-1α regulates the expression of genes involved in adaptive responses to hypoxia, such as angiogenesis, glucose metabolism, and cell survival.\nAmifostine, also known as ethyol, is a cytoprotective prodrug that has been shown to have a protective effect against various types of tissue damage, including hypoxia-induced damage. It has been used in the treatment of various conditions, including cancer, organ transplantation, and radiation therapy.\nStudies have shown that the administration of amifostine can increase the concentration of HIF-1α in certain tissues, such as the heart and brain. For example, a study published in the Journal of Cardiovascular Pharmacology found that amifostine treatment increased HIF-1α protein levels in the heart of rats subjected to ischemia-reperfusion injury. Another study published in the Journal of Neuroscience found that amifostine treatment increased HIF-1α protein levels in the brain of mice subjected to cerebral ischemia.\nHowever, it is important to note that the concentration of HIF-1α may not always increase after the administration of amifostine. The response to amifostine can vary depending on the specific condition being treated, the dose and duration of treatment, and individual variability in drug metabolism and pharmacokinetics.\nIn summary, while there is evidence to suggest that the administration of amifostine can increase the concentration of HIF-1α in certain tissues, the relationship between the two is complex and can vary depending on the specific conditions being studied. Further research is needed to fully understand the mechanisms by which amifostine affects HIF-1α concentration and to determine the potential therapeutic applications of",
    "llama-2-7b-chat-hf_fact_raw": "1. HIF-1α (Hypoxia-Inducible Factor-1 alpha) is a transcription factor involved in the body's response to hypoxia.\n2. Amifostine, also known as ethyol, is a cytoprotective prodrug used in the treatment of conditions including cancer, organ transplantation, and radiation therapy.\n3. Administration of amifostine has been shown to increase the concentration of HIF-1α in certain tissues.\n4. A study in the Journal of Cardiovascular Pharmacology found that amifostine treatment increased HIF-1α levels in the heart of rats after ischemia-reperfusion injury.\n5. Another study in the Journal of Neuroscience found that amifostine treatment increased HIF-1α levels in the brain of mice after cerebral ischemia.",
    "llama-2-7b-chat-hf_fact": [
      "HIF-1α (Hypoxia-Inducible Factor-1 alpha) is a transcription factor involved in the body's response to hypoxia.",
      "Amifostine, also known as ethyol, is a cytoprotective prodrug used in the treatment of conditions including cancer, organ transplantation, and radiation therapy.",
      "Administration of amifostine has been shown to increase the concentration of HIF-1α in certain tissues.",
      "A study in the Journal of Cardiovascular Pharmacology found that amifostine treatment increased HIF-1α levels in the heart of rats after ischemia-reperfusion injury.",
      "Another study in the Journal of Neuroscience found that amifostine treatment increased HIF-1α levels in the brain of mice after cerebral ischemia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase enzyme that deposits specific histone marks on histone proteins in the nucleosome. Here are some of the histone marks that are deposited by Set7:\n1. Histone H3 lysine 4 trimethylation (H3K4me3): Set7 is known to catalyze the methylation of histone H3 at lysine 4, leading to the tri-methylation of this residue. This mark is typically associated with active gene expression and is found at the promoters of many genes.\n2. Histone H3 lysine 27 trimethylation (H3K27me3): Set7 has also been shown to methylate histone H3 at lysine 27, leading to the tri-methylation of this residue. This mark is associated with gene silencing and is often found at the 5' ends of genes.\n3. Histone H2A lysine 5 trimethylation (H2AK5me3): Set7 has been shown to methylate histone H2A at lysine 5, leading to the tri-methylation of this residue. This mark is associated with gene silencing and is often found at the 5' ends of genes.\n4. Histone H3 lysine 79 dimethylation (H3K79me2): Set7 has been shown to dimethylate histone H3 at lysine 79, leading to the di-methylation of this residue. This mark is associated with the regulation of chromatin dynamics and is often found at the 5' ends of genes.\n5. Histone H2A lysine 119 ubiquitination (H2AK119ub): Set7 has been shown to ubiquitinate histone H2A at lysine 119, leading to the mono-ubiquitination of this residue. This mark is associated with the regulation of chromatin dynamics and is often found at the 5' ends of genes.\nIt's worth noting that Set7 is a highly specific enzyme and can also deposit other histone marks, such",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 catalyzes the methylation of histone H3 at lysine 4, resulting in H3K4me3.\n2. Set7 can also methylate histone H3 at lysine 27 to produce H3K27me3.\n3. Set7 is known to methylate histone H2A at lysine 5, leading to H2AK5me3.\n4. Set7 can dimethylate histone H3 at lysine 79, resulting in H3K79me2.\n5. Set7 has been shown to ubiquitinate histone H2A at lysine 119, leading to H2AK119ub.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 catalyzes the methylation of histone H3 at lysine 4, resulting in H3K4me3.",
      "Set7 can also methylate histone H3 at lysine 27 to produce H3K27me3.",
      "Set7 is known to methylate histone H2A at lysine 5, leading to H2AK5me3.",
      "Set7 can dimethylate histone H3 at lysine 79, resulting in H3K79me2.",
      "Set7 has been shown to ubiquitinate histone H2A at lysine 119, leading to H2AK119ub."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SETD7 (Set7) catalyzes the methylation of histone H3 at lysine 4, resulting in H3K4me1, not H3K4me3.\n2. FALSE [correction]: Set7 is not known to methylate histone H3 at lysine 27; this methylation is associated with the enzyme EZH2, resulting in H3K27me3.\n3. FALSE [correction]: Set7 is not known to methylate histone H2A at lysine 5; this methylation event has not been well-documented in literature.\n4. FALSE [correction]: Set7 does not catalyze the dimethylation of histone H3 at lysine 79; this reaction is associated with the enzyme DOT1L, resulting in H3K79me2.\n5. FALSE [correction]: Set7 has not been shown to ubiquitinate histone H2A at lysine 119; ubiquitination at this site is typically associated with the Polycomb Repressive Complex 1 (PRC1).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin is a protein that plays a crucial role in regulating iron metabolism in the body. It is a small peptide hormone that is produced in the liver and secreted into the bloodstream, where it binds to iron-regulatory proteins (IRPs) and ferroportin, a protein that regulates iron efflux from cells.\nHepcidin has been found to have multiple disulfide bridges, which are crucial for its proper folding and function. The exact number of disulfide bridges in hepcidin can vary depending on the specific isoform of the protein, but in general, hepcidin contains 4-6 disulfide bonds.\nHere is a brief overview of the disulfide bonds in hepcidin:\n1. Cys16-Cys101: This is the first disulfide bond formed in hepcidin during its biosynthesis, and it is involved in the folding of the protein into its active conformation.\n2. Cys34-Cys70: This disulfide bond is located in the N-terminal region of hepcidin and is involved in the stabilization of the protein's tertiary structure.\n3. Cys48-Cys70: This disulfide bond is located in the central region of hepcidin and is involved in the stabilization of the protein's tertiary structure.\n4. Cys62-Cys70: This disulfide bond is located in the C-terminal region of hepcidin and is involved in the stabilization of the protein's tertiary structure.\n5. Cys101-Cys106: This disulfide bond is located in the N-terminal region of hepcidin and is involved in the stabilization of the protein's tertiary structure.\n6. Cys163-Cys166: This disulfide bond is located in the C-terminal region of hepcidin and is involved in the stabilization of the protein's tertiary structure.\nIt is worth noting that the number and location of disulfide bonds in hepcidin can vary depending on the specific iso",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is a protein that regulates iron metabolism in the body.\n2. Hepcidin is produced in the liver and secreted into the bloodstream.\n3. Hepcidin typically contains 4-6 disulfide bonds.\n4. The first disulfide bond formed in hepcidin during its biosynthesis is Cys16-Cys101.\n5. The specific number of disulfide bridges in hepcidin can vary depending on the isoform of the protein.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is a protein that regulates iron metabolism in the body.",
      "Hepcidin is produced in the liver and secreted into the bloodstream.",
      "Hepcidin typically contains 4-6 disulfide bonds.",
      "The first disulfide bond formed in hepcidin during its biosynthesis is Cys16-Cys101.",
      "The specific number of disulfide bridges in hepcidin can vary depending on the isoform of the protein."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hepcidin typically contains 8 disulfide bonds.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "The protein encoded by the gene DNAJC11 is a member of the DJ-1 protein family, which are involved in various cellular processes, including protein degradation, protein folding, and antioxidant defense. The localization of the DNAJC11 protein is primarily cytoplasmic, but it can also be found in the nucleus in some cell types.\nDNAJC11 is a gene that codes for a protein of approximately 27 kDa in size. The protein is synthesized in the cytoplasm and then transported to the nucleus, where it plays a role in regulating gene expression. The protein is also involved in the degradation of misfolded proteins, which is an important process that helps maintain cellular protein homeostasis.\nIn terms of its localization, the DNAJC11 protein is predominantly cytoplasmic, meaning it is found in the cytoplasm of cells. However, it has been shown to be nuclear in some cell types, such as neurons and immune cells. The exact localization of the protein can vary depending on the cell type and the specific stage of cell development.\nIn neurons, for example, DNAJC11 has been shown to be localized to the nucleus, where it regulates the expression of genes involved in synaptic plasticity and neuronal survival. In immune cells, the protein is primarily cytoplasmic, where it plays a role in regulating the degradation of misfolded proteins and maintaining cellular protein homeostasis.\nOverall, the localization of the DNAJC11 protein is complex and can vary depending on the cell type and the specific stage of cell development. Further research is needed to fully understand the role of this protein in different cellular processes and its potential as a therapeutic target for various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is primarily localized in the cytoplasm.\n2. The DNAJC11 protein can also be found in the nucleus in some cell types.\n3. DNAJC11 is a member of the DJ-1 protein family.\n4. DNAJC11 protein plays a role in protein degradation, protein folding, and antioxidant defense.\n5. The exact localization of the DNAJC11 protein can vary depending on the cell type and the specific stage of cell development.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is primarily localized in the cytoplasm.",
      "The DNAJC11 protein can also be found in the nucleus in some cell types.",
      "DNAJC11 is a member of the DJ-1 protein family.",
      "DNAJC11 protein plays a role in protein degradation, protein folding, and antioxidant defense.",
      "The exact localization of the DNAJC11 protein can vary depending on the cell type and the specific stage of cell development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: DNAJC11 is not a member of the DJ-1 protein family, it is a member of the DnaJ/Hsp40 family.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Ultraconserved elements are regions of the genome that are highly conserved across different species, often showing a high degree of sequence similarity. Copy number variants (CNVs), on the other hand, refer to genetic variations that involve changes in the number of copies of a particular DNA sequence in the genome.\nThe relationship between ultraconserved elements and CNVs is complex and can vary depending on the specific context. However, there are several lines of evidence that suggest that ultraconserved elements are not necessarily depleted among CNVs:\n1. High conservation of ultraconserved elements in CNVs: Despite the fact that CNVs can involve changes in the number of copies of a particular DNA sequence, many ultraconserved elements have been found to be highly conserved within CNVs. For example, a study published in the journal Nature in 2017 found that 70% of ultraconserved elements were also conserved within CNVs in the human genome.\n2. Overlapping ultraconserved elements and CNVs: Many ultraconserved elements have been found to overlap with CNVs. For example, a study published in the journal Science in 2015 found that 40% of ultraconserved elements in the human genome overlapped with CNVs. This suggests that the two types of genetic elements may be related or even identical in some cases.\n3. CNVs can affect the expression of ultraconserved elements: While CNVs may not necessarily deplete ultraconserved elements, they can still affect the expression of these elements. For example, a study published in the journal Nature Communications in 2018 found that CNVs in the human genome could affect the expression of ultraconserved elements by altering the binding of transcription factors to specific DNA sequences.\n4. Ultraconserved elements can be involved in the regulation of CNVs: Some ultraconserved elements have been found to be involved in the regulation of CNVs. For example, a study published in the journal Cell in 2017 found that an ultraconserved element in the human genome called H19 was involved in the regulation",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements are highly conserved across different species.\n2. A study published in Nature in 2017 found that 70% of ultraconserved elements were conserved within CNVs in the human genome.\n3. A study published in Science in 2015 found that 40% of ultraconserved elements in the human genome overlapped with CNVs.\n4. A study published in Nature Communications in 2018 found that CNVs could affect the expression of ultraconserved elements by altering the binding of transcription factors.\n5. A study published in Cell in 2017 found that an ultraconserved element called H19 was involved in the regulation of CNVs.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements are highly conserved across different species.",
      "A study published in Nature in 2017 found that 70% of ultraconserved elements were conserved within CNVs in the human genome.",
      "A study published in Science in 2015 found that 40% of ultraconserved elements in the human genome overlapped with CNVs.",
      "A study published in Nature Communications in 2018 found that CNVs could affect the expression of ultraconserved elements by altering the binding of transcription factors.",
      "A study published in Cell in 2017 found that an ultraconserved element called H19 was involved in the regulation of CNVs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: A study published in Cell in 2017 found that an ultraconserved element called H19 was involved in the regulation of imprinted genes, not CNVs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "The substrate of the Haspin kinase during mitosis is the histone H3. Haspin is a protein kinase that plays a crucial role in the regulation of mitosis, particularly in the proper progression of the G2/M checkpoint. The G2/M checkpoint is a critical control point in the cell cycle that ensures that cells are ready to enter mitosis and that the proper conditions are in place for a successful cell division.\nHaspin is a key regulator of the G2/M checkpoint, and it does this by phosphorylating and activating various downstream targets, including the histone H3. Histone H3 is a key component of chromatin, the complex of DNA and proteins that make up the chromosomes in the nucleus of a cell. During mitosis, histone H3 undergoes a series of modifications that are essential for the proper separation of chromosomes and the formation of the spindle fibers that pull the sister chromatids apart.\nHaspin phosphorylates histone H3 on specific residues, leading to the activation of various downstream signaling pathways that regulate the progression of mitosis. For example, Haspin phosphorylation of histone H3 leads to the activation of the Aurora A kinase, which is involved in the formation of the spindle fibers. Haspin also phosphorylates the chromatin remodeling complex SWI/SNF, which is involved in the reorganization of chromatin during mitosis.\nIn addition to its role in the G2/M checkpoint, Haspin has been implicated in other cellular processes, including cell fate determination, DNA damage response, and cancer. Dysregulation of Haspin has been implicated in various cancers, including breast, ovarian, and lung cancer, highlighting the importance of this protein in maintaining proper cellular function.\nIn summary, the substrate of the Haspin kinase during mitosis is the histone H3, which is phosphorylated and activated by Haspin to regulate the proper progression of mitosis and ensure the proper separation of chromosomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is the histone H3.\n2. Haspin kinase plays a role in the regulation of the G2/M checkpoint in the cell cycle.\n3. Histone H3 is a component of chromatin in the nucleus of a cell.\n4. Haspin phosphorylates histone H3, leading to the activation of the Aurora A kinase.\n5. Dysregulation of Haspin has been implicated in various cancers, including breast, ovarian, and lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is the histone H3.",
      "Haspin kinase plays a role in the regulation of the G2/M checkpoint in the cell cycle.",
      "Histone H3 is a component of chromatin in the nucleus of a cell.",
      "Haspin phosphorylates histone H3, leading to the activation of the Aurora A kinase.",
      "Dysregulation of Haspin has been implicated in various cancers, including breast, ovarian, and lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Haspin kinase plays a role in the regulation of the spindle assembly checkpoint in the cell cycle.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate through a unique mechanism that does not involve the standard cellular machinery of protein synthesis and DNA replication. Here is a detailed explanation of the mechanism of viroid replication:\n1. Attachment to Host Cells: Viroids are transmitted to host plants through various means, such as insect vectors, grafting, or seed transmission. Once inside the host plant, viroids attach to the plasma membrane of plant cells through specific receptors.\n2. Endosymbiotic Replication: Once attached to the host cell, viroids enter the cytoplasm and establish a symbiotic relationship with the host cell. This involves the formation of membranous structures called viroid-induced membranous structures (VIMs), which are thought to play a role in the replication of the viroid genome.\n3. Replication Cycle: The replication cycle of viroids involves the synthesis of complementary RNA (cRNA) strands by the host cell's RNA-dependent RNA polymerase (RdRP) enzyme. This enzyme is recruited to the VIMs, where it synthesizes cRNA strands that are complementary to the viroid genome.\n4. Self-Assembly: The cRNA strands are then self-assembled into a structure called a viroid particle, which is composed of multiple copies of the viroid genome. This structure is thought to be stabilized by ionic interactions and hydrogen bonds between the RNA molecules.\n5. Release from Host Cells: Once the viroid particles are assembled, they are released from the host cell through a process called lysis. This involves the breakdown of the host cell membrane, releasing the viroid particles into the extracellular space.\n6. Transmission to Other Hosts: The released viroid particles can then infect other host cells through the same mechanism of attachment and endosymbiotic replication. This allows the viroid to spread to other plants, perpetuating the infection.\n7. Persistence: Viroids are able to persist in the host plant for long periods of time, sometimes for years or even decades, without causing any obvious symptoms. This is thought",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are small, single-stranded RNA molecules that replicate without the standard cellular machinery of protein synthesis and DNA replication.\n2. Viroids attach to the plasma membrane of plant cells through specific receptors.\n3. The replication cycle of viroids involves the synthesis of complementary RNA strands by the host cell's RNA-dependent RNA polymerase enzyme.\n4. Viroid particles are composed of multiple copies of the viroid genome and are self-assembled.\n5. Viroids are released from the host cell through a process called lysis, which involves the breakdown of the host cell membrane.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are small, single-stranded RNA molecules that replicate without the standard cellular machinery of protein synthesis and DNA replication.",
      "Viroids attach to the plasma membrane of plant cells through specific receptors.",
      "The replication cycle of viroids involves the synthesis of complementary RNA strands by the host cell's RNA-dependent RNA polymerase enzyme.",
      "Viroid particles are composed of multiple copies of the viroid genome and are self-assembled.",
      "Viroids are released from the host cell through a process called lysis, which involves the breakdown of the host cell membrane."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids typically do not encode proteins and therefore do not have receptors to attach to the plasma membrane of plant cells. Instead, they invade plant cells and replicate within the nucleus or chloroplasts.\n3. TRUE\n4. FALSE [correction]: Viroid particles are not composed of multiple copies of the genome and do not assemble as typical viruses. They exist as single, circular RNA molecules.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Fibronectin is a protein that plays a crucial role in the development and maintenance of muscle tissue, and it has been investigated as a potential biomarker for Duchenne muscular dystrophy (DMD), a severe and progressive genetic disorder that affects muscle strength and function.\nDMD is caused by mutations in the dystrophin gene, which codes for the dystrophin protein. Dystrophin is essential for maintaining the structural integrity of muscle fibers, and its deficiency leads to muscle weakness, wasting, and degeneration.\nFibronectin is a extracellular matrix protein that is involved in the organization and maintenance of muscle tissue. It is synthesized by muscle fibers and plays a role in the adhesion of muscle cells to each other and to the extracellular matrix. Fibronectin also regulates the activity of various cellular signaling pathways, including those involved in muscle cell growth and differentiation.\nStudies have shown that the levels of fibronectin in the blood or cerebrospinal fluid of individuals with DMD are significantly lower than those in healthy individuals. This decrease in fibronectin levels may serve as a biomarker for DMD, allowing for early detection and monitoring of the disease.\nOne study published in the Journal of Neuromuscular Diseases found that the levels of fibronectin in the blood of DMD patients were significantly lower than those in healthy controls, and that this decrease was correlated with the severity of the disease. Another study published in the journal Muscle & Nerve found that the levels of fibronectin in the cerebrospinal fluid of DMD patients were also lower than those in healthy controls, and that this decrease was associated with muscle weakness and wasting.\nHowever, it is important to note that fibronectin levels may not always accurately reflect the severity of DMD, as other factors such as age, disease duration, and genetic mutations can also influence fibronectin levels. Additionally, fibronectin levels may fluctuate over time, and a single measurement may not accurately reflect the individual's overall muscle health.\nIn summary, fibronectin constitutes a potential biomarker for",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin has been investigated as a potential biomarker for Duchenne muscular dystrophy (DMD).\n2. Duchenne muscular dystrophy is a genetic disorder caused by mutations in the dystrophin gene.\n3. Dystrophin is essential for maintaining the structural integrity of muscle fibers.\n4. Studies have shown that fibronectin levels in the blood or cerebrospinal fluid of DMD patients are significantly lower than those in healthy individuals.\n5. A study in the Journal of Neuromuscular Diseases found a correlation between decreased levels of fibronectin in blood and severity of DMD.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin has been investigated as a potential biomarker for Duchenne muscular dystrophy (DMD).",
      "Duchenne muscular dystrophy is a genetic disorder caused by mutations in the dystrophin gene.",
      "Dystrophin is essential for maintaining the structural integrity of muscle fibers.",
      "Studies have shown that fibronectin levels in the blood or cerebrospinal fluid of DMD patients are significantly lower than those in healthy individuals.",
      "A study in the Journal of Neuromuscular Diseases found a correlation between decreased levels of fibronectin in blood and severity of DMD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Studies have shown that fibronectin levels in the blood or cerebrospinal fluid of DMD patients are significantly higher than those in healthy individuals.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "DeepBlue is a comprehensive epigenomic data server that provides access to a wide range of epigenome data from various projects. Here are some of the major epigenome projects whose data are contained in the DeepBlue server:\n1. ENCODE (ENCyclopedia Of DNA Elements): The ENCODE project is a large-scale effort to create a comprehensive catalog of all the functional elements in the human genome. The project has generated a wealth of epigenetic data, including DNA methylation, histone modification, and chromatin accessibility data, for over 100 cell types and tissues.\n2. Roadmap Epigenomics Consortium: The Roadmap Epigenomics Consortium is a collaborative effort to generate comprehensive epigenetic maps of multiple organisms, including humans, mice, and worms. The consortium has generated a large amount of epigenetic data, including DNA methylation, histone modification, and chromatin structure data, using a variety of techniques.\n3. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to generate comprehensive genomic and epigenomic data for over 10,000 cancer samples from multiple cancer types. The project has generated a wealth of epigenetic data, including DNA methylation, histone modification, and chromatin structure data, for cancer cells and normal tissues.\n4. The Human Epigenome Atlas (HEA): The HEA is a large-scale effort to generate comprehensive epigenetic maps of human tissues and cells. The project has generated a wide range of epigenetic data, including DNA methylation, histone modification, and chromatin structure data, for over 100 human tissues and cell types.\n5. The Mouse Epigenome Project (MEP): The MEP is a large-scale effort to generate comprehensive epigenetic maps of mouse tissues and cells. The project has generated a wealth of epigenetic data, including DNA methylation, histone modification, and chromatin structure data, for over 100 mouse tissues and cell types.\n6. The Epigenomics of Human Disease (EHD): The EHD is a",
    "llama-2-7b-chat-hf_fact_raw": "1. The ENCODE project has generated epigenetic data for over 100 cell types and tissues.\n2. The Roadmap Epigenomics Consortium has generated comprehensive epigenetic maps of multiple organisms.\n3. The Cancer Genome Atlas project has generated genomic and epigenomic data for over 10,000 cancer samples.\n4. The Human Epigenome Atlas has generated epigenetic data for over 100 human tissues and cell types.\n5. The Mouse Epigenome Project has generated comprehensive epigenetic maps for over 100 mouse tissues and cell types.",
    "llama-2-7b-chat-hf_fact": [
      "The ENCODE project has generated epigenetic data for over 100 cell types and tissues.",
      "The Roadmap Epigenomics Consortium has generated comprehensive epigenetic maps of multiple organisms.",
      "The Cancer Genome Atlas project has generated genomic and epigenomic data for over 10,000 cancer samples.",
      "The Human Epigenome Atlas has generated epigenetic data for over 100 human tissues and cell types.",
      "The Mouse Epigenome Project has generated comprehensive epigenetic maps for over 100 mouse tissues and cell types."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Roadmap Epigenomics Consortium has generated comprehensive epigenetic maps for multiple human tissues and cell types, not multiple organisms.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "There are several tools that employ self-organizing maps (SOMs) for analyzing synonymous codon usage. Here are a few examples:\n1. Codon usage software (CUS): CUS is a widely used tool for analyzing codon usage in protein-coding genes. It uses a SOM to represent the codon usage patterns in a gene or a set of genes, and it can identify clusters of synonymous codons that are overrepresented or underrepresented in the gene. CUS also provides a visual representation of the codon usage patterns, which can be useful for identifying potential areas of interest.\n2. Synonymous codon usage analysis tool (SCUAT): SCUAT is a tool that uses a SOM to analyze the synonymous codon usage in a gene or a set of genes. It can identify clusters of synonymous codons that are overrepresented or underrepresented in the gene, and it can also provide information on the functional implications of these codon usage patterns.\n3. CodonW: CodonW is a tool that uses a SOM to analyze the codon usage in a gene or a set of genes. It can identify clusters of synonymous codons that are overrepresented or underrepresented in the gene, and it can also provide information on the functional implications of these codon usage patterns.\n4. CODON: CODON is a tool that uses a SOM to analyze the codon usage in a gene or a set of genes. It can identify clusters of synonymous codons that are overrepresented or underrepresented in the gene, and it can also provide information on the functional implications of these codon usage patterns.\n5. CodonExplorer: CodonExplorer is a tool that uses a SOM to analyze the codon usage in a gene or a set of genes. It can identify clusters of synonymous codons that are overrepresented or underrepresented in the gene, and it can also provide information on the functional implications of these codon usage patterns.\n6. GeneCodon: GeneCodon is a tool that uses a SOM to analyze the codon usage in a gene or a set of genes. It can identify clusters of synonymous codons that are overrepresented or underrepresented in the gene, and",
    "llama-2-7b-chat-hf_fact_raw": "1. The Codon usage software (CUS) uses a self-organizing map (SOM) to represent the codon usage patterns in a gene or a set of genes.\n2. Synonymous codon usage analysis tool (SCUAT) employs a SOM for analyzing synonymous codon usage in a gene or a set of genes.\n3. CodonW is a tool that utilizes a SOM to analyze codon usage and identify clusters of synonymous codons.\n4. CODON uses a SOM to analyze codon usage and provide information on the functional implications of these patterns.\n5. CodonExplorer employs a SOM to analyze codon usage in genes and identify overrepresented or underrepresented clusters of synonymous codons.",
    "llama-2-7b-chat-hf_fact": [
      "The Codon usage software (CUS) uses a self-organizing map (SOM) to represent the codon usage patterns in a gene or a set of genes.",
      "Synonymous codon usage analysis tool (SCUAT) employs a SOM for analyzing synonymous codon usage in a gene or a set of genes.",
      "CodonW is a tool that utilizes a SOM to analyze codon usage and identify clusters of synonymous codons.",
      "CODON uses a SOM to analyze codon usage and provide information on the functional implications of these patterns.",
      "CodonExplorer employs a SOM to analyze codon usage in genes and identify overrepresented or underrepresented clusters of synonymous codons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific knowledge of the features and methods used in these codon usage software tools, it is not possible to determine the accuracy of the statements provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 is a research project funded by the US Defense Advanced Research Projects Agency (DARPA) that aims to develop a neural interface system capable of directly connecting the human brain to a computer. The project is named after its lead investigator, Dr. Mindy Parsons.\nThe goal of MINDY-1 is to create a system that allows people to control electronic devices with their thoughts, using only their brain signals. This would enable individuals with paralysis or other motor disorders to communicate and interact with their environment in a more natural and intuitive way.\nThe MINDY-1 project involves several research teams working on different aspects of the neural interface system. These teams include experts in neuroscience, computer science, engineering, and clinical research.\nSome of the key technologies being developed as part of MINDY-1 include:\n1. Brain-Computer Interfaces (BCIs): These are systems that allow the brain to communicate with a computer through electroencephalography (EEG) or other methods. BCIs are being developed to detect and interpret brain signals, such as electrical activity, blood flow, or chemical changes in the brain.\n2. Neural Decoding Algorithms: These are algorithms that can interpret the brain signals detected by BCIs and translate them into commands that can control electronic devices. Neural decoding algorithms are being developed to improve the accuracy and speed of brain signal interpretation.\n3. Neural Prosthetics: These are devices that can be implanted in the brain or nervous system to restore or enhance cognitive or motor functions. Neural prosthetics are being developed to treat a range of conditions, including paralysis, epilepsy, and chronic pain.\n4. User Interface Design: The MINDY-1 project is also focused on developing user interfaces that can be controlled using brain signals. These interfaces could take the form of visual displays, auditory feedback, or haptic (tactile) feedback.\nThe MINDY-1 project is still in its early stages, and significant challenges remain before the technology can be widely available. However, the potential benefits of MINDY-1 are substantial, and the project has the potential to revolutionize the way people interact with technology.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a research project funded by the US Defense Advanced Research Projects Agency (DARPA).\n2. The project aims to develop a neural interface system to connect the human brain to a computer.\n3. Dr. Mindy Parsons is the lead investigator of the MINDY-1 project.\n4. Brain-Computer Interfaces (BCIs) are being developed as part of MINDY-1.\n5. Neural prosthetics are being developed to treat conditions such as paralysis, epilepsy, and chronic pain.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a research project funded by the US Defense Advanced Research Projects Agency (DARPA).",
      "The project aims to develop a neural interface system to connect the human brain to a computer.",
      "Dr. Mindy Parsons is the lead investigator of the MINDY-1 project.",
      "Brain-Computer Interfaces (BCIs) are being developed as part of MINDY-1.",
      "Neural prosthetics are being developed to treat conditions such as paralysis, epilepsy, and chronic pain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, which are regions of the genome that are evolutionarily conserved across different species. Here are some of the most popular and widely used software packages for this purpose:\n1. BLAST (Basic Local Alignment Search Tool): BLAST is a widely used tool for comparing a query sequence (e.g., a genomic sequence) against a database of known sequences. It can be used to identify conserved regions in a genomic sequence by comparing it to a database of related sequences.\n2. ClustalW: ClustalW is a multiple sequence alignment tool that can be used to identify conserved regions in a set of related sequences. It can align multiple sequences and identify regions of high conservation.\n3. MUSCLE (Multiple Sequence Comparison by Log-Expectation): MUSCLE is a multiple sequence alignment tool that can be used to identify conserved regions in a set of related sequences. It uses a log-expectation approach to estimate the probability of each alignment, which can help identify regions of high conservation.\n4. MAFFT (Multiple Alignment Using Fast Fourier Transform): MAFFT is a multiple sequence alignment tool that can be used to identify conserved regions in a set of related sequences. It uses a fast Fourier transform approach to estimate the probability of each alignment, which can help identify regions of high conservation.\n5. Phyre2: Phyre2 is a web-based tool that can be used to identify conserved regions in a genomic sequence. It uses a combination of multiple sequence alignment and phylogenetic analysis to identify regions of high conservation.\n6. HMMER: HMMER is a tool that can be used to identify conserved regions in a genomic sequence by comparing it to a database of known sequences. It uses a hidden Markov model approach to identify regions of high conservation.\n7. GLIMMER: GLIMMER is a tool that can be used to identify conserved regions in a genomic sequence by comparing it to a database of known sequences. It uses a hidden Markov model approach to identify regions of high conservation.\n8. Prodigal: Prodigal is a tool that can be used to identify conserved regions in a genomic sequence by comparing it to a database of known sequences. It uses a hidden Markov model approach to identify regions",
    "llama-2-7b-chat-hf_fact_raw": "1. BLAST (Basic Local Alignment Search Tool) is a tool for comparing a query sequence against a database of known sequences.\n2. ClustalW is a multiple sequence alignment tool used for identifying conserved regions in a set of related sequences.\n3. MUSCLE (Multiple Sequence Comparison by Log-Expectation) uses a log-expectation approach for multiple sequence alignment.\n4. MAFFT (Multiple Alignment Using Fast Fourier Transform) employs a fast Fourier transform approach for multiple sequence alignment.\n5. HMMER, GLIMMER, and Prodigal all use a hidden Markov model approach to identify conserved regions in genomic sequences.",
    "llama-2-7b-chat-hf_fact": [
      "BLAST (Basic Local Alignment Search Tool) is a tool for comparing a query sequence against a database of known sequences.",
      "ClustalW is a multiple sequence alignment tool used for identifying conserved regions in a set of related sequences.",
      "MUSCLE (Multiple Sequence Comparison by Log-Expectation) uses a log-expectation approach for multiple sequence alignment.",
      "MAFFT (Multiple Alignment Using Fast Fourier Transform) employs a fast Fourier transform approach for multiple sequence alignment.",
      "HMMER, GLIMMER, and Prodigal all use a hidden Markov model approach to identify conserved regions in genomic sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Certainly! The PIEZO2 gene is a gene that plays a crucial role in the development and maintenance of sensory neurons, particularly those involved in the sense of touch. Mutations in the PIEZO2 gene have been associated with several rare genetic disorders that affect the nervous system and skin. Here are three diseases associated with the PIEZO2 gene:\n1. PIEZO2-related neurological disorder: This is a rare genetic disorder that is caused by mutations in the PIEZO2 gene. The disorder is characterized by a range of symptoms including muscle weakness, seizures, developmental delays, and skin abnormalities. Affected individuals may also experience sensory loss, including loss of touch and pain sensation.\n2. Hippocampal atrophy with congenital insensitivity to pain (HACI): HACI is a rare genetic disorder that is caused by mutations in the PIEZO2 gene. The disorder is characterized by a lack of pain sensation, as well as cognitive impairments and seizures. Affected individuals may also experience skin abnormalities and other symptoms.\n3. Neuronal polarity disorder (NPD): NPD is a rare genetic disorder that is caused by mutations in the PIEZO2 gene. The disorder is characterized by a range of symptoms including developmental delays, intellectual disability, seizures, and skin abnormalities. Affected individuals may also experience sensory loss, including loss of touch and pain sensation.\nIt's important to note that these are just a few examples of diseases associated with the PIEZO2 gene, and there may be other rare genetic disorders that have not yet been identified. If you have any further questions or concerns, please don't hesitate to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been associated with PIEZO2-related neurological disorder, characterized by muscle weakness, seizures, developmental delays, and skin abnormalities.\n2. Hippocampal atrophy with congenital insensitivity to pain (HACI) is caused by mutations in the PIEZO2 gene and is characterized by a lack of pain sensation, cognitive impairments, and seizures.\n3. Neuronal polarity disorder (NPD) is caused by mutations in the PIEZO2 gene and involves developmental delays, intellectual disability, seizures, and skin abnormalities.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been associated with PIEZO2-related neurological disorder, characterized by muscle weakness, seizures, developmental delays, and skin abnormalities.",
      "Hippocampal atrophy with congenital insensitivity to pain (HACI) is caused by mutations in the PIEZO2 gene and is characterized by a lack of pain sensation, cognitive impairments, and seizures.",
      "Neuronal polarity disorder (NPD) is caused by mutations in the PIEZO2 gene and involves developmental delays, intellectual disability, seizures, and skin abnormalities."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hippocampal atrophy with congenital insensitivity to pain (HACI) is not known to be caused by mutations in the PIEZO2 gene. The condition is characterized by a lack of pain sensation, but cognitive impairments and seizures are not typical features.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization is the process by which two proteins, ERAP1 and ERAP2, come together to form a complex. This dimerization is important for the proper functioning of the endoplasmic reticulum (ER) and is involved in several cellular processes, including:\n1. Endoplasmic reticulum-associated degradation (ERAD): ERAP1 and ERAP2 are involved in the degradation of misfolded proteins in the ER. The dimerization of these two proteins facilitates the recognition and degradation of these misfolded proteins, which is an important quality control mechanism in the cell.\n2. Protein folding and transport: ERAP1 and ERAP2 are also involved in the folding and transport of proteins across the ER membrane. The dimerization of these two proteins helps to facilitate the proper folding and transport of these proteins, which is essential for their proper functioning in the cell.\n3. Cellular stress response: ERAP1 and ERAP2 are involved in the cellular stress response, which is a complex network of pathways that help the cell to respond to stressful conditions such as oxidative stress, heat shock, and ER stress. The dimerization of these two proteins helps to coordinate the cellular stress response and ensure that the cell is able to respond appropriately to stressful conditions.\n4. Autophagy: ERAP1 and ERAP2 are also involved in the process of autophagy, which is the cellular process of breaking down and recycling damaged or dysfunctional organelles and proteins. The dimerization of these two proteins helps to facilitate the recognition and degradation of these damaged or dysfunctional molecules, which is an important aspect of autophagy.\n5. Inflammation: ERAP1 and ERAP2 are also involved in the inflammatory response, which is the cellular response to tissue damage or infection. The dimerization of these two proteins helps to coordinate the inflammatory response and ensure that the cell is able to mount an appropriate response to inflammation.\nIn summary, ERAP1-ERAP2 dimerization is a complex process that is involved in several cellular processes, including protein folding and transport, end",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization is involved in the degradation of misfolded proteins in the endoplasmic reticulum.\n2. ERAP1 and ERAP2 facilitate the folding and transport of proteins across the ER membrane.\n3. ERAP1 and ERAP2 play a role in the cellular stress response to conditions such as oxidative stress, heat shock, and ER stress.\n4. ERAP1-ERAP2 dimerization supports the process of autophagy in cellular maintenance.\n5. The dimerization of ERAP1 and ERAP2 coordinates the inflammatory response to tissue damage or infection.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization is involved in the degradation of misfolded proteins in the endoplasmic reticulum.",
      "ERAP1 and ERAP2 facilitate the folding and transport of proteins across the ER membrane.",
      "ERAP1 and ERAP2 play a role in the cellular stress response to conditions such as oxidative stress, heat shock, and ER stress.",
      "ERAP1-ERAP2 dimerization supports the process of autophagy in cellular maintenance.",
      "The dimerization of ERAP1 and ERAP2 coordinates the inflammatory response to tissue damage or infection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ERAP1 and ERAP2 do not facilitate the folding and transport of proteins across the ER membrane, but rather are involved in trimming peptides for presentation by MHC class I molecules.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: ERAP1 and ERAP2 have been implicated in the inflammatory response, but their dimerization specifically coordinating this response is not well established.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of gallbladder function, particularly in non-damaged gallbladders. Here is a detailed answer to your question:\nR-spondin 1 (Rspo1) is a secreted protein that belongs to the R-spondin family of proteins. Rspo1 is primarily expressed in the liver and the gallbladder, where it plays a crucial role in regulating the expression of genes involved in bile acid synthesis and gallbladder function. In non-damaged gallbladders, Rspo1 regulates the expression of genes involved in the transport and storage of bile acids, as well as the expression of genes involved in the contraction and relaxation of gallbladder smooth muscle.\nNoggin (Ngn) is a secreted protein that belongs to the Bone Morphogenetic Protein (BMP) family of proteins. Noggin is primarily expressed in the liver and the gallbladder, where it regulates the expression of genes involved in bile acid synthesis and gallbladder function. In non-damaged gallbladders, Noggin regulates the expression of genes involved in the transport and storage of bile acids, as well as the expression of genes involved in the contraction and relaxation of gallbladder smooth muscle.\nIn non-damaged gallbladders, Rspo1 and Noggin work together to regulate the expression of genes involved in bile acid synthesis and gallbladder function. Rspo1 regulates the expression of genes involved in the transport and storage of bile acids, while Noggin regulates the expression of genes involved in the contraction and relaxation of gallbladder smooth muscle. This coordination of gene expression is important for maintaining the proper function of the gallbladder, including the ability to store and release bile acids in response to food intake.\nIn addition to their role in regulating gallbladder function, Rspo1 and Noggin have been implicated in the regulation of other physiological processes, including embryonic development, tissue repair, and immune response. Dysregulation of R",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 (Rspo1) is a secreted protein that is primarily expressed in the liver and gallbladder.\n2. Rspo1 regulates the expression of genes involved in bile acid synthesis and gallbladder function in non-damaged gallbladders.\n3. Noggin (Ngn) is a secreted protein that is primarily expressed in the liver and gallbladder.\n4. Noggin regulates the expression of genes involved in the transport and storage of bile acids and the contraction and relaxation of gallbladder smooth muscle in non-damaged gallbladders.\n5. Rspo1 and Noggin work together to regulate gene expression for maintaining proper gallbladder function, including bile acid storage and release in response to food intake.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 (Rspo1) is a secreted protein that is primarily expressed in the liver and gallbladder.",
      "Rspo1 regulates the expression of genes involved in bile acid synthesis and gallbladder function in non-damaged gallbladders.",
      "Noggin (Ngn) is a secreted protein that is primarily expressed in the liver and gallbladder.",
      "Noggin regulates the expression of genes involved in the transport and storage of bile acids and the contraction and relaxation of gallbladder smooth muscle in non-damaged gallbladders.",
      "Rspo1 and Noggin work together to regulate gene expression for maintaining proper gallbladder function, including bile acid storage and release in response to food intake."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Noggin (Ngn) is not primarily expressed in the liver and gallbladder. It is a bone morphogenetic protein antagonist that is involved in neural and skeletal development.\n4. FALSE [correction]: Noggin does not regulate gene expression involved in the transport and storage of bile acids or the contraction and relaxation of gallbladder smooth muscle.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme, meaning it is composed of four subunits: two catalytic subunits (Nox5A and Nox5B) and two regulatory subunits (Nox5R1 and Nox5R2). These subunits work together to form a functional enzyme complex.\nThe catalytic subunits (Nox5A and Nox5B) are responsible for the oxidation of NADPH to form superoxide anion (O2-), which is the first step in the production of reactive oxygen species (ROS). The regulatory subunits (Nox5R1 and Nox5R2) play a crucial role in regulating the activity of the enzyme, by modulating the binding of the catalytic subunits and the substrate NADPH.\nThe specific composition of the Nox5 subunits can vary depending on the cellular context and the specific isoform of the enzyme. For example, Nox5A is predominantly expressed in brain and pancreatic tissues, while Nox5B is more widely expressed in various tissues, including the heart, lung, and immune cells. Nox5R1 is predominantly expressed in the brain, while Nox5R2 is expressed in a wider range of tissues.\nIn summary, NADPH oxidase 5 requires the presence of all four subunits (Nox5A, Nox5B, Nox5R1, and Nox5R2) to function properly. The specific composition of these subunits can vary depending on the cellular context and the isoform of the enzyme.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme composed of four subunits.\n2. The enzyme complex includes two catalytic subunits (Nox5A and Nox5B) and two regulatory subunits (Nox5R1 and Nox5R2).\n3. The catalytic subunits are responsible for the oxidation of NADPH to form superoxide anion.\n4. The regulatory subunits modulate the activity of the enzyme by affecting the binding of catalytic subunits and NADPH.\n5. The specific composition of the Nox5 subunits can vary depending on the cellular context and the specific isoform of the enzyme.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a heterotetrameric enzyme composed of four subunits.",
      "The enzyme complex includes two catalytic subunits (Nox5A and Nox5B) and two regulatory subunits (Nox5R1 and Nox5R2).",
      "The catalytic subunits are responsible for the oxidation of NADPH to form superoxide anion.",
      "The regulatory subunits modulate the activity of the enzyme by affecting the binding of catalytic subunits and NADPH.",
      "The specific composition of the Nox5 subunits can vary depending on the cellular context and the specific isoform of the enzyme."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a heterotetrameric enzyme; it is a homodimer composed of two identical subunits.\n2. FALSE [correction]: The enzyme complex does not include two catalytic subunits (Nox5A and Nox5B) and two regulatory subunits (Nox5R1 and Nox5R2). NOX5 does not have separate catalytic and regulatory subunits.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are two proteins that are involved in the regulation of iron metabolism in the body. While they have different functions, they are connected in the following ways:\n1. Co-regulation of iron metabolism: Furin and hepcidin are both involved in the regulation of iron metabolism in the body. Furin is a protease that activates several iron-regulatory proteins, including hepcidin, which is a hormone that regulates iron absorption and distribution in the body.\n2. Regulation of iron efflux: Hepcidin inhibits the activity of ferroportin, a protein that is responsible for iron efflux from cells. Furin, on the other hand, can activate ferroportin, promoting iron efflux from cells. This means that furin and hepcidin have opposite effects on iron efflux, with hepcidin promoting iron retention and furin promoting iron release.\n3. Iron homeostasis: Furin and hepcidin are both involved in maintaining iron homeostasis in the body. Iron homeostasis is the balance between iron absorption, storage, and utilization in the body. Furin helps to regulate this balance by activating iron-regulatory proteins, while hepcidin helps to regulate iron efflux from cells.\n4. Regulation of erythropoiesis: Furin and hepcidin are also involved in the regulation of erythropoiesis, the production of red blood cells. Furin is involved in the maturation of red blood cells, while hepcidin inhibits the production of red blood cells. This means that furin and hepcidin have opposite effects on erythropoiesis, with furin promoting red blood cell production and hepcidin inhibiting it.\n5. Clinical implications: Dysregulation of furin and hepcidin has been implicated in several iron-related disorders, including iron deficiency anemia, hemochromatosis, and iron-overload disorders. For example, mutations in the FURIN gene have been associated with hereditary hemochromatosis, while hepcidin levels have been elevated in patients with iron deficiency an",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease that activates several iron-regulatory proteins, including hepcidin.\n2. Hepcidin is a hormone that regulates iron absorption and distribution in the body.\n3. Furin can activate ferroportin, promoting iron efflux from cells.\n4. Furin and hepcidin are involved in maintaining iron homeostasis in the body.\n5. Dysregulation of furin and hepcidin has been implicated in several iron-related disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease that activates several iron-regulatory proteins, including hepcidin.",
      "Hepcidin is a hormone that regulates iron absorption and distribution in the body.",
      "Furin can activate ferroportin, promoting iron efflux from cells.",
      "Furin and hepcidin are involved in maintaining iron homeostasis in the body.",
      "Dysregulation of furin and hepcidin has been implicated in several iron-related disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a protease that activates several proteins, but not iron-regulatory proteins like hepcidin.\n2. TRUE\n3. FALSE [correction]: Hepcidin regulates ferroportin, not furin, controlling iron efflux from cells.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis/gluconeogenesis gene cluster, also known as the \"HxK\" gene cluster. This gene cluster is responsible for the breakdown and synthesis of glucose, and it contains the majority of the genes involved in glycolysis and gluconeogenesis in yeast.\nThe glycolysis/gluconeogenesis gene cluster is located on chromosome III of the yeast genome and consists of 14 genes. These genes include:\n1. HXK1 (hexokinase): an enzyme that phosphorylates glucose to initiate glycolysis\n2. HXK2 (hexokinase): an enzyme that phosphorylates glucose to initiate glycolysis\n3. PFK1 (phosphofructokinase): an enzyme that converts fructose-6-phosphate to fructose-1,6-bisphosphate, a key step in glycolysis\n4. PFK2 (phosphofructokinase): an enzyme that converts fructose-6-phosphate to fructose-1,6-bisphosphate\n5. Fructose-1,6-bisphosphatase: an enzyme that breaks down fructose-1,6-bisphosphate back into fructose-6-phosphate\n6. GAP (phosphoglucose isomerase): an enzyme that converts glucose-6-phosphate to glucose\n7. PGM (phosphoglucomutase): an enzyme that converts glucose-1,6-bisphosphate to glucose\n8. G6P (glucose-6-phosphatase): an enzyme that breaks down glucose-6-phosphate back into glucose\n9. HIS3 (histidine kinase): an enzyme that plays a role in the regulation of glycolysis\n10. HIS4 (histidine kinase): an enzyme that plays a role in the regulation of glycolysis\n11. T",
    "llama-2-7b-chat-hf_fact_raw": "1. The glycolysis/gluconeogenesis gene cluster is the largest metabolic gene cluster in yeast.\n2. The glycolysis/gluconeogenesis gene cluster contains the majority of the genes involved in glycolysis and gluconeogenesis in yeast.\n3. The glycolysis/gluconeogenesis gene cluster is located on chromosome III of the yeast genome.\n4. The glycolysis/gluconeogenesis gene cluster consists of 14 genes.\n5. The genes in the glycolysis/gluconeogenesis gene cluster include HXK1, HXK2, PFK1, PFK2, Fructose-1,6-bisphosphatase, GAP, PGM, G6P, HIS3, and HIS4.",
    "llama-2-7b-chat-hf_fact": [
      "The glycolysis/gluconeogenesis gene cluster is the largest metabolic gene cluster in yeast.",
      "The glycolysis/gluconeogenesis gene cluster contains the majority of the genes involved in glycolysis and gluconeogenesis in yeast.",
      "The glycolysis/gluconeogenesis gene cluster is located on chromosome III of the yeast genome.",
      "The glycolysis/gluconeogenesis gene cluster consists of 14 genes.",
      "The genes in the glycolysis/gluconeogenesis gene cluster include HXK1, HXK2, PFK1, PFK2, Fructose-1,6-bisphosphatase, GAP, PGM, G6P, HIS3, and HIS4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT (Long Non-Coding RNA in Muscle Tissue) is a long non-coding RNA (lncRNA) that plays a crucial role in the regulation of muscle cell differentiation and muscle tissue development. Here are some of the key functions of LIMT lncRNA:\n1. Regulation of Myogenesis: LIMT lncRNA regulates the process of myogenesis, which is the formation of muscle cells from precursor cells. It does this by controlling the expression of genes involved in muscle cell differentiation and by modulating the activity of transcription factors that are important for muscle cell development.\n2. Maintenance of Muscle Cell Identity: LIMT lncRNA helps to maintain the identity of muscle cells by regulating the expression of genes that are specific to muscle cells. It does this by binding to specific DNA sequences in the genome and preventing the activation of genes that are involved in other cell types.\n3. Regulation of Muscle Fiber Differentiation: LIMT lncRNA regulates the differentiation of muscle fibers by controlling the expression of genes involved in muscle fiber type determination. It does this by modulating the activity of transcription factors that are important for muscle fiber differentiation.\n4. Modulation of Muscle Contractility: LIMT lncRNA regulates muscle contractility by controlling the expression of genes involved in muscle contraction. It does this by modulating the activity of transcription factors that are important for muscle contraction.\n5. Regulation of Muscle Regeneration: LIMT lncRNA regulates muscle regeneration by controlling the expression of genes involved in muscle cell proliferation and differentiation. It does this by modulating the activity of transcription factors that are important for muscle regeneration.\n6. Modulation of Muscle Metabolism: LIMT lncRNA regulates muscle metabolism by controlling the expression of genes involved in muscle metabolic pathways. It does this by modulating the activity of transcription factors that are important for muscle metabolism.\n7. Regulation of Muscle Growth and Development: LIMT lncRNA regulates muscle growth and development by controlling",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA regulates the process of myogenesis.\n2. LIMT lncRNA helps maintain the identity of muscle cells by regulating gene expression specific to muscle cells.\n3. LIMT lncRNA regulates the differentiation of muscle fibers.\n4. LIMT lncRNA modulates muscle contractility by controlling gene expression involved in muscle contraction.\n5. LIMT lncRNA plays a role in muscle regeneration by modulating the activity of transcription factors.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA regulates the process of myogenesis.",
      "LIMT lncRNA helps maintain the identity of muscle cells by regulating gene expression specific to muscle cells.",
      "LIMT lncRNA regulates the differentiation of muscle fibers.",
      "LIMT lncRNA modulates muscle contractility by controlling gene expression involved in muscle contraction.",
      "LIMT lncRNA plays a role in muscle regeneration by modulating the activity of transcription factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Great, I'm happy to help! There are several R packages that can be used for SNP (Single Nucleotide Polymorphism) enrichment analysis, but some of the most popular and widely used packages are:\n1. `SNPpy`: This package provides a comprehensive set of tools for SNP analysis, including enrichment analysis. It uses a Bayesian approach to detect genetic associations and can handle large datasets.\n2. `MAS5`: This package is a widely used tool for genome-wide association studies (GWAS) and SNP enrichment analysis. It uses a statistical framework called the \"Mixed Model Asymptotically Free\" (MAS5) to detect associations between SNPs and phenotypes.\n3. `GSEA`: This package is a popular tool for gene set enrichment analysis (GSEA), which is a type of SNP enrichment analysis that focuses on identifying gene sets that are overrepresented among a set of associated SNPs.\n4. `Bioconductor`: This is a collection of R packages for genomics and bioinformatics, including several packages for SNP analysis and enrichment analysis. Some of the most popular packages in this collection include `SNPs`, `GenomicRanges`, and `GSEA`.\n5. `Plink`: This package is a popular tool for genome-wide association studies (GWAS) and can be used for SNP enrichment analysis. It provides a simple and efficient way to perform association analysis and can handle large datasets.\n6. `SNPset`: This package provides a comprehensive set of tools for SNP analysis, including enrichment analysis. It uses a Bayesian approach to detect genetic associations and can handle large datasets.\n7. `Enrichr`: This package is a web-based tool for SNP enrichment analysis that uses a Bayesian approach to detect associations between SNPs and phenotypes. It can handle large datasets and provides a user-friendly interface.\n8. `Pathway Studio`: This package is a comprehensive tool for pathway analysis that can be used for SNP enrichment analysis. It provides a wide range of tools for analyzing gene expression data, including pathway analysis, gene set enrichment analysis, and network analysis.\n9. `GAT",
    "llama-2-7b-chat-hf_fact_raw": "1. `SNPpy` is an R package that provides tools for SNP analysis, including enrichment analysis.\n2. `MAS5` uses the \"Mixed Model Asymptotically Free\" statistical framework for SNP enrichment analysis.\n3. `GSEA` is a gene set enrichment analysis tool that is also used for SNP enrichment analysis.\n4. `Bioconductor` is a collection of R packages for genomics and bioinformatics, which includes packages for SNP analysis.\n5. `Plink` is a tool for genome-wide association studies that can also be used for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "`SNPpy` is an R package that provides tools for SNP analysis, including enrichment analysis.",
      "`MAS5` uses the \"Mixed Model Asymptotically Free\" statistical framework for SNP enrichment analysis.",
      "`GSEA` is a gene set enrichment analysis tool that is also used for SNP enrichment analysis.",
      "`Bioconductor` is a collection of R packages for genomics and bioinformatics, which includes packages for SNP analysis.",
      "`Plink` is a tool for genome-wide association studies that can also be used for SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: `MAS5` uses the \"Microarray Suite 5.0\" statistical framework for microarray data analysis, not specifically for SNP enrichment analysis.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are a type of glial cell that are found in the developing nervous system, particularly in the ventricular zone, where they play a crucial role in the specification and differentiation of ependymal cells. Here are some of the key players involved in radial glial specification to ependymal cells:\n1. Notch signaling pathway: The Notch signaling pathway is a critical regulator of radial glial cell fate and differentiation. Notch ligands, such as Jagged1 and Delta-like 1, are expressed by radial glial cells, and their expression is important for the maintenance of radial glial cell identity. The Notch signaling pathway also regulates the expression of genes involved in ependymal cell differentiation, such as the transcription factor NeuroD.\n2. Wnt signaling pathway: The Wnt signaling pathway is also involved in the regulation of radial glial cell fate and differentiation. Wnt ligands, such as Wnt3a, are expressed by radial glial cells and promote their proliferation and maintenance. The Wnt signaling pathway also regulates the expression of genes involved in ependymal cell differentiation, such as the transcription factor Myt1l.\n3. Bone morphogenetic proteins (BMPs): BMPs are a family of growth factors that are involved in the regulation of radial glial cell fate and differentiation. BMP2 and BMP4 are expressed by radial glial cells and promote their differentiation into ependymal cells.\n4. Shh signaling pathway: The Shh signaling pathway is also involved in the regulation of radial glial cell fate and differentiation. Shh is expressed by radial glial cells and promotes their proliferation and maintenance. The Shh signaling pathway also regulates the expression of genes involved in ependymal cell differentiation, such as the transcription factor Patched1.\n5. Sox2: Sox2 is a transcription factor that is expressed by radial glial cells and plays a critical role in their maintenance and differentiation. Sox2 is required for the proper differentiation of radial glial cells into ependymal cells.\n6. FGF signaling pathway: The FGF signaling pathway is",
    "llama-2-7b-chat-hf_fact_raw": "1. The Notch signaling pathway regulates radial glial cell fate and differentiation.\n2. The Wnt signaling pathway plays a role in the regulation of radial glial cell fate and differentiation.\n3. Bone morphogenetic proteins (BMP2 and BMP4) are expressed by radial glial cells and promote their differentiation into ependymal cells.\n4. The Shh signaling pathway is involved in the regulation of radial glial cell fate and differentiation.\n5. Sox2 is a transcription factor required for the proper differentiation of radial glial cells into ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "The Notch signaling pathway regulates radial glial cell fate and differentiation.",
      "The Wnt signaling pathway plays a role in the regulation of radial glial cell fate and differentiation.",
      "Bone morphogenetic proteins (BMP2 and BMP4) are expressed by radial glial cells and promote their differentiation into ependymal cells.",
      "The Shh signaling pathway is involved in the regulation of radial glial cell fate and differentiation.",
      "Sox2 is a transcription factor required for the proper differentiation of radial glial cells into ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Bone morphogenetic proteins (BMP2 and BMP4) are expressed by radial glial cells and promote their differentiation into astrocytes, not ependymal cells.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas are a type of brain tumor that is characterized by the absence of certain biomarkers that are typically used to diagnose and classify gliomas. These biomarkers include:\n1. Tumor suppressor proteins: Triple negative gliomas typically lack the expression of tumor suppressor proteins such as TP53, PTEN, and CDKN2A. The loss of these proteins can lead to uncontrolled cell growth and the development of gliomas.\n2. Receptor proteins: Triple negative gliomas often lack the expression of certain receptor proteins, such as EGFR, HER2, and IGF-1R. These proteins play a role in cell signaling and proliferation, and their absence can contribute to the growth and progression of gliomas.\n3. Markers of malignancy: Triple negative gliomas typically lack the expression of markers of malignancy, such as MIB-1 and CD10. These markers are used to assess the aggressiveness of gliomas and to predict their response to treatment.\n4. Genetic alterations: Triple negative gliomas often have genetic alterations in genes such as EGFRvIII, PD-1, and PD-L1. These alterations can lead to uncontrolled cell growth and the development of resistance to immune-based therapies.\n5. Immunophenotype: Triple negative gliomas often have a distinct immunophenotype, characterized by the absence of certain immune cells, such as T cells and B cells. This can make them less susceptible to immune-based therapies.\n6. Clinical features: Triple negative gliomas typically present with more aggressive clinical features, such as rapid growth, seizures, and cognitive decline, compared to other types of gliomas.\n7. Prognosis: The prognosis for triple negative gliomas is generally poorer than for other types of gliomas, with a lower overall survival rate and a higher risk of recurrence.\n8. Treatment: The treatment of triple negative gliomas often involves a combination of surgery, radiation therapy, and chemotherapy. However, the response to treatment is often poor, and",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack the expression of tumor suppressor proteins such as TP53, PTEN, and CDKN2A.\n2. Triple negative gliomas often lack the expression of receptor proteins, such as EGFR, HER2, and IGF-1R.\n3. Triple negative gliomas typically lack the expression of markers of malignancy, such as MIB-1 and CD10.\n4. Triple negative gliomas often have genetic alterations in genes such as EGFRvIII, PD-1, and PD-L1.\n5. Triple negative gliomas often have a distinct immunophenotype, characterized by the absence of certain immune cells.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack the expression of tumor suppressor proteins such as TP53, PTEN, and CDKN2A.",
      "Triple negative gliomas often lack the expression of receptor proteins, such as EGFR, HER2, and IGF-1R.",
      "Triple negative gliomas typically lack the expression of markers of malignancy, such as MIB-1 and CD10.",
      "Triple negative gliomas often have genetic alterations in genes such as EGFRvIII, PD-1, and PD-L1.",
      "Triple negative gliomas often have a distinct immunophenotype, characterized by the absence of certain immune cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Triple negative gliomas often lack the expression of hormone receptors, such as estrogen receptor, progesterone receptor, and HER2, not receptor proteins like EGFR, HER2, and IGF-1R. \n3. UNKNOWN\n4. FALSE [correction]: Genetic alterations in genes such as EGFRvIII, PD-1, and PD-L1 are more commonly associated with other types of cancers, not specifically triple negative gliomas.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 is a software framework designed for simulating and modeling various types of complex systems, including quantum systems, condensed matter systems, and optical systems. It is an open-source toolbox developed by the Topaz Project, a collaboration between researchers at the University of California, Berkeley and the University of Michigan.\nTOPAZ1 is built on top of the MATLAB programming language and provides a set of tools and functions for creating and solving complex mathematical models. It is particularly useful for simulating systems that involve nonlinear dynamics, chaos, and complex behaviors, such as those found in quantum mechanics, quantum field theory, and condensed matter physics.\nSome of the key features of TOPAZ1 include:\n1. Symbolic manipulation: TOPAZ1 allows users to define and manipulate mathematical expressions using a symbolic language, which can be used to represent complex mathematical models.\n2. Numerical integration: TOPAZ1 provides a range of numerical integration methods for solving differential equations and other mathematical problems.\n3. Optimization: TOPAZ1 includes tools for optimizing mathematical functions, which can be useful for finding the minimum or maximum of a function, or for solving optimization problems.\n4. Machine learning: TOPAZ1 provides tools for using machine learning algorithms to analyze and classify data, which can be useful for analyzing complex systems.\n5. Visualization: TOPAZ1 includes tools for visualizing mathematical models and their solutions, which can be useful for understanding complex systems.\n6. Parallel computing: TOPAZ1 can be run on parallel computing architectures, such as GPUs or clusters, which can significantly speed up the simulation and analysis of complex systems.\n7. Interoperability: TOPAZ1 is designed to be compatible with a wide range of other software tools and frameworks, including MATLAB, Python, and C++.\n8. Modularity: TOPAZ1 is designed to be highly modular, with a flexible architecture that allows users to easily add new functionality and customize the toolbox for their specific needs.\n9. Documentation: TOPAZ1 includes extensive documentation, including user guides, tutorials, and example problems, which can help users get started with the toolbox and learn how to use its various features.\n10. Community support: The Topaz Project has a active",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a software framework for simulating and modeling complex systems such as quantum systems, condensed matter systems, and optical systems.\n2. It is an open-source toolbox developed by the Topaz Project, a collaboration between the University of California, Berkeley and the University of Michigan.\n3. TOPAZ1 is built on top of the MATLAB programming language.\n4. TOPAZ1 includes features such as symbolic manipulation, numerical integration, optimization, machine learning, and visualization tools.\n5. TOPAZ1 can be run on parallel computing architectures like GPUs or clusters.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a software framework for simulating and modeling complex systems such as quantum systems, condensed matter systems, and optical systems.",
      "It is an open-source toolbox developed by the Topaz Project, a collaboration between the University of California, Berkeley and the University of Michigan.",
      "TOPAZ1 is built on top of the MATLAB programming language.",
      "TOPAZ1 includes features such as symbolic manipulation, numerical integration, optimization, machine learning, and visualization tools.",
      "TOPAZ1 can be run on parallel computing architectures like GPUs or clusters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: TOPAZ1 is built on top of the Python programming language, not MATLAB.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in the regulation of erythroid cell development, particularly during the early stages of erythropoiesis. There are several isoforms of GATA-1, including GATA-1α, GATA-1β, and GATA-1γ, each with distinct functions and expression patterns. The expression of these isoforms is tightly regulated during erythropoiesis, and several genes have been identified that control their expression. Here are some of the key genes that control the expression of GATA-1 isoforms:\n1. GATA1 gene: The GATA1 gene encodes the full-length GATA-1 protein, which is the most abundant isoform of GATA-1. The GATA1 gene is located on chromosome 2q11.2 and contains 17 exons. The expression of the GATA1 gene is tightly regulated during erythropoiesis, with high levels of expression observed in the early stages of erythropoiesis and lower levels in more mature erythroid cells.\n2. KLF1 gene: The KLF1 gene (also known as KLF-A) encodes a transcription factor that regulates the expression of GATA-1 isoforms. KLF1 is a zinc finger protein that contains a conserved DNA-binding domain and is involved in the regulation of a wide range of genes involved in cellular differentiation and development. The KLF1 gene is located on chromosome 6q21 and contains 10 exons.\n3. NF-E2 gene: The NF-E2 gene (also known as KLF-2) encodes a transcription factor that regulates the expression of GATA-1 isoforms. NF-E2 is a zinc finger protein that contains a conserved DNA-binding domain and is involved in the regulation of a wide range of genes involved in cellular differentiation and development. The NF-E2 gene is located on chromosome 2q13 and contains 10 exons.\n4. BCL11A gene: The BCL11A gene encodes a transcription factor that regulates the expression of GATA-1 iso",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA1 gene encodes the full-length GATA-1 protein and is located on chromosome 2q11.2.\n2. The GATA1 gene contains 17 exons.\n3. The KLF1 gene regulates the expression of GATA-1 isoforms and is located on chromosome 6q21.\n4. The KLF1 gene contains 10 exons.\n5. The NF-E2 gene is located on chromosome 2q13 and contains 10 exons.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA1 gene encodes the full-length GATA-1 protein and is located on chromosome 2q11.2.",
      "The GATA1 gene contains 17 exons.",
      "The KLF1 gene regulates the expression of GATA-1 isoforms and is located on chromosome 6q21.",
      "The KLF1 gene contains 10 exons.",
      "The NF-E2 gene is located on chromosome 2q13 and contains 10 exons."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The GATA1 gene is located on the X chromosome, not chromosome 2q11.2.\n2. FALSE [correction]: The GATA1 gene contains 6 exons, not 17.\n3. TRUE\n4. FALSE [correction]: The KLF1 gene contains 3 exons, not 10.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a powerful tool in the field of RNA sequencing (RNA-seq) that enables the comprehensive analysis of RNA molecules in a given sample. The acronym MIRA-seq stands for \"Microarray-based RNA Sequencing,\" which reflects the hybridization-based approach used in this technology.\nHere's a detailed explanation of MIRA-seq:\n1. Principle: MIRA-seq is based on the concept of microarray analysis, where RNA molecules are hybridized to a glass slide or chip containing thousands of known RNA probes. The probes are designed to capture specific sequences of RNA molecules, allowing researchers to measure the abundance of different RNA species in a sample.\n2. Workflow: The MIRA-seq workflow involves the following steps:\na. Sample Preparation: The starting material for MIRA-seq is typically total RNA or mRNA isolated from a sample of interest. The RNA is then fragmented, and the fragments are adapters are added to the ends of the RNA molecules to enable hybridization to the microarray.\nb. Hybridization: The fragmented RNA is then hybridized to the microarray, which is typically immobilized on a glass slide or chip. The microarray contains thousands of probes that are complementary to specific RNA sequences.\nc. Detection: After hybridization, the microarray is scanned using a laser-based scanner to detect the intensity of the signal at each probe. The intensity of the signal reflects the abundance of the corresponding RNA molecule in the sample.\nd. Data Analysis: The raw data from the microarray scanner is then analyzed using specialized software to extract meaningful information about the RNA molecules in the sample. The software can perform various quality control measures, such as filtering out low-quality probes or samples, and normalizing the data to account for differences in experimental conditions.\n3. Advantages: MIRA-seq offers several advantages over other RNA sequencing technologies, including:\na. High resolution: MIRA-seq can detect RNA molecules with high resolution, allowing researchers to identify subtle differences in RNA expression between samples.\nb. Sensitivity: MIRA",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq stands for \"Microarray-based RNA Sequencing.\"\n2. MIRA-seq is used for the comprehensive analysis of RNA molecules in a sample.\n3. The principle of MIRA-seq involves hybridizing RNA molecules to a glass slide or chip with RNA probes.\n4. The MIRA-seq workflow includes sample preparation, hybridization, detection, and data analysis.\n5. MIRA-seq can detect RNA molecules with high resolution and sensitivity.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq stands for \"Microarray-based RNA Sequencing.\"",
      "MIRA-seq is used for the comprehensive analysis of RNA molecules in a sample.",
      "The principle of MIRA-seq involves hybridizing RNA molecules to a glass slide or chip with RNA probes.",
      "The MIRA-seq workflow includes sample preparation, hybridization, detection, and data analysis.",
      "MIRA-seq can detect RNA molecules with high resolution and sensitivity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq stands for \"Methylated CpG Island Recovery Assay sequencing.\"\n2. TRUE\n3. FALSE [correction]: The principle of MIRA-seq involves capturing methylated DNA, not RNA, to microarrays or sequencing platforms.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST is a prescription medication used to treat adults with moderate to severe osteoarthritis (OA) of the knee. It is an injectable medication that contains the active ingredient, rilonacept, which is a fusion protein that blocks the activity of two proteins called interleukin-1 beta (IL-1β) and interleukin-1 alpha (IL-1α). These proteins are involved in the inflammation and pain associated with OA.\nThe indication for ARCALYST is to reduce the signs and symptoms of OA of the knee, including pain, stiffness, and swelling. It is specifically approved for use in adults who have experienced inadequate response to, or are intolerant of, other treatments for OA of the knee, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.\nARCALYST is given as an injection into the knee joint every 2 weeks for a total of 6 injections. The medication is designed to be injected directly into the knee joint, where it can help to reduce inflammation and pain.\nIt is important to note that ARCALYST is not recommended for use in children or adolescents under the age of 18, as its safety and effectiveness have not been established in this age group. Additionally, ARCALYST is not recommended for use in patients with active infections or in those with a history of hypersensitivity reactions to rilonacept or any of the other ingredients in the medication.\nIf you have any questions or concerns about ARCALYST or its indication, it is best to consult with a healthcare professional who can provide you with more detailed information and advice.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is used to treat adults with moderate to severe osteoarthritis of the knee.\n2. The active ingredient in ARCALYST is rilonacept.\n3. Rilonacept blocks the activity of interleukin-1 beta (IL-1β) and interleukin-1 alpha (IL-1α).\n4. ARCALYST is given as an injection into the knee joint every 2 weeks for a total of 6 injections.\n5. ARCALYST is not recommended for use in children or adolescents under the age of 18.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is used to treat adults with moderate to severe osteoarthritis of the knee.",
      "The active ingredient in ARCALYST is rilonacept.",
      "Rilonacept blocks the activity of interleukin-1 beta (IL-1β) and interleukin-1 alpha (IL-1α).",
      "ARCALYST is given as an injection into the knee joint every 2 weeks for a total of 6 injections.",
      "ARCALYST is not recommended for use in children or adolescents under the age of 18."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ARCALYST is used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, not osteoarthritis of the knee.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Robertsonian translocation is a type of chromosomal abnormality that occurs when a portion of one chromosome breaks off and attaches to another chromosome. In humans, there are 23 pairs of acrocentric chromosomes, which are characterized by their short arms and long arms. Of these, the following acrocentric chromosomes can be involved in Robertsonian translocations:\n1. Chromosome 13: This is the most common chromosome involved in Robertsonian translocations, accounting for approximately 40% of all cases. Translocations involving chromosome 13 can result in a variety of clinical features, including intellectual disability, delayed speech and language development, and a higher risk of certain medical conditions such as heart defects and immune system problems.\n2. Chromosome 14: Chromosome 14 is the second most common chromosome involved in Robertsonian translocations, accounting for approximately 20% of all cases. Translocations involving chromosome 14 can result in a range of clinical features, including intellectual disability, delayed speech and language development, and a higher risk of certain medical conditions such as heart defects and immune system problems.\n3. Chromosome 15: Chromosome 15 is involved in approximately 10% of Robertsonian translocations. Translocations involving chromosome 15 can result in a range of clinical features, including intellectual disability, delayed speech and language development, and a higher risk of certain medical conditions such as heart defects and immune system problems.\n4. Chromosome 21: Chromosome 21 is the most well-known chromosome involved in Robertsonian translocations, as it is the chromosome that carries the genetic material for Down syndrome. Down syndrome is a genetic disorder that occurs when there is an extra copy of chromosome 21. Translocations involving chromosome 21 can result in a range of clinical features, including intellectual disability, delayed speech and language development, and a higher risk of certain medical conditions such as heart defects and immune system problems.\n5. Chromosome 22: Chromosome 22",
    "llama-2-7b-chat-hf_fact_raw": "1. In humans, there are 23 pairs of acrocentric chromosomes that can be involved in Robertsonian translocations.\n2. Chromosome 13 is the most common chromosome involved in Robertsonian translocations, accounting for around 40% of all cases.\n3. Chromosome 14 is the second most common chromosome involved in Robertsonian translocations, with approximately 20% of cases.\n4. Chromosome 15 is involved in approximately 10% of Robertsonian translocations.\n5. Chromosome 21, which carries the genetic material for Down syndrome, is well-known for being involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "In humans, there are 23 pairs of acrocentric chromosomes that can be involved in Robertsonian translocations.",
      "Chromosome 13 is the most common chromosome involved in Robertsonian translocations, accounting for around 40% of all cases.",
      "Chromosome 14 is the second most common chromosome involved in Robertsonian translocations, with approximately 20% of cases.",
      "Chromosome 15 is involved in approximately 10% of Robertsonian translocations.",
      "Chromosome 21, which carries the genetic material for Down syndrome, is well-known for being involved in Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: In humans, there are 5 pairs of acrocentric chromosomes (chromosome 13, 14, 15, 21, and 22) that can be involved in Robertsonian translocations.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific type of analysis and the data available. Here are a few options:\n1. `brainTumor`: This package provides a comprehensive set of tools for analyzing brain tumor data, including segmentation, shape analysis, and classification. It can be used to identify different types of pediatric brain tumors, such as gliomas, astrocytomas, and medulloblastomas.\n2. `pediatricTumor`: This package is specifically designed for the analysis of pediatric tumors, including brain tumors. It provides a range of functions for analyzing tumor shape, size, and location, as well as for identifying patterns of tumor growth and progression.\n3. `neurosurgical`: This package provides a set of tools for analyzing neurosurgical data, including brain tumor data. It can be used to identify different types of pediatric brain tumors, as well as to analyze the effects of surgical interventions on tumor growth and progression.\n4. `brainTumorSegmentation`: This package provides a range of functions for segmenting brain tumors from magnetic resonance imaging (MRI) scans. It can be used to identify different types of pediatric brain tumors, as well as to analyze the spatial distribution of tumor cells within the brain.\n5. `RNM`: This package provides a set of tools for analyzing medical imaging data, including MRI scans. It can be used to identify different types of pediatric brain tumors, as well as to analyze the effects of tumor growth and progression on brain structure and function.\n6. `brainTumorClassification`: This package provides a range of functions for classifying brain tumors based on their morphological and molecular features. It can be used to identify different types of pediatric brain tumors, as well as to predict the prognosis and response to treatment for individual patients.\n7. `brainTumorRegression`: This package provides a set of functions for analyzing the growth and regression of brain tumors over time. It can be used to identify the factors that influence the growth and progression of pediatric brain tumors, as well as to predict the response to treatment",
    "llama-2-7b-chat-hf_fact_raw": "1. The `brainTumor` R package provides tools for analyzing brain tumor data, including segmentation and classification.\n2. `pediatricTumor` is an R package designed for the analysis of pediatric tumors, including brain tumors.\n3. The `neurosurgical` R package includes tools for analyzing neurosurgical data and can be used to identify pediatric brain tumors.\n4. `brainTumorSegmentation` is an R package that provides functions for segmenting brain tumors from MRI scans.\n5. The `RNM` R package offers tools for analyzing medical imaging data, including the identification of pediatric brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "The `brainTumor` R package provides tools for analyzing brain tumor data, including segmentation and classification.",
      "`pediatricTumor` is an R package designed for the analysis of pediatric tumors, including brain tumors.",
      "The `neurosurgical` R package includes tools for analyzing neurosurgical data and can be used to identify pediatric brain tumors.",
      "`brainTumorSegmentation` is an R package that provides functions for segmenting brain tumors from MRI scans.",
      "The `RNM` R package offers tools for analyzing medical imaging data, including the identification of pediatric brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "NEMO (Nuclear Envelope-Associated Matrix-Organizing) is a protein that plays a crucial role in the regulation of nuclear envelope dynamics and cellular signaling. While NEMO does contain zinc finger motifs, it is not solely a zinc finger protein.\nZinc finger proteins are a class of proteins that contain one or more zinc ions bound to cysteine residues, which form a structural motif that is involved in protein-protein interactions and DNA binding. NEMO, on the other hand, is a larger protein that contains multiple domains, including a zinc finger domain, a coiled-coil domain, and a PH domain.\nThe zinc finger domain of NEMO is located in the N-terminal region of the protein and is composed of a repeating pattern of cysteine and histidine residues that form a zinc ion-binding site. This domain is thought to be involved in protein-protein interactions and may play a role in regulating the localization and activity of NEMO.\nHowever, while NEMO contains zinc finger motifs, it is not a zinc finger protein in the classical sense. Zinc finger proteins are typically small, with a single or a few zinc ions bound to cysteine residues, and are involved in a variety of cellular processes, including transcriptional regulation, DNA repair, and chromatin remodeling. In contrast, NEMO is a larger protein that is involved in a broader range of cellular processes, including nuclear envelope dynamics, cellular signaling, and the regulation of gene expression.\nIn summary, while NEMO contains zinc finger motifs, it is not a zinc finger protein in the classical sense. It is a larger protein that plays a complex role in cellular signaling and gene expression, and its zinc finger domain is just one of several domains that contribute to its function.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO contains zinc finger motifs but is not solely a zinc finger protein.\n2. Zinc finger proteins contain one or more zinc ions bound to cysteine residues.\n3. The zinc finger domain of NEMO is located in the N-terminal region of the protein.\n4. NEMO's zinc finger domain is thought to be involved in protein-protein interactions.\n5. NEMO is a larger protein with multiple domains and is involved in broader cellular processes compared to typical zinc finger proteins.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO contains zinc finger motifs but is not solely a zinc finger protein.",
      "Zinc finger proteins contain one or more zinc ions bound to cysteine residues.",
      "The zinc finger domain of NEMO is located in the N-terminal region of the protein.",
      "NEMO's zinc finger domain is thought to be involved in protein-protein interactions.",
      "NEMO is a larger protein with multiple domains and is involved in broader cellular processes compared to typical zinc finger proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The zinc finger domain of NEMO is located in the C-terminal region of the protein.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "TFIIS (Transcription Factor IIIS) is a transcriptional elongation factor that plays a crucial role in the regulation of gene expression by modulating the processivity of RNA polymerase II (RNAPII) during transcription. While TFIIS does not directly affect nucleosome positioning, it can indirectly influence the accessibility of DNA to transcriptional machinery, including nucleosomes. Here's how:\n1. Nucleosome dynamics: TFIIS can influence the dynamics of nucleosomes by altering the rate at which nucleosomes are disrupted or re-formed during transcription elongation. By modulating the activity of enzymes involved in nucleosome remodeling, such as CHD4 and SWI/SNF complexes, TFIIS can affect the positioning of nucleosomes along the DNA template.\n2. Chromatin structure: TFIIS can also impact the higher-order chromatin structure by regulating the interactions between nucleosomes and other chromatin-associated proteins. For example, TFIIS can bind to the histone H3 lysine 4 trimethylation (H3K4me3) mark, which is associated with active gene expression and open chromatin structure. By modulating the levels of H3K4me3, TFIIS can influence the compaction of chromatin and the accessibility of DNA to transcriptional machinery.\n3. Transcriptional pausing: TFIIS can also regulate the processivity of RNAPII during transcription elongation by modulating the frequency and duration of transcriptional pauses. When RNAPII pauses at a gene, the associated nucleosomes can be disrupted, allowing for the binding of transcriptional activators or repressors. By influencing the rate and duration of transcriptional pauses, TFIIS can indirectly affect the positioning of nucleosomes downstream of the transcription start site.\nIn summary, while TFIIS does not directly affect nucleosome positioning, it can indirectly influence the accessibility of DNA to transcriptional machinery by modulating nucleosome dynamics, chromatin structure, and transcriptional pausing. By reg",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS is a transcriptional elongation factor that modulates the processivity of RNA polymerase II.\n2. TFIIS can influence the dynamics of nucleosomes by altering the rate at which they are disrupted or re-formed during transcription elongation.\n3. TFIIS can bind to histone H3 lysine 4 trimethylation (H3K4me3) mark, which is associated with active gene expression and open chromatin structure.\n4. TFIIS can regulate the processivity of RNAPII during transcription elongation by modulating the frequency and duration of transcriptional pauses.\n5. TFIIS indirectly influences the accessibility of DNA to transcriptional machinery.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS is a transcriptional elongation factor that modulates the processivity of RNA polymerase II.",
      "TFIIS can influence the dynamics of nucleosomes by altering the rate at which they are disrupted or re-formed during transcription elongation.",
      "TFIIS can bind to histone H3 lysine 4 trimethylation (H3K4me3) mark, which is associated with active gene expression and open chromatin structure.",
      "TFIIS can regulate the processivity of RNAPII during transcription elongation by modulating the frequency and duration of transcriptional pauses.",
      "TFIIS indirectly influences the accessibility of DNA to transcriptional machinery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: While TFIIS modulates RNA polymerase II's processivity, it is the histone chaperone FACT that can bind to H3K4me3 and influence nucleosome dynamics.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "The timing of origin firing during the yeast cell cycle is a complex process that involves the coordination of multiple factors and regulatory pathways. In budding yeast (Saccharomyces cerevisiae), there are two types of origins of replication: early origins and late origins.\nEarly origins of replication are located near the centromere and fire around the G1/S transition, which is the transition from the G1 phase to the S phase of the cell cycle. These origins are typically active in the first few minutes after the cell has entered the S phase and are responsible for initiating DNA replication at the entire genome. The early origins of replication are regulated by a complex network of transcription factors, including SBF (Swi6-Brm-Fis) and MBF (Mcm1-Bdf1-Fis), which are activated by the binding of the transcription factor SBF to specific DNA sequences called \"consensus\" sequences.\nLate origins of replication, on the other hand, are located far away from the centromere and fire later in the cell cycle, around the G1/M transition, which is the transition from the G1 phase to the M phase of the cell cycle. These origins are typically active in the late S phase or early M phase and are responsible for initiating DNA replication at specific genetic loci, such as the ribosomal DNA repeats. The late origins of replication are regulated by a different set of transcription factors, including the SBF-like factor Rpd3-Swi6 and the Mcm1-like factor Mcm2-Mcm5.\nIn terms of the specific question asked, \"Do origins of replication close to yeast centromeres fire early or late?\", the answer is that early origins of replication are located near the centromere and fire early in the cell cycle, around the G1/S transition, while late origins of replication are located far away from the centromere and fire later in the cell cycle, around the G1/M transition.\nIt's worth noting that the timing of origin firing can vary depending on the specific conditions of the cell, such as the presence of certain nutrients or stressors, and can also be influenced by the cell cycle phase and the presence of certain regulatory",
    "llama-2-7b-chat-hf_fact_raw": "1. In Saccharomyces cerevisiae, early origins of replication are located near the centromere.\n2. Early origins of replication fire around the G1/S transition.\n3. Late origins of replication are located far away from the centromere.\n4. Late origins of replication fire around the G1/M transition.\n5. The timing of origin firing can vary depending on cell conditions and cycle phase.",
    "llama-2-7b-chat-hf_fact": [
      "In Saccharomyces cerevisiae, early origins of replication are located near the centromere.",
      "Early origins of replication fire around the G1/S transition.",
      "Late origins of replication are located far away from the centromere.",
      "Late origins of replication fire around the G1/M transition.",
      "The timing of origin firing can vary depending on cell conditions and cycle phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: In Saccharomyces cerevisiae, early origins of replication are not necessarily located near the centromere; they can be located throughout the genome.\n2. TRUE\n3. FALSE [correction]: Late origins of replication are not necessarily located far away from the centromere; they too can be located throughout the genome.\n4. FALSE [correction]: Late origins of replication fire around the S/G2 transition, not the G1/M transition.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as mammalian germline-associated (GA) sequences, are specific DNA sequences found in the genomes of mammals that are associated with the germline cells, which are the cells that give rise to gametes (sperm or egg cells) during reproduction. These sequences are typically located in the non-coding regions of the genome and are thought to play important roles in the regulation of gene expression, particularly during meiosis and gametogenesis.\nHere are some of the properties of mammalian GA-sequences:\n1. Location: GA-sequences are found in the non-coding regions of the mammalian genome, typically in the intergenic regions, introns, and near the telomeres.\n2. Length: GA-sequences are typically short, ranging from a few hundred to a few thousand base pairs in length.\n3. Consensus sequence: GA-sequences have a characteristic consensus sequence that is rich in purine and pyramidine residues, which are nucleotides that are similar to the bases found in RNA.\n4. Conservation: GA-sequences are highly conserved across different mammalian species, indicating their importance in the germline cells.\n5. Gene regulation: GA-sequences are thought to play a role in the regulation of gene expression, particularly during meiosis and gametogenesis. They may act as enhancers or silencers of gene expression, or they may be involved in the formation of chromatin structures that affect gene accessibility.\n6. Epigenetic marks: GA-sequences are enriched in epigenetic marks such as DNA methylation and histone modifications, which are important for the regulation of gene expression and chromatin structure.\n7. Evolutionary history: GA-sequences are thought to have evolved as a result of the duplication and divergence of germline-specific genes, and they may have played a role in the evolution of mammalian reproduction.\n8. Functional diversity: GA-sequences are functionally diverse, with some sequences involved in the regulation of gene expression, while others may be involved in the formation of chromatin structures or the maintenance of gen",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are typically located in the non-coding regions of the genome.\n2. The length of mammalian GA-sequences ranges from a few hundred to a few thousand base pairs.\n3. GA-sequences have a consensus sequence that is rich in purine and pyramidine residues.\n4. GA-sequences are highly conserved across different mammalian species.\n5. GA-sequences play a role in the regulation of gene expression during meiosis and gametogenesis.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are typically located in the non-coding regions of the genome.",
      "The length of mammalian GA-sequences ranges from a few hundred to a few thousand base pairs.",
      "GA-sequences have a consensus sequence that is rich in purine and pyramidine residues.",
      "GA-sequences are highly conserved across different mammalian species.",
      "GA-sequences play a role in the regulation of gene expression during meiosis and gametogenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GA-sequences have a consensus sequence that is rich in guanine (G) and adenine (A) residues, which are purines.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I must inform you that the question you have asked is quite intriguing, but it is based on a false premise. There are no Groucho-related genes (GRG) contained in the mouse genome or any other genome for that matter.\nGroucho is a fictional character from the Marx Brothers comedy films, and he does not have any genetic counterpart in the real world. The genetic code that determines an organism's physical and behavioral traits is complex and diverse, and it does not include any genes that are specifically related to a fictional character.\nSo, to answer your question directly, there are no GRGs contained in the mouse genome or any other genome. I hope this clears up any confusion, and please let me know if you have any other questions!",
    "llama-2-7b-chat-hf_fact_raw": "1. There are no Groucho-related genes (GRG) contained in the mouse genome.\n2. Groucho is a fictional character from the Marx Brothers comedy films.\n3. There are no genes specifically related to the fictional character Groucho in any genome.",
    "llama-2-7b-chat-hf_fact": [
      "There are no Groucho-related genes (GRG) contained in the mouse genome.",
      "Groucho is a fictional character from the Marx Brothers comedy films.",
      "There are no genes specifically related to the fictional character Groucho in any genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is the primary enzyme responsible for transcribing DNA into RNA in eukaryotic cells. RNAPII is a complex of several subunits, including the core enzyme and additional factors that modulate its activity. Among these subunits, the RNA polymerase II subunit called RPB1 (RNA polymerase II subunit B1) carries RNA cleavage activity.\nRPB1 is one of the largest subunits of RNAPII and plays a crucial role in the transcription elongation process. It is responsible for the catalytic activity of RNAPII, and it also helps to position the enzyme correctly on the DNA template during transcription. In addition to its role in transcription elongation, RPB1 has been shown to carry RNA cleavage activity, which is essential for the proper termination of transcription.\nThe RNA cleavage activity of RPB1 is mediated by a conserved domain called the RNA cleavage domain (RCD). The RCD is located in the C-terminal region of RPB1 and is composed of a series of conserved amino acids that are essential for RNA cleavage. The RCD recognizes and binds to specific sequences in the RNA transcript, and then catalyzes the cleavage of the RNA molecule at these sites.\nThe RNA cleavage activity of RPB1 is important for the proper termination of transcription, as it allows the RNA transcript to be cleaved at the correct location and to be released from the transcription complex. This process is critical for the proper regulation of gene expression, as it allows the cell to control the amount of RNA molecules produced from a particular gene.\nIn summary, the RNA polymerase II subunit RPB1 carries RNA cleavage activity, which is essential for the proper termination of transcription in eukaryotic cells. The RNA cleavage activity of RPB1 is mediated by the conserved RNA cleavage domain (RCD) located in the C-terminal region of the subunit.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNAPII) transcribes DNA into RNA in eukaryotic cells.\n2. The RNA polymerase II subunit RPB1 carries RNA cleavage activity.\n3. RPB1 is responsible for the catalytic activity of RNAPII during transcription elongation.\n4. The RNA cleavage domain (RCD) within RPB1 is responsible for its RNA cleavage activity.\n5. The RNA cleavage activity of RPB1 is critical for proper termination of transcription.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNAPII) transcribes DNA into RNA in eukaryotic cells.",
      "The RNA polymerase II subunit RPB1 carries RNA cleavage activity.",
      "RPB1 is responsible for the catalytic activity of RNAPII during transcription elongation.",
      "The RNA cleavage domain (RCD) within RPB1 is responsible for its RNA cleavage activity.",
      "The RNA cleavage activity of RPB1 is critical for proper termination of transcription."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The RNA polymerase II subunit RPB1 does not carry RNA cleavage activity. It is the subunit RPB9 that is involved in RNA cleavage.\n3. TRUE\n4. FALSE [correction]: There is no specific \"RNA cleavage domain\" within RPB1 responsible for RNA cleavage activity.\n5. FALSE [correction]: RNA cleavage is not a function of RPB1, and it is not critical for the termination of transcription by RNAPII. Termination involves other factors and processes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome, also known as Ohdo-Kurosawa syndrome, is a rare genetic disorder that affects the development of the brain and nervous system. The genetic basis of Ohdo syndrome is caused by mutations in the PTEN gene, which is located on chromosome 10.\nThe PTEN gene encodes a protein called phosphatase and tensin homolog (PTEN), which plays a critical role in regulating the growth and development of cells. PTEN is a tumor suppressor protein that inhibits the activity of the PI3K/Akt signaling pathway, which is involved in cell survival and proliferation. Mutations in the PTEN gene can lead to the loss of PTEN function, resulting in uncontrolled cell growth and division, which can lead to the development of tumors.\nOhdo syndrome is characterized by a range of symptoms, including intellectual disability, seizures, delayed speech and language development, and a distinctive facial appearance. The disorder is usually diagnosed in infancy or early childhood, and the progression of the disease can vary depending on the severity of the mutations and the presence of other genetic mutations.\nThere are several different types of mutations that can occur in the PTEN gene that can cause Ohdo syndrome, including:\n1. Point mutations: These are the most common type of mutation and occur when a single base pair in the PTEN gene is changed.\n2. Deletions: These occur when a portion of the PTEN gene is deleted, leading to a loss of function.\n3. Duplications: These occur when there is an extra copy of the PTEN gene, leading to an increase in the amount of PTEN protein produced.\n4. Inversions: These occur when a portion of the PTEN gene is reversed, leading to a change in the way the gene functions.\nThe genetic basis of Ohdo syndrome is complex and can involve multiple genetic mutations, including those in the PTEN gene, as well as other genes that interact with the PTEN pathway. Understanding the genetic basis of Ohdo syndrome is important for developing effective treatments and improving the quality of life for individuals with the disorder.\nIt is important to note",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome, also known as Ohdo-Kurosawa syndrome, is a rare genetic disorder.\n2. Mutations in the PTEN gene, located on chromosome 10, cause Ohdo syndrome.\n3. The PTEN gene encodes a protein called phosphatase and tensin homolog (PTEN).\n4. Mutations in the PTEN gene can lead to uncontrolled cell growth and division and the development of tumors.\n5. Ohdo syndrome is characterized by symptoms including intellectual disability, seizures, and delayed speech and language development.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome, also known as Ohdo-Kurosawa syndrome, is a rare genetic disorder.",
      "Mutations in the PTEN gene, located on chromosome 10, cause Ohdo syndrome.",
      "The PTEN gene encodes a protein called phosphatase and tensin homolog (PTEN).",
      "Mutations in the PTEN gene can lead to uncontrolled cell growth and division and the development of tumors.",
      "Ohdo syndrome is characterized by symptoms including intellectual disability, seizures, and delayed speech and language development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the MED12 gene, located on the X chromosome, cause Ohdo syndrome.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Here are some of the most popular ones:\n1. PsychGen: This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders. It includes functions for genome-wide association study (GWAS) analysis, gene-set enrichment analysis, and pathway analysis.\n2. PsychiatricGenetics: This package provides a set of tools for the analysis of genetic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and functional annotation of genes.\n3. PsychGWAS: This package provides a set of functions for GWAS analysis in psychiatric disorders, including imputation, association testing, and gene-set enrichment analysis.\n4. PsychiatricGenomics: This package provides a set of tools for the analysis of genomic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and pathway analysis.\n5. PsychiatricRisk: This package provides a set of functions for identifying genetic variants associated with psychiatric disorders, including GWAS, gene-set enrichment analysis, and functional annotation of genes.\n6. PsychiatricGenomicsCloud: This package provides a set of tools for the analysis of genomic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and pathway analysis. It also includes functions for data visualization and interpretation.\n7. PsychiatricGenomicsDB: This package provides a set of tools for the analysis of genomic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and pathway analysis. It also includes functions for data visualization and interpretation.\n8. PsychiatricGenomicsR: This package provides a set of functions for the analysis of genomic data in psychiatric disorders, including GWAS, gene-set enrichment analysis, and pathway analysis. It also includes functions for data visualization and interpretation.\n9. PsychiatricGenomicsS: This package provides a set of functions for the analysis of genomic data in psychiatric disorders, including GWAS, gene-set en",
    "llama-2-7b-chat-hf_fact_raw": "1. PsychGen is an R/Bioconductor package developed for the analysis of genetic data in psychiatric disorders.\n2. PsychiatricGenetics is an R/Bioconductor package that includes tools for functional annotation of genes in psychiatric disorders.\n3. PsychGWAS is an R/Bioconductor package designed for GWAS analysis in psychiatric disorders.\n4. PsychiatricGenomicsCloud includes functions for data visualization and interpretation in the analysis of genomic data in psychiatric disorders.\n5. PsychiatricGenomicsDB is an R/Bioconductor package that provides tools for pathway analysis in psychiatric disorders.",
    "llama-2-7b-chat-hf_fact": [
      "PsychGen is an R/Bioconductor package developed for the analysis of genetic data in psychiatric disorders.",
      "PsychiatricGenetics is an R/Bioconductor package that includes tools for functional annotation of genes in psychiatric disorders.",
      "PsychGWAS is an R/Bioconductor package designed for GWAS analysis in psychiatric disorders.",
      "PsychiatricGenomicsCloud includes functions for data visualization and interpretation in the analysis of genomic data in psychiatric disorders.",
      "PsychiatricGenomicsDB is an R/Bioconductor package that provides tools for pathway analysis in psychiatric disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or information about these specific R/Bioconductor packages, it is not possible to determine the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Certainly, I'd be happy to help!\nSwirl sign, also known as the \"whirlpool sign,\" is a clinical sign that can be observed in some patients with intracerebral hemorrhage (ICH). It is characterized by a swirling or whirlpool-like pattern of blood in the affected hemisphere of the brain, typically seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\nThe swirl sign is caused by the blood that has escaped from the ruptured blood vessel and has accumulated in the surrounding brain tissue. The blood can form a swirling pattern due to the movement of the blood cells and the surrounding fluid. The sign is more commonly observed in the frontal and temporal lobes, where the blood vessels are more prone to rupture.\nThe swirl sign can be an important diagnostic clue in the evaluation of ICH, as it can help identify the location and extent of the hemorrhage. It can also provide information about the underlying cause of the hemorrhage, such as a ruptured aneurysm or arteriovenous malformation (AVM).\nHowever, it is important to note that the swirl sign is not specific to ICH and can also be seen in other conditions, such as cerebral edema or abscess. Therefore, a thorough clinical evaluation and other diagnostic tests, such as CT or MRI scans, are necessary to confirm the diagnosis of ICH and rule out other potential causes.\nIn summary, the swirl sign is a clinical sign that can be observed on CT or MRI scans in patients with intracerebral hemorrhage. It is characterized by a swirling or whirlpool-like pattern of blood in the affected hemisphere of the brain and can provide important diagnostic information about the location and extent of the hemorrhage.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign, also known as the \"whirlpool sign,\" can be observed in some patients with intracerebral hemorrhage (ICH).\n2. Swirl sign is characterized by a swirling or whirlpool-like pattern of blood in the affected hemisphere of the brain.\n3. The sign is typically seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\n4. Swirl sign is more commonly observed in the frontal and temporal lobes of the brain.\n5. Swirl sign can provide information about the underlying cause of the hemorrhage, such as a ruptured aneurysm or arteriovenous malformation (AVM).",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign, also known as the \"whirlpool sign,\" can be observed in some patients with intracerebral hemorrhage (ICH).",
      "Swirl sign is characterized by a swirling or whirlpool-like pattern of blood in the affected hemisphere of the brain.",
      "The sign is typically seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.",
      "Swirl sign is more commonly observed in the frontal and temporal lobes of the brain.",
      "Swirl sign can provide information about the underlying cause of the hemorrhage, such as a ruptured aneurysm or arteriovenous malformation (AVM)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA-binding protein 1) is a transcription factor that plays a crucial role in regulating plant growth and development. The expression of ROF1 is induced by a variety of environmental and developmental cues, including:\n1. Light: ROF1 expression is induced by light, particularly blue light. This is mediated by the photoreceptor cryptochrome, which interacts with ROF1 to regulate its activity.\n2. Temperature: ROF1 expression is also temperature-sensitive, with higher expression at higher temperatures. This is thought to be mediated by the heat shock response, which involves the activation of transcription factors that regulate the expression of heat-shock proteins.\n3. Water availability: ROF1 expression is induced by drought stress, as well as by high levels of water availability. This is thought to be mediated by the abscisic acid (ABA) signaling pathway, which regulates plant water balance.\n4. Hormones: ROF1 expression is also regulated by plant hormones, including auxin and ethylene. For example, auxin has been shown to induce ROF1 expression in Arabidopsis, while ethylene has been shown to repress it.\n5. Developmental cues: ROF1 expression is also regulated by developmental cues, such as the transition from the seedling to the adult stage. This is thought to be mediated by the activation of transcription factors that regulate the expression of ROF1.\n6. Nutrient availability: ROF1 expression is also regulated by the availability of nutrients, such as nitrogen and phosphorus. For example, nitrogen starvation has been shown to induce ROF1 expression in Arabidopsis.\n7. Defense against pathogens: ROF1 expression is also regulated by the defense against pathogens, such as bacteria and fungi. For example, ROF1 expression is induced by the bacterial pathogen Pseudomonas syringae in Arabidopsis.\n8. Interactions with other transcription factors: ROF1 expression is also regulated by the interactions with other transcription factors, such as the transcription factor PIF4. PIF4 has been shown to repress ROF",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by light, particularly blue light.\n2. Higher temperatures lead to higher expression of ROF1.\n3. Drought stress and high levels of water availability induce ROF1 expression.\n4. Plant hormones, including auxin and ethylene, regulate ROF1 expression.\n5. The transition from the seedling to the adult stage is a developmental cue that regulates ROF1 expression.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by light, particularly blue light.",
      "Higher temperatures lead to higher expression of ROF1.",
      "Drought stress and high levels of water availability induce ROF1 expression.",
      "Plant hormones, including auxin and ethylene, regulate ROF1 expression.",
      "The transition from the seedling to the adult stage is a developmental cue that regulates ROF1 expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific context or passage that these statements are extracted from, it is difficult to determine the accuracy of these statements. They pertain to very specific scientific information that would require reference to research or studies on the gene ROF1 in the model plant Arabidopsis.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Hereditary renal amyloidosis, also known as familial amyloid nephropathy (FAN), is a rare genetic disorder that affects the kidneys and is caused by the accumulation of abnormal protein deposits, known as amyloid, in the kidneys. The most common cause of hereditary renal amyloidosis is the accumulation of a protein called alpha-2-macroglobulin (A2M).\nA2M is a large, glycoprotein that is produced in the liver and is normally present in the bloodstream at low levels. In people with hereditary renal amyloidosis, the A2M protein is overproduced and misfolded, leading to its accumulation in the kidneys. The misfolded A2M protein then forms abnormal amyloid fibrils that deposit in the kidneys and cause progressive damage to the kidney tissue, leading to kidney failure.\nOther proteins, such as apolipoprotein A-I and transthyretin, have also been associated with hereditary renal amyloidosis, but A2M is the most common cause. The inheritance pattern of hereditary renal amyloidosis is usually autosomal dominant, meaning that a single copy of the mutated gene is enough to cause the condition.\nIt's important to note that hereditary renal amyloidosis is a rare condition, and most people with kidney problems do not have this condition. If you have a family history of kidney disease or are experiencing symptoms of kidney problems, it's important to speak with a healthcare provider to determine the underlying cause and develop an appropriate treatment plan.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hereditary renal amyloidosis is a rare genetic disorder caused by the accumulation of abnormal protein deposits, known as amyloid, in the kidneys.\n2. The most common cause of hereditary renal amyloidosis is the accumulation of a protein called alpha-2-macroglobulin (A2M).\n3. A2M is a protein produced in the liver and is normally present in the bloodstream at low levels.\n4. The inheritance pattern of hereditary renal amyloidosis is usually autosomal dominant.\n5. Other proteins associated with hereditary renal amyloidosis include apolipoprotein A-I and transthyretin.",
    "llama-2-7b-chat-hf_fact": [
      "Hereditary renal amyloidosis is a rare genetic disorder caused by the accumulation of abnormal protein deposits, known as amyloid, in the kidneys.",
      "The most common cause of hereditary renal amyloidosis is the accumulation of a protein called alpha-2-macroglobulin (A2M).",
      "A2M is a protein produced in the liver and is normally present in the bloodstream at low levels.",
      "The inheritance pattern of hereditary renal amyloidosis is usually autosomal dominant.",
      "Other proteins associated with hereditary renal amyloidosis include apolipoprotein A-I and transthyretin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common cause of hereditary renal amyloidosis is the accumulation of a protein called transthyretin (TTR).\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed through various proteomic studies. The hippocampus is a complex brain structure involved in memory formation, spatial navigation, and emotion regulation, and its proteome is known to be involved in these functions. Here are some key findings from proteomic studies of the mouse hippocampus:\n1. Protein identification: Studies have identified thousands of proteins in the mouse hippocampus using techniques such as two-dimensional gel electrophoresis (2DGE), mass spectrometry (MS), and label-free quantification. These proteins include structural proteins, enzymes, receptors, and regulatory proteins (1,2).\n2. Protein abundance: Proteomic studies have shown that the abundance of certain proteins in the mouse hippocampus can change in response to various stimuli, such as exercise, stress, and disease. For example, studies have shown that exercise can increase the abundance of proteins involved in synaptic plasticity and learning, while stress can decrease the abundance of proteins involved in neuroprotection (3,4).\n3. Post-translational modifications (PTMs): PTMs, such as phosphorylation, acetylation, and ubiquitination, play a crucial role in regulating protein function in the hippocampus. Proteomic studies have identified a wide range of PTMs in the mouse hippocampus, including those involved in synaptic plasticity and learning (5,6).\n4. Protein-protein interactions: Proteomic studies have also identified protein-protein interactions in the mouse hippocampus, which are important for neural function and plasticity. For example, studies have shown that the interaction between the N-methyl-D-aspartate (NMDA) receptor and the glutamate receptor is involved in synaptic plasticity and learning (7,8).\n5. Disease-related changes: Proteomic studies have also been used to investigate changes in the hippocampal proteome in various neurological disorders, such as Alzheimer's disease, Parkinson's disease, and autism. These studies have shown that the proteome of the hi",
    "llama-2-7b-chat-hf_fact_raw": "1. Proteomic studies have identified thousands of proteins in the mouse hippocampus using techniques such as two-dimensional gel electrophoresis (2DGE), mass spectrometry (MS), and label-free quantification.\n2. Protein abundance in the mouse hippocampus can change in response to various stimuli, such as exercise and stress.\n3. Post-translational modifications play a crucial role in regulating protein function in the mouse hippocampus.\n4. Proteomic studies have identified protein-protein interactions in the mouse hippocampus that are important for neural function and plasticity.\n5. Proteomic studies have been used to investigate changes in the hippocampal proteome in various neurological disorders, such as Alzheimer's disease, Parkinson's disease, and autism.",
    "llama-2-7b-chat-hf_fact": [
      "Proteomic studies have identified thousands of proteins in the mouse hippocampus using techniques such as two-dimensional gel electrophoresis (2DGE), mass spectrometry (MS), and label-free quantification.",
      "Protein abundance in the mouse hippocampus can change in response to various stimuli, such as exercise and stress.",
      "Post-translational modifications play a crucial role in regulating protein function in the mouse hippocampus.",
      "Proteomic studies have identified protein-protein interactions in the mouse hippocampus that are important for neural function and plasticity.",
      "Proteomic studies have been used to investigate changes in the hippocampal proteome in various neurological disorders, such as Alzheimer's disease, Parkinson's disease, and autism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Great question! As a helpful assistant, I'm here to provide you with accurate and informative answers.\nAcrocentric chromosomes are a type of chromosome that has a prominent centromere, which is the point where the chromosome is most condensed and organized during cell division. In mammals, including mice, the chromosomes are not acrocentric. Instead, they are called metacentric, which means that the centromere is located near the center of the chromosome.\nIn mice, each chromosome has a unique combination of genes and regulatory elements that control the expression of those genes. The chromosomes are also organized into different bands, which are regions of the chromosome that are rich in genetic material. These bands are important for the proper segregation of the chromosomes during cell division, and they can also influence the expression of genes near the bands.\nSo, to summarize, mouse chromosomes are not acrocentric, but rather metacentric. This means that the centromere is located near the center of the chromosome, rather than at one end, as it is in acrocentric chromosomes. I hope this helps clarify things for you! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrocentric chromosomes have a prominent centromere that is most condensed and organized during cell division.\n2. Mammalian chromosomes, including those in mice, are not acrocentric, but rather metacentric.\n3. Metacentric chromosomes have a centromere located near the center of the chromosome.\n4. Mouse chromosomes are organized into different bands that are regions rich in genetic material.\n5. These bands on mouse chromosomes play a role in the proper segregation of chromosomes during cell division and can influence gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "Acrocentric chromosomes have a prominent centromere that is most condensed and organized during cell division.",
      "Mammalian chromosomes, including those in mice, are not acrocentric, but rather metacentric.",
      "Metacentric chromosomes have a centromere located near the center of the chromosome.",
      "Mouse chromosomes are organized into different bands that are regions rich in genetic material.",
      "These bands on mouse chromosomes play a role in the proper segregation of chromosomes during cell division and can influence gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Acrocentric chromosomes have a centromere that is located near one end of the chromosome, not prominently condensed and organized during cell division.\n2. FALSE [correction]: Some mammalian chromosomes, including those in mice, are acrocentric.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs that are currently in clinical trials for the treatment of pancreatic cancer. Here are a few examples:\n1. Vitrakvi (larotrectinib): Vitrakvi is an oral TRK inhibitor that is being developed by Bayer and Loxo Oncology. It has shown promising results in clinical trials for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. In 2018, Vitrakvi was approved by the FDA for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion, including pancreatic cancer.\n2. BMS-986205: BMS-986205 is an investigational RNA interference (RNAi) therapy being developed by Bristol-Myers Squibb for the treatment of various cancers, including pancreatic cancer. It works by targeting and silencing specific genes that are involved in the growth and progression of cancer cells. BMS-986205 is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\n3. ALN-PC01: ALN-PC01 is an investigational RNAi therapy being developed by Alnylam Pharmaceuticals for the treatment of pancreatic cancer. It works by targeting and silencing the gene that encodes the protein PD-L1, which is involved in the immune evasion of cancer cells. ALN-PC01 is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\n4. AR-509: AR-509 is an investigational RNAi therapy being developed by Arrowhead Research Corporation for the treatment of various cancers, including pancreatic cancer. It works by targeting and silencing specific genes that are involved in the growth and progression of cancer cells. AR-509 is currently in Phase 1 clinical trials for the treatment of pancreatic cancer.\n5. ASG-20: ASG-20 is an investigational RNAi therapy being developed by Ascletis",
    "llama-2-7b-chat-hf_fact_raw": "1. Vitrakvi (larotrectinib) is an oral TRK inhibitor developed by Bayer and Loxo Oncology and was approved by the FDA in 2018 for treatment of solid tumors with an NTRK gene fusion.\n2. BMS-986205 is an investigational RNAi therapy developed by Bristol-Myers Squibb and is in Phase 1 clinical trials for pancreatic cancer treatment.\n3. ALN-PC01 is an investigational RNAi therapy developed by Alnylam Pharmaceuticals and is in Phase 1 clinical trials for pancreatic cancer treatment.\n4. AR-509 is an investigational RNAi therapy developed by Arrowhead Research Corporation and is in Phase 1 clinical trials for pancreatic cancer treatment.\n5. ASG-20 is an investigational RNAi therapy being developed by Ascletis.",
    "llama-2-7b-chat-hf_fact": [
      "Vitrakvi (larotrectinib) is an oral TRK inhibitor developed by Bayer and Loxo Oncology and was approved by the FDA in 2018 for treatment of solid tumors with an NTRK gene fusion.",
      "BMS-986205 is an investigational RNAi therapy developed by Bristol-Myers Squibb and is in Phase 1 clinical trials for pancreatic cancer treatment.",
      "ALN-PC01 is an investigational RNAi therapy developed by Alnylam Pharmaceuticals and is in Phase 1 clinical trials for pancreatic cancer treatment.",
      "AR-509 is an investigational RNAi therapy developed by Arrowhead Research Corporation and is in Phase 1 clinical trials for pancreatic cancer treatment.",
      "ASG-20 is an investigational RNAi therapy being developed by Ascletis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: BMS-986205 is an investigational IDO1 inhibitor developed by Bristol-Myers Squibb, not an RNAi therapy.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG pore, also known as the hemoglobin-protoporphyrin IX pore, is a structural feature of the hemoglobin protein found in red blood cells. It is a small opening in the hemoglobin molecule through which protoporphyrin IX, a byproduct of heme biosynthesis, can pass.\nThe HPG pore is located in the beta-globin subunit of the hemoglobin molecule and is formed by the alignment of four beta-strands in the hemoglobin molecule. This pore is responsible for the exchange of oxygen and carbon dioxide between the red blood cell and the tissues.\nThe HPG pore is important for the proper functioning of the red blood cell because it allows for the efficient exchange of oxygen and carbon dioxide between the red blood cell and the tissues. Oxygen enters the red blood cell through the HPG pore and is then transported to the tissues, where it is used to produce energy. Carbon dioxide, on the other hand, is removed from the tissues through the HPG pore and is transported back to the red blood cell, where it is released into the bloodstream.\nMutations in the hemoglobin gene that encodes the beta-globin subunit of the hemoglobin molecule can lead to changes in the size and shape of the HPG pore, which can affect the ability of the red blood cell to transport oxygen and carbon dioxide. Some of these mutations can lead to severe anemia and other health problems.\nIn addition to its role in oxygen and carbon dioxide transport, the HPG pore has also been implicated in the regulation of red blood cell function and survival. For example, the HPG pore has been shown to play a role in the regulation of red blood cell deformation, which is important for the red blood cell's ability to navigate through small blood vessels and capillaries.\nOverall, the HPG pore is a critical structural feature of the hemoglobin molecule that plays a central role in the proper functioning of the red blood cell. Its unique structure and function allow for the efficient exchange of oxygen and carbon dioxide between the red blood cell and the tissues, and its reg",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore, also known as the hemoglobin-protoporphyrin IX pore, is found in the hemoglobin protein of red blood cells.\n2. The HPG pore allows for the exchange of oxygen and carbon dioxide between the red blood cell and tissues.\n3. The HPG pore is located in the beta-globin subunit of the hemoglobin molecule.\n4. Mutations in the hemoglobin gene can lead to changes in the HPG pore, affecting oxygen and carbon dioxide transport.\n5. The HPG pore has a role in the regulation of red blood cell function and survival, including red blood cell deformation.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore, also known as the hemoglobin-protoporphyrin IX pore, is found in the hemoglobin protein of red blood cells.",
      "The HPG pore allows for the exchange of oxygen and carbon dioxide between the red blood cell and tissues.",
      "The HPG pore is located in the beta-globin subunit of the hemoglobin molecule.",
      "Mutations in the hemoglobin gene can lead to changes in the HPG pore, affecting oxygen and carbon dioxide transport.",
      "The HPG pore has a role in the regulation of red blood cell function and survival, including red blood cell deformation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: The HPG pore is located in the alpha-globin subunit of the hemoglobin molecule.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a large-scale research project aimed at sequencing and analyzing the genomes of 959 species of nematodes, which are a group of microscopic worms that are found in almost every environment on Earth. The initiative is led by the University of California, Berkeley and involves a collaboration of over 100 researchers from institutions around the world.\nNematodes are incredibly diverse, with over 70,000 known species, and they play important roles in ecosystems, including as predators, prey, and decomposers. However, despite their ecological importance, the genomes of most nematode species have remained largely unstudied. The 959 Nematode Genomes initiative aims to change this by sequencing and analyzing the genomes of a representative sample of nematode species, with the goal of gaining a better understanding of the evolution, diversity, and ecological roles of these fascinating organisms.\nThe initiative is using a combination of cutting-edge sequencing technologies, including single-molecule real-time sequencing and long-read sequencing, to generate high-quality genome assemblies for each of the 959 species. The genomes will be analyzed for gene content, gene expression, and other features, and the data will be made publicly available through a user-friendly database.\nSome of the key goals of the 959 Nematode Genomes initiative include:\n1. Understanding the evolutionary relationships between different nematode species and groups.\n2. Identifying genes that are unique to specific nematode species or groups, and investigating their functions.\n3. Investigating the role of nematodes in different ecosystems, including their interactions with other organisms and their impact on ecosystem processes.\n4. Developing new tools and methods for analyzing nematode genomes, including improved genome assembly and annotation pipelines.\n5. Training the next generation of nematode researchers through workshops and educational resources.\nThe 959 Nematode Genomes initiative is a groundbreaking effort that will provide a wealth of new insights into the biology and evolution of these fascinating organisms,",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 nematode species.\n2. The initiative is led by the University of California, Berkeley.\n3. Over 100 researchers from institutions around the world are collaborating on the project.\n4. Nematodes are microscopic worms with over 70,000 known species.\n5. The initiative is using single-molecule real-time sequencing and long-read sequencing technologies.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 nematode species.",
      "The initiative is led by the University of California, Berkeley.",
      "Over 100 researchers from institutions around the world are collaborating on the project.",
      "Nematodes are microscopic worms with over 70,000 known species.",
      "The initiative is using single-molecule real-time sequencing and long-read sequencing technologies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Here are some of the popular ones:\n1. NIPTkit: This is a comprehensive R package for NIPT data analysis, developed by the University of California, San Diego. It provides a wide range of tools for analyzing NIPT data, including quality control, sample classification, and statistical analysis.\n2. PrenatalTesting: This package is designed for the analysis of NIPT data, including cell-free DNA (cfDNA) and placental DNA. It provides functions for data cleaning, visualization, and statistical analysis, as well as tools for interpreting test results.\n3. NIPTAnalysis: This package is specifically designed for the analysis of NIPT data, including cfDNA and placental DNA. It provides functions for data cleaning, visualization, and statistical analysis, as well as tools for interpreting test results.\n4. PrenaTest: This package is designed for the analysis of NIPT data, including cfDNA and placental DNA. It provides functions for data cleaning, visualization, and statistical analysis, as well as tools for interpreting test results.\n5. NIPTworkflow: This package is designed for the analysis of NIPT data, including cfDNA and placental DNA. It provides functions for data cleaning, visualization, and statistical analysis, as well as tools for interpreting test results.\n6. NIPT-R: This package is designed for the analysis of NIPT data, including cfDNA and placental DNA. It provides functions for data cleaning, visualization, and statistical analysis, as well as tools for interpreting test results.\n7. PrenatalGenetics: This package is designed for the analysis of NIPT data, including cfDNA and placental DNA. It provides functions for data cleaning, visualization, and statistical analysis, as well as tools for interpreting test results.\n8. NIPT-analysis: This package is designed for the analysis of NIPT data, including cfDNA and placental DNA. It provides functions for data cleaning, visualization, and statistical analysis, as well as tools for interpreting test results.\n9. Pren",
    "llama-2-7b-chat-hf_fact_raw": "1. NIPTkit is an R package for NIPT data analysis developed by the University of California, San Diego.\n2. PrenatalTesting provides functions for data cleaning, visualization, and statistical analysis of NIPT data.\n3. NIPTAnalysis is an R package specifically designed for analyzing NIPT data.\n4. PrenaTest provides tools for interpreting Non-invasive prenatal testing results.\n5. NIPTworkflow is an R package that offers functions for data cleaning, visualization, and statistical analysis of NIPT data.",
    "llama-2-7b-chat-hf_fact": [
      "NIPTkit is an R package for NIPT data analysis developed by the University of California, San Diego.",
      "PrenatalTesting provides functions for data cleaning, visualization, and statistical analysis of NIPT data.",
      "NIPTAnalysis is an R package specifically designed for analyzing NIPT data.",
      "PrenaTest provides tools for interpreting Non-invasive prenatal testing results.",
      "NIPTworkflow is an R package that offers functions for data cleaning, visualization, and statistical analysis of NIPT data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach's triad or Achenbach's complex, is a rare genetic disorder that affects the brain and nervous system. It is characterized by a combination of three distinct symptoms, which can vary in severity and may occur separately or together. These symptoms include:\n1. Ataxia: Achenbach's syndrome can cause problems with coordination, balance, and movement. People with this condition may experience difficulty walking, standing, or performing other physical activities due to a lack of coordination and balance.\n2. Intellectual disability: Individuals with Achenbach's syndrome may have mild to severe intellectual disability, which can affect their ability to learn, communicate, and perform daily tasks. This can range from mild cognitive impairment to profound intellectual disability.\n3. Cerebellar hypoplasia: The cerebellum is a part of the brain that plays a crucial role in coordination, balance, and movement. In Achenbach's syndrome, the cerebellum is underdeveloped or abnormally shaped, leading to problems with movement and coordination.\nOther symptoms of Achenbach's syndrome can include:\n* Delayed speech and language development\n* Vision problems, such as strabismus (crossed eyes) or amblyopia (lazy eye)\n* Hearing loss or deafness\n* Seizures\n* Sleep disturbances\n* Emotional and behavioral problems, such as anxiety, depression, or irritability\nThe exact cause of Achenbach's syndrome is not fully understood, but it is thought to be related to genetic mutations or variations. It is a rare disorder, and the prevalence is estimated to be around 1 in 100,000 to 1 in 50,000 births.\nThere is no cure for Achenbach's syndrome, but various treatments can help manage the symptoms. These may include physical therapy, occupational therapy, speech therapy, and medications to control seizures or other symptoms. Early intervention and specialized care can significantly improve the quality of life for individuals with Achenbach's syndrome.\nIt",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is a rare genetic disorder that affects the brain and nervous system.\n2. The syndrome is characterized by a combination of ataxia, intellectual disability, and cerebellar hypoplasia.\n3. Symptoms of Achenbach's syndrome may include delayed speech and language development, vision problems, hearing loss, seizures, and sleep disturbances.\n4. The exact cause of Achenbach's syndrome is thought to be related to genetic mutations or variations.\n5. The estimated prevalence of Achenbach's syndrome is between 1 in 100,000 to 1 in 50,000 births.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is a rare genetic disorder that affects the brain and nervous system.",
      "The syndrome is characterized by a combination of ataxia, intellectual disability, and cerebellar hypoplasia.",
      "Symptoms of Achenbach's syndrome may include delayed speech and language development, vision problems, hearing loss, seizures, and sleep disturbances.",
      "The exact cause of Achenbach's syndrome is thought to be related to genetic mutations or variations.",
      "The estimated prevalence of Achenbach's syndrome is between 1 in 100,000 to 1 in 50,000 births."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not a genetic disorder affecting the brain and nervous system; it is a condition that affects the blood vessels in the hands, causing bruising or bleeding.\n2. FALSE [correction]: The syndrome is characterized by sudden, unexplained bruising or bleeding under the skin of the hands.\n3. FALSE [correction]: Symptoms of Achenbach's syndrome are limited to sudden bruising or bleeding in the hands, not delayed speech or language development, vision problems, hearing loss, seizures, and sleep disturbances.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Long repeat expansions are a type of genomic variation that can occur when a segment of DNA is repeated multiple times in a row. Detecting these expansions is important for understanding the genetic basis of various diseases and disorders, as well as for identifying genetic mutations that may be associated with an increased risk of developing certain conditions.\nThere are several algorithms that can be used for the detection of long repeat expansions, including:\n1. RepeatMasker: This algorithm is widely used for identifying repetitive elements in genomic sequences. It uses a combination of heuristics and statistical models to identify potential repeat regions, and then uses a series of filters to refine the predictions. RepeatMasker can be used to detect both short and long repeat expansions.\n2. GATK (Genome Analysis Toolkit): This is a popular software package for genomic analysis that includes tools for detecting repeat expansions. The GATK tool \"RepeatMasker\" is a popular tool for detecting repeat expansions, and it uses a similar approach to RepeatMasker.\n3. LD-REPEAT: This algorithm is specifically designed for detecting long repeat expansions. It uses a combination of statistical models and machine learning algorithms to identify potential repeat regions, and then uses a series of filters to refine the predictions.\n4. REPEAT-FINDER: This algorithm is a fast and sensitive tool for detecting repeat expansions. It uses a combination of heuristics and statistical models to identify potential repeat regions, and then uses a series of filters to refine the predictions.\n5. RIP (Repeat Indices for Protein-coding Genes): This algorithm is specifically designed for detecting repeat expansions in protein-coding genes. It uses a combination of statistical models and machine learning algorithms to identify potential repeat regions, and then uses a series of filters to refine the predictions.\n6. DeepRepeats: This is a deep learning-based algorithm for detecting repeat expansions. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to identify potential repeat regions, and then uses a series of filters to refine the predictions.\n7. RepeatHunter: This algorithm is specifically designed for detecting repeat expansions in genomic sequences. It uses a",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm used for identifying repetitive elements in genomic sequences.\n2. GATK (Genome Analysis Toolkit) includes tools for detecting repeat expansions.\n3. LD-REPEAT is an algorithm specifically designed for detecting long repeat expansions.\n4. REPEAT-FINDER is a tool for detecting repeat expansions.\n5. DeepRepeats is a deep learning-based algorithm for detecting repeat expansions.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is an algorithm used for identifying repetitive elements in genomic sequences.",
      "GATK (Genome Analysis Toolkit) includes tools for detecting repeat expansions.",
      "LD-REPEAT is an algorithm specifically designed for detecting long repeat expansions.",
      "REPEAT-FINDER is a tool for detecting repeat expansions.",
      "DeepRepeats is a deep learning-based algorithm for detecting repeat expansions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: GATK (Genome Analysis Toolkit) does not specifically include tools for detecting repeat expansions; it is a software package for analyzing high-throughput sequencing data.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 is a protein that has been implicated in the development and progression of various types of brain tumors, including:\n1. Glioblastoma: Glioblastoma, also known as glioblastoma multiforme (GBM), is the most common and aggressive type of primary brain cancer. Neuroligin-3 has been shown to be overexpressed in a significant proportion of glioblastomas, and high levels of neuroligin-3 expression have been associated with poorer prognosis.\n2. Medulloblastoma: Medulloblastoma is a type of pediatric brain cancer that arises in the cerebellum. Neuroligin-3 has been found to be overexpressed in a subset of medulloblastomas, and high levels of neuroligin-3 expression have been associated with more aggressive tumor behavior.\n3. Meningioma: Meningioma is a type of non-cancerous brain tumor that arises in the meninges, the protective membranes covering the brain and spinal cord. While meningioma is generally a slow-growing tumor, some cases can be more aggressive and may overexpress neuroligin-3.\n4. Pineal parenchymal tumors: Pineal parenchymal tumors are rare brain tumors that arise in the pineal gland, a small endocrine gland located in the brain. Neuroligin-3 has been found to be overexpressed in some pineal parenchymal tumors, particularly those that are malignant.\n5. Acoustic neuroma: Acoustic neuroma is a type of non-cancerous brain tumor that arises on the nerve that connects the inner ear to the brain. While acoustic neuroma is generally slow-growing and benign, some cases can overexpress neuroligin-3 and may be more aggressive.\nIt is important to note that the expression of neuroligin-3 in these brain tumors is not always uniform, and the levels of expression can vary depending on the specific type of tumor and the individual patient. Additionally, while neuroligin-3 has been implicated in the development and progression of these brain tumors, it is not a definit",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 has been implicated in the development and progression of various types of brain tumors.\n2. Glioblastoma is the most common and aggressive type of primary brain cancer and has been shown to overexpress neuroligin-3.\n3. Medulloblastoma is a type of pediatric brain cancer where neuroligin-3 has been found to be overexpressed in a subset of cases.\n4. Meningioma is a type of non-cancerous brain tumor that may overexpress neuroligin-3 in some aggressive cases.\n5. Pineal parenchymal tumors, which are rare brain tumors, have been found to overexpress neuroligin-3, particularly in malignant cases.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 has been implicated in the development and progression of various types of brain tumors.",
      "Glioblastoma is the most common and aggressive type of primary brain cancer and has been shown to overexpress neuroligin-3.",
      "Medulloblastoma is a type of pediatric brain cancer where neuroligin-3 has been found to be overexpressed in a subset of cases.",
      "Meningioma is a type of non-cancerous brain tumor that may overexpress neuroligin-3 in some aggressive cases.",
      "Pineal parenchymal tumors, which are rare brain tumors, have been found to overexpress neuroligin-3, particularly in malignant cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Meningioma is a type of brain tumor that is typically non-cancerous and there is no conclusive evidence to suggest that they overexpress neuroligin-3 in aggressive cases.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles are small, hollow structures found in some bacteria and archaea that are used for buoyancy and/or motility. The size of gas vesicles can vary greatly depending on the species of organism and the specific function they serve. Here are some approximate sizes of gas vesicles in different organisms:\n1. Halobacterium salinarum: Gas vesicles in this species are typically around 100-200 nanometers (nm) in diameter.\n2. Escherichia coli (E. coli): Gas vesicles in E. coli are around 200-400 nm in diameter.\n3. Pseudomonas aeruginosa: Gas vesicles in this species are around 300-600 nm in diameter.\n4. Vibrio cholerae: Gas vesicles in V. cholerae are around 400-800 nm in diameter.\n5. Thiomargarita namibiensis: Gas vesicles in this species are among the largest known, reaching up to 750 μm (micrometers) in diameter.\n6. Sulfurihydrothermarchaeus obliquus: Gas vesicles in this species are around 200-400 nm in diameter.\nIt's worth noting that these sizes are approximate and can vary depending on the specific conditions in which the organism is living. Additionally, some organisms may have different types of gas vesicles with different sizes.\nIt's also important to mention that gas vesicles are not present in all bacteria and archaea, and their presence and size can be used as a characteristic to identify and distinguish between different species.",
    "llama-2-7b-chat-hf_fact_raw": "1. Halobacterium salinarum has gas vesicles typically around 100-200 nanometers in diameter.\n2. Escherichia coli has gas vesicles around 200-400 nanometers in diameter.\n3. Pseudomonas aeruginosa has gas vesicles around 300-600 nanometers in diameter.\n4. Vibrio cholerae has gas vesicles around 400-800 nanometers in diameter.\n5. Thiomargarita namibiensis has gas vesicles reaching up to 750 micrometers in diameter.",
    "llama-2-7b-chat-hf_fact": [
      "Halobacterium salinarum has gas vesicles typically around 100-200 nanometers in diameter.",
      "Escherichia coli has gas vesicles around 200-400 nanometers in diameter.",
      "Pseudomonas aeruginosa has gas vesicles around 300-600 nanometers in diameter.",
      "Vibrio cholerae has gas vesicles around 400-800 nanometers in diameter.",
      "Thiomargarita namibiensis has gas vesicles reaching up to 750 micrometers in diameter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Escherichia coli does not have gas vesicles.\n3. FALSE [correction]: Pseudomonas aeruginosa does not have gas vesicles.\n4. FALSE [correction]: Vibrio cholerae does not have gas vesicles.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "BET (Bromodomain and Extra-Terminal) proteins are a family of proteins that play a crucial role in regulating gene expression by modulating the structure of chromatin, the complex of DNA and proteins that make up the chromosomes. BET proteins are named after their bromodomain, a specific structural motif that recognizes and binds to acetylated lysine residues on histone proteins, which are the building blocks of chromatin.\nThere are four subtypes of BET proteins: BET1, BET2, BET3, and BET4. Each subtype has distinct functions and regulates different cellular processes. Here are the list of BET proteins:\n1. BET1 (BRD1): BET1 is the founding member of the BET protein family and plays a crucial role in regulating gene expression, cell proliferation, and differentiation. It is involved in the maintenance of pluripotency in stem cells and the regulation of cell fate decisions.\n2. BET2 (BRD2): BET2 is a key regulator of gene expression and cellular differentiation. It is involved in the activation of transcriptional elongation and the regulation of cellular processes such as cell proliferation, migration, and survival.\n3. BET3 (BRDT): BET3 is a bromodomain-containing protein that is primarily involved in the regulation of gene expression and cellular differentiation. It is also involved in the maintenance of genome stability and the regulation of cellular processes such as cell proliferation and migration.\n4. BET4 (BRDM1): BET4 is a bromodomain-containing protein that is primarily involved in the regulation of gene expression and cellular differentiation. It is also involved in the regulation of cellular processes such as cell proliferation, migration, and survival.\nBET proteins play a crucial role in various cellular processes, including:\n* Gene expression: BET proteins regulate the expression of target genes by modulating the structure of chromatin and recruiting transcription factors.\n* Cellular differentiation: BET proteins are involved in the regulation of cellular differentiation and the",
    "llama-2-7b-chat-hf_fact_raw": "1. BET proteins are named after their bromodomain, which recognizes and binds to acetylated lysine residues on histone proteins.\n2. There are four subtypes of BET proteins: BET1, BET2, BET3, and BET4.\n3. BET1 is involved in the maintenance of pluripotency in stem cells and regulation of cell fate decisions.\n4. BET2 is involved in activation of transcriptional elongation and regulation of cellular processes like cell proliferation and migration.\n5. BET3 and BET4 are involved in the regulation of gene expression and cellular differentiation, as well as cellular processes such as cell proliferation and migration.",
    "llama-2-7b-chat-hf_fact": [
      "BET proteins are named after their bromodomain, which recognizes and binds to acetylated lysine residues on histone proteins.",
      "There are four subtypes of BET proteins: BET1, BET2, BET3, and BET4.",
      "BET1 is involved in the maintenance of pluripotency in stem cells and regulation of cell fate decisions.",
      "BET2 is involved in activation of transcriptional elongation and regulation of cellular processes like cell proliferation and migration.",
      "BET3 and BET4 are involved in the regulation of gene expression and cellular differentiation, as well as cellular processes such as cell proliferation and migration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are four BET proteins: BRD2, BRD3, BRD4, and BRDT.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "There have been several deep learning algorithms developed for protein subcellular localization prediction. Here are some of the most notable ones:\n1. DeepLoc: Developed by Zhang et al. in 2018, DeepLoc is a deep learning-based method for predicting protein subcellular localization. It uses a combination of sequence-based features and structural information to predict the localization of proteins. DeepLoc achieves state-of-the-art performance on several benchmark datasets and has been widely adopted in the field.\n2. LocNet: LocNet is another deep learning-based method for protein subcellular localization prediction. Developed by Li et al. in 2018, LocNet uses a multi-task learning framework to predict the localization of proteins. It uses a combination of sequence-based features, structural information, and experimental data to make predictions. LocNet achieves high accuracy on several benchmark datasets and has been shown to outperform other state-of-the-art methods.\n3. PSORT-MCRN: PSORT-MCRN is a deep learning-based method for protein subcellular localization prediction. Developed by Wang et al. in 2019, PSORT-MCRN uses a combination of sequence-based features and structural information to predict the localization of proteins. It also incorporates information from multiple databases and resources to improve the accuracy of predictions. PSORT-MCRN achieves high accuracy on several benchmark datasets and has been shown to outperform other state-of-the-art methods.\n4. DeepLoc2: Developed by Zhang et al. in 2020, DeepLoc2 is an improved version of the original DeepLoc method. It uses a combination of sequence-based features, structural information, and experimental data to predict the localization of proteins. DeepLoc2 achieves state-of-the-art performance on several benchmark datasets and has been shown to outperform other state-of-the-art methods.\n5. ProteinLoc: ProteinLoc is a deep learning-based method for protein subcellular localization prediction. Developed by Zhang et al. in 2020, ProteinLoc uses a combination of sequence-based features and structural information to predict the localization of proteins. It also incorporates information from multiple databases and resources to improve",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepLoc was developed by Zhang et al. in 2018 for predicting protein subcellular localization.\n2. LocNet was developed by Li et al. in 2018 and uses a multi-task learning framework for localization prediction.\n3. PSORT-MCRN, developed by Wang et al. in 2019, incorporates information from multiple databases for improved accuracy.\n4. DeepLoc2 was developed by Zhang et al. in 2020 as an improved version of DeepLoc.\n5. ProteinLoc, developed by Zhang et al. in 2020, combines sequence-based features with structural information for prediction.",
    "llama-2-7b-chat-hf_fact": [
      "DeepLoc was developed by Zhang et al. in 2018 for predicting protein subcellular localization.",
      "LocNet was developed by Li et al. in 2018 and uses a multi-task learning framework for localization prediction.",
      "PSORT-MCRN, developed by Wang et al. in 2019, incorporates information from multiple databases for improved accuracy.",
      "DeepLoc2 was developed by Zhang et al. in 2020 as an improved version of DeepLoc.",
      "ProteinLoc, developed by Zhang et al. in 2020, combines sequence-based features with structural information for prediction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Hello! I'm here to help you with your question. However, I must inform you that \"MULTOVL\" is not a valid or recognized term in any field of study or industry. It appears to be a made-up or fictional term with no meaning or context.\nIf you have any further questions or if there's anything else I can help you with, please feel free to ask!",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "GDF15 (Growth Differentiation Factor 15) has been gaining attention as a potential biomarker for metformin treatment in recent years. Metformin is a commonly used medication for type 2 diabetes, and GDF15 has been found to be elevated in response to metformin treatment in some studies. Here are some details on why GDF15 might be a useful biomarker for metformin treatment:\n1. Elevated GDF15 levels in response to metformin: Several studies have shown that GDF15 levels are increased in response to metformin treatment in patients with type 2 diabetes. For example, a study published in the Journal of Clinical Endocrinology and Metabolism found that GDF15 levels were significantly higher in patients with type 2 diabetes who were treated with metformin compared to those who were not treated with metformin.\n2. Relationship with insulin sensitivity: GDF15 has been shown to be related to insulin sensitivity, which is an important factor in the treatment of type 2 diabetes. Studies have found that GDF15 levels are inversely correlated with insulin sensitivity, meaning that higher GDF15 levels are associated with lower insulin sensitivity. This suggests that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment, which is designed to improve insulin sensitivity.\n3. Potential for non-invasive measurement: Unlike some other biomarkers, such as hemoglobin A1c (HbA1c), which require a blood draw for measurement, GDF15 can be measured in a non-invasive manner using a simple blood test. This makes it a more practical option for monitoring metformin treatment in clinical settings.\n4. Ability to detect early changes: GDF15 levels have been shown to change early in the course of metformin treatment, before HbA1c levels begin to decline. This means that GDF15 may be able to detect early changes in insulin sensitivity that are not yet reflected in HbA1c levels, making it a useful biomarker for monitoring the effectiveness of metformin treatment over",
    "llama-2-7b-chat-hf_fact_raw": "1. Metformin is a commonly used medication for type 2 diabetes.\n2. GDF15 levels have been found to be elevated in response to metformin treatment in some studies.\n3. A study published in the Journal of Clinical Endocrinology and Metabolism found that GDF15 levels were significantly higher in patients with type 2 diabetes who were treated with metformin compared to those who were not.\n4. GDF15 levels are inversely correlated with insulin sensitivity.\n5. GDF15 can be measured using a non-invasive blood test.",
    "llama-2-7b-chat-hf_fact": [
      "Metformin is a commonly used medication for type 2 diabetes.",
      "GDF15 levels have been found to be elevated in response to metformin treatment in some studies.",
      "A study published in the Journal of Clinical Endocrinology and Metabolism found that GDF15 levels were significantly higher in patients with type 2 diabetes who were treated with metformin compared to those who were not.",
      "GDF15 levels are inversely correlated with insulin sensitivity.",
      "GDF15 can be measured using a non-invasive blood test."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Recursive splicing is a type of splicing event in which the same intron is spliced back into the RNA transcript, resulting in the formation of a circular splicing pattern. This type of splicing is more common in short introns, which are introns that are shorter than 100 nucleotides in length.\nThere are several reasons why recursive splicing is more common in short introns:\n1. Ease of recognition: Short introns are more easily recognized by the splicing machinery, which makes it more likely for them to be spliced in a recursive manner.\n2. Lower energy cost: Recursive splicing requires less energy than non-recursive splicing, which makes it more likely to occur in short introns where the energy cost of splicing is higher.\n3. Increased stability: Recursive splicing can lead to increased stability of the RNA transcript, as the circular structure can provide a more stable framework for the splicing reaction.\n4. Regulatory elements: Short introns may contain regulatory elements that promote recursive splicing, such as stem-loops or other secondary structure elements.\n5. Selection pressure: Recursive splicing may be favored by selection pressure, as it can lead to the production of more stable or functional RNA molecules.\n6. RNA structure: The RNA structure of short introns may be more conducive to recursive splicing, as the circular structure can provide a more stable framework for the splicing reaction.\n7. Splicing factors: Some splicing factors, such as SR proteins, are more efficient at recognizing and splicing short introns, which can lead to more recursive splicing events.\n8. Intron-exon boundaries: The boundaries between introns and exons in short introns may be less well-defined, which can make it more difficult for the splicing machinery to recognize the intron-exon structure and lead to more recursive splicing events.\n9. RNA polymerase II: RNA polymerase II, the enzyme responsible for transcribing DNA into RNA, may play a role in the formation of recursive splicing in short introns.\n10. Genetic drift: Recursive splicing may be favored",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing occurs when the same intron is spliced back into the RNA transcript.\n2. Short introns are classified as those shorter than 100 nucleotides in length.\n3. Recursive splicing is more common in short introns.\n4. Recursive splicing requires less energy than non-recursive splicing.\n5. Short introns may contain regulatory elements that promote recursive splicing.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing occurs when the same intron is spliced back into the RNA transcript.",
      "Short introns are classified as those shorter than 100 nucleotides in length.",
      "Recursive splicing is more common in short introns.",
      "Recursive splicing requires less energy than non-recursive splicing.",
      "Short introns may contain regulatory elements that promote recursive splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing occurs when additional splicing events happen within an intron that has already been spliced out.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "The TALE-iD method is a machine learning approach used for identifying and characterizing transcriptional enhancers, which are specific DNA sequences that play a crucial role in regulating gene expression. Enhancers are located far away from their target genes and work by looping back to the promoter region of the gene, bringing in RNA polymerase II and other transcription factors to initiate transcription.\nThe TALE-iD method is based on the use of TAL (Transcriptional Activator-Like) effectors, which are proteins that can recognize and bind to specific DNA sequences. In the case of TALE-iD, the TAL effector is fused to a DNA-binding domain (DBD) that recognizes the enhancer sequence of interest. The TALE-iD method involves the following steps:\n1. Designing the TAL effector: The TAL effector is designed to recognize a specific enhancer sequence using a combination of computational and experimental methods.\n2. Expressing the TALE-iD fusion protein: The TAL effector-DBD fusion protein is expressed in cells, typically using a plasmid or viral vector.\n3. Identifying enhancer sequences: The TALE-iD fusion protein is used to pull down the enhancer sequences in the cells. This is done by using a chromatin immunoprecipitation (ChIP) assay, which involves crosslinking proteins to DNA, followed by immunoprecipitation with antibodies against the TAL effector.\n4. Sequencing the isolated DNA: The isolated DNA is then sequenced to identify the enhancer sequences bound by the TALE-iD fusion protein.\n5. Analyzing the data: The sequencing data is analyzed to identify the specific enhancer sequences bound by the TALE-iD fusion protein. This information can be used to understand the regulation of gene expression and to identify potential therapeutic targets for diseases.\nThe TALE-iD method has several advantages over other enhancer identification methods, including its high resolution and specificity, as well as its ability to identify distant enhancer-promoter interactions. It has been used to study the regulation of gene expression in a variety of organisms, including humans,",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is a machine learning approach used for identifying and characterizing transcriptional enhancers.\n2. Transcriptional enhancers are specific DNA sequences that regulate gene expression.\n3. The TALE-iD method uses TAL effectors fused to a DNA-binding domain to recognize and bind to specific enhancer sequences.\n4. The TALE-iD method involves designing the TAL effector, expressing the fusion protein, using a ChIP assay for pulling down enhancer sequences, sequencing the isolated DNA, and analyzing the data.\n5. The TALE-iD method has been used to study gene expression regulation in various organisms, including humans.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is a machine learning approach used for identifying and characterizing transcriptional enhancers.",
      "Transcriptional enhancers are specific DNA sequences that regulate gene expression.",
      "The TALE-iD method uses TAL effectors fused to a DNA-binding domain to recognize and bind to specific enhancer sequences.",
      "The TALE-iD method involves designing the TAL effector, expressing the fusion protein, using a ChIP assay for pulling down enhancer sequences, sequencing the isolated DNA, and analyzing the data.",
      "The TALE-iD method has been used to study gene expression regulation in various organisms, including humans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing. Here are some of the most popular ones:\n1. CL-Image: CL-Image is a Lisp library for image processing. It provides a wide range of image processing functions, including filtering, resizing, and color manipulation. It also supports multiple image formats, including PNG, JPEG, and TIFF.\n2. ImageTk: ImageTk is a Lisp library that provides a simple and easy-to-use interface for image processing. It includes a wide range of image processing functions, including resizing, cropping, and color manipulation. It also supports multiple image formats, including PNG, JPEG, and TIFF.\n3. Lisp-Image: Lisp-Image is a Lisp library for image processing. It provides a wide range of image processing functions, including filtering, resizing, and color manipulation. It also supports multiple image formats, including PNG, JPEG, and TIFF.\n4. SLIM: SLIM (Simple Lisp Image Manipulation) is a Lisp library for image processing. It provides a simple and easy-to-use interface for image processing, including resizing, cropping, and color manipulation. It also supports multiple image formats, including PNG, JPEG, and TIFF.\n5. Lisp-based Image Processing: Lisp-based Image Processing is a Lisp library that provides a wide range of image processing functions, including filtering, resizing, and color manipulation. It also supports multiple image formats, including PNG, JPEG, and TIFF.\n6. Lisp-Image-Processing: Lisp-Image-Processing is a Lisp library that provides a wide range of image processing functions, including filtering, resizing, and color manipulation. It also supports multiple image formats, including PNG, JPEG, and TIFF.\n7. Image-Lisp: Image-Lisp is a Lisp library that provides a simple and easy-to-use interface for image processing. It includes a wide range of image processing functions, including resizing, cropping, and color manipulation. It also supports multiple image formats, including PNG, JPEG, and TIFF.\n8. Lisp-Image-Tools: Lisp-Image-Tools is",
    "llama-2-7b-chat-hf_fact_raw": "1. CL-Image is a Lisp library for image processing that supports multiple formats such as PNG, JPEG, and TIFF.\n2. ImageTk is a Lisp library that provides an interface for image processing functions including resizing and cropping.\n3. SLIM stands for Simple Lisp Image Manipulation and is a Lisp library for image processing.\n4. Lisp-based Image Processing is a Lisp library that offers a variety of image processing functions.\n5. Lisp-Image-Processing is a Lisp library that supports various image formats, including PNG, JPEG, and TIFF.",
    "llama-2-7b-chat-hf_fact": [
      "CL-Image is a Lisp library for image processing that supports multiple formats such as PNG, JPEG, and TIFF.",
      "ImageTk is a Lisp library that provides an interface for image processing functions including resizing and cropping.",
      "SLIM stands for Simple Lisp Image Manipulation and is a Lisp library for image processing.",
      "Lisp-based Image Processing is a Lisp library that offers a variety of image processing functions.",
      "Lisp-Image-Processing is a Lisp library that supports various image formats, including PNG, JPEG, and TIFF."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: ImageTk is a Python library that provides a Tkinter-compatible photo image interface.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Great, I'd be happy to help you with that!\nAncient whole genome duplication refers to the process by which an entire genome is duplicated, resulting in two identical copies of the genetic material. This process has occurred multiple times in the evolutionary history of many organisms, including the yeast species Saccharomyces cerevisiae (baker's yeast).\nIn S. cerevisiae, there are approximately 600-700 genes that are thought to have arisen from an ancient whole genome duplication event, which occurred around 100-200 million years ago (Myr) in the distant past. These genes are known as \"duplicated genes\" or \"duplicates.\"\nThe process of ancient whole genome duplication can be inferred through various methods, including:\n1. Genome sequencing: By comparing the DNA sequences of different organisms, scientists can identify regions of the genome that have been duplicated.\n2. Gene prediction: By using computational methods to predict the location and structure of genes in a genome, scientists can identify genes that are likely to have arisen from duplication events.\n3. Phylogenetic analysis: By analyzing the evolutionary relationships between different organisms, scientists can identify genes that are conserved across different species and are likely to have been present in the common ancestor of those species.\n4. Gene ontology analysis: By analyzing the functional categories of genes in a genome, scientists can identify genes that are enriched in certain categories, such as those involved in metabolism or signaling pathways, which are likely to have arisen from duplication events.\nIt's worth noting that the exact number of genes that are the result of ancient whole genome duplication in S. cerevisiae is still a matter of debate among scientists, and some studies have estimated the number to be slightly different. However, the general consensus is that around 600-700 genes in S. cerevisiae are the result of ancient whole genome duplication.\nI hope this information helps you with your question! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae (baker's yeast) has approximately 600-700 genes resulting from an ancient whole genome duplication event.\n2. The ancient whole genome duplication event in S. cerevisiae occurred around 100-200 million years ago.\n3. Scientists use genome sequencing, gene prediction, phylogenetic analysis, and gene ontology analysis to infer ancient whole genome duplication.\n4. The exact number of genes resulting from ancient whole genome duplication in S. cerevisiae is debated among scientists.\n5. The duplicated genes in S. cerevisiae are known as \"duplicated genes\" or \"duplicates\".",
    "llama-2-7b-chat-hf_fact": [
      "Saccharomyces cerevisiae (baker's yeast) has approximately 600-700 genes resulting from an ancient whole genome duplication event.",
      "The ancient whole genome duplication event in S. cerevisiae occurred around 100-200 million years ago.",
      "Scientists use genome sequencing, gene prediction, phylogenetic analysis, and gene ontology analysis to infer ancient whole genome duplication.",
      "The exact number of genes resulting from ancient whole genome duplication in S. cerevisiae is debated among scientists.",
      "The duplicated genes in S. cerevisiae are known as \"duplicated genes\" or \"duplicates\"."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Saccharomyces cerevisiae (baker's yeast) has approximately 5,000-6,000 genes, not 600-700.\n2. FALSE [correction]: The ancient whole genome duplication event in S. cerevisiae occurred around 100 million years ago.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that is bound by a variety of complexes, including:\n1. Estrogen: Esrrb is activated by estrogen, and it plays a crucial role in regulating gene expression in response to estrogen signaling.\n2. Coactivators: Esrrb is activated by coactivators, such as p300 and CBP (CREB-binding protein), which enhance its transcriptional activity.\n3. Corepressors: Esrrb is also regulated by corepressors, such as N-CoR (nuclear receptor corepressor) and SMRT (silencing mediator for retinoid and thyroid hormone receptors), which can repress its transcriptional activity.\n4. Chromatin-modifying complexes: Esrrb can also be regulated by chromatin-modifying complexes, such as histone acetyltransferases (HATs) and histone deacetylases (HDACs), which can alter the chromatin structure and accessibility to the receptor.\n5. Non-coding RNAs: Esrrb can also be regulated by non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), which can bind to the receptor and modulate its activity.\n6. Signal transduction pathways: Esrrb can also be regulated by signal transduction pathways, such as the PI3K/Akt pathway, which can activate the receptor and enhance its transcriptional activity.\n7. Other transcription factors: Esrrb can also be regulated by other transcription factors, such as SP1 and SP3, which can bind to specific DNA sequences and modulate the receptor's activity.\n8. Epigenetic modifications: Esrrb can also be regulated by epigenetic modifications, such as DNA methylation and histone modifications, which can affect the receptor's activity and stability.\n9. Protein-protein interactions: Esrrb can also be regulated by protein-protein interactions, such as those with other nuclear receptors, coactivators, and",
    "llama-2-7b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is activated by estrogen.\n2. Coactivators such as p300 and CBP enhance the transcriptional activity of Esrrb.\n3. Corepressors like N-CoR and SMRT can repress the transcriptional activity of Esrrb.\n4. Chromatin-modifying complexes, including histone acetyltransferases and histone deacetylases, can regulate Esrrb.\n5. Non-coding RNAs, including microRNAs and long non-coding RNAs, can modulate the activity of Esrrb.",
    "llama-2-7b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is activated by estrogen.",
      "Coactivators such as p300 and CBP enhance the transcriptional activity of Esrrb.",
      "Corepressors like N-CoR and SMRT can repress the transcriptional activity of Esrrb.",
      "Chromatin-modifying complexes, including histone acetyltransferases and histone deacetylases, can regulate Esrrb.",
      "Non-coding RNAs, including microRNAs and long non-coding RNAs, can modulate the activity of Esrrb."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Estrogen-related receptor β (Esrrb) is not activated by estrogen; it is an orphan receptor that is not known to be naturally liganded by estrogen.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a gene that encodes for a protein called zinc finger CCHC-type containing 17 (ZCCHC17). This protein is a transcriptional regulator that plays a crucial role in the development and maintenance of various tissues, including the nervous system, immune system, and epithelial cells.\nZCCHC17 is a member of the CCHC (zinc finger CCHC-type) family of proteins, which are characterized by the presence of a zinc finger domain that is involved in DNA binding and transcriptional regulation. The ZCCHC17 protein contains multiple zinc fingers, which are responsible for recognizing and binding to specific DNA sequences.\nThe role of ZCCHC17 in transcriptional regulation is complex and involves the modulation of gene expression in response to various stimuli, including developmental signals, growth factors, and stress signals. ZCCHC17 has been shown to regulate the expression of genes involved in cell proliferation, differentiation, and survival, as well as genes involved in the response to stress and inflammation.\nIn the nervous system, ZCCHC17 has been implicated in the regulation of synaptic plasticity and learning and memory processes. For example, ZCCHC17 has been shown to regulate the expression of genes involved in the formation and maintenance of synapses, and to modulate the strength of synaptic connections between neurons.\nIn the immune system, ZCCHC17 has been shown to regulate the expression of genes involved in the immune response, including genes involved in the activation and differentiation of immune cells, such as T cells and B cells.\nIn epithelial cells, ZCCHC17 has been implicated in the regulation of cell growth and differentiation, and has been shown to play a role in the development and progression of various epithelial-based cancers, including breast cancer and lung cancer.\nOverall, the role of ZCCHC17 is to regulate the expression of genes involved in a wide range of biological processes, including cell growth and differentiation, immune response, and nervous system function. Dysregulation of ZCCHC17 has been",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a gene that encodes for a protein called zinc finger CCHC-type containing 17.\n2. ZCCHC17 plays a role in the development and maintenance of the nervous system, immune system, and epithelial cells.\n3. The ZCCHC17 protein contains multiple zinc fingers which aid in DNA binding and transcriptional regulation.\n4. ZCCHC17 is involved in regulating gene expression in response to developmental signals, growth factors, and stress signals.\n5. Dysregulation of ZCCHC17 has been implicated in various epithelial-based cancers, including breast cancer and lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a gene that encodes for a protein called zinc finger CCHC-type containing 17.",
      "ZCCHC17 plays a role in the development and maintenance of the nervous system, immune system, and epithelial cells.",
      "The ZCCHC17 protein contains multiple zinc fingers which aid in DNA binding and transcriptional regulation.",
      "ZCCHC17 is involved in regulating gene expression in response to developmental signals, growth factors, and stress signals.",
      "Dysregulation of ZCCHC17 has been implicated in various epithelial-based cancers, including breast cancer and lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that spans the nuclear envelope in eukaryotic cells, including human cells. The NPC serves as a selective barrier between the nucleus and the cytoplasm, regulating the transport of molecules between these two compartments.\nThe NPC is composed of several proteins, including:\n1. Nucleoporins (Nups): These are the main proteins that make up the NPC. There are 30 different nucleoporins in human cells, which are encoded by genes located on chromosomes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23.\n2. Nuclear membrane proteins (NMPs): These proteins are involved in the formation and maintenance of the nuclear envelope, and play a role in the transport of molecules across the nuclear envelope. Examples of NMPs include lamin proteins, which are involved in the structure and organization of the nuclear envelope, and importin alpha/beta proteins, which are involved in the transport of proteins and nucleic acids across the nuclear envelope.\n3. Spectrin proteins: Spectrin proteins are involved in the structural organization of the nuclear envelope, and play a role in the transport of molecules across the nuclear envelope.\n4. Chromatin-associated proteins: These proteins are involved in the organization and regulation of chromatin, and play a role in the transport of molecules across the nuclear envelope. Examples of chromatin-associated proteins include histone proteins, which are involved in the structure and organization of chromatin, and non-histone chromatin-associated proteins, which are involved in the regulation of chromatin dynamics.\n5. Other proteins: There are many other proteins that are involved in the formation and regulation of the NPC, including proteins involved in the regulation of protein transport, protein degradation, and cell signal",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex is a structure that spans the nuclear envelope in eukaryotic cells.\n2. There are 30 different nucleoporins that make up the nuclear pore complex in human cells.\n3. Nucleoporin genes are located on chromosomes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23.\n4. Lamin proteins are involved in the structure and organization of the nuclear envelope.\n5. Importin alpha/beta proteins are involved in the transport of proteins and nucleic acids across the nuclear envelope.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex is a structure that spans the nuclear envelope in eukaryotic cells.",
      "There are 30 different nucleoporins that make up the nuclear pore complex in human cells.",
      "Nucleoporin genes are located on chromosomes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, and 23.",
      "Lamin proteins are involved in the structure and organization of the nuclear envelope.",
      "Importin alpha/beta proteins are involved in the transport of proteins and nucleic acids across the nuclear envelope."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are over 30 different nucleoporins that make up the nuclear pore complex in human cells.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a novel, orally available topoisomerase inhibitor that is currently being investigated as a potential treatment for various types of cancer, including solid tumors and hematological malignancies.\nTopoisomerase inhibitors are a class of drugs that work by interfering with the activity of topoisomerases, which are enzymes that play a crucial role in DNA replication, repair, and transcription. Topoisomerases help to relieve the tension that builds up in DNA during these processes by cutting and rejoining the DNA strands. However, cancer cells often have high levels of topoisomerase activity, which can contribute to their rapid growth and division.\nGepotidacin is a small molecule inhibitor of topoisomerase II (Topo II), which is a key enzyme involved in DNA replication and transcription. Topo II is overexpressed in many types of cancer, and its overexpression can lead to uncontrolled cell growth and proliferation. Gepotidacin binds to the active site of Topo II, preventing it from cutting and rejoining DNA strands, and thereby inhibiting DNA replication and transcription.\nGepotidacin has been shown to have activity against a wide range of cancer cell types, including those from breast, lung, colon, and ovarian cancers. It has also been shown to be effective in combination with other chemotherapeutic agents, such as paclitaxel and carboplatin, in preclinical studies.\nIn clinical trials, gepotidacin has been evaluated as a monotherapy or in combination with other chemotherapeutic agents in patients with various types of cancer. While the drug has shown promise in early clinical trials, it has also been associated with significant side effects, including nausea, vomiting, and diarrhea. As a result, researchers are continuing to investigate ways to optimize the dosing and combination regimens of gepotidacin to minimize side effects while maintaining its antitumor activity.\nOverall, gepotidacin is a promising topoisomerase inhibitor that is being investigated as a potential treatment for various types of cancer. While it has shown activity against a wide range of cancer",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is an orally available topoisomerase inhibitor.\n2. It is being investigated as a treatment for various types of cancer, including solid tumors and hematological malignancies.\n3. Gepotidacin is a small molecule inhibitor of topoisomerase II (Topo II).\n4. Topo II is overexpressed in many types of cancer and its overexpression can contribute to uncontrolled cell growth.\n5. Gepotidacin has been evaluated in clinical trials both as a monotherapy and in combination with other chemotherapeutic agents.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is an orally available topoisomerase inhibitor.",
      "It is being investigated as a treatment for various types of cancer, including solid tumors and hematological malignancies.",
      "Gepotidacin is a small molecule inhibitor of topoisomerase II (Topo II).",
      "Topo II is overexpressed in many types of cancer and its overexpression can contribute to uncontrolled cell growth.",
      "Gepotidacin has been evaluated in clinical trials both as a monotherapy and in combination with other chemotherapeutic agents."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Student Performance Wrap) is a powerful tool designed to help educators and administrators track and analyze student performance in a more comprehensive and efficient manner. Here are some key features and benefits of Canvas SPW:\n1. Comprehensive Data Collection: Canvas SPW collects a wide range of data points, including assessment scores, quiz results, discussion board posts, and more. This data is aggregated and organized in a single dashboard, providing a comprehensive view of student performance.\n2. Real-time Feedback: With Canvas SPW, educators can provide real-time feedback to students, helping them identify areas of improvement and track their progress over time. This feedback can be delivered through automated emails, in-app notifications, or even through the Canvas messaging system.\n3. Customizable Dashboards: Educators can create custom dashboards tailored to their specific needs and goals. Dashboards can be organized by student, course, or program, and can include a variety of data points, such as grades, progress, and engagement metrics.\n4. Predictive Analytics: Canvas SPW uses machine learning algorithms to identify patterns and trends in student performance, allowing educators to predict future performance and identify potential areas of improvement.\n5. Integration with Canvas Tools: Canvas SPW integrates seamlessly with other Canvas tools, such as quizzes, assignments, and discussions. This allows educators to track student performance across multiple dimensions and gain a more complete picture of student learning.\n6. Collaboration and Communication: Canvas SPW facilitates collaboration and communication between educators and students, helping to ensure that everyone is on the same page. Educators can use the tool to send messages, provide feedback, and track student progress in real-time.\n7. Mobile Accessibility: Canvas SPW is accessible from any device, allowing educators to track student performance on the go. This makes it easy to stay up-to-date on student progress, even when you're not in the classroom.\n8. Data-Driven Decision Making: Canvas SPW provides educators with the data and insights they need to make informed decisions about instruction and assessment. By analyzing student performance data, educators can identify areas of strength and weakness, and adjust their teaching",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW (Student Performance Wrap) is designed to help educators and administrators track and analyze student performance.\n2. It collects various data points including assessment scores, quiz results, and discussion board posts.\n3. Canvas SPW provides real-time feedback to students through automated emails, in-app notifications, or the Canvas messaging system.\n4. Canvas SPW uses machine learning algorithms for predictive analytics on student performance.\n5. It integrates with other Canvas tools like quizzes, assignments, and discussions.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW (Student Performance Wrap) is designed to help educators and administrators track and analyze student performance.",
      "It collects various data points including assessment scores, quiz results, and discussion board posts.",
      "Canvas SPW provides real-time feedback to students through automated emails, in-app notifications, or the Canvas messaging system.",
      "Canvas SPW uses machine learning algorithms for predictive analytics on student performance.",
      "It integrates with other Canvas tools like quizzes, assignments, and discussions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There is no information given that Canvas SPW uses machine learning algorithms for predictive analytics on student performance.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'd be happy to provide you with a list of STING agonists!\nSTING (Stimulator of Interferon Genes) is a protein found on the surface of immune cells, including dendritic cells and macrophages. STING agonists are molecules that bind to STING and activate its signaling pathway, leading to the production of cytokines and the activation of immune cells. Here are some examples of STING agonists:\n1. Poly IC: Poly IC is a synthetic molecule that binds to STING and activates its signaling pathway. It is commonly used as a vaccine adjuvant to enhance the immune response to viral infections.\n2. CpG ODN: CpG ODN (CpG oligodeoxynucleotide) is a synthetic molecule that contains a CpG motif, which is a specific sequence of DNA that is recognized by the STING pathway. CpG ODN is commonly used as an immune adjuvant to enhance the immune response to viral infections.\n3. Toll-like receptor (TLR) agonists: TLRs are a family of receptors that recognize pathogen-associated molecular patterns (PAMPs) and activate the STING pathway. Examples of TLR agonists include lipopolysaccharide (LPS), flagellin, and viral RNA.\n4. R848: R848 is a synthetic molecule that binds to STING and activates its signaling pathway. It is commonly used as a vaccine adjuvant to enhance the immune response to viral infections.\n5. IMQ: IMQ (imiquimod) is a synthetic molecule that activates the STING pathway and is commonly used as a topical immunotherapy for the treatment of skin conditions such as basal cell carcinoma and actinic keratosis.\n6. Resiquimod: Resiquimod is a synthetic molecule that activates the STING pathway and is commonly used as a topical immunotherapy for the treatment of skin conditions such as basal cell",
    "llama-2-7b-chat-hf_fact_raw": "1. Poly IC is a synthetic molecule used as a vaccine adjuvant that binds to STING and activates its signaling pathway.\n2. CpG ODN contains a CpG motif and is used as an immune adjuvant to enhance the immune response to viral infections.\n3. Toll-like receptor agonists activate the STING pathway and include lipopolysaccharide, flagellin, and viral RNA.\n4. R848 is a synthetic molecule used as a vaccine adjuvant that binds to STING and activates its signaling pathway.\n5. IMQ, or imiquimod, is a synthetic molecule used as a topical immunotherapy for the treatment of skin conditions and activates the STING pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Poly IC is a synthetic molecule used as a vaccine adjuvant that binds to STING and activates its signaling pathway.",
      "CpG ODN contains a CpG motif and is used as an immune adjuvant to enhance the immune response to viral infections.",
      "Toll-like receptor agonists activate the STING pathway and include lipopolysaccharide, flagellin, and viral RNA.",
      "R848 is a synthetic molecule used as a vaccine adjuvant that binds to STING and activates its signaling pathway.",
      "IMQ, or imiquimod, is a synthetic molecule used as a topical immunotherapy for the treatment of skin conditions and activates the STING pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Poly IC is a synthetic molecule used as a vaccine adjuvant that binds to TLR3 and activates its signaling pathway, not STING.\n2. TRUE\n3. FALSE [correction]: Toll-like receptor agonists do not activate the STING pathway; they activate the TLR pathway. STING agonists include cyclic dinucleotides.\n4. FALSE [correction]: R848 is a synthetic molecule used as a vaccine adjuvant that binds to TLR7 and TLR8, not STING.\n5. FALSE [correction]: IMQ, or imiquimod, is a synthetic molecule used as a topical immunotherapy for the treatment of skin conditions and activates the TLR7 pathway, not the STING pathway.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE is a popular method for clustering gene expression data, which is a type of unsupervised machine learning algorithm. It is an acronym for \"Self-Organizing Map with Incremental Clustering and Automatic Gene Selection.\"\nHere's how it works:\n1. Preprocessing: The gene expression data is preprocessed to remove any missing values, outliers, and normalize the data.\n2. Dimensionality reduction: The high-dimensional gene expression data is reduced to a lower-dimensional space using techniques such as principal component analysis (PCA) or independent component analysis (ICA).\n3. Self-Organizing Map (SOM): The reduced gene expression data is then projected onto a lower-dimensional representation using a SOM. The SOM is a type of neural network that maps the high-dimensional data to a lower-dimensional representation, called a map, in a way that tries to preserve the topological relationships between the data points.\n4. Incremental clustering: The SOM is then used to perform incremental clustering of the gene expression data. This involves iteratively adding new clusters to the map, while also updating the existing clusters.\n5. Automatic gene selection: The algorithm automatically selects the most relevant genes for each cluster, based on their expression levels within the cluster.\n6. Evaluation: The performance of the SLIC-CAGE algorithm is evaluated using various metrics such as silhouette score, Calinski-Harabasz index, and Davies-Bouldin index.\nAdvantages of SLIC-CAGE:\n1. Non-parametric: SLIC-CAGE is a non-parametric algorithm, which means it doesn't make any assumptions about the underlying distribution of the data.\n2. Robust: SLIC-CAGE is a robust algorithm, which means it can handle noisy or missing data.\n3. Flexible: SLIC-CAGE can handle different types of gene expression data, including microarray and RNA-seq data.\n4. Interpretable: The algorithm provides an interpretable map of the gene expression data, which can be used to identify biologically relevant clusters of genes.\n5. Scalable: SLIC-CAGE can be applied to large-scale gene expression data sets, making it a useful tool for analyzing complex datasets.\nDisadv",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is a method for clustering gene expression data and is an acronym for \"Self-Organizing Map with Incremental Clustering and Automatic Gene Selection.\"\n2. The algorithm uses preprocessing to remove missing values, outliers, and normalize gene expression data.\n3. SLIC-CAGE uses dimensionality reduction techniques such as PCA or ICA to reduce high-dimensional gene expression data to a lower-dimensional space.\n4. Self-Organizing Map (SOM) is used in SLIC-CAGE to project reduced gene expression data onto a lower-dimensional representation.\n5. SLIC-CAGE is non-parametric, robust, flexible, interpretable, and scalable.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is a method for clustering gene expression data and is an acronym for \"Self-Organizing Map with Incremental Clustering and Automatic Gene Selection.\"",
      "The algorithm uses preprocessing to remove missing values, outliers, and normalize gene expression data.",
      "SLIC-CAGE uses dimensionality reduction techniques such as PCA or ICA to reduce high-dimensional gene expression data to a lower-dimensional space.",
      "Self-Organizing Map (SOM) is used in SLIC-CAGE to project reduced gene expression data onto a lower-dimensional representation.",
      "SLIC-CAGE is non-parametric, robust, flexible, interpretable, and scalable."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SLIC-CAGE is a method for clustering gene expression data but it is not an acronym for \"Self-Organizing Map with Incremental Clustering and Automatic Gene Selection.\" It stands for \"Sparse Linear Iterative Clustering - Clustering Affinity Graph Engine.\"\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (Lymphocyte-specific protein 3) is a protein that plays a crucial role in the immune system, particularly in the regulation of T cell activation and differentiation. Here are some of the key roles of LEM-3:\n1. T cell activation: LEM-3 is involved in the activation of T cells, particularly CD4+ T cells, upon antigen recognition. It helps to recruit and activate T cell receptors (TCRs), which are responsible for recognizing and binding to antigens.\n2. T cell differentiation: LEM-3 regulates the differentiation of T cells into different subtypes, such as Th1, Th2, and Treg cells. It promotes the differentiation of Th1 cells, which are involved in the immune response against intracellular pathogens, and inhibits the differentiation of Th2 cells, which are involved in the immune response against extracellular parasites.\n3. T cell tolerance: LEM-3 also plays a role in T cell tolerance, which is the ability of the immune system to distinguish between self and non-self antigens. It helps to maintain T cell tolerance by preventing the activation of autoreactive T cells, which are T cells that recognize self-antigens.\n4. Immune homeostasis: LEM-3 helps to maintain immune homeostasis by regulating the number and activity of T cells in the body. It promotes the elimination of excessive or damaged T cells, which helps to prevent autoimmune diseases.\n5. Cancer immunotherapy: LEM-3 has been shown to be involved in the immune response against cancer. It can inhibit the growth and spread of cancer cells by promoting the activation and differentiation of immune cells, such as T cells and natural killer cells.\n6. Inflammation: LEM-3 has been implicated in the regulation of inflammation. It can inhibit the production of pro-inflammatory cytokines, such as TNF-alpha, and promote the production of anti-inflammatory cytokines, such as IL-10.\n7. Neurodegeneration: LEM-3 has been shown to be involved in the regulation of ne",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the activation of T cells, particularly CD4+ T cells.\n2. LEM-3 regulates the differentiation of T cells into different subtypes like Th1, Th2, and Treg cells.\n3. LEM-3 plays a role in T cell tolerance, helping to prevent the activation of autoreactive T cells.\n4. LEM-3 helps maintain immune homeostasis by regulating the number and activity of T cells.\n5. LEM-3 is involved in the immune response against cancer and can inhibit the growth and spread of cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the activation of T cells, particularly CD4+ T cells.",
      "LEM-3 regulates the differentiation of T cells into different subtypes like Th1, Th2, and Treg cells.",
      "LEM-3 plays a role in T cell tolerance, helping to prevent the activation of autoreactive T cells.",
      "LEM-3 helps maintain immune homeostasis by regulating the number and activity of T cells.",
      "LEM-3 is involved in the immune response against cancer and can inhibit the growth and spread of cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without specific context or scientific references provided, it is impossible to determine the accuracy of statements about LEM-3's functions in T cell regulation and immune responses.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm happy to provide you with the releases of tmVar, a popular open-source library for Time Series Analysis and Forecasting. Here are the releases of tmVar, along with their release dates:\n1. tmVar 0.1.0 (June 2017) - This was the initial release of tmVar, which introduced the basic functionality of the library, including time series decomposition, forecasting, and visualization.\n2. tmVar 0.2.0 (September 2017) - In this release, several new features were added, including support for multiple time series decomposition methods, improved forecasting algorithms, and better visualization tools.\n3. tmVar 0.3.0 (February 2018) - This release introduced several major improvements, including support for long-term forecasting, improved model selection and evaluation, and better integration with other popular data science libraries.\n4. tmVar 0.4.0 (June 2018) - This release added several new features, including support for real-time data processing, improved performance and scalability, and better support for multivariate time series analysis.\n5. tmVar 0.5.0 (December 2018) - In this release, several major improvements were made, including support for more advanced forecasting methods, improved visualization tools, and better integration with other popular data science frameworks.\n6. tmVar 0.6.0 (June 2019) - This release introduced several new features, including support for machine learning-based forecasting methods, improved performance and scalability, and better support for time series forecasting in Python.\n7. tmVar 0.7.0 (December 2019) - In this release, several major improvements were made, including support for more advanced time series decomposition methods, improved visualization tools, and better integration with other popular data science libraries.\n8. tmVar 0.8.0 (June 2020) - This release introduced several new features, including support for real-time data processing, improved performance and scalability, and better support for multivariate time series analysis.\n9. tmVar 0.9.0 (December 2020) - In this release, several",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar 0.1.0 was released in June 2017.\n2. tmVar 0.2.0 was released in September 2017.\n3. tmVar 0.3.0 was released in February 2018.\n4. tmVar 0.4.0 was released in June 2018.\n5. tmVar 0.5.0 was released in December 2018.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar 0.1.0 was released in June 2017.",
      "tmVar 0.2.0 was released in September 2017.",
      "tmVar 0.3.0 was released in February 2018.",
      "tmVar 0.4.0 was released in June 2018.",
      "tmVar 0.5.0 was released in December 2018."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases that contain information on somatic mutations in normal cells. Here are some of the most well-known and widely used databases in this field:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. While TCGA primarily focuses on cancer genomics, it also includes a small number of normal tissue samples from which somatic mutations can be identified.\n2. The 1000 Genomes Project: The 1000 Genomes Project is a large-scale effort to catalogue the genetic variation in a diverse set of individuals from around the world. While the project primarily focuses on identifying genetic variation in the context of disease, it also includes a small number of normal tissue samples from which somatic mutations can be identified.\n3. The ExAC database: The ExAC database is a large-scale effort to catalogue the genetic variation in a diverse set of individuals from around the world. It includes both germline and somatic mutations, and is particularly useful for identifying rare and novel mutations.\n4. The ClinVar database: ClinVar is a curated database of human genetic variation that is associated with clinical phenotypes. It includes both germline and somatic mutations, and is particularly useful for identifying mutations that are associated with specific diseases or conditions.\n5. The MutationTaster database: MutationTaster is a web-based tool that allows users to identify somatic mutations in a given DNA sequence. It uses a combination of machine learning algorithms and curated databases to identify potential mutations, and can be particularly useful for identifying mutations in specific genes or regions of the genome.\n6. The Somatic Mutation Database (SMDB): SMDB is a curated database of somatic mutations from a variety of sources, including cancer genomics, genetic disease, and gene expression profiling. It includes both germline and somatic mutations, and is particularly useful for identifying mutations that are associated with specific diseases or conditions.\n7. The Cancer Cell Line Encyclopedia (CCLE): CCLE is a collection of over 1",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The 1000 Genomes Project is a large-scale effort to catalogue genetic variation in individuals from around the world.\n3. The ExAC database includes both germline and somatic mutations.\n4. ClinVar is a curated database of human genetic variation associated with clinical phenotypes.\n5. The Somatic Mutation Database (SMDB) includes somatic mutations from various sources, such as cancer genomics and genetic disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The 1000 Genomes Project is a large-scale effort to catalogue genetic variation in individuals from around the world.",
      "The ExAC database includes both germline and somatic mutations.",
      "ClinVar is a curated database of human genetic variation associated with clinical phenotypes.",
      "The Somatic Mutation Database (SMDB) includes somatic mutations from various sources, such as cancer genomics and genetic disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ExAC database includes only germline mutations.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in Java. Here are some of the popular ones:\n1. NetworkX: NetworkX is a Python library for creating, manipulating, and analyzing complex networks. It provides a wide range of algorithms and tools for working with graphs, including graph kernel methods. However, there is also a Java interface available for NetworkX, which allows you to use the library from Java applications.\n2. JGraphT: JGraphT is a Java library for graph theory. It provides a simple and efficient API for creating, manipulating, and querying graphs. It also includes a number of graph kernel algorithms, including the PageRank algorithm.\n3. Graphiti: Graphiti is a Java library for graph theory and network analysis. It provides a wide range of graph kernel algorithms, including the PageRank algorithm, as well as tools for visualizing and analyzing graphs.\n4. GraphMol: GraphMol is a Java library for molecular graph analysis. It provides a range of graph kernel algorithms, including the PageRank algorithm, as well as tools for working with molecular graphs.\n5. GraphBLAS: GraphBLAS is a Java library for graph-based linear algebra. It provides a range of graph kernel algorithms, including the PageRank algorithm, as well as tools for working with large-scale graph-based data structures.\n6. JGraph: JGraph is a Java library for graph theory. It provides a simple and efficient API for creating, manipulating, and querying graphs. It also includes a number of graph kernel algorithms, including the PageRank algorithm.\n7. GraphCompute: GraphCompute is a Java library for graph-based computing. It provides a range of graph kernel algorithms, including the PageRank algorithm, as well as tools for working with large-scale graph-based data structures.\n8. GraphX: GraphX is a Java library for graph-based computing. It provides a range of graph kernel algorithms, including the PageRank algorithm, as well as tools for working with large-scale graph-based data structures.\n9. JGraphAlgorithms: JGraphAlgorithms is a Java library for graph algorithms. It provides a range of graph kernel algorithms, including the PageRank algorithm, as well as tools for working with graphs.\n10. GraphSolver: GraphSolver is a Java library for solving graph problems. It provides a range",
    "llama-2-7b-chat-hf_fact_raw": "1. NetworkX is a Python library with a Java interface that includes graph kernel methods.\n2. JGraphT is a Java library that provides graph kernel algorithms, such as the PageRank algorithm.\n3. Graphiti is a Java library offering graph kernel algorithms and tools for graph visualization and analysis.\n4. GraphMol is a Java library focused on molecular graph analysis and includes graph kernel algorithms.\n5. GraphBLAS is a Java library for graph-based linear algebra that features graph kernel algorithms.",
    "llama-2-7b-chat-hf_fact": [
      "NetworkX is a Python library with a Java interface that includes graph kernel methods.",
      "JGraphT is a Java library that provides graph kernel algorithms, such as the PageRank algorithm.",
      "Graphiti is a Java library offering graph kernel algorithms and tools for graph visualization and analysis.",
      "GraphMol is a Java library focused on molecular graph analysis and includes graph kernel algorithms.",
      "GraphBLAS is a Java library for graph-based linear algebra that features graph kernel algorithms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NetworkX is a Python library that includes graph algorithms, but it does not have a Java interface.\n2. TRUE\n3. FALSE [correction]: Graphiti is a Java library that provides tools for graph visualization and analysis but does not specifically offer graph kernel algorithms.\n4. UNKNOWN\n5. FALSE [correction]: GraphBLAS is a library for graph-based linear algebra, but it is not specifically a Java library and does not feature graph kernel algorithms.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with the information you're seeking! The SHERLOCKv2 platform is a next-generation sequencing (NGS) data analysis tool that offers several advancements over its predecessor, SHERLOCK. Here are the four key advances integrated into the SHERLOCKv2 platform:\n1. Improved accuracy and speed: SHERLOCKv2 uses a novel algorithm that improves the accuracy and speed of NGS data analysis. This algorithm leverages the latest advances in machine learning and computational biology to provide more accurate and reliable results than its predecessor.\n2. Enhanced gene expression analysis: SHERLOCKv2 includes a range of new features for gene expression analysis, including the ability to detect novel transcripts and splice variants. This allows researchers to gain a more comprehensive understanding of gene expression patterns and how they relate to specific biological processes.\n3. Integration of multi-omics data: SHERLOCKv2 can integrate data from multiple omics sources, including genomics, transcriptomics, and proteomics. This enables researchers to gain a more holistic view of cellular processes and how they are affected by different factors.\n4. Enhanced user experience: SHERLOCKv2 has a user-friendly interface that makes it easier for researchers to analyze and interpret their NGS data. The platform includes a range of visualization tools and pre-built workflows that can help researchers to quickly and easily identify key findings and insights.\nBy integrating these four advances, SHERLOCKv2 provides a powerful tool for researchers to analyze and interpret NGS data, enabling them to gain new insights into cellular processes and identify potential therapeutic targets.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses a novel algorithm that improves the accuracy and speed of NGS data analysis.\n2. SHERLOCKv2 includes new features for gene expression analysis, such as the ability to detect novel transcripts and splice variants.\n3. SHERLOCKv2 can integrate data from multiple omics sources, including genomics, transcriptomics, and proteomics.\n4. SHERLOCKv2 has a user-friendly interface with visualization tools and pre-built workflows.\n5. SHERLOCKv2 is designed to provide more accurate and reliable results than its predecessor, SHERLOCK.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses a novel algorithm that improves the accuracy and speed of NGS data analysis.",
      "SHERLOCKv2 includes new features for gene expression analysis, such as the ability to detect novel transcripts and splice variants.",
      "SHERLOCKv2 can integrate data from multiple omics sources, including genomics, transcriptomics, and proteomics.",
      "SHERLOCKv2 has a user-friendly interface with visualization tools and pre-built workflows.",
      "SHERLOCKv2 is designed to provide more accurate and reliable results than its predecessor, SHERLOCK."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The bartender algorithm is a problem-solving approach that was introduced by David G. Gordon in 1997. It is a heuristic algorithm that is used to find the shortest path between two points in a graph, where the cost of each edge is determined by the number of edges that must be traversed before reaching the destination. The algorithm is called the bartender algorithm because it is reminiscent of a bartender pouring drinks at a bar.\nHere is how the bartender algorithm works:\n1. Start at the source node: The algorithm starts at the source node, which is the node that the algorithm is trying to reach.\n2. Pour a drink: The algorithm pours a drink (i.e., moves to the next node) based on the cost of the edge that connects the source node to the current node. The cost of the edge is determined by the number of edges that must be traversed before reaching the destination.\n3. Repeat step 2: The algorithm repeats step 2 until it reaches the destination node.\n4. Serve the drink: Once the algorithm reaches the destination node, it \"serves\" the drink (i.e., it stops moving and returns a solution).\nHere is a step-by-step example of how the bartender algorithm works:\nSuppose we are trying to find the shortest path between nodes A and E in a graph with the following edges:\n* Edge A-B costs 2\n* Edge B-C costs 3\n* Edge C-D costs 4\n* Edge D-E costs 5\nUsing the bartender algorithm, we can find the shortest path between nodes A and E as follows:\n1. Start at node A: The algorithm starts at node A, which is the source node.\n2. Pour a drink (move to node B): The algorithm pours a drink (i.e., moves to node B) because the cost of the edge from node A to node B is 2.\n3. Pour another drink (move to node C): The algorithm pours another drink (i.e., moves to node C) because the cost of the edge from node B to node C is 3.\n4. Pour another drink (move to node D): The algorithm pours another drink (i.e., moves to node D) because the cost of the edge",
    "llama-2-7b-chat-hf_fact_raw": "1. The bartender algorithm was introduced by David G. Gordon in 1997.\n2. It is a heuristic algorithm used to find the shortest path between two points in a graph.\n3. The cost of each edge in the graph is determined by the number of edges that must be traversed before reaching the destination.\n4. The bartender algorithm starts at the source node and moves to the next node based on the cost of the connecting edge.\n5. The algorithm serves the drink (returns a solution) once it reaches the destination node.",
    "llama-2-7b-chat-hf_fact": [
      "The bartender algorithm was introduced by David G. Gordon in 1997.",
      "It is a heuristic algorithm used to find the shortest path between two points in a graph.",
      "The cost of each edge in the graph is determined by the number of edges that must be traversed before reaching the destination.",
      "The bartender algorithm starts at the source node and moves to the next node based on the cost of the connecting edge.",
      "The algorithm serves the drink (returns a solution) once it reaches the destination node."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The bartender algorithm is not used to find the shortest path between two points in a graph, it is a scheduling algorithm used to determine the order of service in a multi-agent system such as a bar.\n3. FALSE [correction]: The cost of each edge in the graph is not determined by the number of edges that must be traversed, but rather by the priority of the agents or tasks in the system.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with a list of popular web-based pedigree editors that you can use to create and manage your family tree online. Here are some of the most popular options:\n1. Ancestry.com: Ancestry.com is one of the most popular genealogy websites, and it offers a web-based pedigree editor that allows you to create and manage your family tree. With Ancestry.com, you can access a vast database of historical records, including birth, marriage, and death certificates, census records, and more.\n2. FamilySearch: FamilySearch is a non-profit organization dedicated to helping people discover their family history. Its web-based pedigree editor allows you to create and manage your family tree, and it also provides access to a vast database of historical records.\n3. MyHeritage: MyHeritage is another popular genealogy website that offers a web-based pedigree editor. With MyHeritage, you can create and manage your family tree, and you can also access a vast database of historical records, including birth, marriage, and death certificates, census records, and more.\n4. WeRelate: WeRelate is a free, open-source genealogy website that allows you to create and manage your family tree. It also provides access to a vast database of historical records, including birth, marriage, and death certificates, census records, and more.\n5. GenoPro: GenoPro is a web-based genealogy software that allows you to create and manage your family tree. It also provides access to a vast database of historical records, including birth, marriage, and death certificates, census records, and more.\n6. Legacy Family Tree: Legacy Family Tree is a web-based genealogy software that allows you to create and manage your family tree. It also provides access to a vast database of historical records, including birth, marriage, and death certificates, census records, and more.\n7. FamilyTreeMaker: FamilyTreeMaker is a web-based genealogy software that allows you to create and manage your family tree. It also provides access to a vast database of historical records, including birth, marriage, and death certificates, census records, and more.\n8. Gramps: Gramps is a free, open-source genealogy software that allows you",
    "llama-2-7b-chat-hf_fact_raw": "1. Ancestry.com offers a web-based pedigree editor and a database of historical records.\n2. FamilySearch is a non-profit organization with a web-based pedigree editor and historical records database.\n3. MyHeritage provides a web-based pedigree editor and access to historical records.\n4. WeRelate is a free, open-source genealogy website with a pedigree editor and historical records database.\n5. GenoPro, Legacy Family Tree, and FamilyTreeMaker are web-based genealogy software that allow for family tree creation and management, with access to historical records.",
    "llama-2-7b-chat-hf_fact": [
      "Ancestry.com offers a web-based pedigree editor and a database of historical records.",
      "FamilySearch is a non-profit organization with a web-based pedigree editor and historical records database.",
      "MyHeritage provides a web-based pedigree editor and access to historical records.",
      "WeRelate is a free, open-source genealogy website with a pedigree editor and historical records database.",
      "GenoPro, Legacy Family Tree, and FamilyTreeMaker are web-based genealogy software that allow for family tree creation and management, with access to historical records."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: GenoPro, Legacy Family Tree, and FamilyTreeMaker are not exclusively web-based; they offer downloadable software for family tree creation and management, with some offering access to historical records.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases available for spider-venom toxins, which are collections of venom peptides and proteins from various spider species. Here are some of the most well-known and widely used databases:\n1. Toxinology Database: This database is a comprehensive collection of venom peptides and proteins from various spider species, including their sequences, structures, and functional properties. It also includes information on the venom composition, venom delivery, and toxicity of each spider species.\n2. SpiderVenomDB: This database is a centralized repository of spider venom peptides and proteins, including their sequences, structures, and functional properties. It also includes information on the venom composition, venom delivery, and toxicity of each spider species.\n3. VenomDB: This database is a comprehensive collection of venom peptides and proteins from various animal species, including spiders, snakes, scorpions, and more. It includes information on the venom composition, venom delivery, and toxicity of each species, as well as sequences and structures of venom peptides and proteins.\n4. ToxinDB: This database is a collection of toxins from various sources, including spider venom, snake venom, and sea anemone venom. It includes information on the toxin composition, structure, and functional properties, as well as information on the venomous animals that produce them.\n5. VenomTox: This database is a collection of venom peptides and proteins from various spider species, including their sequences, structures, and functional properties. It also includes information on the venom composition, venom delivery, and toxicity of each spider species.\n6. SpiderTox: This database is a collection of spider venom peptides and proteins, including their sequences, structures, and functional properties. It also includes information on the venom composition, venom delivery, and toxicity of each spider species.\n7. VenomWeb: This database is a comprehensive collection of venom peptides and proteins from various animal species, including spiders, snakes, scorpions, and more. It includes information on the venom composition, venom delivery, and toxicity of each species, as well as",
    "llama-2-7b-chat-hf_fact_raw": "1. The Toxinology Database is a collection of venom peptides and proteins from various spider species.\n2. SpiderVenomDB is a centralized repository of spider venom peptides and proteins.\n3. VenomDB includes venom peptides and proteins from different animal species such as spiders, snakes, and scorpions.\n4. ToxinDB is a collection of toxins from sources including spider venom, snake venom, and sea anemone venom.\n5. VenomTox is a database that contains venom peptides and proteins from various spider species.",
    "llama-2-7b-chat-hf_fact": [
      "The Toxinology Database is a collection of venom peptides and proteins from various spider species.",
      "SpiderVenomDB is a centralized repository of spider venom peptides and proteins.",
      "VenomDB includes venom peptides and proteins from different animal species such as spiders, snakes, and scorpions.",
      "ToxinDB is a collection of toxins from sources including spider venom, snake venom, and sea anemone venom.",
      "VenomTox is a database that contains venom peptides and proteins from various spider species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib is a tyrosine kinase inhibitor that has been investigated for its potential in treating various types of cancer, including pancreatic cancer. While the results of clinical trials have shown promise, it is important to note that the current evidence is not yet conclusive regarding the effectiveness of axitinib in prolonging survival for pancreatic cancer patients.\nAxitinib has been studied in several clinical trials for the treatment of pancreatic cancer, including a phase 3 clinical trial known as the ARISTOTLE trial. This trial compared the use of axitinib plus chemotherapy to chemotherapy alone in patients with advanced pancreatic cancer. While the overall survival rate was similar between the two groups, the axitinib plus chemotherapy group experienced a longer time to disease progression compared to the chemotherapy alone group.\nHowever, it is important to interpret these findings with caution. The ARISTOTLE trial was stopped early due to the lack of efficacy in the chemotherapy alone group, which may have biased the results in favor of the axitinib plus chemotherapy group. Additionally, the trial was not powered to detect differences in overall survival, which is a key outcome measure in cancer clinical trials.\nMore recent studies have also suggested that axitinib may have limited activity in treating pancreatic cancer. For example, a phase 2 clinical trial published in 2020 found that axitinib did not demonstrate significant activity in patients with metastatic pancreatic cancer.\nGiven the current state of the evidence, it is unlikely that axitinib will be approved by regulatory authorities for the treatment of pancreatic cancer in the near future. However, ongoing clinical trials are exploring the use of axitinib in combination with other therapies, such as immunotherapy, to improve outcomes for patients with pancreatic cancer.\nIn summary, while there is some evidence to suggest that axitinib may have potential in treating pancreatic cancer, the current evidence is not yet conclusive regarding its ability to prolong survival for patients with this disease. Further research is needed to fully understand the efficacy and safety of axitinib in treating pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor that is being investigated for its potential to treat pancreatic cancer.\n2. The phase 3 clinical trial known as the ARISTOTLE trial compared the use of axitinib plus chemotherapy to chemotherapy alone in patients with advanced pancreatic cancer.\n3. In the ARISTOTLE trial, the overall survival rate was similar between the two groups, but the axitinib plus chemotherapy group had a longer time to disease progression.\n4. A phase 2 clinical trial published in 2020 found that axitinib did not demonstrate significant activity in patients with metastatic pancreatic cancer.\n5. Ongoing clinical trials are exploring the use of axitinib in combination with other therapies, such as immunotherapy, for pancreatic cancer treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor that is being investigated for its potential to treat pancreatic cancer.",
      "The phase 3 clinical trial known as the ARISTOTLE trial compared the use of axitinib plus chemotherapy to chemotherapy alone in patients with advanced pancreatic cancer.",
      "In the ARISTOTLE trial, the overall survival rate was similar between the two groups, but the axitinib plus chemotherapy group had a longer time to disease progression.",
      "A phase 2 clinical trial published in 2020 found that axitinib did not demonstrate significant activity in patients with metastatic pancreatic cancer.",
      "Ongoing clinical trials are exploring the use of axitinib in combination with other therapies, such as immunotherapy, for pancreatic cancer treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Microtubule-associated protein) regulates F-actin dynamics through several protein interactions. Here are some of the key interactions:\n1. MLP interacts with the F-actin severing protein, gelsolin: MLP binds to gelsolin and inhibits its activity, leading to increased F-actin stability and network formation. This interaction is important for regulating the dynamics of F-actin in cells and is involved in various cellular processes, including cell migration and adhesion.\n2. MLP interacts with the F-actin regulatory protein, cofilin: MLP binds to cofilin and inhibits its activity, leading to increased F-actin stability and network formation. Cofilin is a key regulator of F-actin dynamics and is involved in various cellular processes, including cell migration and adhesion.\n3. MLP interacts with the F-actin regulator, actin-related protein 2/3 complex (ARP2/3 complex): MLP binds to the ARP2/3 complex and inhibits its activity, leading to increased F-actin stability and network formation. The ARP2/3 complex is a key regulator of F-actin dynamics and is involved in various cellular processes, including cell migration and adhesion.\n4. MLP interacts with the F-actin regulator, formin: MLP binds to formin and inhibits its activity, leading to increased F-actin stability and network formation. Formin is a key regulator of F-actin dynamics and is involved in various cellular processes, including cell migration and adhesion.\n5. MLP interacts with the F-actin regulator, actin-depolymerizing factor (ADF): MLP binds to ADF and inhibits its activity, leading to increased F-actin stability and network formation. ADF is a key regulator of F-actin dynamics and is involved in various cellular processes, including cell migration and adhesion.\nIn summary, MLP regulates F-actin dynamics through multiple protein interactions, including those with gelsolin, cofilin, ARP2/3 complex, formin, and ADF. These interactions lead to increased F-actin stability and",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics through interaction with the F-actin severing protein, gelsolin.\n2. MLP interacts with the F-actin regulatory protein, cofilin.\n3. MLP binds to the actin-related protein 2/3 complex (ARP2/3 complex).\n4. MLP inhibits the activity of the F-actin regulator, formin.\n5. MLP interacts with the F-actin regulator, actin-depolymerizing factor (ADF).",
    "llama-2-7b-chat-hf_fact": [
      "MLP regulates F-actin dynamics through interaction with the F-actin severing protein, gelsolin.",
      "MLP interacts with the F-actin regulatory protein, cofilin.",
      "MLP binds to the actin-related protein 2/3 complex (ARP2/3 complex).",
      "MLP inhibits the activity of the F-actin regulator, formin.",
      "MLP interacts with the F-actin regulator, actin-depolymerizing factor (ADF)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without specific context or passage information, it is impossible to determine the accuracy of these statements related to MLP and its interactions with various proteins.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "The human kinome, which refers to the collection of protein kinases (kinases) found in the human genome, contains a total of approximately 500-600 pseudokinases.\nPseudokinases are proteins that have some characteristics of kinases, but do not have the full range of kinase activity. They do not have the ability to phosphorylate other proteins, which is the primary function of kinases. Instead, pseudokinases can bind to and regulate the activity of other proteins, or they can act as enzymes involved in non-protein substrate-based reactions.\nThe exact number of pseudokinases in the human kinome can vary depending on the source and method of classification, but the range of 500-600 is a commonly cited estimate. Some examples of pseudokinases in the human kinome include:\n1. G protein-coupled receptors (GPCRs): These are a family of transmembrane receptors that are activated by G proteins and play a role in a wide range of physiological processes, including signal transduction and regulation of gene expression.\n2. Tyrosine kinases: These are enzymes that phosphorylate tyrosine residues on target proteins, and play a role in cell signaling pathways.\n3. Serine/threonine kinases: These are enzymes that phosphorylate serine or threonine residues on target proteins, and play a role in cell signaling pathways.\n4. Lipid kinases: These are enzymes that phosphorylate lipids, and play a role in cell signaling pathways.\n5. Protein phosphatases: These are enzymes that remove phosphate groups from proteins, and play a role in regulating protein activity.\n6. Ubiquitin ligases: These are enzymes that attach ubiquitin to target proteins, which can lead to protein degradation.\n7. Ubiquitin-protein ligases: These are enzymes that attach ubiquitin to target proteins, which can lead to protein degradation.\n8. Protein-protein interaction modules: These are small protein domains that interact with other proteins to regulate protein",
    "llama-2-7b-chat-hf_fact_raw": "1. The human kinome contains approximately 500-600 pseudokinases.\n2. Pseudokinases do not have the ability to phosphorylate other proteins.\n3. Pseudokinases can bind to and regulate the activity of other proteins.\n4. The number of pseudokinases can vary depending on the source and method of classification.\n5. G protein-coupled receptors (GPCRs) are examples of pseudokinases in the human kinome.",
    "llama-2-7b-chat-hf_fact": [
      "The human kinome contains approximately 500-600 pseudokinases.",
      "Pseudokinases do not have the ability to phosphorylate other proteins.",
      "Pseudokinases can bind to and regulate the activity of other proteins.",
      "The number of pseudokinases can vary depending on the source and method of classification.",
      "G protein-coupled receptors (GPCRs) are examples of pseudokinases in the human kinome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: G protein-coupled receptors (GPCRs) are not considered pseudokinases; they are a different class of membrane receptors. Pseudokinases lack catalytic activity while GPCRs can activate intracellular signaling pathways.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Certainly! ApoE mimetics are compounds that mimic the structure and function of apolipoprotein E (apoE), a protein that plays a crucial role in lipid metabolism and cardiovascular health. Here are three examples of apoE mimetics:\n1. ApoE mimetic peptides: These are short peptides that mimic the structure of apoE and have been shown to have lipid-lowering and anti-inflammatory effects in preclinical studies. One example of an apoE mimetic peptide is the peptide Gly-Ser-Gly-Ala-Gly-Ser-Gly-Gly-Gly (GSGAGGGSG), which has been shown to reduce triglyceride levels and improve insulin sensitivity in mice fed a high-fat diet.\n2. ApoE-mimetic small molecules: These are synthetic compounds that mimic the structure of apoE and have been designed to target specific cellular receptors and pathways involved in lipid metabolism. One example of an apoE mimetic small molecule is the compound GW3965, which has been shown to activate the LXRα receptor and increase the expression of genes involved in cholesterol efflux in macrophages.\n3. ApoE-mimetic nanoparticles: These are nanoparticles that are designed to mimic the structure of apoE and deliver lipids and cholesterol to specific cells or tissues in the body. One example of an apoE mimetic nanoparticle is the nanoparticle Glyco-ApoE, which has been shown to deliver cholesterol to macrophages in the liver and improve cholesterol efflux in these cells.\nIt's important to note that while apoE mimetics have shown promise in preclinical studies, their efficacy and safety in humans have not yet been fully evaluated, and more research is needed to determine their potential as therapeutic agents for lipid-related disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. ApoE mimetic peptides are designed to mimic the structure of apolipoprotein E and have been shown to have lipid-lowering and anti-inflammatory effects.\n2. An example of an apoE mimetic peptide is the peptide Gly-Ser-Gly-Ala-Gly-Ser-Gly-Gly-Gly (GSGAGGGSG).\n3. ApoE-mimetic small molecules, such as the compound GW3965, are synthetic compounds that target cellular receptors and pathways involved in lipid metabolism.\n4. ApoE-mimetic nanoparticles like Glyco-ApoE are designed to deliver lipids and cholesterol to specific cells or tissues in the body.\n5. The efficacy and safety of apoE mimetics in humans have not been fully evaluated and require more research.",
    "llama-2-7b-chat-hf_fact": [
      "ApoE mimetic peptides are designed to mimic the structure of apolipoprotein E and have been shown to have lipid-lowering and anti-inflammatory effects.",
      "An example of an apoE mimetic peptide is the peptide Gly-Ser-Gly-Ala-Gly-Ser-Gly-Gly-Gly (GSGAGGGSG).",
      "ApoE-mimetic small molecules, such as the compound GW3965, are synthetic compounds that target cellular receptors and pathways involved in lipid metabolism.",
      "ApoE-mimetic nanoparticles like Glyco-ApoE are designed to deliver lipids and cholesterol to specific cells or tissues in the body.",
      "The efficacy and safety of apoE mimetics in humans have not been fully evaluated and require more research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ApoE-mimetic nanoparticles like Glyco-ApoE are designed to mimic the function of apolipoprotein E and have potential applications in drug delivery and targeting specific cells or tissues in the body.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (Sterile alpha and TIR domain-containing protein HD1) is a protein that plays a crucial role in regulating the innate immune response to viral infections. Recent studies have shown that there are sex differences in SAMHD1 activity, which can impact the immune response to viral infections. Here are some of the key findings:\n1. SAMHD1 expression: Studies have shown that SAMHD1 expression is higher in females than in males, particularly in the brain and other tissues. This higher expression may contribute to the observed sex differences in SAMHD1 activity.\n2. Enzymatic activity: SAMHD1 is an enzyme that degrades the viral DNA-binding protein, HIV-1 Tat. Studies have shown that SAMHD1 activity is higher in females than in males, which can lead to more efficient clearance of viral DNA.\n3. Regulation by estrogen: Estrogen has been shown to regulate SAMHD1 expression and activity. In females, estrogen can increase SAMHD1 expression and activity, while in males, estrogen can have the opposite effect.\n4. Impact on HIV-1 infection: Sex differences in SAMHD1 activity have been shown to impact the immune response to HIV-1 infection. Females have been shown to be more resistant to HIV-1 infection than males, and this resistance is in part due to the higher SAMHD1 activity in females.\n5. Impact on other viral infections: Sex differences in SAMHD1 activity have also been observed in response to other viral infections, such as influenza and dengue fever.\n6. Mechanisms underlying sex differences: The mechanisms underlying sex differences in SAMHD1 activity are complex and involve the interplay of genetic, hormonal, and epigenetic factors. For example, studies have shown that the X chromosome, which is present in higher levels in females, can influence SAMHD1 expression and activity.\n7. Clinical implications: Understanding the sex differences in SAMHD1 activity can have important clinical implications, particularly in the context of HIV-1 infection. For example, drugs that target SAMHD1 may be more effective in females than",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 expression is higher in females than in males, particularly in the brain and other tissues.\n2. SAMHD1 activity is higher in females than in males, which can lead to more efficient clearance of viral DNA.\n3. Estrogen can increase SAMHD1 expression and activity in females, while it can have the opposite effect in males.\n4. Females have been shown to be more resistant to HIV-1 infection than males due to higher SAMHD1 activity.\n5. Sex differences in SAMHD1 activity have been observed in response to other viral infections, such as influenza and dengue fever.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 expression is higher in females than in males, particularly in the brain and other tissues.",
      "SAMHD1 activity is higher in females than in males, which can lead to more efficient clearance of viral DNA.",
      "Estrogen can increase SAMHD1 expression and activity in females, while it can have the opposite effect in males.",
      "Females have been shown to be more resistant to HIV-1 infection than males due to higher SAMHD1 activity.",
      "Sex differences in SAMHD1 activity have been observed in response to other viral infections, such as influenza and dengue fever."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: Estrogen can increase SAMHD1 expression and activity in females, but there is no evidence that it has the opposite effect in males.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "RUNX2 (RUNX2 gene) is a transcription factor that plays a crucial role in the regulation of cellular processes, including cell proliferation, differentiation, and survival. While RUNX2 has been shown to be involved in the differentiation of various cell types, including hematopoietic cells, its role in astrocyte differentiation is less well-studied.\nRecent studies have suggested that RUNX2 may inhibit astrocyte differentiation in certain contexts. For example, one study found that RUNX2 overexpression inhibited the differentiation of neural progenitor cells into astrocytes, while another study showed that RUNX2 knockdown promoted astrocyte differentiation.\nThe mechanisms by which RUNX2 regulates astrocyte differentiation are not fully understood, but it is thought to involve the regulation of gene expression. RUNX2 has been shown to bind to specific DNA sequences and recruit other transcription factors to regulate the expression of target genes. In the context of astrocyte differentiation, RUNX2 may repress the expression of genes involved in astrocyte differentiation and promote the expression of genes involved in other cell types.\nIt is worth noting that the effects of RUNX2 on astrocyte differentiation may depend on the specific cellular context and the presence of other transcription factors. For example, one study found that the combination of RUNX2 and the transcription factor Brn2 (also known as BETA2) inhibited astrocyte differentiation, while another study showed that the combination of RUNX2 and the transcription factor NeuroD1 promoted astrocyte differentiation.\nIn summary, while the role of RUNX2 in astrocyte differentiation is not fully understood, recent studies suggest that it may inhibit astrocyte differentiation in certain contexts. Further research is needed to fully elucidate the mechanisms by which RUNX2 regulates astrocyte differentiation and to determine the implications of these findings for our understanding of brain development and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 is involved in the differentiation of various cell types, including hematopoietic cells.\n2. Studies suggest that RUNX2 may inhibit astrocyte differentiation in certain contexts.\n3. RUNX2 overexpression inhibited the differentiation of neural progenitor cells into astrocytes in one study.\n4. RUNX2 knockdown promoted astrocyte differentiation in another study.\n5. The combination of RUNX2 and Brn2 inhibited astrocyte differentiation in one study, while RUNX2 and NeuroD1 promoted it in another study.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 is involved in the differentiation of various cell types, including hematopoietic cells.",
      "Studies suggest that RUNX2 may inhibit astrocyte differentiation in certain contexts.",
      "RUNX2 overexpression inhibited the differentiation of neural progenitor cells into astrocytes in one study.",
      "RUNX2 knockdown promoted astrocyte differentiation in another study.",
      "The combination of RUNX2 and Brn2 inhibited astrocyte differentiation in one study, while RUNX2 and NeuroD1 promoted it in another study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure that involves the excision of a portion of the bone and replacement with an artificial joint. The procedure is typically performed to treat degenerative joint disease, also known as osteoarthritis, in the knee joint.\nThe Cobb-Stainsby excision arthroplasty is typically performed through an incision made in the front of the knee, just above the kneecap. The incision is usually about 4-6 inches long and is made to allow the surgeon to access the knee joint and remove the damaged bone and cartilage.\nOnce the incision is made, the surgeon will remove the damaged bone and cartilage, and then replace it with an artificial joint made of metal, plastic, or ceramic materials. The artificial joint is designed to mimic the natural movement of the knee joint and provide pain relief and improved mobility.\nAfter the procedure, the knee will be immobilized in a brace or cast for several weeks to allow the new joint to heal properly. Physical therapy will also be necessary to help the patient regain strength and mobility in the knee.\nIt's important to note that the Cobb-Stainsby excision arthroplasty is typically reserved for patients with severe degenerative joint disease who have not responded to other treatments, such as physical therapy, injections, or bracing. The procedure is usually performed under general anesthesia and may require an overnight hospital stay.\nIn summary, the Cobb-Stainsby excision arthroplasty is a surgical procedure that involves the excision of damaged bone and cartilage in the knee joint and replacement with an artificial joint. The procedure is typically performed through an incision made in the front of the knee and may require several weeks of immobilization and physical therapy to recover properly.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed on the knee joint.\n2. This procedure is used to treat degenerative joint disease, also known as osteoarthritis.\n3. The incision for the Cobb-Stainsby excision arthroplasty is usually about 4-6 inches long.\n4. The artificial joint used in the procedure can be made of metal, plastic, or ceramic materials.\n5. Recovery from the Cobb-Stainsby excision arthroplasty typically involves immobilization in a brace or cast and physical therapy.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed on the knee joint.",
      "This procedure is used to treat degenerative joint disease, also known as osteoarthritis.",
      "The incision for the Cobb-Stainsby excision arthroplasty is usually about 4-6 inches long.",
      "The artificial joint used in the procedure can be made of metal, plastic, or ceramic materials.",
      "Recovery from the Cobb-Stainsby excision arthroplasty typically involves immobilization in a brace or cast and physical therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is performed on the hip joint.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "GRHL2 (Growth Factor Reducer with Homology to Hox Gene 2) is a transcription factor that plays a crucial role in regulating various cellular processes, including cell proliferation, differentiation, and survival. Over-expression of GRHL2 has been implicated in various cancers, including breast, lung, and colon cancer, and has been shown to promote cancer cell migration, invasion, and metastasis.\nEMT (Epithelial-to-Mesenchymal Transition) is a process by which epithelial cells lose their cell-cell adhesion and acquire mesenchymal characteristics, such as increased migration and invasiveness. EMT is a crucial step in the development and progression of cancer, as it allows cancer cells to invade surrounding tissues and organs, leading to the formation of metastases.\nWhile GRHL2 over-expression does not directly cause EMT, there is evidence to suggest that GRHL2 can promote EMT in certain contexts. For example, studies have shown that GRHL2 over-expression can lead to the downregulation of epithelial markers, such as E-cadherin, and the upregulation of mesenchymal markers, such as N-cadherin and vimentin, in various cancer cell types.\nAdditionally, GRHL2 has been shown to interact with other transcription factors that are involved in EMT, such as ZEB1 and Snail. These interactions can lead to the repression of epithelial gene expression and the activation of mesenchymal gene expression, promoting EMT.\nFurthermore, GRHL2 has been shown to promote the migration and invasion of cancer cells by modulating the expression of genes involved in these processes, such as matrix metalloproteinases (MMPs) and chemokine receptors. These effects can also contribute to the progression of cancer by enabling cancer cells to migrate and invade surrounding tissues.\nIn summary, while GRHL2 over-expression does not directly cause EMT, it can promote EMT by modulating the expression of genes involved in epithelial-to-mesenchymal transition and by interacting with other transcription factors that are involved in this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 is a transcription factor that regulates cell proliferation, differentiation, and survival.\n2. Over-expression of GRHL2 has been implicated in various cancers, including breast, lung, and colon cancer.\n3. GRHL2 over-expression has been shown to promote cancer cell migration, invasion, and metastasis.\n4. Studies have shown that GRHL2 over-expression can lead to the downregulation of epithelial markers and upregulation of mesenchymal markers in cancer cells.\n5. GRHL2 interacts with other transcription factors involved in EMT, such as ZEB1 and Snail.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 is a transcription factor that regulates cell proliferation, differentiation, and survival.",
      "Over-expression of GRHL2 has been implicated in various cancers, including breast, lung, and colon cancer.",
      "GRHL2 over-expression has been shown to promote cancer cell migration, invasion, and metastasis.",
      "Studies have shown that GRHL2 over-expression can lead to the downregulation of epithelial markers and upregulation of mesenchymal markers in cancer cells.",
      "GRHL2 interacts with other transcription factors involved in EMT, such as ZEB1 and Snail."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE \n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with information on T-UCRs (tumor-associated circular RNAs) and their implication in lung cancer.\nT-UCRs are a type of non-coding RNA that are derived from the back-splicing of protein-coding genes. In recent years, T-UCRs have been found to play a crucial role in various types of cancer, including lung cancer. Here are some T-UCRs that have been implicated in lung cancer:\n1. TUCR-1: TUCR-1 is one of the most well-studied T-UCRs in lung cancer. It is overexpressed in many lung cancer tissues and cell lines, and its overexpression is associated with poor prognosis. TUCR-1 has been shown to promote the proliferation and migration of lung cancer cells and to inhibit the apoptosis of cancer cells.\n2. TUCR-2: TUCR-2 is another T-UCR that has been implicated in lung cancer. It is overexpressed in many lung cancer tissues and cell lines, and its overexpression is associated with poor prognosis. TUCR-2 has been shown to promote the proliferation and migration of lung cancer cells and to inhibit the apoptosis of cancer cells.\n3. TUCR-3: TUCR-3 is a T-UCR that is overexpressed in many lung cancer tissues and cell lines. Its overexpression is associated with poor prognosis, and it has been shown to promote the proliferation and migration of lung cancer cells and to inhibit the apoptosis of cancer cells.\n4. TUCR-4: TUCR-4 is a T-UCR that is overexpressed in many lung cancer tissues and cell lines. Its overexpression is associated with poor prognosis, and it has been shown to promote the proliferation and migration of lung cancer cells and to inhibit the apoptosis of cancer cells.\n5. TUCR-5: TUCR-5 is a T-UCR that is overexpressed in many lung cancer tissues and cell lines. Its overexpression is associated with poor prognosis, and it has been shown to promote the pro",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer.\n2. TUCR-1 is overexpressed in many lung cancer tissues and cell lines and is associated with poor prognosis.\n3. TUCR-2 is overexpressed in many lung cancer tissues and cell lines and is associated with poor prognosis.\n4. TUCR-3 is overexpressed in many lung cancer tissues and cell lines and is associated with poor prognosis.\n5. TUCR-4 is overexpressed in many lung cancer tissues and cell lines and is associated with poor prognosis.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCRs (tumor-associated circular RNAs) have been implicated in various types of cancer, including lung cancer.",
      "TUCR-1 is overexpressed in many lung cancer tissues and cell lines and is associated with poor prognosis.",
      "TUCR-2 is overexpressed in many lung cancer tissues and cell lines and is associated with poor prognosis.",
      "TUCR-3 is overexpressed in many lung cancer tissues and cell lines and is associated with poor prognosis.",
      "TUCR-4 is overexpressed in many lung cancer tissues and cell lines and is associated with poor prognosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151, also known as the orphan receptor GPR151, is a member of the G protein-coupled receptor (GPCR) superfamily. It is a transmembrane receptor that is primarily expressed in the brain, specifically in regions involved in regulating feeding behavior, metabolism, and energy homeostasis, such as the hypothalamus, brainstem, and spinal cord.\nGPR151 was first identified in the early 2000s as a novel orphan receptor, meaning that it did not have a clearly defined endogenous ligand or a well-established biological function. However, since its discovery, a significant amount of research has been conducted to investigate its role in various physiological processes, including:\n1. Energy homeostasis: GPR151 has been shown to play a key role in regulating energy balance and body weight. Activation of GPR151 by its endogenous ligands, such as oleamide and N-oleoyl-phorbol-13-acetate (OPA), has been shown to decrease food intake and increase energy expenditure in animal models of obesity.\n2. Glucose metabolism: GPR151 has been implicated in the regulation of glucose metabolism, with studies suggesting that it may play a role in glucose uptake and storage in the brain.\n3. Inflammation: GPR151 has been shown to have anti-inflammatory effects, with activation of the receptor leading to the inhibition of pro-inflammatory cytokines and the activation of anti-inflammatory cytokines.\n4. Neuroprotection: GPR151 has been shown to have neuroprotective effects, with activation of the receptor leading to the protection of neurons against oxidative stress and excitotoxicity.\n5. Modulation of pain: GPR151 has been implicated in the regulation of pain perception, with studies suggesting that it may play a role in the modulation of pain sensitivity.\n6. Regulation of circadian rhythms: GPR151 has been shown to be involved in the regulation of circadian rhyth",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is a member of the G protein-coupled receptor superfamily.\n2. GPR151 is primarily expressed in the brain, specifically in regions regulating feeding behavior, metabolism, and energy homeostasis.\n3. GPR151 was first identified in the early 2000s as an orphan receptor.\n4. Activation of GPR151 by endogenous ligands has been shown to decrease food intake and increase energy expenditure in animal models of obesity.\n5. GPR151 has been implicated in the regulation of glucose metabolism and may play a role in glucose uptake and storage in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is a member of the G protein-coupled receptor superfamily.",
      "GPR151 is primarily expressed in the brain, specifically in regions regulating feeding behavior, metabolism, and energy homeostasis.",
      "GPR151 was first identified in the early 2000s as an orphan receptor.",
      "Activation of GPR151 by endogenous ligands has been shown to decrease food intake and increase energy expenditure in animal models of obesity.",
      "GPR151 has been implicated in the regulation of glucose metabolism and may play a role in glucose uptake and storage in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with the information you're looking for! The Fluzone Intradermal Quadrivalent vaccine contains the following attenuated live viruses:\n1. FluB (Influenza B): The Fluzone Intradermal Quadrivalent vaccine contains the B/Victoria lineage of the Influenza B virus. This strain is included in the vaccine to provide protection against the B/Victoria subtype of Influenza B.\n2. FluA (Influenza A): The vaccine contains the A/H1N1 and A/H3N2 subtypes of the Influenza A virus. These strains are included in the vaccine to provide protection against the A/H1N1 and A/H3N2 subtypes of Influenza A.\n3. FluB (Influenza B): The vaccine also contains the B/Yamagata lineage of the Influenza B virus. This strain is included in the vaccine to provide protection against the B/Yamagata subtype of Influenza B.\nIt's important to note that the Fluzone Intradermal Quadrivalent vaccine is designed to provide protection against four different strains of the flu virus: two strains of Influenza A (H1N1 and H3N2) and two strains of Influenza B (Victoria and Yamagata). By providing protection against multiple strains of the flu virus, the vaccine can help reduce the risk of illness and hospitalization due to the flu.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone Intradermal Quadrivalent vaccine contains attenuated live viruses of the B/Victoria lineage of the Influenza B virus.\n2. The vaccine includes attenuated live viruses of the A/H1N1 subtype of the Influenza A virus.\n3. The vaccine includes attenuated live viruses of the A/H3N2 subtype of the Influenza A virus.\n4. The vaccine also contains attenuated live viruses of the B/Yamagata lineage of the Influenza B virus.\n5. The vaccine is designed to provide protection against four different strains of the flu virus: H1N1, H3N2, Victoria, and Yamagata.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone Intradermal Quadrivalent vaccine contains attenuated live viruses of the B/Victoria lineage of the Influenza B virus.",
      "The vaccine includes attenuated live viruses of the A/H1N1 subtype of the Influenza A virus.",
      "The vaccine includes attenuated live viruses of the A/H3N2 subtype of the Influenza A virus.",
      "The vaccine also contains attenuated live viruses of the B/Yamagata lineage of the Influenza B virus.",
      "The vaccine is designed to provide protection against four different strains of the flu virus: H1N1, H3N2, Victoria, and Yamagata."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone Intradermal Quadrivalent vaccine contains inactivated, not attenuated live, viruses of the B/Victoria lineage of the Influenza B virus.\n2. FALSE [correction]: The vaccine contains inactivated, not attenuated live, viruses of the A/H1N1 subtype of the Influenza A virus.\n3. FALSE [correction]: The vaccine contains inactivated, not attenuated live, viruses of the A/H3N2 subtype of the Influenza A virus.\n4. FALSE [correction]: The vaccine contains inactivated, not attenuated live, viruses of the B/Yamagata lineage of the Influenza B virus.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Systemic Lupus Erythematosus (SLE) is a complex and multifactorial autoimmune disease that can affect multiple organ systems in the body. While the exact cause of SLE is still not fully understood, research has identified several genetic variants that are associated with an increased risk of developing the disease. One of these genes is the Tumor Necrosis Factor Receptor 2 (TNFR2) gene.\nThe TNFR2 gene encodes a protein called TNFR2, which is a key player in the regulation of immune responses. TNFR2 is a member of the tumor necrosis factor receptor superfamily and is primarily involved in the regulation of inflammation and immune responses.\nSeveral genetic variants in the TNFR2 gene have been associated with an increased risk of developing SLE. These variants are found in the promoter region of the TNFR2 gene, which is the region of DNA where the gene is regulated. Specifically, two common genetic variants in the TNFR2 promoter region have been identified as risk factors for SLE:\n1. -173G>C: This variant is a single nucleotide polymorphism (SNP) that is located in the promoter region of the TNFR2 gene. It has been associated with an increased risk of developing SLE, particularly in certain ethnic groups such as African Americans.\n2. -308G>A: This variant is another SNP located in the promoter region of the TNFR2 gene. It has been associated with an increased risk of developing SLE in multiple ethnic groups, including Caucasians and Asians.\nBoth of these variants are thought to increase the expression of the TNFR2 gene, leading to an overactive immune response and an increased risk of developing SLE. However, it's important to note that the exact mechanisms by which these variants contribute to the development of SLE are still not fully understood and are likely to be complex and multifactorial.\nIt's worth noting that while genetic variants in the TNFR2 gene are associated with an increased risk of developing SLE, they do not guarantee the development of the disease. Many people with these genetic variants will never develop SLE, and many people without these variants will still develop the disease",
    "llama-2-7b-chat-hf_fact_raw": "1. Several genetic variants in the TNFR2 gene are associated with an increased risk of developing Systemic Lupus Erythematosus (SLE).\n2. The TNFR2 gene encodes a protein involved in the regulation of immune responses and inflammation.\n3. Two common genetic variants in the TNFR2 promoter region, -173G>C and -308G>A, have been identified as risk factors for SLE.\n4. The -173G>C variant has been associated with an increased risk of SLE particularly in African Americans.\n5. The -308G>A variant has been associated with an increased risk of SLE in multiple ethnic groups, including Caucasians and Asians.",
    "llama-2-7b-chat-hf_fact": [
      "Several genetic variants in the TNFR2 gene are associated with an increased risk of developing Systemic Lupus Erythematosus (SLE).",
      "The TNFR2 gene encodes a protein involved in the regulation of immune responses and inflammation.",
      "Two common genetic variants in the TNFR2 promoter region, -173G>C and -308G>A, have been identified as risk factors for SLE.",
      "The -173G>C variant has been associated with an increased risk of SLE particularly in African Americans.",
      "The -308G>A variant has been associated with an increased risk of SLE in multiple ethnic groups, including Caucasians and Asians."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm glad you're interested in learning more about peanut allergy and potential treatments.\nUnfortunately, there is currently no widely available vaccine for peanut allergy. Peanut allergy is an immune-mediated reaction, meaning it occurs when the body's immune system mistakenly identifies peanuts as harmful and tries to fight them off. Developing a vaccine for peanut allergy is a complex and challenging task, as it would require a way to safely and effectively expose the immune system to small amounts of peanut protein without causing an allergic reaction.\nHowever, there are ongoing research and clinical trials exploring new approaches to treating peanut allergy, including oral immunotherapy (OIT) and sublingual immunotherapy (SLIT). These therapies involve gradually introducing small amounts of peanut protein to the body in a controlled and monitored environment, with the goal of desensitizing the immune system to the allergen.\nOIT typically involves consuming increasing amounts of peanut protein over time, under the close supervision of a healthcare provider. This approach has shown promise in reducing the severity of allergic reactions in some individuals, although it can also carry risks, such as anaphylaxis.\nSLIT, on the other hand, involves administering small amounts of peanut protein sublingually (under the tongue) on a regular basis. This approach has also shown potential in reducing the severity of allergic reactions, although more research is needed to fully understand its effectiveness and safety.\nIt's important to note that these therapies are not suitable for everyone with peanut allergy, and they should only be undertaken under the close supervision of a healthcare provider.\nIn summary, while there is currently no vaccine available for peanut allergy, ongoing research and clinical trials are exploring new approaches to treating this common and potentially life-threatening allergy. If you have peanut allergy, it's important to work closely with your healthcare provider to manage your symptoms and reduce the risk of an allergic reaction.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no widely available vaccine for peanut allergy.\n2. Peanut allergy is an immune-mediated reaction.\n3. Oral immunotherapy (OIT) involves consuming increasing amounts of peanut protein over time under healthcare provider supervision.\n4. Sublingual immunotherapy (SLIT) involves administering small amounts of peanut protein sublingually on a regular basis.\n5. Ongoing research and clinical trials are exploring new approaches to treating peanut allergy.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no widely available vaccine for peanut allergy.",
      "Peanut allergy is an immune-mediated reaction.",
      "Oral immunotherapy (OIT) involves consuming increasing amounts of peanut protein over time under healthcare provider supervision.",
      "Sublingual immunotherapy (SLIT) involves administering small amounts of peanut protein sublingually on a regular basis.",
      "Ongoing research and clinical trials are exploring new approaches to treating peanut allergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene, also known as the Forkhead box P2 (FoxP2) gene, is located on chromosome 7 in mammals, including mice. Specifically, the Fxy gene is located on the distal part of chromosome 7, near the centromere region.\nThe chromosomal position of the Fxy gene is important because it determines the gene's expression pattern and function. The Fxy gene is a transcription factor gene that plays a crucial role in the development and function of the nervous system, particularly in the formation of the cerebral cortex and basal ganglia. The gene is expressed in a specific pattern during embryonic development, with high levels of expression in the brain and spinal cord.\nThe Fxy gene is also important for the regulation of gene expression in the adult brain, particularly in the context of learning and memory. Studies have shown that the Fxy gene is involved in the formation of synapses, the connections between neurons that are critical for learning and memory. The gene is also involved in the regulation of the expression of other genes involved in synaptic plasticity, such as the N-methyl-D-aspartate (NMDA) receptor gene.\nIn addition to its role in the nervous system, the Fxy gene has been implicated in other biological processes, including the regulation of cell growth and differentiation, and the response to stress. Dysregulation of the Fxy gene has been implicated in a number of diseases, including intellectual disability, autism spectrum disorder, and schizophrenia.\nIn summary, the chromosomal position of the Fxy gene on chromosome 7 is important for its function in the development and regulation of the nervous system, particularly in the formation of the cerebral cortex and basal ganglia. The gene's expression pattern and function are critical for the regulation of synaptic plasticity and learning and memory, and dysregulation of the gene has been implicated in a number of diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene, also known as Forkhead box P2 (FoxP2), is located on chromosome 7 in mammals.\n2. Specifically, the Fxy gene is positioned on the distal part of chromosome 7, near the centromere region.\n3. The Fxy gene is a transcription factor gene involved in the development and function of the nervous system.\n4. The gene is expressed during embryonic development with high levels of expression in the brain and spinal cord.\n5. Dysregulation of the Fxy gene has been implicated in diseases such as intellectual disability, autism spectrum disorder, and schizophrenia.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene, also known as Forkhead box P2 (FoxP2), is located on chromosome 7 in mammals.",
      "Specifically, the Fxy gene is positioned on the distal part of chromosome 7, near the centromere region.",
      "The Fxy gene is a transcription factor gene involved in the development and function of the nervous system.",
      "The gene is expressed during embryonic development with high levels of expression in the brain and spinal cord.",
      "Dysregulation of the Fxy gene has been implicated in diseases such as intellectual disability, autism spectrum disorder, and schizophrenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The mouse Fxy gene, also known as Forkhead box P2 (FoxP2), is not located on chromosome 7 in mammals. In mice, it is located on chromosome 6, and in humans, it is on chromosome 7.\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "MPE-seq, or methylation-profiling by PCR-based sequencing, is a method used to profile DNA methylation patterns in a sample. The method is based on the following steps:\n1. Sample Preparation:\nThe sample is first prepared by isolating the DNA from the cells or tissue of interest. This is typically done using standard molecular biology techniques such as phenol-chloroform extraction or using a DNA isolation kit.\n2. Bisulfite Conversion:\nThe isolated DNA is then treated with bisulfite, which deaminates unmethylated cytosine residues but not methylated ones. This step is important because it allows for the detection of methylated regions in the genome.\n3. PCR Amplification:\nThe bisulfite-treated DNA is then used as template for PCR amplification. The PCR primers are designed to target regions of the genome that are known to be highly methylated or demethylated. The PCR reaction is performed under conditions that allow for the amplification of the targeted regions while minimizing the amplification of non-targeted regions.\n4. Sequencing:\nThe amplified DNA is then sequenced using Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio. The resulting sequencing data is then analyzed to identify regions of the genome that are highly methylated or demethylated.\n5. Data Analysis:\nThe sequencing data is analyzed using specialized software that can identify regions of the genome that are highly methylated or demethylated. The software can also quantify the degree of methylation at each CpG site in the genome. The resulting data can be used to identify differentially methylated regions between different samples, such as between cancerous and non-cancerous tissues.\nThe basis of the MPE-seq method is the use of PCR-based amplification of specific regions of the genome that are known to be highly methylated or demethylated. The bisulfite treatment step is important because it allows for the detection of methylated regions in the genome, while the PCR amplification step allows for the enrichment of the",
    "llama-2-7b-chat-hf_fact_raw": "1. MPE-seq is a method used to profile DNA methylation patterns in a sample.\n2. Sample preparation involves isolating DNA from cells or tissue using molecular biology techniques like phenol-chloroform extraction.\n3. Bisulfite conversion is used to differentiate between unmethylated and methylated cytosine residues in the DNA.\n4. PCR amplification is performed with primers designed to target highly methylated or demethylated regions of the genome.\n5. The amplified DNA is sequenced using Next-Generation Sequencing technologies such as Illumina or PacBio.",
    "llama-2-7b-chat-hf_fact": [
      "MPE-seq is a method used to profile DNA methylation patterns in a sample.",
      "Sample preparation involves isolating DNA from cells or tissue using molecular biology techniques like phenol-chloroform extraction.",
      "Bisulfite conversion is used to differentiate between unmethylated and methylated cytosine residues in the DNA.",
      "PCR amplification is performed with primers designed to target highly methylated or demethylated regions of the genome.",
      "The amplified DNA is sequenced using Next-Generation Sequencing technologies such as Illumina or PacBio."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: PCR amplification is performed with primers designed to target specific regions of interest, not necessarily based on their methylation status.\n5. TRUE.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR is a complex and intricate web of interconnected systems, and as such, it has been implemented using a variety of programming languages and technologies. While I cannot provide a definitive answer to your question, I can offer some insights into the programming languages that have been used in the development of GWAR.\nFirstly, it is important to note that GWAR is a fictional entity, and as such, it does not have a \"real\" implementation in the classical sense. GWAR is a conceptual construct that has been created through a combination of art, science, and fiction. As such, the implementation of GWAR is not a straightforward technical exercise, but rather a creative and imaginative process that involves a range of disciplines and techniques.\nThat being said, there are a number of programming languages and tools that have been used in the development of GWAR-related projects and applications. For example:\n1. Python: Python is a popular programming language that has been used in the development of various GWAR-related projects, including the GWAR Wiki and the GWAR-themed game \"GWAR: Armageddon.\" Python's ease of use, flexibility, and extensive libraries make it a popular choice for web development and game development.\n2. JavaScript: JavaScript is another popular programming language that has been used in the development of GWAR-related projects. For example, the GWAR-themed web application \"GWAR: The Official Website\" was built using JavaScript and the React framework.\n3. C++: C++ is a powerful programming language that has been used in the development of some GWAR-related applications, such as the GWAR-themed game \"GWAR: The Game.\" C++ is known for its performance and reliability, making it a popular choice for games and other high-performance applications.\n4. Blender: Blender is a 3D modeling and animation software that has been used in the creation of GWAR-related assets, such as models, textures, and animations. Blender is a popular choice for 3D artists and animators, and it has been used in a variety of GWAR-related projects.\n5. Unity: Unity is a game engine that has been used in the development of some GWAR-related games, such as \"GWAR:",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden, also known as masitinib, is a drug that has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS). ALS is a progressive neurological disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, and eventually death.\nThere is limited research available on the use of xaliproden for ALS, but here is what the current evidence suggests:\n1. Clinical trials: Several clinical trials have been conducted to evaluate the safety and efficacy of xaliproden in ALS patients. These trials have shown that xaliproden can slow down the progression of ALS, as measured by the rate of decline in forced vital capacity (FVC) and the time to disease progression.\nFor example, a phase II clinical trial published in the Journal of the Neurological Sciences in 2013 found that xaliproden treatment resulted in a slower decline in FVC compared to placebo in ALS patients.\nAnother phase III clinical trial published in the Lancet in 2017 found that xaliproden treatment resulted in a significant delay in the time to disease progression compared to placebo in ALS patients.\n2. Mechanism of action: Xaliproden is thought to work by reducing oxidative stress and inflammation in the brain and spinal cord, which are believed to contribute to the progression of ALS. It is also thought to promote the survival and function of remaining motor neurons.\n3. Side effects: Xaliproden has been shown to be generally well-tolerated in clinical trials, with the most common side effects including nausea, diarrhea, and fatigue. However, it is important to note that xaliproden can cause significant weight loss, which may be a concern for some patients.\n4. Availability: Xaliproden is currently approved for use in France and Belgium for the treatment of ALS, and it is being investigated in other countries as well. However, it is not yet approved for use in the United States or other countries.\nIn summary, while the evidence is limited, the current research suggests that x",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden, also known as masitinib, has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).\n2. Several clinical trials have shown that xaliproden can slow down the progression of ALS.\n3. A phase II clinical trial published in the Journal of the Neurological Sciences in 2013 found that xaliproden treatment resulted in a slower decline in forced vital capacity (FVC) in ALS patients.\n4. A phase III clinical trial published in the Lancet in 2017 found that xaliproden treatment resulted in a significant delay in the time to disease progression in ALS patients.\n5. Xaliproden is currently approved for use in France and Belgium for the treatment of ALS.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden, also known as masitinib, has been investigated for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).",
      "Several clinical trials have shown that xaliproden can slow down the progression of ALS.",
      "A phase II clinical trial published in the Journal of the Neurological Sciences in 2013 found that xaliproden treatment resulted in a slower decline in forced vital capacity (FVC) in ALS patients.",
      "A phase III clinical trial published in the Lancet in 2017 found that xaliproden treatment resulted in a significant delay in the time to disease progression in ALS patients.",
      "Xaliproden is currently approved for use in France and Belgium for the treatment of ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xaliproden and masitinib are not the same; masitinib has been investigated for the potential to improve the prognosis of ALS, while xaliproden is a different drug.\n2. UNKNOWN\n3. FALSE [correction]: Without access to the specific article from the Journal of the Neurological Sciences, it cannot be confirmed if this statement about xaliproden is accurate.\n4. FALSE [correction]: The referenced phase III clinical trial published in the Lancet in 2017 was for the drug edaravone, not xaliproden.\n5. FALSE [correction]: Xaliproden is not currently approved for use in any country for the treatment of ALS.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "The LiPS-A3S line is a genetically modified (GM) mouse line that has been engineered to express the humanized liver-specific albumin (hLA) gene under the control of the albumin promoter. The hLA gene is inserted into the chromosome 17 in the LiPS-A3S line.\nSpecifically, the hLA gene is inserted into the distal part of chromosome 17, at the locus designated as 17q21.3. This region is known as the human chromosome 17q21.3, and it is a region that is highly conserved across different species, including mice and humans.\nThe LiPS-A3S line was generated by a team of researchers at the University of California, San Diego, who used a process called homologous recombination to introduce the hLA gene into the mouse genome. Homologous recombination is a technique that allows researchers to introduce specific genetic changes into an organism's genome by using a template with a similar sequence to the target gene. In the case of the LiPS-A3S line, the hLA gene was introduced into the mouse genome using a template that contained the human chromosome 17q21.3 region.\nOnce the hLA gene was inserted into the mouse genome, the researchers used a process called gene targeting to remove the endogenous albumin gene and replace it with the hLA gene. This resulted in the LiPS-A3S line, which expresses the humanized liver-specific albumin gene in the liver cells of the mouse.\nOverall, the insertion of the hLA gene into the chromosome 17 of the LiPS-A3S line is a complex process that involves the use of homologous recombination and gene targeting techniques. This allows researchers to generate a GM mouse line that can be used to study the function of the humanized liver-specific albumin gene in a mouse model.",
    "llama-2-7b-chat-hf_fact_raw": "1. The humanized liver-specific albumin (hLA) gene is inserted into chromosome 17 in the LiPS-A3S line.\n2. The hLA gene is specifically inserted into the distal part of chromosome 17, at the locus 17q21.3.\n3. The region 17q21.3 is conserved across different species, including mice and humans.\n4. The University of California, San Diego researchers generated the LiPS-A3S line using homologous recombination.\n5. Gene targeting was used to replace the endogenous albumin gene with the hLA gene in the LiPS-A3S line.",
    "llama-2-7b-chat-hf_fact": [
      "The humanized liver-specific albumin (hLA) gene is inserted into chromosome 17 in the LiPS-A3S line.",
      "The hLA gene is specifically inserted into the distal part of chromosome 17, at the locus 17q21.3.",
      "The region 17q21.3 is conserved across different species, including mice and humans.",
      "The University of California, San Diego researchers generated the LiPS-A3S line using homologous recombination.",
      "Gene targeting was used to replace the endogenous albumin gene with the hLA gene in the LiPS-A3S line."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that have been developed for predicting drug synergy, which is the ability of two or more drugs to produce a combined effect that is greater than the sum of their individual effects. Here are some of the most notable ones:\n1. DeepSynth: Developed by the University of California, DeepSynth is a deep learning model that can predict drug synergy by analyzing the chemical structures of drugs and their targets. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict the synergy between drugs.\n2. Drug2Drug: Developed by the University of California, Drug2Drug is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of drugs. It uses a combination of graph convolutional neural networks (GCNNs) and attention mechanisms to predict the synergy between drugs.\n3. Synergizer: Developed by the University of Toronto, Synergizer is a deep learning model that predicts drug synergy by analyzing the gene expression profiles of drugs. It uses a combination of CNNs and RNNs to predict the synergy between drugs.\n4. DrugCombinator: Developed by the University of California, DrugCombinator is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a combination of CNNs and RNNs to predict the synergy between drugs.\n5. MultiDrug: Developed by the University of California, MultiDrug is a deep learning model that predicts drug synergy by analyzing the protein-protein interaction networks of drugs. It uses a combination of GCNNs and attention mechanisms to predict the synergy between drugs.\n6. DrugSynergyNet: Developed by the University of California, DrugSynergyNet is a deep learning model that predicts drug synergy by analyzing the chemical structures of drugs and their targets. It uses a combination of CNNs and RNNs to predict the synergy between drugs.\n7. DeepDrug: Developed by the University of California, DeepDrug is a deep learning model that predicts drug synergy by analyzing the protein-",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynth, developed by the University of California, uses CNNs and RNNs to predict drug synergy.\n2. Drug2Drug, developed by the University of California, uses GCNNs and attention mechanisms to predict drug synergy.\n3. Synergizer, developed by the University of Toronto, predicts drug synergy based on gene expression profiles.\n4. DrugCombinator, developed by the University of California, uses CNNs and RNNs to predict drug synergy.\n5. MultiDrug, developed by the University of California, uses GCNNs and attention mechanisms to predict drug synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynth, developed by the University of California, uses CNNs and RNNs to predict drug synergy.",
      "Drug2Drug, developed by the University of California, uses GCNNs and attention mechanisms to predict drug synergy.",
      "Synergizer, developed by the University of Toronto, predicts drug synergy based on gene expression profiles.",
      "DrugCombinator, developed by the University of California, uses CNNs and RNNs to predict drug synergy.",
      "MultiDrug, developed by the University of California, uses GCNNs and attention mechanisms to predict drug synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "There are several cloud-based platforms that have been developed for comparing Genome-Wide Association Studies (GWAS). Here are some of the most popular ones:\n1. GWAS-Compare: GWAS-Compare is a cloud-based platform developed by the University of California, San Diego. It allows users to compare GWAS data from different populations, study samples, or time points. The platform provides a user-friendly interface for uploading and analyzing GWAS data, as well as tools for visualizing and interpreting the results.\n2. GWAS-Toolkit: GWAS-Toolkit is a collection of software tools for GWAS analysis developed by the Broad Institute. The platform includes a cloud-based interface for comparing GWAS data, as well as tools for quality control, imputation, and association analysis.\n3. PLINK: PLINK is a popular software package for GWAS analysis that also includes a cloud-based platform for comparing GWAS data. The platform allows users to upload and analyze GWAS data from multiple samples, as well as perform meta-analyses and generate summary statistics.\n4. METAL: METAL is a software package for GWAS analysis that includes a cloud-based platform for comparing GWAS data. The platform allows users to upload and analyze GWAS data from multiple samples, as well as perform meta-analyses and generate summary statistics.\n5. EAGLE: EAGLE is a cloud-based platform for GWAS analysis that allows users to compare GWAS data from different populations, study samples, or time points. The platform provides a user-friendly interface for uploading and analyzing GWAS data, as well as tools for visualizing and interpreting the results.\n6. GWAS-R: GWAS-R is a cloud-based platform for GWAS analysis that allows users to compare GWAS data from different populations, study samples, or time points. The platform provides a user-friendly interface for uploading and analyzing GWAS data, as well as tools for visualizing and interpreting the results.\n7. GWAS-Viewer: GWAS-Viewer is a cloud-based platform for visualizing and interpreting GWAS data. The platform allows users to upload and view GWAS data from multiple samples,",
    "llama-2-7b-chat-hf_fact_raw": "1. GWAS-Compare is a cloud-based platform developed by the University of California, San Diego.\n2. GWAS-Toolkit is a collection of software tools for GWAS analysis developed by the Broad Institute.\n3. PLINK is a popular software package that includes a cloud-based platform for GWAS analysis.\n4. METAL is a software package that includes a cloud-based platform for GWAS analysis.\n5. EAGLE is a cloud-based platform for GWAS analysis that provides tools for visualizing and interpreting results.",
    "llama-2-7b-chat-hf_fact": [
      "GWAS-Compare is a cloud-based platform developed by the University of California, San Diego.",
      "GWAS-Toolkit is a collection of software tools for GWAS analysis developed by the Broad Institute.",
      "PLINK is a popular software package that includes a cloud-based platform for GWAS analysis.",
      "METAL is a software package that includes a cloud-based platform for GWAS analysis.",
      "EAGLE is a cloud-based platform for GWAS analysis that provides tools for visualizing and interpreting results."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: PLINK is a popular software package for GWAS analysis, but it is not a cloud-based platform.\n4. FALSE [correction]: METAL is a software package for meta-analysis of GWAS data, but it is not a cloud-based platform.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a small molecule inhibitor of the enzyme cyclin-dependent kinase 5 (CDK5), which is a key regulator of cellular processes such as proliferation, differentiation, and survival. CDK5 is overexpressed in many types of cancer, including sarcomas, and has been implicated in the development and progression of these tumors.\nThere is some evidence to suggest that CMB305 may be effective against sarcomas. For example, a study published in the journal Cancer Research in 2017 found that CMB305 inhibited the growth of several types of sarcoma cells, including those derived from osteosarcoma, chondrosarcoma, and liposarcoma. The study also found that CMB305 induced cell cycle arrest and apoptosis (programmed cell death) in these cells, which are both mechanisms by which cancer cells can be killed.\nAnother study published in the journal Oncogene in 2019 found that CMB305 inhibited the growth of sarcoma cells by blocking the activation of the PI3K/Akt signaling pathway, which is commonly altered in sarcomas.\nIt is important to note that these studies were conducted in vitro (in a laboratory setting) and in vivo (in living animals), and more research is needed to determine whether CMB305 is effective against sarcomas in humans. Additionally, CMB305 is currently being studied as a potential treatment for other types of cancer, including breast cancer and lung cancer, so it is not yet clear whether it will be most effective against sarcomas or which types of sarcomas it may be most effective against.\nIn summary, while there is some evidence to suggest that CMB305 may be effective against sarcomas, more research is needed to fully understand its potential as a treatment for these types of cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a small molecule inhibitor of the enzyme cyclin-dependent kinase 5 (CDK5).\n2. CDK5 is overexpressed in many types of cancer, including sarcomas.\n3. A study published in the journal Cancer Research in 2017 found that CMB305 inhibited the growth of several types of sarcoma cells.\n4. Another study published in the journal Oncogene in 2019 found that CMB305 blocked the activation of the PI3K/Akt signaling pathway in sarcoma cells.\n5. CMB305 is being studied as a potential treatment for other types of cancer, including breast cancer and lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a small molecule inhibitor of the enzyme cyclin-dependent kinase 5 (CDK5).",
      "CDK5 is overexpressed in many types of cancer, including sarcomas.",
      "A study published in the journal Cancer Research in 2017 found that CMB305 inhibited the growth of several types of sarcoma cells.",
      "Another study published in the journal Oncogene in 2019 found that CMB305 blocked the activation of the PI3K/Akt signaling pathway in sarcoma cells.",
      "CMB305 is being studied as a potential treatment for other types of cancer, including breast cancer and lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific study references or additional context, it's not possible to verify the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Three Principles or Three Jewels, is a fundamental concept in Buddhism. It consists of three essential elements that are considered to be the foundation of the Buddhist path:\n1. The Buddha: The Buddha refers to the historical figure of Siddhartha Gautama, who lived in ancient India around 2,500 years ago and is considered to be the founder of Buddhism. The Buddha is revered as a teacher and guide, and his teachings are seen as the basis for the Buddhist path.\n2. The Dharma: The Dharma refers to the teachings and principles of Buddhism, as revealed by the Buddha and passed down through generations of Buddhist practitioners. The Dharma includes the Four Noble Truths, the Eightfold Path, and other key concepts that are central to Buddhist thought.\n3. The Sangha: The Sangha refers to the community of Buddhist practitioners and monastics who share a commitment to the Buddhist path. The Sangha provides a supportive environment for practitioners to learn, grow, and practice their faith together.\nManifestations of the Saint's Triad can be seen in various aspects of Buddhist practice and belief. Here are some examples:\n1. Meditation: Meditation is a key manifestation of the Saint's Triad, as it allows practitioners to connect with their own inner wisdom and cultivate a deeper understanding of the Buddha's teachings. Through meditation, practitioners can develop a greater sense of inner peace, compassion, and mindfulness, which are all essential qualities of the Buddhist path.\n2. Ethical conduct: The practice of ethical conduct, such as following the Five Precepts or Eightfold Path, is another manifestation of the Saint's Triad. By following these principles, practitioners can cultivate a sense of integrity, compassion, and respect for themselves and others, which are all essential qualities of the Buddhist path.\n3. Service: Service to others is a manifestation of the Saint's Triad, as it allows practitioners to apply their understanding of the Buddha's teachings in a practical way. By serving others, practitioners can cultivate a sense of compass",
    "llama-2-7b-chat-hf_fact_raw": "1. The Buddha refers to the historical figure of Siddhartha Gautama, who lived in ancient India around 2,500 years ago.\n2. The Dharma includes the Four Noble Truths and the Eightfold Path, which are central to Buddhist thought.\n3. The Sangha refers to the community of Buddhist practitioners and monastics.\n4. Meditation is a practice that allows practitioners to connect with their own inner wisdom and understand the Buddha's teachings.\n5. Ethical conduct in Buddhism involves following principles like the Five Precepts or Eightfold Path.",
    "llama-2-7b-chat-hf_fact": [
      "The Buddha refers to the historical figure of Siddhartha Gautama, who lived in ancient India around 2,500 years ago.",
      "The Dharma includes the Four Noble Truths and the Eightfold Path, which are central to Buddhist thought.",
      "The Sangha refers to the community of Buddhist practitioners and monastics.",
      "Meditation is a practice that allows practitioners to connect with their own inner wisdom and understand the Buddha's teachings.",
      "Ethical conduct in Buddhism involves following principles like the Five Precepts or Eightfold Path."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "LY6K is a protein that has been found to be overexpressed in various types of cancer, including non-small cell lung cancer (NSCLC). Overexpression of LY6K has been associated with poor prognosis in some cancer types, but the prognostic significance of LY6K in NSCLC is still unclear.\nLY6K is a member of the LY6 family of proteins, which are involved in the regulation of cellular processes such as cell adhesion, migration, and signaling. Overexpression of LY6K has been observed in many types of cancer, including NSCLC, and has been linked to cancer progression and poor prognosis.\nHowever, the prognostic significance of LY6K in NSCLC is complex and context-dependent. Some studies have found that high levels of LY6K are associated with poorer prognosis in NSCLC patients, while others have found no significant association.\nA study published in the journal Cancer Research in 2017 found that high levels of LY6K were associated with poorer overall survival and progression-free survival in a cohort of NSCLC patients. The study analyzed the expression of LY6K in 177 NSCLC tumors and found that high levels of LY6K were associated with a higher risk of disease recurrence and death.\nAnother study published in the journal Clinical Cancer Research in 2019 found that LY6K expression was associated with poorer prognosis in NSCLC patients, particularly in those with adenocarcinoma histology. The study analyzed the expression of LY6K in 220 NSCLC tumors and found that high levels of LY6K were associated with a higher risk of disease recurrence and death.\nHowever, not all studies have found a significant association between LY6K expression and prognosis in NSCLC. A study published in the journal Oncotarget in 2018 found that LY6K expression was not associated with prognosis in a cohort of NSCLC patients.\nThe discrepancy in the results of these studies may be due to the different patient populations, tumor characteristics, and methods of LY6K detection used in each study. For example, the study published in Cancer Research used a different method of LY6",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K has been associated with poor prognosis in some cancer types.\n2. A study published in the journal Cancer Research in 2017 found that high levels of LY6K were associated with poorer overall survival and progression-free survival in NSCLC patients.\n3. The same study analyzed the expression of LY6K in 177 NSCLC tumors.\n4. Another study published in the journal Clinical Cancer Research in 2019 found that LY6K expression was associated with poorer prognosis in NSCLC patients, particularly in those with adenocarcinoma histology.\n5. A study published in the journal Oncotarget in 2018 found that LY6K expression was not associated with prognosis in a cohort of NSCLC patients.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K has been associated with poor prognosis in some cancer types.",
      "A study published in the journal Cancer Research in 2017 found that high levels of LY6K were associated with poorer overall survival and progression-free survival in NSCLC patients.",
      "The same study analyzed the expression of LY6K in 177 NSCLC tumors.",
      "Another study published in the journal Clinical Cancer Research in 2019 found that LY6K expression was associated with poorer prognosis in NSCLC patients, particularly in those with adenocarcinoma histology.",
      "A study published in the journal Oncotarget in 2018 found that LY6K expression was not associated with prognosis in a cohort of NSCLC patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Certainly! Cytokinesis is the process by which a cell divides into two daughter cells, and it involves the dephosphorylation of various cell division cycle (CDK) targets. Here are some of the CDK targets that are dephosphorylated during cytokinesis:\n1. Cyclin-dependent kinase 1 (CDK1): CDK1 is a key regulator of the cell cycle, and it is dephosphorylated during cytokinesis to allow for the proper separation of the daughter cells.\n2. Cyclin-dependent kinase 2 (CDK2): CDK2 is another important regulator of the cell cycle, and it is also dephosphorylated during cytokinesis to facilitate the separation of the daughter cells.\n3. Cyclin B: Cyclin B is a regulatory protein that helps to coordinate the progression of the cell cycle, and it is dephosphorylated during cytokinesis to allow for the proper separation of the daughter cells.\n4. Cyclin E: Cyclin E is another regulatory protein that helps to coordinate the cell cycle, and it is dephosphorylated during cytokinesis to allow for the proper separation of the daughter cells.\n5. Polo-like kinase 1 (PLK1): PLK1 is a key regulator of the cell cycle, and it is dephosphorylated during cytokinesis to allow for the proper separation of the daughter cells.\n6. Aurora kinase A (AURKA): AURKA is a key regulator of the cell cycle, and it is dephosphorylated during cytokinesis to allow for the proper separation of the daughter cells.\n7. Aurora kinase B (AURKB): AURKB is another regulator of the cell cycle, and it is dephosphorylated during cytokinesis to allow for the proper separation of the daughter cells.\n8. Bora (BORO): BORO is a regulator of the cell cycle, and it is dephosphorylated during cytokinesis to allow for the proper separation of the daughter cells.\n9. Spindle-associated protein 1 (SAP1): SAP1 is a regulator of the cell cycle, and it",
    "llama-2-7b-chat-hf_fact_raw": "1. Cyclin-dependent kinase 1 (CDK1) is dephosphorylated during cytokinesis.\n2. Cyclin-dependent kinase 2 (CDK2) is dephosphorylated during cytokinesis.\n3. Cyclin B is dephosphorylated during cytokinesis.\n4. Cyclin E is dephosphorylated during cytokinesis.\n5. Polo-like kinase 1 (PLK1) is dephosphorylated during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Cyclin-dependent kinase 1 (CDK1) is dephosphorylated during cytokinesis.",
      "Cyclin-dependent kinase 2 (CDK2) is dephosphorylated during cytokinesis.",
      "Cyclin B is dephosphorylated during cytokinesis.",
      "Cyclin E is dephosphorylated during cytokinesis.",
      "Polo-like kinase 1 (PLK1) is dephosphorylated during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cyclin-dependent kinase 1 (CDK1) is phosphorylated during cytokinesis.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a term that has gained popularity in recent years, particularly in the context of psychedelic therapy and mental health. It refers to a hypothetical state of consciousness that is characterized by a heightened sense of empathy, emotional intensity, and interconnectedness with the universe.\nThe concept of Xanamem was first introduced by the psychedelic researcher and therapist, James Fadiman, in his book \"The Psychedelic Explorer's Guide.\" Fadiman defines Xanamem as a state of consciousness that is \"beyond the ordinary waking state, but not necessarily a dream or a psychotic state.\" In this state, individuals may experience a sense of oneness with the universe, a deeper understanding of the interconnectedness of all things, and a heightened sense of empathy and compassion for others.\nXanamem is often described as a state of consciousness that is more profound and transformative than the typical psychedelic experience. It is said to be characterized by a sense of unity, transcendence, and interconnectedness that is not limited to the individual's own experiences, but rather extends to the collective unconscious and the universe as a whole.\nWhile the concept of Xanamem is still largely theoretical, it has gained significant attention in recent years due to its potential therapeutic applications. Some researchers believe that Xanamem may be a key factor in the therapeutic effects of psychedelics, such as psilocybin, LSD, and ayahuasca. These substances have been shown to promote long-term positive changes in mood, behavior, and cognition, and Xanamem may play a role in explaining how they achieve these effects.\nOverall, Xanamem is a fascinating and complex concept that is still being explored and understood by researchers and therapists. While its exact nature and mechanisms are not yet fully clear, it has the potential to offer new insights into the nature of consciousness and the therapeutic potential of psychedelics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is associated with a state of consciousness characterized by heightened empathy, emotional intensity, and interconnectedness with the universe.\n2. The concept of Xanamem was introduced by James Fadiman in \"The Psychedelic Explorer's Guide.\"\n3. Psychedelic researcher and therapist James Fadiman defines Xanamem as a state beyond the ordinary waking state, not necessarily a dream or psychotic state.\n4. Xanamem is described as more profound and transformative than the typical psychedelic experience.\n5. Substances like psilocybin, LSD, and ayahuasca have shown therapeutic effects that some researchers believe may be linked to Xanamem.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is associated with a state of consciousness characterized by heightened empathy, emotional intensity, and interconnectedness with the universe.",
      "The concept of Xanamem was introduced by James Fadiman in \"The Psychedelic Explorer's Guide.\"",
      "Psychedelic researcher and therapist James Fadiman defines Xanamem as a state beyond the ordinary waking state, not necessarily a dream or psychotic state.",
      "Xanamem is described as more profound and transformative than the typical psychedelic experience.",
      "Substances like psilocybin, LSD, and ayahuasca have shown therapeutic effects that some researchers believe may be linked to Xanamem."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n(Note: The term \"Xanamem\" does not appear to be a widely recognized or established concept in psychedelic research, making it difficult to verify these statements.)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Hof1-Cyk3 is a protein complex that plays a crucial role in the regulation of cellular processes in yeast, including cell division, growth, and stress response. The Hof1-Cyk3 interaction is a key component of this complex and is involved in the modulation of various cellular pathways. Here is a detailed answer to your question:\nThe Hof1-Cyk3 interaction is a protein-protein interaction that occurs between the Hof1 protein and the Cyk3 protein in yeast. Hof1 is a protein that is involved in the regulation of the cell cycle and is a key component of the spindle checkpoint, which ensures that the chromosomes are properly aligned during cell division. Cyk3, on the other hand, is a protein that is involved in the regulation of the G1/S checkpoint, which controls the progression of the cell cycle from the G1 phase to the S phase.\nThe Hof1-Cyk3 interaction plays a crucial role in the regulation of these checkpoints and is involved in the modulation of various cellular pathways. When the Hof1 protein is phosphorylated, it interacts with the Cyk3 protein and activates its activity, leading to the inhibition of the G1/S checkpoint. This allows the cell to progress through the cell cycle even if the chromosomes are not properly aligned, which is important for ensuring proper cell division.\nIn addition to its role in the regulation of the cell cycle, the Hof1-Cyk3 interaction also plays a role in the response to stress. When the cell is exposed to stress, the Hof1 protein is phosphorylated, leading to the activation of the Cyk3 protein and the inhibition of the G1/S checkpoint. This allows the cell to slow down its growth and division in response to stress, which is important for protecting the cell from damage.\nIn summary, the Hof1-Cyk3 interaction plays a crucial role in the regulation of cellular processes in yeast, including cell division, growth, and stress response. It is involved in the modulation of various cellular pathways and is a key component of the spindle checkpoint and the G1/S checkpoint. Understanding the role of the Hof1-Cyk3 interaction is important for understanding the regulation of cellular processes",
    "llama-2-7b-chat-hf_fact_raw": "1. Hof1-Cyk3 is a protein complex that regulates cellular processes in yeast such as cell division, growth, and stress response.\n2. The Hof1 protein is involved in the spindle checkpoint of the cell cycle, ensuring proper chromosome alignment during cell division.\n3. The Cyk3 protein regulates the G1/S checkpoint, controlling cell cycle progression from G1 phase to S phase.\n4. The Hof1-Cyk3 interaction activates the Cyk3 protein, leading to inhibition of the G1/S checkpoint, allowing cell cycle progression even with misaligned chromosomes.\n5. The Hof1-Cyk3 interaction also responds to stress by slowing down cell growth and division to protect the cell from damage.",
    "llama-2-7b-chat-hf_fact": [
      "Hof1-Cyk3 is a protein complex that regulates cellular processes in yeast such as cell division, growth, and stress response.",
      "The Hof1 protein is involved in the spindle checkpoint of the cell cycle, ensuring proper chromosome alignment during cell division.",
      "The Cyk3 protein regulates the G1/S checkpoint, controlling cell cycle progression from G1 phase to S phase.",
      "The Hof1-Cyk3 interaction activates the Cyk3 protein, leading to inhibition of the G1/S checkpoint, allowing cell cycle progression even with misaligned chromosomes.",
      "The Hof1-Cyk3 interaction also responds to stress by slowing down cell growth and division to protect the cell from damage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Hof1 protein is involved in the cytokinesis and cell wall remodeling, not the spindle checkpoint.\n3. UNKNOWN\n4. FALSE [correction]: The Hof1-Cyk3 interaction does not lead to inhibition of the G1/S checkpoint with misaligned chromosomes. Instead, it promotes coordinated cell division and cell wall remodeling.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Gastric cancer, also known as stomach cancer, is a common malignancy worldwide, and understanding the underlying molecular mechanisms is crucial for developing effective diagnostic biomarkers and therapeutic strategies. Recently, there has been growing interest in the role of transcriptional regulators (T-UCRs) in gastric cancer. Here are some T-UCRs that have been implicated in gastric cancer:\n1. TP53: TP53 is a tumor suppressor gene that is frequently mutated in gastric cancer. The TP53 protein plays a crucial role in regulating cell cycle progression, apoptosis, and DNA repair. Mutations in TP53 can lead to uncontrolled cell growth and tumorigenesis.\n2. E2F1: E2F1 is a transcription factor that regulates cell cycle progression and apoptosis. Overexpression of E2F1 has been observed in many types of cancer, including gastric cancer. E2F1 can promote cell proliferation and inhibit apoptosis, leading to tumorigenesis.\n3. HIF1A: HIF1A is a transcription factor that regulates the expression of genes involved in angiogenesis, glucose metabolism, and cell survival. Hypoxia-inducible factor 1-alpha (HIF1A) is overexpressed in many types of cancer, including gastric cancer, and promotes tumorigenesis by enhancing angiogenesis and glucose metabolism.\n4. KRAS: KRAS is a small GTPase that regulates cell signaling pathways involved in cell growth and differentiation. Mutations in KRAS are common in gastric cancer and are associated with poor prognosis. KRAS mutations can lead to uncontrolled cell growth and tumorigenesis.\n5. P57: P57 is a transcription factor that regulates cell cycle progression and apoptosis. Loss of P57 function has been implicated in gastric cancer, and P57 mutations can lead to uncontrolled cell growth and tumorigenesis.\n6. SMAD4: SMAD4 is a transcription factor that",
    "llama-2-7b-chat-hf_fact_raw": "1. TP53 is a tumor suppressor gene that is frequently mutated in gastric cancer.\n2. Overexpression of E2F1, a transcription factor, has been observed in gastric cancer.\n3. HIF1A is overexpressed in many types of cancer, including gastric cancer.\n4. Mutations in KRAS are common in gastric cancer and are associated with poor prognosis.\n5. Loss of P57 function has been implicated in gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "TP53 is a tumor suppressor gene that is frequently mutated in gastric cancer.",
      "Overexpression of E2F1, a transcription factor, has been observed in gastric cancer.",
      "HIF1A is overexpressed in many types of cancer, including gastric cancer.",
      "Mutations in KRAS are common in gastric cancer and are associated with poor prognosis.",
      "Loss of P57 function has been implicated in gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Mutations in KRAS are common in colorectal cancer and are associated with poor prognosis, not specifically gastric cancer.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical index used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various organs and tissues throughout the body. The LSI was developed by a team of researchers led by Dr. Daniel J. Wallace in the 1980s as a standardized method for evaluating the severity of SLE.\nThe LSI is based on a combination of clinical and laboratory variables, including:\n1. Serosal inflammation: The presence and severity of serosal inflammation, which is characterized by the presence of inflammatory cells in the serous membranes that surround various organs, such as the heart, lungs, and abdomen.\n2. Joint involvement: The degree of joint inflammation and damage, which can range from mild to severe.\n3. Renal involvement: The degree of kidney inflammation and damage, which can range from mild to severe.\n4. Neuropsychiatric involvement: The degree of neurological and psychiatric symptoms, such as headaches, confusion, and depression.\n5. Haematological involvement: The degree of blood abnormalities, such as anemia, leukopenia, and thrombocytopenia.\n6. Immunological involvement: The degree of immune system dysfunction, including the presence of autoantibodies and the level of immune complexes in the blood.\n7. Disease duration: The length of time the patient has been diagnosed with SLE.\n8. Medication use: The use of medications to treat SLE, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive drugs.\n9. Organ damage: The degree of damage to various organs, such as the kidneys, liver, and heart.\n10. Quality of life: The patient's overall quality of life, including their ability to perform daily activities and their level of pain and discomfort.\nThe LSI is calculated by assigning a score to each of these variables, with higher scores indicating more severe disease. The",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed by a team led by Dr. Daniel J. Wallace in the 1980s.\n3. The LSI evaluates severity based on clinical and laboratory variables, including serosal inflammation and joint, renal, neuropsychiatric, haematological, and immunological involvement.\n4. The LSI also considers disease duration, medication use, organ damage, and quality of life.\n5. The LSI assigns a score to each variable, with higher scores indicating more severe disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed by a team led by Dr. Daniel J. Wallace in the 1980s.",
      "The LSI evaluates severity based on clinical and laboratory variables, including serosal inflammation and joint, renal, neuropsychiatric, haematological, and immunological involvement.",
      "The LSI also considers disease duration, medication use, organ damage, and quality of life.",
      "The LSI assigns a score to each variable, with higher scores indicating more severe disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has been implicated in various neurodevelopmental disorders, including intellectual disability, autism spectrum disorder, and epilepsy. De novo mutations in ZSWIM6, which are new mutations that occur spontaneously and are not inherited from parents, have been identified as a potential cause of some of these disorders. Here are some of the disorders that have been linked to de novo mutations in ZSWIM6:\n1. Intellectual disability: De novo mutations in ZSWIM6 have been identified in individuals with intellectual disability, which is a neurodevelopmental disorder characterized by below-average intelligence and cognitive abilities. These mutations can lead to changes in the structure and function of the brain, which can result in cognitive impairments.\n2. Autism spectrum disorder: De novo mutations in ZSWIM6 have been found in individuals with autism spectrum disorder (ASD), which is a neurodevelopmental disorder characterized by social and communication impairments. These mutations may contribute to the development of ASD by disrupting the normal functioning of brain circuits involved in social cognition and communication.\n3. Epilepsy: De novo mutations in ZSWIM6 have been identified in individuals with epilepsy, which is a neurological disorder characterized by recurrent seizures. These mutations may affect the functioning of the brain's electrical activity, leading to seizure activity.\n4. Neurodevelopmental disorders: De novo mutations in ZSWIM6 have been found in individuals with a range of neurodevelopmental disorders, including ADHD, Tourette's syndrome, and schizophrenia. These mutations may contribute to the development of these disorders by disrupting the normal functioning of brain circuits involved in attention, motivation, and cognition.\nIt's important to note that the relationship between de novo mutations in ZSWIM6 and these disorders is complex and not fully understood. More research is needed to determine the exact mechanisms by which these mutations contribute to the development of these disorders. Additionally, it's important to note that not all individuals with de novo mutations in ZSWIM6 will develop these dis",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 have been identified in individuals with intellectual disability.\n2. ZSWIM6 de novo mutations are linked to autism spectrum disorder (ASD).\n3. Individuals with epilepsy have been found to have de novo mutations in ZSWIM6.\n4. De novo mutations in ZSWIM6 are associated with a range of neurodevelopmental disorders, including ADHD, Tourette's syndrome, and schizophrenia.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 have been identified in individuals with intellectual disability.",
      "ZSWIM6 de novo mutations are linked to autism spectrum disorder (ASD).",
      "Individuals with epilepsy have been found to have de novo mutations in ZSWIM6.",
      "De novo mutations in ZSWIM6 are associated with a range of neurodevelopmental disorders, including ADHD, Tourette's syndrome, and schizophrenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify diseases based on their etiology, or cause. It was developed by Dr. Johannes Koos in the early 20th century and is still widely used today.\nAccording to the Koos Classification, diseases can be classified into one of the following categories:\n1. Infectious diseases: These are diseases caused by the presence of microorganisms such as bacteria, viruses, fungi, or parasites. Examples of infectious diseases include tuberculosis, pneumonia, and malaria.\n2. Autoimmune diseases: These are diseases caused by the immune system attacking the body's own tissues. Examples of autoimmune diseases include rheumatoid arthritis, lupus, and multiple sclerosis.\n3. Allergic diseases: These are diseases caused by an overactive immune response to a substance that is not harmful to most people. Examples of allergic diseases include asthma, eczema, and hay fever.\n4. Neoplastic diseases: These are diseases caused by the growth of abnormal cells. Examples of neoplastic diseases include cancer, leukemia, and lymphoma.\n5. Genetic diseases: These are diseases caused by inherited genetic mutations. Examples of genetic diseases include sickle cell anemia, cystic fibrosis, and Huntington's disease.\n6. Metabolic diseases: These are diseases caused by problems with the body's metabolism, such as the way it processes nutrients. Examples of metabolic diseases include diabetes, thyroid disorders, and gout.\n7. Nutritional diseases: These are diseases caused by a lack of essential nutrients or an excess of certain nutrients. Examples of nutritional diseases include scurvy, beriberi, and obesity.\n8. Psychiatric diseases: These are diseases caused by mental or emotional disorders. Examples of psychiatric diseases include depression, anxiety disorders, and schizophrenia.\n9. Traumatic diseases: These are diseases caused by physical",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification system was developed by Dr. Johannes Koos in the early 20th century.\n2. The Koos Classification is used to classify diseases based on their etiology, or cause.\n3. Infectious diseases are classified in the Koos Classification system and include tuberculosis, pneumonia, and malaria.\n4. Autoimmune diseases are classified in the Koos Classification system and include rheumatoid arthritis, lupus, and multiple sclerosis.\n5. Genetic diseases are classified in the Koos Classification system and include sickle cell anemia, cystic fibrosis, and Huntington's disease.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification system was developed by Dr. Johannes Koos in the early 20th century.",
      "The Koos Classification is used to classify diseases based on their etiology, or cause.",
      "Infectious diseases are classified in the Koos Classification system and include tuberculosis, pneumonia, and malaria.",
      "Autoimmune diseases are classified in the Koos Classification system and include rheumatoid arthritis, lupus, and multiple sclerosis.",
      "Genetic diseases are classified in the Koos Classification system and include sickle cell anemia, cystic fibrosis, and Huntington's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The Koos Classification system is not a well-known or widely recognized classification system for diseases. Therefore, without specific context or additional information, it's not possible to determine the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme protease, specifically a cysteine protease called cathepsin L. It is used as a research tool to study the role of cathepsin L in various biological processes, including cancer and inflammation. In vivo, AZD8601 has been shown to have a range of effects, including:\n1. Inhibition of tumor growth: AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer, both in vitro and in vivo. It does this by blocking the activity of cathepsin L, which is overexpressed in many types of cancer.\n2. Reduction of inflammation: Cathepsin L is also involved in the inflammatory response, and AZD8601 has been shown to reduce inflammation in various models of disease, including arthritis and colitis.\n3. Modulation of the immune response: AZD8601 has been shown to modulate the immune response, both in vitro and in vivo. It can suppress the activation of immune cells, such as T cells and macrophages, and also enhance the activity of other immune cells, such as natural killer cells.\n4. Anti-parasitic activity: AZD8601 has been shown to have anti-parasitic activity against certain parasites, including the malaria parasite Plasmodium falciparum.\n5. Neuroprotection: AZD8601 has been shown to have neuroprotective effects in various models of neurodegenerative disease, including Alzheimer's disease and Parkinson's disease.\n6. Cardiovascular protection: AZD8601 has been shown to have cardiovascular protective effects in various models of cardiovascular disease, including hypertension and atherosclerosis.\n7. Anti-viral activity: AZD8601 has been shown to have anti-viral activity against certain viruses, including HIV and hepatitis B virus.\n8. Anti-angiogenic activity:",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is a small molecule inhibitor of the enzyme protease, specifically cathepsin L.\n2. AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer.\n3. AZD8601 has been shown to reduce inflammation in models of disease, such as arthritis and colitis.\n4. AZD8601 has demonstrated anti-parasitic activity against the malaria parasite Plasmodium falciparum.\n5. AZD8601 has shown neuroprotective effects in models of neurodegenerative disease, including Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is a small molecule inhibitor of the enzyme protease, specifically cathepsin L.",
      "AZD8601 has been shown to inhibit the growth of various types of tumors, including breast, lung, and colon cancer.",
      "AZD8601 has been shown to reduce inflammation in models of disease, such as arthritis and colitis.",
      "AZD8601 has demonstrated anti-parasitic activity against the malaria parasite Plasmodium falciparum.",
      "AZD8601 has shown neuroprotective effects in models of neurodegenerative disease, including Alzheimer's disease and Parkinson's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not a small molecule inhibitor, it is an experimental drug that delivers a specific form of modified messenger RNA (mRNA) encoding for the protein VEGF-A.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFS, or Super-Advanced High-Energy Physics Facilities, are cutting-edge research facilities that are designed to study some of the most fundamental and complex phenomena in the universe. These facilities are created through a combination of advanced engineering, technological innovation, and international collaboration. Here is a detailed answer to your question:\n1. Advanced Engineering: SAHFS are built with state-of-the-art engineering techniques and materials, including superconducting magnets, advanced particle accelerators, and sophisticated detectors. These components are designed to work together seamlessly to create a highly efficient and precise research environment.\n2. Technological Innovation: SAHFS are at the forefront of technological innovation in the field of high-energy physics. They are equipped with the latest detectors, data acquisition systems, and computational tools, which enable researchers to collect and analyze vast amounts of data in real-time.\n3. International Collaboration: SAHFS are often built as collaborative projects involving multiple countries and research institutions. This collaboration allows for the sharing of resources, expertise, and data, which helps to accelerate the pace of discovery and advance our understanding of the universe.\n4. Design and Planning: The design and planning of SAHFS are highly complex and involve a range of experts, including physicists, engineers, and architects. These facilities are designed to be highly efficient, with a focus on minimizing background noise and maximizing the sensitivity of the detectors.\n5. Construction and Assembly: The construction and assembly of SAHFS involve the use of advanced materials and technologies, including superconducting materials, advanced particle accelerators, and sophisticated detectors. These components are designed to work together seamlessly to create a highly efficient and precise research environment.\n6. Commissioning and Testing: Once the SAHFS is built, it undergoes a rigorous commissioning and testing process to ensure that it is functioning correctly and at its full potential. This process involves a range of tests, including beam tests, detector tests, and data analysis.\n7. Operations and Maintenance: Once the SAHFS is fully operational, it requires ongoing maintenance and upkeep to ensure that it continues to function at its best. This involves a range of activities, including routine maintenance, repairs, and up",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS are created with advanced engineering techniques and materials, including superconducting magnets and particle accelerators.\n2. They incorporate technological innovations such as the latest detectors and data acquisition systems.\n3. The development of SAHFS often involves international collaboration between multiple countries and research institutions.\n4. The design of SAHFS requires input from experts such as physicists, engineers, and architects.\n5. SAHFS construction and assembly use advanced materials and technologies, including superconducting materials and sophisticated detectors.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS are created with advanced engineering techniques and materials, including superconducting magnets and particle accelerators.",
      "They incorporate technological innovations such as the latest detectors and data acquisition systems.",
      "The development of SAHFS often involves international collaboration between multiple countries and research institutions.",
      "The design of SAHFS requires input from experts such as physicists, engineers, and architects.",
      "SAHFS construction and assembly use advanced materials and technologies, including superconducting materials and sophisticated detectors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ domain is a protein domain that is found in many proteins, including the SATB1 transcription factor. The PDZ domain is a small protein module that is involved in protein-protein interactions and plays a crucial role in regulating various cellular processes, including cell signaling, adhesion, and gene expression.\nIn the case of SATB1, the PDZ domain is located at the C-terminal end of the protein and is responsible for binding to specific phosphorylated serine/threonine residues on target proteins. These interactions are important for the regulation of SATB1's transcriptional activity and its ability to modulate gene expression.\nThe PDZ domain of SATB1 has been shown to interact with a variety of proteins, including the tumor suppressor protein p53, the transcription factor c-Myc, and the DNA damage response protein 53BP1. These interactions are thought to play a role in regulating SATB1's activity and function in response to various cellular signals and stressors.\nIn addition to its role in protein-protein interactions, the PDZ domain of SATB1 has also been implicated in the regulation of SATB1's subcellular localization. For example, the PDZ domain has been shown to mediate the transport of SATB1 from the nucleus to the cytoplasm in response to certain signals, such as DNA damage.\nOverall, the PDZ domain of SATB1 plays a critical role in regulating the activity and function of this transcription factor, and its dysregulation has been implicated in a variety of diseases, including cancer and neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a protein module involved in protein-protein interactions and regulates various cellular processes.\n2. The PDZ domain in SATB1 is located at the C-terminal end of the protein.\n3. The PDZ domain in SATB1 is responsible for binding to specific phosphorylated serine/threonine residues on target proteins.\n4. The PDZ domain of SATB1 has shown interactions with proteins like p53, c-Myc, and 53BP1.\n5. The PDZ domain of SATB1 has been implicated in regulating its subcellular localization, including transport from the nucleus to the cytoplasm.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a protein module involved in protein-protein interactions and regulates various cellular processes.",
      "The PDZ domain in SATB1 is located at the C-terminal end of the protein.",
      "The PDZ domain in SATB1 is responsible for binding to specific phosphorylated serine/threonine residues on target proteins.",
      "The PDZ domain of SATB1 has shown interactions with proteins like p53, c-Myc, and 53BP1.",
      "The PDZ domain of SATB1 has been implicated in regulating its subcellular localization, including transport from the nucleus to the cytoplasm."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The PDZ domain generally binds to specific C-terminal peptides on target proteins, not necessarily phosphorylated serine/threonine residues.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS technique is a systematic approach to managing pain that was developed by Dr. John E. Sarno in the 1970s. BLISS stands for:\nB - Breathing: The BLISS technique emphasizes the importance of proper breathing techniques in managing pain. Dr. Sarno believed that improper breathing can lead to muscle tension and pain, and that by learning to breathe more efficiently, individuals can reduce their pain.\nL - Location: The BLISS technique encourages individuals to focus on the location of their pain, rather than the intensity. By paying attention to the location of the pain, individuals can gain insight into the underlying causes of their pain and develop strategies for managing it.\nI - Imagery: The BLISS technique involves using mental imagery to help individuals visualize and understand the underlying causes of their pain. By imagining the pain in a specific location, individuals can gain insight into the physical and emotional factors that may be contributing to their pain.\nS - Sensations: The BLISS technique encourages individuals to pay attention to the physical sensations associated with their pain, such as temperature, texture, and pressure. By paying attention to these sensations, individuals can gain a better understanding of the underlying causes of their pain and develop strategies for managing it.\nS - Suggestions: The BLISS technique involves making suggestions to the body to help it heal itself. Dr. Sarno believed that the body has an innate ability to heal itself, and that by making suggestions to the body, individuals can help it to heal more efficiently.\nThe BLISS technique is based on the idea that pain is often caused by psychological and emotional factors, rather than purely physical ones. By using the BLISS technique, individuals can gain insight into the underlying causes of their pain and develop strategies for managing it that are tailored to their specific needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique was developed by Dr. John E. Sarno in the 1970s.\n2. BLISS stands for Breathing, Location, Imagery, Sensations, and Suggestions.\n3. The technique emphasizes proper breathing to manage pain.\n4. The BLISS technique encourages focusing on the location of pain rather than its intensity.\n5. Dr. Sarno believed that pain is often caused by psychological and emotional factors.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique was developed by Dr. John E. Sarno in the 1970s.",
      "BLISS stands for Breathing, Location, Imagery, Sensations, and Suggestions.",
      "The technique emphasizes proper breathing to manage pain.",
      "The BLISS technique encourages focusing on the location of pain rather than its intensity.",
      "Dr. Sarno believed that pain is often caused by psychological and emotional factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The BLISS technique was not developed by Dr. John E. Sarno; he developed the Tension Myositis Syndrome (TMS) concept.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with information on NK3R antagonists. NK3R (Nuclear Krüppel-like factor 3-associated receptor) is a G protein-coupled receptor that plays a crucial role in regulating various physiological processes, including appetite, metabolism, and inflammation. Here are three NK3R antagonists:\n1. A-966472: A-966472 is a potent and selective NK3R antagonist that has been shown to reduce food intake and body weight in animal models of obesity. It works by blocking the action of NK3R on the vagus nerve, which is involved in the regulation of appetite and metabolism. A-966472 has been shown to have potential as a therapeutic agent for the treatment of obesity and related metabolic disorders.\n2. BMS-911894: BMS-911894 is another NK3R antagonist that has been shown to reduce body weight in animal models of obesity. It works by blocking the action of NK3R on the vagus nerve, which leads to decreased food intake and increased energy expenditure. BMS-911894 has been shown to have potential as a therapeutic agent for the treatment of obesity and related metabolic disorders.\n3. LX27610: LX27610 is a potent and selective NK3R antagonist that has been shown to reduce body weight in animal models of obesity. It works by blocking the action of NK3R on the vagus nerve, which leads to decreased food intake and increased energy expenditure. LX27610 has been shown to have potential as a therapeutic agent for the treatment of obesity and related metabolic disorders.\nIt's important to note that while these NK3R antagonists have shown promise in animal models, further research is needed to determine their safety and efficacy in humans. Additionally, it's important to consult with a healthcare professional before using any medication for weight loss or metabolic",
    "llama-2-7b-chat-hf_fact_raw": "1. A-966472 is a selective NK3R antagonist that has been tested in animal models of obesity.\n2. BMS-911894 is an NK3R antagonist that reduces body weight in animal models.\n3. LX27610 is a selective NK3R antagonist shown to decrease body weight in animal studies.",
    "llama-2-7b-chat-hf_fact": [
      "A-966472 is a selective NK3R antagonist that has been tested in animal models of obesity.",
      "BMS-911894 is an NK3R antagonist that reduces body weight in animal models.",
      "LX27610 is a selective NK3R antagonist shown to decrease body weight in animal studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is called BMS-986177.\nGhrelin is a hormone that plays a key role in regulating appetite and metabolism. The ghrelin receptor is a G protein-coupled receptor that is activated by ghrelin and is involved in the regulation of food intake and energy homeostasis. Inverse agonists of the ghrelin receptor are drugs that bind to the receptor and inhibit its activity, leading to decreased appetite and weight loss.\nBMS-986177 is an oral, selective inverse agonist of the ghrelin receptor that was developed by Bristol-Myers Squibb. It was first studied in healthy subjects in a Phase I clinical trial in 2009, and has since been evaluated in several Phase II and Phase III clinical trials for the treatment of obesity and related conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).\nIn healthy subjects, BMS-986177 has been shown to decrease ghrelin levels and reduce hunger and appetite, leading to weight loss. It has also been shown to improve insulin sensitivity and reduce inflammation in the body. However, it is important to note that BMS-986177 is still a relatively new drug and more research is needed to fully understand its safety and efficacy profile in humans.\nIt is worth noting that there are other oral ghrelin receptor inverse agonists in development, including compounds such as LX197489 and LX213264, which are being developed by companies such as Ligand Pharmaceuticals and Lilly. However, BMS-986177 is the most advanced and well-studied of these drugs to date.",
    "llama-2-7b-chat-hf_fact_raw": "1. BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. Ghrelin is a hormone that regulates appetite and metabolism.\n3. The ghrelin receptor is a G protein-coupled receptor involved in food intake and energy homeostasis regulation.\n4. BMS-986177 was developed by Bristol-Myers Squibb.\n5. BMS-986177 was first studied in a Phase I clinical trial in 2009.",
    "llama-2-7b-chat-hf_fact": [
      "BMS-986177 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "Ghrelin is a hormone that regulates appetite and metabolism.",
      "The ghrelin receptor is a G protein-coupled receptor involved in food intake and energy homeostasis regulation.",
      "BMS-986177 was developed by Bristol-Myers Squibb.",
      "BMS-986177 was first studied in a Phase I clinical trial in 2009."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora is a cholera vaccine that has been shown to be highly effective in preventing moderate to severe cholera in various clinical trials. The protective efficacy of Vaxchora against moderate to severe cholera has been demonstrated in several studies, including:\n1. A phase 3 clinical trial published in The Lancet in 2016, which found that Vaxchora provided 80% protection against moderate to severe cholera in individuals who received a single dose of the vaccine.\n2. A phase 2 clinical trial published in Clinical Infectious Diseases in 2014, which found that Vaxchora provided 60% protection against moderate to severe cholera in individuals who received a single dose of the vaccine.\n3. A systematic review and meta-analysis published in Vaccine in 2018, which pooled data from multiple clinical trials and found that Vaxchora provided an overall protective efficacy of 71% against moderate to severe cholera.\nIt is important to note that the protective efficacy of Vaxchora may vary depending on several factors, including the individual's age, health status, and the severity of the cholera outbreak. Additionally, Vaxchora is not 100% effective, and it is still possible to contract cholera even after receiving the vaccine. Therefore, it is important to continue practicing good hygiene and sanitation practices, such as frequent handwashing and proper food handling, to reduce the risk of cholera infection.\nIn summary, the protective efficacy of Vaxchora against moderate to severe cholera has been shown to be high in clinical trials, with an overall efficacy of around 71%. However, it is important to continue practicing good hygiene and sanitation practices to reduce the risk of cholera infection, even after receiving the vaccine.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a cholera vaccine.\n2. A phase 3 clinical trial published in The Lancet in 2016 found Vaxchora to provide 80% protection against moderate to severe cholera.\n3. A phase 2 clinical trial published in Clinical Infectious Diseases in 2014 found Vaxchora to provide 60% protection against moderate to severe cholera.\n4. A systematic review and meta-analysis published in Vaccine in 2018 found Vaxchora to have an overall protective efficacy of 71% against moderate to severe cholera.\n5. Vaxchora is not 100% effective in preventing cholera.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a cholera vaccine.",
      "A phase 3 clinical trial published in The Lancet in 2016 found Vaxchora to provide 80% protection against moderate to severe cholera.",
      "A phase 2 clinical trial published in Clinical Infectious Diseases in 2014 found Vaxchora to provide 60% protection against moderate to severe cholera.",
      "A systematic review and meta-analysis published in Vaccine in 2018 found Vaxchora to have an overall protective efficacy of 71% against moderate to severe cholera.",
      "Vaxchora is not 100% effective in preventing cholera."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The phase 2 clinical trial published in Clinical Infectious Diseases in 2014 found Vaxchora to provide 90% protection against moderate to severe cholera for up to 6 months post-vaccination.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the Shanchol vaccine, which was approved by the Food and Drug Administration (FDA) in 2007. Shanchol is a live, oral cholera vaccine that is given in a series of two doses, spaced one month apart. It is manufactured by the pharmaceutical company Dynavax Technologies and is designed to provide protection against cholera caused by the Vibrio cholerae bacteria.\nThe development of the Shanchol vaccine was a significant milestone in the history of cholera vaccine development, as it was the first vaccine to be approved for use in the US since the 19th century. Prior to the approval of Shanchol, the only cholera vaccine available in the US was a killed-virus vaccine that was developed in the 1980s and was not widely used due to its limited effectiveness.\nThe Shanchol vaccine was developed using a novel approach that involves using a weakened form of the cholera bacteria to stimulate an immune response in the body. This approach allows the vaccine to provide long-lasting protection against cholera without causing the severe diarrhea and vomiting that can occur with the natural infection.\nSince its approval, the Shanchol vaccine has been used to protect individuals traveling to areas where cholera is common, as well as for use in emergency situations where cholera is a significant public health threat. While the Shanchol vaccine is not 100% effective, it has been shown to provide significant protection against cholera and has the potential to save lives in areas where the disease is prevalent.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was the Shanchol vaccine.\n2. The Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 2007.\n3. Shanchol is manufactured by Dynavax Technologies.\n4. Shanchol is designed to provide protection against cholera caused by the Vibrio cholerae bacteria.\n5. The Shanchol vaccine uses a weakened form of the cholera bacteria to stimulate an immune response.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was the Shanchol vaccine.",
      "The Shanchol vaccine was approved by the Food and Drug Administration (FDA) in 2007.",
      "Shanchol is manufactured by Dynavax Technologies.",
      "Shanchol is designed to provide protection against cholera caused by the Vibrio cholerae bacteria.",
      "The Shanchol vaccine uses a weakened form of the cholera bacteria to stimulate an immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was Vaxchora, not Shanchol.\n2. FALSE [correction]: Vaxchora, the first cholera vaccine approved in the US, was approved by the FDA in 2016, not 2007.\n3. UNKNOWN\n4. TRUE\n5. FALSE [correction]: Shanchol is an inactivated (killed) vaccine, not a weakened form of the cholera bacteria.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system's ability to function properly, leading to recurrent infections and other immune-related problems. Monogenic causes of CVID refer to genetic mutations that occur in a single gene and are responsible for the development of the disorder.\nAmong Europeans, the most common monogenic cause of CVID is mutations in the CD40 ligand gene (CD40LG). The CD40LG gene provides instructions for making a protein called CD40 ligand, which is involved in the activation and differentiation of immune cells, particularly B cells. Mutations in the CD40LG gene can lead to a deficiency in CD40 ligand production, which can result in impaired B cell activation and function, ultimately leading to the immune deficiency characteristic of CVID.\nStudies have shown that CD40LG mutations are present in approximately 70-80% of CVID patients of European descent. These mutations can be identified through genetic testing, which can help diagnose CVID and determine the underlying genetic cause of the disorder.\nOther genetic causes of CVID in Europeans include mutations in the genes encoding the proteins CD19, CD20, and CD21, which are also involved in B cell development and function. However, CD40LG mutations are the most common and most well-established genetic cause of CVID in this population.\nIt is important to note that CVID can also be caused by a combination of genetic and environmental factors, and the exact genetic cause may not always be identified in every case. A comprehensive diagnostic evaluation, including genetic testing, is necessary to determine the underlying cause of CVID in any individual.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system.\n2. Monogenic causes of CVID are genetic mutations that occur in a single gene.\n3. The most common monogenic cause of CVID among Europeans is mutations in the CD40 ligand gene (CD40LG).\n4. CD40LG mutations are present in approximately 70-80% of CVID patients of European descent.\n5. Genetic testing can identify CD40LG mutations and help diagnose CVID.",
    "llama-2-7b-chat-hf_fact": [
      "Common variable immunodeficiency (CVID) is a primary immunodeficiency disorder that affects the immune system.",
      "Monogenic causes of CVID are genetic mutations that occur in a single gene.",
      "The most common monogenic cause of CVID among Europeans is mutations in the CD40 ligand gene (CD40LG).",
      "CD40LG mutations are present in approximately 70-80% of CVID patients of European descent.",
      "Genetic testing can identify CD40LG mutations and help diagnose CVID."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The most common monogenic cause of CVID among Europeans is mutations in the TNFRSF13B gene (also known as TACI).\n4. FALSE [correction]: CD40LG mutations are not present in 70-80% of CVID patients of European descent; they are actually rare.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene is a critical player in the development and progression of Systemic Lupus Erythematosus (SLE), a complex and multifactorial autoimmune disease. Here's a detailed explanation of the role of the IFIT1 gene in SLE:\n1. Autoantigen presentation: The IFIT1 gene encodes a protein called IFIT1, which is involved in the presentation of self-antigens to T cells. In SLE, the IFIT1 gene is mutated, leading to the production of aberrant self-antigens that can trigger an autoimmune response.\n2. T cell activation and differentiation: IFIT1 plays a crucial role in the activation and differentiation of T cells, particularly in the context of SLE. Mutations in the IFIT1 gene can lead to the overactivation of T cells, which can contribute to the development of autoimmune responses.\n3. Cytokine production: IFIT1 also regulates the production of cytokines, such as interleukin-17 (IL-17), which are involved in the inflammatory response. In SLE, the IFIT1 gene is mutated, leading to an imbalance in cytokine production, which can exacerbate autoimmune responses.\n4. Nuclear factor kappa B (NF-κB) signaling: IFIT1 interacts with NF-κB, a transcription factor that regulates the expression of genes involved in inflammation. In SLE, the IFIT1 gene is mutated, leading to dysregulation of NF-κB signaling, which can contribute to the development of autoimmune responses.\n5. Epigenetic regulation: IFIT1 can also regulate the epigenetic landscape of genes involved in autoimmune responses. In SLE, the IFIT1 gene is mutated, leading to changes in the epigenetic marks on target genes, which can contribute to the development of autoimmune responses.\n6. T cell receptor (TCR) signaling: IFIT1 is involved in the regulation of TCR signaling, which is critical for the activation and differentiation of T cells. In SLE, the IFIT1 gene is mutated, leading to dysregulation of TCR signaling, which can",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene encodes a protein involved in presenting self-antigens to T cells.\n2. Mutations in the IFIT1 gene can lead to the production of aberrant self-antigens in SLE.\n3. IFIT1 plays a role in the activation and differentiation of T cells in the context of SLE.\n4. The IFIT1 gene regulates the production of cytokines like interleukin-17 involved in inflammation.\n5. Mutations in the IFIT1 gene can result in dysregulation of NF-κB signaling in SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene encodes a protein involved in presenting self-antigens to T cells.",
      "Mutations in the IFIT1 gene can lead to the production of aberrant self-antigens in SLE.",
      "IFIT1 plays a role in the activation and differentiation of T cells in the context of SLE.",
      "The IFIT1 gene regulates the production of cytokines like interleukin-17 involved in inflammation.",
      "Mutations in the IFIT1 gene can result in dysregulation of NF-κB signaling in SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The IFIT1 gene encodes a protein involved in the innate immune response to viral infection, not in presenting self-antigens to T cells.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a clinical assessment tool used to evaluate the severity of elbow pain and disability in patients. It is a simple and quick method that assesses the patient's symptoms, functional ability, and quality of life related to elbow pain. The score is used to help clinicians identify the most appropriate treatment options for their patients.\nThe LES consists of 10 items that are rated on a 5-point Likert scale, with a maximum score of 50. The items include:\n1. Pain on flexion (bending) of the elbow\n2. Pain on extension (straightening) of the elbow\n3. Stiffness of the elbow\n4. Limited range of motion in flexion or extension\n5. Decreased grip strength\n6. Difficulty with activities of daily living (ADLs) such as dressing, grooming, and feeding\n7. Difficulty with instrumental activities of daily living (IADLs) such as cooking, cleaning, and managing finances\n8. Impact on social and recreational activities\n9. Impact on work or school\n10. Overall quality of life\nEach item is given a score of 0-4, with higher scores indicating greater severity of symptoms. The total score ranges from 0 to 50, with higher scores indicating greater severity of elbow pain and disability.\nThe LES has been found to have good reliability and validity in various studies, and it has been used in different clinical settings, including primary care, orthopedic clinics, and rehabilitation centers. It is a useful tool for clinicians to assess the severity of elbow pain and disability in their patients, and to monitor changes in symptoms over time.\nIn addition, the LES has been found to be associated with other clinical and radiological findings, such as osteoarthritis, ligament sprains, and fractures. This information can help clinicians to identify the underlying cause of elbow pain and to develop an appropriate treatment plan.\nOverall, the Liverpool Elbow Score is a simple and useful tool for clinicians to assess and manage elbow pain and disability in their patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow pain and disability in patients.\n2. The LES consists of 10 items that are rated on a 5-point Likert scale.\n3. A maximum score of 50 on the LES indicates greater severity of elbow pain and disability.\n4. The LES has been found to have good reliability and validity in various studies.\n5. The LES is associated with clinical and radiological findings such as osteoarthritis, ligament sprains, and fractures.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate the severity of elbow pain and disability in patients.",
      "The LES consists of 10 items that are rated on a 5-point Likert scale.",
      "A maximum score of 50 on the LES indicates greater severity of elbow pain and disability.",
      "The LES has been found to have good reliability and validity in various studies.",
      "The LES is associated with clinical and radiological findings such as osteoarthritis, ligament sprains, and fractures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project is a large-scale genomics initiative launched in 2015 by the National Health Service (NHS) in the UK, with the goal of analyzing 100,000 genomes from NHS patients in order to improve the diagnosis and treatment of rare and common diseases. Sarcoma is one of the cancer types included in the project, and here are some details on the efforts made to understand sarcoma through the 100,000 Genomes Project:\n1. Sarcoma subtype classification: The project aims to classify sarcomas into different subtypes based on their genetic mutations. This will help clinicians to identify the most appropriate treatment for each patient. For example, the project has identified a subtype of sarcoma called \"leiomyosarcoma\" that is characterized by mutations in the KRAS gene.\n2. Identification of new therapeutic targets: The project has identified new therapeutic targets for sarcoma treatment, such as the PI3K/AKT pathway, which is commonly mutated in sarcomas. This information can be used to develop new drugs that target these mutations, improving treatment outcomes for sarcoma patients.\n3. Improved diagnosis: The project has improved the diagnosis of sarcoma by identifying specific genetic mutations that can be used to distinguish sarcoma from other types of cancer. For example, the project has identified a mutation in the TP53 gene that is specific to sarcoma, allowing for more accurate diagnosis.\n4. Development of personalized treatment plans: The project has enabled the development of personalized treatment plans for sarcoma patients based on the specific genetic mutations present in their tumors. This approach can lead to more effective and targeted treatment, improving patient outcomes.\n5. Collaboration with international researchers: The 100,000 Genomes Project has collaborated with international researchers to share data and insights on sarcoma, leading to a better understanding of the disease and improved treatment options.\n6. Identification of rare genetic mutations: The project has identified rare genetic mutations in sarcoma that may not have been previously known. This information can",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2015 by the National Health Service in the UK.\n2. The project aims to analyze 100,000 genomes from NHS patients to improve diagnosis and treatment for diseases, including sarcoma.\n3. Sarcoma has been classified into different subtypes within the project, and \"leiomyosarcoma\" is characterized by mutations in the KRAS gene.\n4. The project has identified the PI3K/AKT pathway as a new therapeutic target for sarcoma treatment.\n5. A specific mutation in the TP53 gene, identified by the project, is specific to sarcoma for improved diagnosis.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2015 by the National Health Service in the UK.",
      "The project aims to analyze 100,000 genomes from NHS patients to improve diagnosis and treatment for diseases, including sarcoma.",
      "Sarcoma has been classified into different subtypes within the project, and \"leiomyosarcoma\" is characterized by mutations in the KRAS gene.",
      "The project has identified the PI3K/AKT pathway as a new therapeutic target for sarcoma treatment.",
      "A specific mutation in the TP53 gene, identified by the project, is specific to sarcoma for improved diagnosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Protein ALEX1 is a fascinating protein that has been the subject of much research in the scientific community. While it does not contain armadillo repeats, it does have a unique structure and function that makes it an important player in various cellular processes.\nALEX1 is a transmembrane protein that is primarily localized to the endoplasmic reticulum (ER) and is involved in the regulation of calcium homeostasis in the cell. It is composed of multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal PDZ-binding domain. These domains allow ALEX1 to interact with a variety of protein partners and play a role in various cellular processes, including calcium signaling, protein transport, and cell adhesion.\nOne of the most interesting features of ALEX1 is its ability to bind to and regulate the activity of the enzyme inositol 1,4,5-trisphosphate receptor (IP3R). IP3R is a critical regulator of calcium signaling in the ER, and ALEX1 has been shown to modulate its activity by binding to its C-terminal domain. This interaction helps to regulate the release of calcium ions from the ER and is important for maintaining proper calcium homeostasis in the cell.\nIn addition to its role in calcium signaling, ALEX1 has also been implicated in the regulation of protein transport in the ER. It has been shown to interact with the protein import receptor, TRAM, and help to facilitate the transport of proteins across the ER membrane.\nWhile ALEX1 does not contain armadillo repeats, it does have a unique structure that allows it to interact with a variety of protein partners and play a role in multiple cellular processes. Its ability to regulate calcium signaling and protein transport makes it an important protein in the ER, and further research is likely to uncover additional functions and interactions for this fascinating protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 does not contain armadillo repeats.\n2. ALEX1 is a transmembrane protein primarily localized to the endoplasmic reticulum (ER).\n3. ALEX1 is involved in the regulation of calcium homeostasis in the cell.\n4. ALEX1 can bind to and regulate the activity of the enzyme inositol 1,4,5-trisphosphate receptor (IP3R).\n5. ALEX1 interacts with the protein import receptor, TRAM, to facilitate protein transport across the ER membrane.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 does not contain armadillo repeats.",
      "ALEX1 is a transmembrane protein primarily localized to the endoplasmic reticulum (ER).",
      "ALEX1 is involved in the regulation of calcium homeostasis in the cell.",
      "ALEX1 can bind to and regulate the activity of the enzyme inositol 1,4,5-trisphosphate receptor (IP3R).",
      "ALEX1 interacts with the protein import receptor, TRAM, to facilitate protein transport across the ER membrane."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without specific information about the protein ALEX1 provided in the context or access to scientific databases to verify the statements, it is impossible to determine the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Enzymes that remove histone modifications are known as histone demethylases. These enzymes are responsible for removing methyl groups from histone proteins, which can alter chromatin structure and gene expression. Here are some examples of histone demethylases:\n1. Histone demethylase (KDM4B): This enzyme is known to demethylate histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27). KDM4B is involved in the regulation of gene expression, particularly in the context of cancer.\n2. JMJD2B: JMJD2B is a histone demethylase that specifically demethylates H3K4. It is involved in the regulation of gene expression, particularly in the context of stem cells and development.\n3. KDM5B: KDM5B is a histone demethylase that demethylates H3K4, H3K27, and H3K9. It is involved in the regulation of gene expression, particularly in the context of cancer and immune cell differentiation.\n4. SETDB1: SETDB1 is a histone methyltransferase that demethylates H3K9. It is involved in the regulation of gene expression, particularly in the context of stem cells and development.\n5. Eset: Eset is a histone demethylase that demethylates H3K4. It is involved in the regulation of gene expression, particularly in the context of cancer and immune cell differentiation.\n6. KDM5A: KDM5A is a histone demethylase that demethylates H3K4, H3K27, and H3K9. It is involved in the regulation of gene expression, particularly in the context of cancer and immune cell differentiation.\n7. JMJD3: JMJD3 is a histone demethylase that demethylates H3K4. It is involved in the regulation of gene expression, particularly in the context of stem cells and development.\n8. KDM6A: KDM6A is a histone demethylase that demethylates H3K4, H",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases are enzymes that remove methyl groups from histone proteins.\n2. KDM4B demethylates histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).\n3. JMJD2B is a histone demethylase that specifically demethylates H3K4.\n4. KDM5B demethylates H3K4, H3K27, and H3K9.\n5. SETDB1 is a histone methyltransferase that demethylates H3K9.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases are enzymes that remove methyl groups from histone proteins.",
      "KDM4B demethylates histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).",
      "JMJD2B is a histone demethylase that specifically demethylates H3K4.",
      "KDM5B demethylates H3K4, H3K27, and H3K9.",
      "SETDB1 is a histone methyltransferase that demethylates H3K9."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: KDM4B demethylates histone H3 lysine 9 (H3K9) and histone H3 lysine 36 (H3K36), not H3K4 or H3K27.\n3. FALSE [correction]: JMJD2B is a histone demethylase that specifically demethylates H3K9, not H3K4.\n4. FALSE [correction]: KDM5B demethylates H3K4, not H3K27 or H3K9.\n5. FALSE [correction]: SETDB1 is a histone methyltransferase that methylates H3K9, not demethylates it.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you understand the potential risks associated with head CT scans and brain tumors.\nFirstly, it's important to understand that head CT scans are a diagnostic tool used to detect a variety of conditions, including brain tumors. While CT scans can help identify brain tumors, they are not a definitive diagnostic tool for every type of brain tumor.\nThere is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, particularly in children and young adults. A study published in the Journal of the American Medical Association found that children who underwent frequent CT scans had a higher risk of developing a brain tumor compared to those who did not receive as many CT scans. However, it's important to note that the overall risk of developing a brain tumor from a single CT scan is still relatively low.\nThe exact mechanism by which head CT scans may increase the risk of brain tumors is not fully understood, but it's thought that the radiation exposure from CT scans may play a role. Radiation exposure can damage the DNA in cells, which can lead to mutations that can increase the risk of cancer.\nHowever, it's important to keep in mind that the benefits of head CT scans in diagnosing and treating brain tumors can far outweigh the potential risks. If you have a concern about a brain tumor, a head CT scan can help your doctor identify the tumor and develop an appropriate treatment plan.\nIf you are concerned about the potential risks of head CT scans, there are several steps you can take to minimize your exposure to radiation:\n1. Discuss your concerns with your doctor: Your doctor can help you understand the potential risks and benefits of head CT scans and make recommendations based on your individual situation.\n2. Consider alternative imaging tests: Depending on the type of condition being evaluated, alternative imaging tests such as MRI or ultrasound may be available. These tests do not involve radiation exposure and may be a safer option for some patients.\n3. Optimize the CT scan protocol: Your doctor can work with the imaging team to optimize the CT scan protocol to minimize the amount of radiation exposure needed to obtain a diagnostic image.\n4. Monitor your radiation exposure: Keep track of",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans are a diagnostic tool used to detect brain tumors among other conditions.\n2. A study published in the Journal of the American Medical Association found that children who underwent frequent CT scans had a higher risk of developing a brain tumor.\n3. The overall risk of developing a brain tumor from a single CT scan is relatively low.\n4. Radiation exposure from CT scans can damage DNA in cells, potentially leading to an increased risk of cancer.\n5. Alternative imaging tests, such as MRI or ultrasound, do not involve radiation exposure and may be considered safer options for some patients.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans are a diagnostic tool used to detect brain tumors among other conditions.",
      "A study published in the Journal of the American Medical Association found that children who underwent frequent CT scans had a higher risk of developing a brain tumor.",
      "The overall risk of developing a brain tumor from a single CT scan is relatively low.",
      "Radiation exposure from CT scans can damage DNA in cells, potentially leading to an increased risk of cancer.",
      "Alternative imaging tests, such as MRI or ultrasound, do not involve radiation exposure and may be considered safer options for some patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is a transcription factor that is associated with neural pluripotency. Neural pluripotency refers to the ability of a cell to differentiate into any type of neuron in the nervous system. Otx2 is expressed in embryonic stem cells and is important for their maintenance of pluripotency, as well as their ability to differentiate into neural lineages.\nThere are several types of pluripotency, including:\n1. Embryonic pluripotency: This refers to the ability of cells in the embryo to differentiate into any cell type in the body.\n2. Induced pluripotency: This refers to the ability of adult cells to be reprogrammed to have the ability to differentiate into any cell type in the body, similar to embryonic stem cells.\n3. Neural pluripotency: This refers to the ability of cells to differentiate into any type of neuron in the nervous system.\n4. Induced neural pluripotency: This refers to the ability of adult cells to be reprogrammed to have the ability to differentiate into any type of neuron in the nervous system, similar to embryonic stem cells.\nOtx2 is specifically associated with neural pluripotency, and is expressed in cells that are committed to the neural lineage, but have not yet differentiated into a specific type of neuron. Otx2 helps to maintain the pluripotency of these cells, and is important for their ability to differentiate into the correct type of neuron in the developing nervous system.\nIn summary, Otx2 is associated with neural pluripotency, which refers to the ability of cells to differentiate into any type of neuron in the nervous system.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is a transcription factor.\n2. Otx2 is associated with neural pluripotency, which allows cells to differentiate into any type of neuron in the nervous system.\n3. Otx2 is expressed in embryonic stem cells.\n4. Otx2 is important for the maintenance of pluripotency in embryonic stem cells and for their differentiation into neural lineages.\n5. There are different types of pluripotency, including embryonic, induced, neural, and induced neural.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is a transcription factor.",
      "Otx2 is associated with neural pluripotency, which allows cells to differentiate into any type of neuron in the nervous system.",
      "Otx2 is expressed in embryonic stem cells.",
      "Otx2 is important for the maintenance of pluripotency in embryonic stem cells and for their differentiation into neural lineages.",
      "There are different types of pluripotency, including embryonic, induced, neural, and induced neural."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The murine beta globin locus region, also known as the beta-globin gene cluster, spans approximately 110 kilobases (kb) on chromosome 7 in mice. The beta globin genes are organized in a tandem array, with the beta-globin gene 1 (Bg1) located at one end and the beta-globin gene 4 (Bg4) located at the other end.\nThere are several DNaseI hypersensitive sites (DHS) located throughout the beta globin locus region. These DHS are specific regions of DNA where the enzyme DNaseI is more active and can be used as a marker to identify regions of open chromatin. The number of DHS marking the beta globin locus region can vary depending on the specific method used to identify them, but here are some estimates based on different studies:\n* Using a method called DNaseI footprinting, which involves treating cells with DNaseI and then isolating the resulting fragments, one study identified 17 DHS in the beta globin locus region (Kim et al., 2010).\n* Using a method called Assay for Transposase-Accessible Chromatin (ATAC-seq), which involves using the enzyme Tn5 transposase to fragment chromatin and then sequencing the resulting fragments, another study identified 31 DHS in the beta globin locus region (Zhang et al., 2015).\n* Using a method called DNase-seq, which involves treating cells with DNaseI and then sequencing the resulting fragments, a third study identified 24 DHS in the beta globin locus region (Liao et al., 2017).\nIt's worth noting that the number of DHS identified in each study may vary due to differences in the methods used and the specific cell types and conditions studied. However, these studies suggest that there are at least 17-31 DHS marking the beta globin locus region in mice.\nReferences:\nKim, J., Lee, J., Kim, J., & Kim, S. (2010). Identification of DNase I hypersensitive sites in the mouse beta-globin locus using",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta globin locus region spans approximately 110 kilobases on chromosome 7 in mice.\n2. The beta globin locus region in mice has been identified to have 17 DHS according to a study using DNaseI footprinting (Kim et al., 2010).\n3. A study using ATAC-seq identified 31 DHS in the murine beta globin locus region (Zhang et al., 2015).\n4. DNase-seq method revealed 24 DHS in the murine beta globin locus region (Liao et al., 2017).\n5. The number of DHS marking the beta globin locus region in mice may vary based on the method used and specific cell types and conditions studied.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta globin locus region spans approximately 110 kilobases on chromosome 7 in mice.",
      "The beta globin locus region in mice has been identified to have 17 DHS according to a study using DNaseI footprinting (Kim et al., 2010).",
      "A study using ATAC-seq identified 31 DHS in the murine beta globin locus region (Zhang et al., 2015).",
      "DNase-seq method revealed 24 DHS in the murine beta globin locus region (Liao et al., 2017).",
      "The number of DHS marking the beta globin locus region in mice may vary based on the method used and specific cell types and conditions studied."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Certainly! There are several European influenza vaccines available in the market, here are some of them:\n1. Fluad: This is a quadrivalent influenza vaccine developed by GlaxoSmithKline (GSK) specifically for adults aged 65 years and older. It contains four strains of influenza virus: two A strains and two B strains.\n2. Fluarix Tetra: This is a quadrivalent influenza vaccine developed by BioNTech for individuals aged 18 years and older. It contains four strains of influenza virus: two A strains and two B strains.\n3. Fluvirin: This is a trivalent influenza vaccine developed by Novartis for individuals aged 6 months and older. It contains three strains of influenza virus: two A strains and one B strain.\n4. Fluzone: This is a trivalent influenza vaccine developed by Sanofi Pasteur for individuals aged 6 months and older. It contains three strains of influenza virus: two A strains and one B strain.\n5. Afluria: This is a quadrivalent influenza vaccine developed by CSL Limited for individuals aged 18 years and older. It contains four strains of influenza virus: two A strains and two B strains.\n6. Focetria: This is a quadrivalent influenza vaccine developed by Novartis for individuals aged 18 years and older. It contains four strains of influenza virus: two A strains and two B strains.\n7. FluMist: This is a quadrivalent influenza vaccine developed by MedImmune for individuals aged 2-49 years. It contains four strains of influenza virus: two A strains and two B strains.\n8. Quadrivax: This is a quadrivalent influenza vaccine developed by Sanofi Pasteur for individuals aged 6 months and older. It contains four strains of influenza virus: two A strains and two B strains.\n9. Vaxigrip: This is a trivalent influenza vaccine developed by Sanofi Pasteur for individuals aged 6 months and older. It contains three strains of influen",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluad is a quadrivalent influenza vaccine developed by GlaxoSmithKline for adults aged 65 years and older.\n2. Fluarix Tetra is a quadrivalent influenza vaccine developed by BioNTech for individuals aged 18 years and older.\n3. Fluvirin is a trivalent influenza vaccine developed by Novartis for individuals aged 6 months and older.\n4. Fluzone is a trivalent influenza vaccine developed by Sanofi Pasteur for individuals aged 6 months and older.\n5. Afluria is a quadrivalent influenza vaccine developed by CSL Limited for individuals aged 18 years and older.",
    "llama-2-7b-chat-hf_fact": [
      "Fluad is a quadrivalent influenza vaccine developed by GlaxoSmithKline for adults aged 65 years and older.",
      "Fluarix Tetra is a quadrivalent influenza vaccine developed by BioNTech for individuals aged 18 years and older.",
      "Fluvirin is a trivalent influenza vaccine developed by Novartis for individuals aged 6 months and older.",
      "Fluzone is a trivalent influenza vaccine developed by Sanofi Pasteur for individuals aged 6 months and older.",
      "Afluria is a quadrivalent influenza vaccine developed by CSL Limited for individuals aged 18 years and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Fluad is a trivalent influenza vaccine developed by Seqirus for adults aged 65 years and older.\n2. FALSE [correction]: Fluarix Tetra is a quadrivalent influenza vaccine developed by GlaxoSmithKline for individuals aged 6 months and older.\n3. TRUE\n4. FALSE [correction]: Fluzone is a quadrivalent influenza vaccine developed by Sanofi Pasteur for individuals aged 6 months and older.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA.\nParamyxoviruses are a family of viruses that include several important pathogens, such as measles virus, mumps virus, and Nipah virus. The genome of these viruses is composed of several segments of negative-sense RNA, which are linearly arranged and range in size from 10 to 15 kilobases (kb) in length.\nThe negative-sense RNA genome of Paramyxoviruses is characterized by the presence of a cap at the 5' end and a poly(A) tail at the 3' end. The RNA genome is also segmented into several distinct regions, each of which encodes a different protein. These regions include the large polymerase (L) gene, the small polymerase (S) gene, the phosphoprotein (P) gene, and the nucleocapsid (N) gene.\nThe negative-sense RNA genome of Paramyxoviruses is transcribed in the opposite direction to the coding strand, meaning that the RNA polymerase reads the genome in a 3' to 5' direction. This is in contrast to positive-sense RNA viruses, which have a single, continuous RNA molecule that encodes the viral genome in a single direction.\nThe segmented, negative-sense RNA genome of Paramyxoviruses is thought to provide several advantages for the virus, including:\n1. Increased genetic flexibility: The segmented genome allows for the exchange of genetic information between different segments, which can lead to the creation of new viral strains with different properties.\n2. Improved RNA replication: The negative-sense RNA genome can be more easily replicated than positive-sense RNA, as the RNA polymerase can read the genome in both directions.\n3. Enhanced protein synthesis: The segmented genome allows for the coordinated synthesis of different viral proteins, which is important for the virus's replication and pathogenesis.\nOverall, the segmented, negative-sense RNA genome of Paramyxoviruses is a key feature of these viruses and plays",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is composed of several segments of negative-sense RNA.\n2. The segments of the Paramyxovirus genome range in size from 10 to 15 kilobases (kb) in length.\n3. The negative-sense RNA genome of Paramyxoviruses has a cap at the 5' end and a poly(A) tail at the 3' end.\n4. The regions of the Paramyxovirus genome encode different proteins such as the large polymerase (L) gene, the small polymerase (S) gene, the phosphoprotein (P) gene, and the nucleocapsid (N) gene.\n5. The RNA polymerase of Paramyxoviruses reads the genome in a 3' to 5' direction.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is composed of several segments of negative-sense RNA.",
      "The segments of the Paramyxovirus genome range in size from 10 to 15 kilobases (kb) in length.",
      "The negative-sense RNA genome of Paramyxoviruses has a cap at the 5' end and a poly(A) tail at the 3' end.",
      "The regions of the Paramyxovirus genome encode different proteins such as the large polymerase (L) gene, the small polymerase (S) gene, the phosphoprotein (P) gene, and the nucleocapsid (N) gene.",
      "The RNA polymerase of Paramyxoviruses reads the genome in a 3' to 5' direction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Paramyxovirus genome is composed of a single strand of negative-sense RNA, not several segments.\n2. FALSE [correction]: The Paramyxovirus genome is typically 15 to 19 kilobases (kb) in length, not 10 to 15 kb.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The RNA polymerase of Paramyxoviruses reads the genome in a 5' to 3' direction.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is a topical medication that is used to treat a specific type of skin condition called psoriasis. Specifically, it is approved for the treatment of plaque psoriasis, which is a chronic autoimmune skin condition characterized by red, scaly patches on the skin.\nRoflumilast cream works by reducing inflammation in the skin, which can help to slow down the growth of skin cells and improve the appearance of the skin. It is applied directly to the affected area of the skin, usually twice a day, and can be used alone or in combination with other treatments.\nWhile roflumilast cream is most commonly associated with the treatment of psoriasis, it has also been studied for its potential use in other conditions, such as atopic dermatitis (eczema) and vitiligo. However, its effectiveness for these conditions is still being researched and studied, and it is not yet approved for these uses.\nIt's important to note that roflumilast cream is a prescription medication, and it should only be used under the guidance and supervision of a healthcare professional. It's also important to follow the instructions for use carefully and to report any side effects or concerns to your healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used to treat plaque psoriasis.\n2. Plaque psoriasis is a chronic autoimmune skin condition.\n3. Roflumilast cream works by reducing inflammation in the skin.\n4. Roflumilast cream is usually applied twice a day.\n5. It is a prescription medication that should be used under the guidance of a healthcare professional.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used to treat plaque psoriasis.",
      "Plaque psoriasis is a chronic autoimmune skin condition.",
      "Roflumilast cream works by reducing inflammation in the skin.",
      "Roflumilast cream is usually applied twice a day.",
      "It is a prescription medication that should be used under the guidance of a healthcare professional."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Roflumilast cream is usually applied once a day.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "There are several tools that have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the most popular tools in this field:\n1. CpG Island Finder: This tool identifies regions of the genome that are enriched in cytosine methylation, which is a common feature of ncRNA promoters. It can be used to identify potential ncRNA promoters in a given genome.\n2. PyroMark: This tool uses methylation-specific PCR (MSP) to detect and quantify 5-methylcytosine (5-mC), which is a hallmark of ncRNA promoters. It can be used to identify and quantify 5-mC levels in a given sample.\n3. MethylC-DNase: This tool uses the enzyme MethylC-DNase to digest 5-methylcytosine (5-mC) in a given DNA sample. The resulting fragments can then be analyzed using PCR or sequencing to identify ncRNA promoters.\n4. EpiNorm: This tool uses a combination of computational methods and experimental validation to identify ncRNA promoters in a given sample. It can be used to identify both known and novel ncRNA promoters.\n5. RNAhybrid: This tool uses a combination of sequence alignment and molecular dynamics simulations to predict the secondary and tertiary structure of ncRNAs. It can be used to identify potential ncRNA promoters by predicting the binding sites for transcription factors.\n6. NCRNAmap: This tool uses a combination of computational methods and experimental validation to identify ncRNA promoters in a given sample. It can be used to identify both known and novel ncRNA promoters.\n7. DeepSeek: This tool uses a combination of RNA-seq and ChIP-seq data to identify ncRNA promoters in a given sample. It can be used to identify both known and novel ncRNA promoters.\n8. HISAT2: This tool uses a combination of RNA-seq and ChIP-seq data to identify ncRNA prom",
    "llama-2-7b-chat-hf_fact_raw": "1. CpG Island Finder is a tool that identifies regions of the genome enriched in cytosine methylation, a feature of ncRNA promoters.\n2. PyroMark detects and quantifies 5-methylcytosine, a hallmark of ncRNA promoters, using methylation-specific PCR.\n3. MethylC-DNase uses the enzyme MethylC-DNase to digest 5-methylcytosine in DNA samples, aiding in identifying ncRNA promoters.\n4. EpiNorm identifies ncRNA promoters through computational methods and experimental validation.\n5. RNAhybrid predicts the secondary and tertiary structure of ncRNAs to identify potential ncRNA promoters.",
    "llama-2-7b-chat-hf_fact": [
      "CpG Island Finder is a tool that identifies regions of the genome enriched in cytosine methylation, a feature of ncRNA promoters.",
      "PyroMark detects and quantifies 5-methylcytosine, a hallmark of ncRNA promoters, using methylation-specific PCR.",
      "MethylC-DNase uses the enzyme MethylC-DNase to digest 5-methylcytosine in DNA samples, aiding in identifying ncRNA promoters.",
      "EpiNorm identifies ncRNA promoters through computational methods and experimental validation.",
      "RNAhybrid predicts the secondary and tertiary structure of ncRNAs to identify potential ncRNA promoters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CpG Island Finder is a tool that identifies regions of the genome enriched in CpG sites, which can be a feature of DNA promoters, not specifically ncRNA promoters.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: RNAhybrid predicts the secondary structure of ncRNAs for potential interactions with other molecules, not specifically for identifying ncRNA promoters.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can provide you with some examples of genes that the SWIM tool has identified as down-regulated in glioblastoma using publicly available data. Please note that the accuracy of these results may vary depending on the quality and quantity of the data used, and that SWIM is a computational tool that can only provide predictions based on the data it has been trained on.\nGlioblastoma is a type of brain cancer that is aggressive and malignant, and it is the most common type of primary brain cancer. The SWIM tool is a machine learning-based approach that can identify genes that are differentially expressed between glioblastoma tumors and normal brain tissue. Here are some examples of genes that SWIM has identified as down-regulated in glioblastoma:\n1. TP53: TP53 is a tumor suppressor gene that is commonly mutated in many types of cancer, including glioblastoma. SWIM has identified TP53 as one of the most significantly down-regulated genes in glioblastoma, with a fold change of -4.3 and a p-value of 3.2e-12.\n2. CDKN2A: CDKN2A is a gene that encodes a protein involved in the regulation of the cell cycle and is a tumor suppressor. SWIM has identified CDKN2A as one of the most significantly down-regulated genes in glioblastoma, with a fold change of -3.9 and a p-value of 2.1e-11.\n3. PTEN: PTEN is a gene that encodes a protein involved in the regulation of the PI3K/AKT signaling pathway, which is commonly altered in glioblastoma. SWIM has identified PTEN as one of the most significantly down-regulated genes in glioblastoma, with a fold change of -3.7 and a p-value of 1.7e-10.\n4. STK11: STK11 is a gene that encodes a protein involved in the regulation of the cell cycle and is a tumor suppressor. SWIM has identified STK11 as one of the most significantly down-regulated genes in glioblastoma",
    "llama-2-7b-chat-hf_fact_raw": "1. Glioblastoma is the most common type of primary brain cancer.\n2. The SWIM tool identified TP53 as down-regulated in glioblastoma with a fold change of -4.3.\n3. The SWIM tool identified CDKN2A as down-regulated in glioblastoma with a fold change of -3.9.\n4. The SWIM tool identified PTEN as down-regulated in glioblastoma with a fold change of -3.7.\n5. The SWIM tool identified STK11 as down-regulated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "Glioblastoma is the most common type of primary brain cancer.",
      "The SWIM tool identified TP53 as down-regulated in glioblastoma with a fold change of -4.3.",
      "The SWIM tool identified CDKN2A as down-regulated in glioblastoma with a fold change of -3.9.",
      "The SWIM tool identified PTEN as down-regulated in glioblastoma with a fold change of -3.7.",
      "The SWIM tool identified STK11 as down-regulated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for studying Transcriptional Activation Domains (TADs). Here are some of the most popular ones:\n1. TADbit: TADbit is a package for identifying and characterizing TADs in genomic sequences. It uses a combination of machine learning algorithms and chromatin interaction data to predict TAD boundaries and identify regulatory elements within them.\n2. TADeep: TADeep is a deep learning-based package for predicting TADs and identifying their functional elements. It uses a convolutional neural network (CNN) to analyze chromatin interaction data and predict TAD boundaries.\n3. ChromHMM: ChromHMM is a package for modeling the 3D structure of chromatin and predicting TADs. It uses a hidden Markov model (HMM) to infer the probability of different chromatin structures and predict TAD boundaries.\n4. Chromatin3D: Chromatin3D is a package for analyzing the 3D structure of chromatin and predicting TADs. It uses a combination of machine learning algorithms and structural bioinformatics tools to predict TAD boundaries and identify regulatory elements within them.\n5. TADtrack: TADtrack is a package for identifying and tracking TADs in genomic sequences. It uses a combination of machine learning algorithms and chromatin interaction data to predict TAD boundaries and identify regulatory elements within them.\n6. TAD-Predictor: TAD-Predictor is a package for predicting TADs in genomic sequences. It uses a combination of machine learning algorithms and chromatin interaction data to predict TAD boundaries and identify regulatory elements within them.\n7. ChromatinGenomics: ChromatinGenomics is a package for analyzing the 3D structure of chromatin and predicting TADs. It uses a combination of machine learning algorithms and structural bioinformatics tools to predict TAD boundaries and identify regulatory elements within them.\n8. ChromatinRegulatoryGenomics: ChromatinRegulatoryGenomics is a package for analyzing the regulatory elements in TADs. It uses a combination of machine learning algorithms and chromatin interaction data to predict the regulatory elements within TADs and their functional roles.\n9. TAD-Rank:",
    "llama-2-7b-chat-hf_fact_raw": "1. TADbit is an R package that identifies and characterizes TADs using machine learning algorithms and chromatin interaction data.\n2. TADeep uses a convolutional neural network to predict TAD boundaries for studying Transcriptional Activation Domains.\n3. ChromHMM is an R package that models 3D chromatin structure and predicts TADs using a hidden Markov model.\n4. Chromatin3D analyzes 3D chromatin structure and predicts TAD boundaries using machine learning algorithms and structural bioinformatics tools.\n5. TADtrack is an R package that identifies and tracks TADs using machine learning algorithms and chromatin interaction data.",
    "llama-2-7b-chat-hf_fact": [
      "TADbit is an R package that identifies and characterizes TADs using machine learning algorithms and chromatin interaction data.",
      "TADeep uses a convolutional neural network to predict TAD boundaries for studying Transcriptional Activation Domains.",
      "ChromHMM is an R package that models 3D chromatin structure and predicts TADs using a hidden Markov model.",
      "Chromatin3D analyzes 3D chromatin structure and predicts TAD boundaries using machine learning algorithms and structural bioinformatics tools.",
      "TADtrack is an R package that identifies and tracks TADs using machine learning algorithms and chromatin interaction data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TADeep is not specifically mentioned as using a convolutional neural network or for studying Transcriptional Activation Domains.\n3. FALSE [correction]: ChromHMM is not an R package; it is a computational tool that uses hidden Markov models to identify chromatin states.\n4. TRUE\n5. FALSE [correction]: TADtrack is not specifically mentioned as an R package or as using machine learning algorithms and chromatin interaction data.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "There are several bioconductor tools that have been developed for accessing bacterial regulatory networks. Here are some of the most popular ones:\n1. CRISPR-CasTools: This is a collection of R packages for analyzing CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12a, and CRISPR-Cas13. CRISPR-CasTools provides functions for designing guide RNAs, predicting off-target effects, and analyzing CRISPR-Cas system dynamics.\n2. Bacterial Regulatory Network Analyzer (BRNA): This tool was developed to analyze bacterial regulatory networks using a combination of machine learning and graph theory. BRNA can predict gene regulation patterns, identify key regulators, and infer network structures.\n3. BactoCyc: This is a database of curated gene regulatory interactions in Escherichia coli (E. coli). BactoCyc contains a comprehensive collection of transcriptional regulatory interactions, including promoter sequences, binding sites, and regulatory interactions.\n4. RegulonDB: This is a database of gene regulation in E. coli, which includes information on transcriptional regulators, their targets, and the regulatory interactions between them. RegulonDB also provides tools for predicting regulatory interactions and analyzing gene expression data.\n5. RRNA-Pro: This tool was developed for predicting the secondary and tertiary structure of RNA molecules, including regulatory RNAs. RRNA-Pro uses a combination of molecular dynamics simulations and machine learning algorithms to predict RNA structure and function.\n6. Bacterial Gene Regulation Predictor (BGRP): This tool was developed to predict the regulation of bacterial genes using a combination of machine learning and sequence analysis. BGRP can predict the regulatory elements in a gene's promoter region and predict the expression level of that gene.\n7. Transcriptional Regulatory Network Analyzer (TRNA): This tool was developed to analyze transcriptional regulatory networks in bacteria. TRNA can predict the regulatory interactions between transcription factors and their target genes, and it can also identify key regulators in a network.\n8. Bacterial Network Anal",
    "llama-2-7b-chat-hf_fact_raw": "1. CRISPR-CasTools is a collection of R packages for analyzing CRISPR-Cas systems.\n2. Bacterial Regulatory Network Analyzer (BRNA) uses machine learning and graph theory to analyze bacterial regulatory networks.\n3. BactoCyc is a database of gene regulatory interactions in Escherichia coli.\n4. RegulonDB is a database that includes information on gene regulation in E. coli.\n5. RRNA-Pro uses molecular dynamics simulations and machine learning algorithms to predict RNA structure and function.",
    "llama-2-7b-chat-hf_fact": [
      "CRISPR-CasTools is a collection of R packages for analyzing CRISPR-Cas systems.",
      "Bacterial Regulatory Network Analyzer (BRNA) uses machine learning and graph theory to analyze bacterial regulatory networks.",
      "BactoCyc is a database of gene regulatory interactions in Escherichia coli.",
      "RegulonDB is a database that includes information on gene regulation in E. coli.",
      "RRNA-Pro uses molecular dynamics simulations and machine learning algorithms to predict RNA structure and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CRISPR-CasTools is not a collection of R packages but a genetic engineering method for genome editing.\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The shikimate pathway is a metabolic pathway that produces aromatic amino acids, chlorophyll, and other important compounds in living organisms. The end products of the shikimate pathway are:\n1. Aromatic amino acids: The shikimate pathway produces several aromatic amino acids, including phenylalanine, tyrosine, and tryptophan. These amino acids are important building blocks of proteins and play critical roles in various cellular processes.\n2. Chlorophyll: The shikimate pathway is responsible for the synthesis of chlorophyll, the green pigment that helps plants absorb light energy for photosynthesis. Chlorophyll is essential for plant growth and development.\n3. Quinates: The shikimate pathway produces quinates, which are important intermediates in the biosynthesis of various compounds, including antibiotics, anticancer agents, and vitamins.\n4. Tryptophan: The shikimate pathway is also involved in the biosynthesis of tryptophan, an amino acid that is important for the production of serotonin, a neurotransmitter involved in mood regulation and other physiological processes.\n5. Kynurenine: The shikimate pathway produces kynurenine, an amino acid that is involved in the biosynthesis of various compounds, including antibiotics and anticancer agents.\n6. Ergothioneine: The shikimate pathway produces ergothioneine, a unique amino acid that is found in high levels in certain bacteria and fungi. Ergothioneine has been shown to have antioxidant and anti-inflammatory properties.\n7. Flavonoids: The shikimate pathway is involved in the biosynthesis of flavonoids, a class of plant compounds that have been shown to have various biological activities, including antioxidant, anti-inflammatory, and anticancer properties.\n8. Carotenoids: The shikimate pathway produces carotenoids, a class of pigments that are important for plant visual appeal and play a role in protecting plants from excessive light energy.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids such as phenylalanine, tyrosine, and tryptophan.\n2. Chlorophyll, the green pigment essential for photosynthesis, is synthesized through the shikimate pathway.\n3. Quinates, used in the biosynthesis of antibiotics, anticancer agents, and vitamins, are produced by the shikimate pathway.\n4. The shikimate pathway is involved in the biosynthesis of tryptophan, which is necessary for the production of serotonin.\n5. The shikimate pathway produces kynurenine, an amino acid involved in the biosynthesis of antibiotics and anticancer agents.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids such as phenylalanine, tyrosine, and tryptophan.",
      "Chlorophyll, the green pigment essential for photosynthesis, is synthesized through the shikimate pathway.",
      "Quinates, used in the biosynthesis of antibiotics, anticancer agents, and vitamins, are produced by the shikimate pathway.",
      "The shikimate pathway is involved in the biosynthesis of tryptophan, which is necessary for the production of serotonin.",
      "The shikimate pathway produces kynurenine, an amino acid involved in the biosynthesis of antibiotics and anticancer agents."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Chlorophyll is not synthesized through the shikimate pathway, it is synthesized through a different pathway known as the porphyrin pathway.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The shikimate pathway does not produce kynurenine. Kynurenine is produced from tryptophan through a different pathway known as the kynurenine pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a rare and potentially life-threatening condition that can occur after surgical removal of a pituitary tumor.\nNelson's syndrome is characterized by the rapid growth of the remaining pituitary tissue after surgical removal of the tumor, leading to an overproduction of hormones and a range of symptoms including headache, vision problems, fatigue, and hypopituitarism (a condition in which the pituitary gland does not produce enough hormones).\nCabergoline, a dopamine receptor agonist, has been shown to be effective in reducing the symptoms of Nelson's syndrome by suppressing the excessive hormone production and reducing the size of the remaining pituitary tissue. It is typically used in combination with other medications, such as corticosteroids, to achieve the best results.\nThe use of cabergoline for the treatment of Nelson's syndrome is based on its ability to suppress the production of prolactin, a hormone that is often overproduced in this condition. Prolactin is a hormone that stimulates the growth of the pituitary gland, and high levels of prolactin can contribute to the rapid growth of the remaining pituitary tissue in Nelson's syndrome. By suppressing prolactin production, cabergoline can help to slow the growth of the pituitary gland and reduce the symptoms of the condition.\nWhile cabergoline has been shown to be effective in treating Nelson's syndrome, it is important to note that it is not a cure for the condition, and ongoing monitoring and treatment may be necessary to manage the symptoms and prevent complications. Additionally, cabergoline can have side effects, including dizziness, headache, and nausea, and patients should be closely monitored for these and other potential side effects.\nIn summary, cabergoline is sometimes used to treat Nelson's syndrome, a rare and potentially life-threatening condition that can occur after surgical removal of a pituitary tumor. It works by suppressing the production of prolactin, a hormone that is often overproduced in this condition,",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is sometimes used to treat Nelson's syndrome.\n2. Nelson's syndrome can occur after surgical removal of a pituitary tumor.\n3. Cabergoline is a dopamine receptor agonist.\n4. Cabergoline has been shown to be effective in reducing symptoms of Nelson's syndrome by suppressing excessive hormone production.\n5. Cabergoline is not a cure for Nelson's syndrome and ongoing monitoring and treatment may be necessary.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is sometimes used to treat Nelson's syndrome.",
      "Nelson's syndrome can occur after surgical removal of a pituitary tumor.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline has been shown to be effective in reducing symptoms of Nelson's syndrome by suppressing excessive hormone production.",
      "Cabergoline is not a cure for Nelson's syndrome and ongoing monitoring and treatment may be necessary."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome. \n2. TRUE\n3. TRUE\n4. FALSE [correction]: Cabergoline is not typically used to suppress hormone production in Nelson's syndrome; it is more commonly used for conditions such as prolactinomas.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome is a rare and complex neurological disorder that is characterized by a range of symptoms affecting the nervous system. The main manifestations of Liebenberg syndrome can vary in severity and frequency, but may include:\n1. Progressive weakness and wasting of muscles: One of the most common symptoms of Liebenberg syndrome is the gradual weakening and wasting of muscles, particularly in the limbs. This can make it difficult for the affected individual to perform everyday activities, such as walking, standing, or even breathing.\n2. Spasticity and rigidity: Liebenberg syndrome can cause increased muscle tone and stiffness, leading to spasticity and rigidity in the affected muscles. This can result in difficulty moving or maintaining posture, and can also lead to muscle cramps and spasms.\n3. Sensory loss and numbness: Many individuals with Liebenberg syndrome experience sensory loss or numbness in the affected limbs, which can make it difficult to feel sensations such as touch, temperature, or pain.\n4. Autonomic dysfunction: Liebenberg syndrome can also affect the autonomic nervous system, leading to problems with regulating various bodily functions, such as heart rate, blood pressure, and digestion.\n5. Cognitive impairment: Some individuals with Liebenberg syndrome may experience cognitive impairment, including difficulty with memory, attention, and problem-solving.\n6. Seizures: Liebenberg syndrome can also cause seizures, which can be a significant manifestation of the disorder.\n7. Hydrocephalus: In some cases, Liebenberg syndrome can lead to the accumulation of cerebrospinal fluid in the brain, which can cause hydrocephalus and pressure on the brain.\n8. Eye abnormalities: Liebenberg syndrome can also cause abnormalities in the eyes, including droopy eyelids, double vision, and difficulty moving the eyes.\n9. Respiratory problems: The disorder can also cause respiratory problems, such as difficulty breathing or shortness of breath.\n10. Emotional changes: Liebenberg syndrome can also lead to emotional changes, such as depression",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is a rare neurological disorder.\n2. Liebenberg syndrome's common symptoms include progressive weakness and wasting of muscles.\n3. Increased muscle tone and stiffness, leading to spasticity and rigidity, are manifestations of Liebenberg syndrome.\n4. Individuals with Liebenberg syndrome may experience sensory loss or numbness in the affected limbs.\n5. Cognitive impairment, seizures, and hydrocephalus can be manifestations of Liebenberg syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is a rare neurological disorder.",
      "Liebenberg syndrome's common symptoms include progressive weakness and wasting of muscles.",
      "Increased muscle tone and stiffness, leading to spasticity and rigidity, are manifestations of Liebenberg syndrome.",
      "Individuals with Liebenberg syndrome may experience sensory loss or numbness in the affected limbs.",
      "Cognitive impairment, seizures, and hydrocephalus can be manifestations of Liebenberg syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Liebenberg syndrome is not a well-known neurological disorder and there is limited information available. Therefore, it is difficult to determine the accuracy of these statements without further context or information.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Certainly! There are several bioavailable MPS1 kinase inhibitors that have been identified and studied for their potential therapeutic applications. Here are some examples:\n1. Ruxolitinib: Ruxolitinib is a selective inhibitor of the enzyme Janus kinase 1 (JAK1), which is involved in the signaling pathways of several cytokines, including interferons and growth factors. Ruxolitinib has been shown to inhibit the activity of MPS1 in various cell types, including hematopoietic cells and fibroblasts.\n2. Baricitinib: Baricitinib is a JAK1 inhibitor that has been approved for the treatment of rheumatoid arthritis. It has been shown to inhibit the activity of MPS1 in various cell types, including T cells and macrophages.\n3. Filgotinib: Filgotinib is a JAK1 inhibitor that is currently being investigated for the treatment of inflammatory diseases, including rheumatoid arthritis and ulcerative colitis. It has been shown to inhibit the activity of MPS1 in various cell types, including T cells and macrophages.\n4. ABX-464: ABX-464 is a highly selective JAK1 inhibitor that is currently being investigated for the treatment of various inflammatory diseases, including rheumatoid arthritis and atopic dermatitis. It has been shown to inhibit the activity of MPS1 in various cell types, including T cells and macrophages.\n5. BMS-911515: BMS-911515 is a JAK1 inhibitor that is currently being investigated for the treatment of various inflammatory diseases, including rheumatoid arthritis and ulcerative colitis. It has been shown to inhibit the activity of MPS1 in various cell types, including T cells and macrophages.\n6. Tofacitinib: Tofacitinib is a JAK1 inhibitor that is currently being investigated for the treatment of various inflammatory diseases, including rheumato",
    "llama-2-7b-chat-hf_fact_raw": "1. Ruxolitinib is a selective inhibitor of the enzyme Janus kinase 1 (JAK1) and inhibits the activity of MPS1.\n2. Baricitinib is a JAK1 inhibitor approved for the treatment of rheumatoid arthritis and inhibits MPS1 activity.\n3. Filgotinib is being investigated for the treatment of inflammatory diseases and inhibits MPS1 activity.\n4. ABX-464 is a selective JAK1 inhibitor under investigation for the treatment of inflammatory diseases and inhibits MPS1 activity.\n5. BMS-911515 is a JAK1 inhibitor under investigation for inflammatory diseases and inhibits MPS1 activity.",
    "llama-2-7b-chat-hf_fact": [
      "Ruxolitinib is a selective inhibitor of the enzyme Janus kinase 1 (JAK1) and inhibits the activity of MPS1.",
      "Baricitinib is a JAK1 inhibitor approved for the treatment of rheumatoid arthritis and inhibits MPS1 activity.",
      "Filgotinib is being investigated for the treatment of inflammatory diseases and inhibits MPS1 activity.",
      "ABX-464 is a selective JAK1 inhibitor under investigation for the treatment of inflammatory diseases and inhibits MPS1 activity.",
      "BMS-911515 is a JAK1 inhibitor under investigation for inflammatory diseases and inhibits MPS1 activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ABX-464 is not a selective JAK1 inhibitor, it is a small molecule targeting the cap-binding complex which is being investigated for inflammatory diseases.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you.\nGolimumab is a medication that is used to treat certain autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is not specifically approved for the treatment of diabetes.\nHowever, there have been some studies that have investigated the potential use of golimumab in patients with type 1 diabetes. These studies have suggested that golimumab may help to improve insulin sensitivity and reduce inflammation in the body, which could potentially improve glycemic control and reduce the risk of complications associated with type 1 diabetes.\nOne study published in the Journal of Clinical Endocrinology and Metabolism in 2018 found that treatment with golimumab for 24 weeks improved insulin sensitivity and reduced inflammation in patients with type 1 diabetes. Another study published in the journal Diabetes, Obesity and Metabolism in 2020 found that treatment with golimumab for 12 months improved glycemic control and reduced the risk of severe hypoglycemia in patients with type 1 diabetes.\nWhile these studies are promising, it's important to note that the evidence is still limited, and more research is needed to fully understand the potential benefits and risks of using golimumab to treat diabetes. Additionally, golimumab is not currently approved by the US Food and Drug Administration (FDA) for the treatment of diabetes, so it is not available for use in this indication outside of a clinical trial.\nIn summary, while there is some evidence to suggest that golimumab may have potential benefits for patients with type 1 diabetes, more research is needed to fully understand its safety and efficacy in this population. If you have diabetes and are interested in learning more about golimumab or other potential treatments, it's best to speak with your healthcare provider or a qualified medical professional.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a medication used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.\n2. Studies have investigated the use of golimumab in patients with type 1 diabetes.\n3. A study published in 2018 in the Journal of Clinical Endocrinology and Metabolism found that golimumab improved insulin sensitivity and reduced inflammation in type 1 diabetes patients.\n4. Another study published in 2020 in the journal Diabetes, Obesity and Metabolism found that golimumab improved glycemic control and reduced the risk of severe hypoglycemia in type 1 diabetes patients.\n5. Golimumab is not currently approved by the FDA for the treatment of diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a medication used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.",
      "Studies have investigated the use of golimumab in patients with type 1 diabetes.",
      "A study published in 2018 in the Journal of Clinical Endocrinology and Metabolism found that golimumab improved insulin sensitivity and reduced inflammation in type 1 diabetes patients.",
      "Another study published in 2020 in the journal Diabetes, Obesity and Metabolism found that golimumab improved glycemic control and reduced the risk of severe hypoglycemia in type 1 diabetes patients.",
      "Golimumab is not currently approved by the FDA for the treatment of diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes accelerated aging in children. While the exact cause of progeria is still not fully understood, research has shown that it is caused by a mutation in the LMNA gene, which is responsible for producing a protein called lamin A.\nThe LMNA gene is located on chromosome 1 and is one of the most highly conserved genes in the human genome. It plays a critical role in maintaining the structure and function of the nucleus in cells, particularly in the production of lamin A, which is a key component of the nuclear lamina. The nuclear lamina is a network of filaments that provides structural support to the nucleus and regulates various cellular processes, including cell division, differentiation, and apoptosis (programmed cell death).\nIn progeria, the mutation in the LMNA gene leads to the production of a truncated form of lamin A, known as progerin, which is unable to perform its normal functions. Progerin accumulates in the nucleus and disrupts the normal structure and function of the nuclear lamina, leading to the characteristic signs and symptoms of progeria, including accelerated aging, growth failure, and a distinctive facial appearance.\nProgeria is an autosomal recessive disorder, which means that a child must inherit two copies of the mutated LMNA gene, one from each parent, in order to develop the condition. The parents of a child with progeria typically carry one copy of the mutated gene and are carriers of the disorder, but they typically do not display any symptoms themselves.\nIn summary, progeria is caused by a mutation in the LMNA gene, which leads to the production of a truncated form of lamin A and disrupts the normal structure and function of the nuclear lamina. Progeria is an autosomal recessive disorder, which means that it is inherited in an inherited pattern, with the child needing to inherit two copies of the mutated gene to develop the condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is caused by a mutation in the LMNA gene.\n2. The LMNA gene is located on chromosome 1.\n3. The LMNA gene is responsible for producing a protein called lamin A.\n4. In progeria, a truncated form of lamin A, known as progerin, accumulates in the nucleus.\n5. Progeria is an autosomal recessive disorder, requiring two copies of the mutated LMNA gene to develop the condition.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is caused by a mutation in the LMNA gene.",
      "The LMNA gene is located on chromosome 1.",
      "The LMNA gene is responsible for producing a protein called lamin A.",
      "In progeria, a truncated form of lamin A, known as progerin, accumulates in the nucleus.",
      "Progeria is an autosomal recessive disorder, requiring two copies of the mutated LMNA gene to develop the condition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Progeria is an autosomal dominant disorder, requiring only one copy of the mutated LMNA gene to develop the condition.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "The chromosomal regions 12q14 and 12q24 are known to be associated with various genetic variants that have been implicated in a range of genetic disorders and complex diseases. Here are some of the common variants found at these regions and their associated conditions:\n12q14:\n* Variants in the HLA gene cluster: The HLA gene cluster on chromosome 12q14 is responsible for encoding proteins involved in the immune system. Variants in this region have been associated with an increased risk of developing certain autoimmune diseases, such as:\n\t+ Rheumatoid arthritis (RA)\n\t+ Lupus\n\t+ Multiple sclerosis (MS)\n\t+ Type 1 diabetes\n\t+ Psoriasis\n\t+ Crohn's disease\n\t+ Ulcerative colitis\n* Variants in the KCNQ2 and KCNQ3 genes: The KCNQ2 and KCNQ3 genes encode potassium channels that are important for the proper functioning of the heart. Variants in these genes have been associated with an increased risk of developing cardiac arrhythmias, such as:\n\t+ Long QT syndrome (LQTS)\n\t+ Brugada syndrome\n\t+ Catecholaminergic polymorphic ventricular tachycardia (CPVT)\n* Variants in the TCF4 gene: The TCF4 gene encodes a transcription factor that plays a crucial role in the development and maintenance of the nervous system. Variants in this gene have been associated with an increased risk of developing neurological disorders, such as:\n\t+ Neurofibromatosis type 1 (NF1)\n\t+ Neurofibromatosis type 2 (NF2)\n\t+ Brain and spinal cord tumors\n12q24:\n* Variants in the BRCA1 and BRCA2 genes: The BRCA1 and BRCA2 genes are tumor suppressor genes that play a crucial role in maintaining genomic stability. Variants in these genes have been associated with an increased risk of developing breast and ovarian cancers, as well as other cancers.",
    "llama-2-7b-chat-hf_fact_raw": "1. Variants in the HLA gene cluster on chromosome 12q14 are associated with an increased risk of autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, psoriasis, Crohn's disease, and ulcerative colitis.\n2. Variants in the KCNQ2 and KCNQ3 genes on chromosome 12q14 are associated with an increased risk of cardiac arrhythmias like Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia.\n3. Variants in the TCF4 gene on chromosome 12q14 are associated with an increased risk of neurological disorders like neurofibromatosis type 1, neurofibromatosis type 2, and brain and spinal cord tumors.\n4. Variants in the BRCA1 and BRCA2 genes on chromosome 12q24 are associated with an increased risk of developing breast and ovarian cancers, as well as other cancers.",
    "llama-2-7b-chat-hf_fact": [
      "Variants in the HLA gene cluster on chromosome 12q14 are associated with an increased risk of autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, psoriasis, Crohn's disease, and ulcerative colitis.",
      "Variants in the KCNQ2 and KCNQ3 genes on chromosome 12q14 are associated with an increased risk of cardiac arrhythmias like Long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia.",
      "Variants in the TCF4 gene on chromosome 12q14 are associated with an increased risk of neurological disorders like neurofibromatosis type 1, neurofibromatosis type 2, and brain and spinal cord tumors.",
      "Variants in the BRCA1 and BRCA2 genes on chromosome 12q24 are associated with an increased risk of developing breast and ovarian cancers, as well as other cancers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Variants in the HLA gene cluster are actually located on chromosome 6p21, not 12q14, and are associated with an increased risk of autoimmune diseases.\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Variants in the BRCA1 and BRCA2 genes are located on chromosomes 17q21 and 13q13, respectively, not 12q24, and are associated with an increased risk of developing breast and ovarian cancers, as well as other cancers.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The Roundabout (Robo) receptors are a family of transmembrane receptors that play a crucial role in regulating cellular processes such as cell migration, differentiation, and survival. There are four known members of the Roundabout receptor family: Robo1, Robo2, Robo3, and Robo4. Each of these receptors has a distinct ligand profile, which are the molecules that bind to and activate the receptors. Here are the known ligands of each Roundabout receptor:\n1. Robo1:\nRobo1 is primarily activated by the epidermal growth factor (EGF) family of ligands, including EGF, TGF-α, and amphiregulin. These ligands bind to the extracellular domain of Robo1, leading to the activation of downstream signaling pathways that regulate cell migration and differentiation.\n2. Robo2:\nRobo2 is primarily activated by the neuregulin (NRG) family of ligands, including NRG1, NRG2, and NRG3. These ligands bind to the extracellular domain of Robo2, leading to the activation of downstream signaling pathways that regulate cell migration, differentiation, and survival.\n3. Robo3:\nRobo3 is primarily activated by the Hedgehog (Hh) family of ligands, including Sonic Hh (Shh), Desert Hh (Dhh), and Indian Hh (Ihh). These ligands bind to the extracellular domain of Robo3, leading to the activation of downstream signaling pathways that regulate cell proliferation, differentiation, and tissue patterning during embryonic development.\n4. Robo4:\nRobo4 is primarily activated by the Wnt family of ligands, including Wnt1, Wnt2, Wnt3, and Wnt5. These ligands bind to the extracellular domain of Robo4, leading to the activation of downstream signaling pathways that regulate cell fate determination, cell proliferation, and tissue patterning during embryonic development.\nIn addition to these specific ligands, Robo receptors can also be activated by other molecules,",
    "llama-2-7b-chat-hf_fact_raw": "1. The Roundabout receptor family consists of Robo1, Robo2, Robo3, and Robo4.\n2. Robo1 is primarily activated by the epidermal growth factor (EGF) family of ligands, including EGF, TGF-α, and amphiregulin.\n3. Robo2 is primarily activated by the neuregulin (NRG) family of ligands, including NRG1, NRG2, and NRG3.\n4. Robo3 is primarily activated by the Hedgehog (Hh) family of ligands, including Sonic Hh (Shh), Desert Hh (Dhh), and Indian Hh (Ihh).\n5. Robo4 is primarily activated by the Wnt family of ligands, including Wnt1, Wnt2, Wnt3, and Wnt5.",
    "llama-2-7b-chat-hf_fact": [
      "The Roundabout receptor family consists of Robo1, Robo2, Robo3, and Robo4.",
      "Robo1 is primarily activated by the epidermal growth factor (EGF) family of ligands, including EGF, TGF-α, and amphiregulin.",
      "Robo2 is primarily activated by the neuregulin (NRG) family of ligands, including NRG1, NRG2, and NRG3.",
      "Robo3 is primarily activated by the Hedgehog (Hh) family of ligands, including Sonic Hh (Shh), Desert Hh (Dhh), and Indian Hh (Ihh).",
      "Robo4 is primarily activated by the Wnt family of ligands, including Wnt1, Wnt2, Wnt3, and Wnt5."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Robo1 is primarily activated by Slit ligands.\n3. FALSE [correction]: Robo2 is also primarily activated by Slit ligands. \n4. FALSE [correction]: Robo3 is also primarily activated by Slit ligands and does not interact with Hedgehog family ligands.\n5. FALSE [correction]: Robo4 is not known to be activated by the Wnt family of ligands, it is also primarily activated by Slit ligands.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "TFII-I (Transcription Factor II-I) is a general transcription factor that plays a crucial role in the regulation of gene expression, particularly in the context of hematopoiesis, the process by which blood cells are produced. While TFII-I has been shown to be involved in the regulation of various hematopoietic genes, its specific role in megakaryopoiesis, the process by which platelets are produced, is less well understood.\nMegakaryopoiesis is a complex process that involves the coordinated regulation of multiple genes and signaling pathways. Platelets are produced from a common myeloid progenitor cell, which undergoes a series of molecular and cellular changes to give rise to mature platelets. The regulation of these changes is complex and involves the interplay of multiple transcription factors, including TFII-I.\nStudies have shown that TFII-I is expressed in megakaryocytes, the cells that give rise to platelets, and plays a role in the regulation of genes involved in platelet function and signaling. For example, TFII-I has been shown to bind to the promoter region of the platelet-derived growth factor receptor alpha (PDGFRα) gene, leading to its activation and the production of platelet-derived growth factor (PDGF), which is involved in platelet activation and aggregation.\nAdditionally, TFII-I has been shown to regulate the expression of genes involved in platelet membrane protein synthesis, such as the glycoprotein Ib (GPIb) gene, which is critical for platelet adhesion and aggregation. TFII-I has also been shown to regulate the expression of genes involved in platelet signaling pathways, such as the protein kinase C beta (PKCβ) gene, which is involved in platelet activation and signaling.\nWhile the exact role of TFII-I in megakaryopoiesis is still being elucidated, it is clear that it plays a significant role in the regulation of genes involved in platelet function and signaling. Further research is needed to fully understand the mechanisms by which TFII-I regulates megakaryopoiesis and platelet function.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I is a general transcription factor involved in the regulation of gene expression.\n2. TFII-I plays a role in hematopoiesis, the process by which blood cells are produced.\n3. TFII-I has been shown to bind to the promoter region of the PDGFRα gene.\n4. TFII-I regulates the expression of the GPIb gene, critical for platelet adhesion and aggregation.\n5. TFII-I regulates the expression of the PKCβ gene, involved in platelet activation and signaling.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I is a general transcription factor involved in the regulation of gene expression.",
      "TFII-I plays a role in hematopoiesis, the process by which blood cells are produced.",
      "TFII-I has been shown to bind to the promoter region of the PDGFRα gene.",
      "TFII-I regulates the expression of the GPIb gene, critical for platelet adhesion and aggregation.",
      "TFII-I regulates the expression of the PKCβ gene, involved in platelet activation and signaling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\nAtenolol, which is the generic name for the brand name drug Tenormin, is a beta-blocker that is used to treat high blood pressure, angina, and heart failure. It is metabolized by several enzymes in the liver, including CYP2D6, CYP3A4, and CYP2C9.\nCYP2D6 is one of the most important enzymes involved in the metabolism of atenolol. This enzyme is responsible for converting atenolol into its active metabolite, which is called beta-hydroxyatenolol. The activity of CYP2D6 can vary greatly among individuals, as some people have a more active form of the enzyme, while others have a less active form.\nApproximately 20-30% of the population is poor metabolizers of CYP2D6, meaning that they have a reduced ability to metabolize drugs that are metabolized by this enzyme. For atenolol, this means that the drug may be more effective and stay in the body longer in these individuals.\nOn the other hand, individuals who are extensive metabolizers of CYP2D6 may metabolize atenolol more quickly and may require lower doses of the drug to achieve the desired effects.\nIt's important to note that the metabolism of atenolol can also be influenced by other factors, such as liver function, kidney function, and the use of other medications that may inhibit or induce the activity of CYP2D6.\nIn summary, atenolol is metabolized by CYP2D6, and the activity of this enzyme can vary greatly among individuals. The metabolism of atenolol can also be influenced by other factors, and it's important to be aware of these factors when taking this medication.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. Atenolol is used to treat high blood pressure, angina, and heart failure.\n3. The liver enzymes CYP2D6, CYP3A4, and CYP2C9 are involved in the metabolism of atenolol.\n4. The active metabolite of atenolol is called beta-hydroxyatenolol.\n5. Approximately 20-30% of the population are poor metabolizers of CYP2D6.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "Atenolol is used to treat high blood pressure, angina, and heart failure.",
      "The liver enzymes CYP2D6, CYP3A4, and CYP2C9 are involved in the metabolism of atenolol.",
      "The active metabolite of atenolol is called beta-hydroxyatenolol.",
      "Approximately 20-30% of the population are poor metabolizers of CYP2D6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by cytochrome P450 enzymes; it is eliminated primarily unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: Atenolol is not significantly metabolized by cytochrome P450 enzymes, including CYP2D6, CYP3A4, and CYP2C9.\n4. FALSE [correction]: Atenolol does not have an active metabolite; it is eliminated primarily unchanged in the urine.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with the list of versions of ExpansionHunter, a popular expansion pack for the popular tabletop game, Dungeons & Dragons. Here are the versions of ExpansionHunter that have been released so far:\n1. ExpansionHunter: This is the original version of the expansion pack, released in 2017. It adds new classes, races, spells, and adventure hooks to the game, providing players with a wealth of new content to explore.\n2. ExpansionHunter: The Lost Mines of Phandelver: This is a standalone adventure module that was released in 2018. It takes players on a journey through the Lost Mines of Phandelver, a vast network of underground tunnels and caverns filled with dangerous creatures and valuable treasures.\n3. ExpansionHunter: The Wave Echoes: This is the latest version of the expansion pack, released in 2020. It adds new classes, races, and spells to the game, as well as a new adventure module called \"The Wave Echoes.\" This module takes players on a journey through the mystical land of Eldoria, where they must uncover the secrets of an ancient civilization and stop a powerful artifact from falling into the wrong hands.\n4. ExpansionHunter: The Fallen Lands: This is a digital-only expansion pack that was released in 2019. It adds new classes, races, and spells to the game, as well as a new adventure module called \"The Fallen Lands.\" This module takes players on a journey through a post-apocalyptic world, where they must survive in a harsh environment filled with dangerous creatures and rival factions.\n5. ExpansionHunter: The Shattered Isles: This is a digital-only expansion pack that was released in 2020. It adds new classes, races, and spells to the game, as well as a new adventure module called \"The Shattered Isles.\" This module takes players on a journey through a series of floating islands, where they must uncover the secrets of a mysterious cult and stop them from unleashing a powerful evil upon the world.\nI hope this information helps you, and please",
    "llama-2-7b-chat-hf_fact_raw": "1. The original version of ExpansionHunter was released in 2017.\n2. ExpansionHunter: The Lost Mines of Phandelver is a standalone adventure module released in 2018.\n3. ExpansionHunter: The Wave Echoes, released in 2020, includes a new adventure module called \"The Wave Echoes.\"\n4. ExpansionHunter: The Fallen Lands is a digital-only expansion pack released in 2019.\n5. The ExpansionHunter: The Shattered Isles digital-only expansion pack was released in 2020.",
    "llama-2-7b-chat-hf_fact": [
      "The original version of ExpansionHunter was released in 2017.",
      "ExpansionHunter: The Lost Mines of Phandelver is a standalone adventure module released in 2018.",
      "ExpansionHunter: The Wave Echoes, released in 2020, includes a new adventure module called \"The Wave Echoes.\"",
      "ExpansionHunter: The Fallen Lands is a digital-only expansion pack released in 2019.",
      "The ExpansionHunter: The Shattered Isles digital-only expansion pack was released in 2020."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Lost Mines of Phandelver is a standalone adventure module for the Dungeons & Dragons game, not related to ExpansionHunter.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 is a protein that plays a crucial role in hormone receptor signaling, specifically in the regulation of estrogen receptor (ER) signaling. Adamts18 is a member of the a disintegrin and metalloproteinase (ADAMTS) protein family, which are involved in the cleavage and processing of various proteins, including hormone receptors.\nAdamts18 is specifically expressed in various tissues, including the uterus, breast, and bone, and it has been shown to play a role in the regulation of ER signaling in these tissues. Adamts18 is able to cleave and activate ER, leading to the activation of downstream signaling pathways that regulate various cellular processes, including cell proliferation, differentiation, and survival.\nStudies have shown that Adamts18 is involved in the regulation of ER signaling in response to estrogen stimulation. For example, Adamts18 has been shown to cleave and activate ER in the uterus, leading to the activation of downstream signaling pathways that regulate uterine growth and differentiation. Adamts18 has also been shown to play a role in the regulation of ER signaling in breast cancer cells, where it can promote the growth and proliferation of cancer cells by activating ER signaling.\nIn addition to its role in ER signaling, Adamts18 has also been implicated in the regulation of other hormone receptors, including the androgen receptor (AR) and the progesterone receptor (PR). Adamts18 has been shown to cleave and activate AR in prostate cancer cells, leading to the activation of downstream signaling pathways that promote cell growth and proliferation. Adamts18 has also been shown to regulate PR signaling in the uterus, where it can modulate the response to progesterone and play a role in the regulation of uterine function.\nOverall, Adamts18 plays a crucial role in the regulation of hormone receptor signaling, particularly in the context of estrogen signaling. Its ability to cleave and activate hormone receptors makes it a key player in the regulation of various cellular processes",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a protein that plays a role in the regulation of hormone receptor signaling, specifically estrogen receptor (ER) signaling.\n2. Adamts18 is a member of the ADAMTS protein family involved in cleavage and processing of proteins.\n3. Adamts18 is expressed in various tissues including the uterus, breast, and bone.\n4. Adamts18 has been shown to cleave and activate the estrogen receptor in the uterus.\n5. Adamts18 has been implicated in the regulation of other hormone receptors like the androgen receptor (AR) and progesterone receptor (PR).",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a protein that plays a role in the regulation of hormone receptor signaling, specifically estrogen receptor (ER) signaling.",
      "Adamts18 is a member of the ADAMTS protein family involved in cleavage and processing of proteins.",
      "Adamts18 is expressed in various tissues including the uterus, breast, and bone.",
      "Adamts18 has been shown to cleave and activate the estrogen receptor in the uterus.",
      "Adamts18 has been implicated in the regulation of other hormone receptors like the androgen receptor (AR) and progesterone receptor (PR)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a relatively new drug that has been shown to have a unique mode of action in the treatment of various diseases, including cancer and neurodegenerative disorders. Here is a detailed explanation of its mode of action:\n1. Inhibition of Acetylcholinesterase: Thiazovivin is an acetylcholinesterase (AChE) inhibitor, which means it blocks the activity of the enzyme acetylcholinesterase. AChE is responsible for breaking down the neurotransmitter acetylcholine (ACh) in the brain. By inhibiting AChE, Thiazovivin increases the levels of ACh in the brain, leading to improved cognitive function and memory.\n2. Activation of NMDA Receptors: Thiazovivin has been shown to activate N-methyl-D-aspartate (NMDA) receptors, which are involved in the regulation of synaptic plasticity and learning. Activation of NMDA receptors can lead to an increase in the strength of synaptic connections, which can improve cognitive function.\n3. Inhibition of Microglial Activation: Microglia are the resident immune cells of the central nervous system (CNS), and they play a crucial role in the inflammatory response. Thiazovivin has been shown to inhibit the activation of microglia, which can reduce inflammation in the CNS and prevent neurodegeneration.\n4. Induction of Autophagy: Thiazovivin has been shown to induce autophagy, a cellular process that helps to remove damaged or dysfunctional cellular components. Induction of autophagy can help to protect cells against stress and damage, and may contribute to the neuroprotective effects of Thiazovivin.\n5. Modulation of Synaptic Plasticity: Thiazovivin has been shown to modulate synaptic plasticity, which is the ability of neurons to change and adapt in response to experience. Modulation of synaptic plasticity can lead to improved cognitive function and memory.\n6. Anti-inflammatory Effects: Thia",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is an acetylcholinesterase inhibitor that blocks the activity of the enzyme acetylcholinesterase.\n2. Thiazovivin increases the levels of acetylcholine in the brain.\n3. Thiazovivin activates N-methyl-D-aspartate receptors.\n4. Thiazovivin inhibits the activation of microglia in the central nervous system.\n5. Thiazovivin induces autophagy, a cellular process that removes damaged or dysfunctional components.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is an acetylcholinesterase inhibitor that blocks the activity of the enzyme acetylcholinesterase.",
      "Thiazovivin increases the levels of acetylcholine in the brain.",
      "Thiazovivin activates N-methyl-D-aspartate receptors.",
      "Thiazovivin inhibits the activation of microglia in the central nervous system.",
      "Thiazovivin induces autophagy, a cellular process that removes damaged or dysfunctional components."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not an acetylcholinesterase inhibitor. It is a small molecule that enhances the survival of human embryonic stem cells.\n2. FALSE [correction]: Since Thiazovivin is not an acetylcholinesterase inhibitor, it does not increase the levels of acetylcholine in the brain.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  }
]